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Summary
Lipid-based formulations have potential to raise the bioavailability of poorly water- 
soluble drugs beyond that which can be achieved from solid dosage forms. 
Physiological lipid processing is expected to be involved, and in this study bile salt and 
lecithin micelles, present in abundance during lipid digestion, were demonstrated to 
enhance the aqueous solubility of steroids. A trend of increased solubility 
enhancement with increasing steroid hydrophobicity was observed.
Lipid-based formulations frequently include surfactants with the capacity to reduce 
lipid digestion in vitro. Aspects of the ability of surfactants to reduce triglyceride 
digestion were investigated using an in vitro model, where lipase activity was 
monitored by titrating liberated fatty acids.
Lipase activity towards triglyceride was characterized in terms of enzyme kinetic 
parameters. Characterization of lipolysis in the presence of hydrophilic surfactants, 
with inhibitory behaviour towards lipase, revealed a lag phase which indicated that the 
surfactants exhibited reversible inhibition. Inhibition was thought to be overcome by 
colipase.
Lipase activity in the presence of a range of non-ionic surfactants suggested a 
relationship between the hydrophile-lipophile balance of a surfactant and the extent of 
inhibition. It was suggested that these observations were related to partitioning of the 
surfactant into the lipid interface.
Lipophilic surfactants were able to overcome lipase inhibition mediated by hydrophilic 
surfactants and the most effective in reversing inhibition were noted to contain 
lipolytic products as part of their composition. These lipolytic products were thought 
to clear the lipid interface, thus promoting colipase binding and lipase activity.
No conclusion could be drawn from an in vivo study comparing drug bioavailability 
from two lipid-based formulations (containing surfactants which rendered one 
available to lipase activity in vitro and the other not). This may reflect the capacity of 
the gut to overcome lipase inhibition due to surfactants. A mathematical model 
adapted for emulsions suggests a lipid-based formulation may improve bioavailability 
of drugs with a log P up to 5 without taking into account the additional advantages 
from digestion.
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Chapter 1 - The benefit of lipid-based formulations in relation to the 
bioavailability of poorly-water soluble drugs.
1
1.1 General Introduction
Prolonged dissolution is frequently held responsible for poor bioavailability of 
hydrophobic drugs when drug is presented in a crystalline state within the dosage 
form. Administration of a hydrophobic drug dissolved in a lipidic solvent could be 
presumed to avoid the dissolution stage hence bioavailability may be improved and/or 
a more consistent profile of drug absorption with time observed.
The ability of lipid-based formulations to improve absorption of poorly-water soluble 
drugs when compared to the use of aqueous suspensions or solid dosage forms has 
been subject to wide discussion1 as have the possible mechanisms involved. Early 
indications that the bioavailability of a poorly-water soluble drug may be improved 
due to the presence of lipid were gleaned from observations of increased drug 
absorption upon dosage with a high fat meal2,3.
Presence of food in the gastrointestinal (GI) tract may alter the bioavailability of a 
particular drug through various mechanisms as reviewed by Charman4. 
Physicochemical interactions between food and drug and the resultant effect upon 
bioavailability will depend on individual characteristics of the drug, the nature of the 
formulation, the interval between drug and food ingestion and the nature of the food 
eaten5. In addition alteration in enzymatic activity and the environment of the GI tract 
upon conversion from the fasted to the fed state are of prime consideration with 
regards to drug bioavailability. The effect of fatty food is of major interest in this 
context due to the scope for improvement in the dissolution rate of a poorly-water 
soluble drug through stimulation of the lipid digestion cascade4.
Activation of lipid digestive processes may occur via administration of drug with a 
dietary source of lipid or by presentation of the drug within a lipid-based formulation. 
The use of a simple solution of drug in lipid is rarely possible due to the limited 
solubility of some hydrophobic drugs in lipids. This generally leads to the design of 
more complex lipid-based formulations containing other components such as co­
solvents and surfactants. The nature of these components requires further
consideration as they may also influence the lipid digestion cascade removing any 
advantage to drug bioavailability conferred by the use of lipid in a formulation. A brief 
review of the stages of dietary lipid digestion is given in section 1 .2  followed by a 
discussion of their possible influence upon the bioavailability of hydrophobic drugs 
(section 1.3). Lipid formulations are briefly described (section 1.4) followed by an 
overview of the work presented in this thesis.
1.2 The lipid digestion cascade.
Over 97 % of dietary lipid is ingested in the form of triglycerides, 6 the majority of 
which are long chain (chain length Ci6-Ci8)7. The lipid digestion cascade describes the 
three steps involved in the conversion of triglyceride into a useful energy source8. 
Briefly lipid assimilation commences with emulsification of the triglyceride into a 
coarse dispersion of droplets. These provide a high surface area for enzymatic 
hydrolysis of triglyceride into monoglycerides and fatty acids. These lipolytic 
digestion products are absorbed by the intestinal enterocytes and subsequently 
transported into the portal vein or the lymph. The chain length of the triglyceride 
determines the route taken at certain stages of the cascade.
1.2.1 Lipids within the stomach.
Lipid emulsification occurs in the stomach where the process is augmented by the 
hydrolytic activity of human gastric lipase (HGL). HGL has been located inside 
granules in the apical region of chief cells9 and is mainly active in the fundic portion of 
the stomach10. The enzyme is able to hydrolyze short, medium and long chain 
triglycerides resulting in the release of diglycerides and fatty acids11. The velocity of 
HGL activity is dependent upon chain length of the triglyceride12 and pH, with 
optimal activity shown at a pH value of 5.413. In addition the enzyme has been shown 
to exhibit partial selectivity for the sn-3 ester bond13. Overall HGL has been proposed 
to be responsible for between 10 to 30 % of total gastrointestinal lipolytic activity8.
In vitro studies have demonstrated a correlation between HGL activity and interfacial 
tension at a triglyceride / water interface14’15. Inclusion of amphiphiles such as bile
salts and some proteins promoted HGL activity by reducing interfacial tension 
whereas the higher pressure of a pure triglyceride / water interface was noted to 
inhibit HGL. This was suggested to be a result of protein unfolding due to 
vulnerability of the enzyme structure to denaturation.
Triglyceride and ingested lecithin in normal dietary proportions (between 50:1 to 
2 0 :1) tend to form an emulsion system consisting of triglyceride droplets surrounded 
by an outer close packed monolayer of lecithin8. The lecithin monolayer decreases 
interfacial tension, thus helping to stabilize the emulsion by preventing droplet 
coalescence and increasing the activity of HGL. Partially digested proteins, complex 
polysaccharides and membrane derived phospholipids also present in the stomach 
possess emulsification properties and can decrease surface tension further thus 
promoting HGL activity8. Diglycerides and fatty acids resulting from HGL activity 
may also further emulsification by lowering surface tension of the triglyceride 
droplets13. The presence of these lipolytic products has the added advantage of 
promoting immediate pancreatic lipase activity upon release of the emulsion into the 
duodenum16.
Another important factor in emulsification is thought to be mechanical forces of the 
stomach antrum17 where contractions increase intraluminal pressure. The stomach 
contents are pushed towards the closed pylorus and then retropelled back to the 
stomach body providing mixing followed by applied shear forces tearing the liquid 
interfaces apart when chyme is released through the pylorus.
Any short and medium chain fatty acids released via HGL activity will be absorbed 
through the stomach mucosa due to their aqueous solubility in unionized and ionized 
forms. The long chain fatty acids are unionized at stomach pH and partition mainly 
into the core of the lipid droplet in a liquid state ready for transference to the 
duodenum8.
1.2.2 Duodenal digestion - the role of pancreatic lipase and colipase.
The enzyme responsible for the majority of triglyceride hydrolysis in the duodenum is 
pancreatic lipase although some HGL activity will remain whilst the pH of chyme is 
between 5 and 718. Pancreatic lipase activity is minimal unless the substrate is present
in sufficient concentration to form an interface, a phenomenon known as interfacial 
activation19. The presence of amphiphiles such as bile salts, phospholipids and proteins 
at the surface of the emulsion droplets prevents binding of pancreatic lipase to the 
triglyceride interface. Under these conditions binding of pancreatic lipase is only 
possible in conjunction with colipase, a non-enzymatic protein cofactor20.
Binding affinity of colipase and thus pancreatic lipase to the lipid interface is enhanced 
by long chain fatty acids already present in the core of the emulsion droplets from 
previous HGL activity. These rise to the droplet surface in the higher pH environment 
of the duodenum and mix with dietary phospholipids to enhance colipase binding21. 
Upon anchorage at the triglyceride interface the hydrolytic activity of pancreatic lipase 
releases lipolytic products of sn-2 monoglycerides and fatty acids22. Diglycerides 
located at the lipid interface from previous HGL activity are also readily available for 
further hydrolysis by pancreatic lipase.
Initially lipase is secreted together with colipase in a proform (procolipase) from 
acinar cells in the pancreas. Procolipase is activated into colipase by trypsin cleavage23 
resulting in removal of the N-terminal pentapeptide which has been proposed to play a 
role in the regulation of fat intake24. The purpose of procolipase cleavage is unclear as 
both procolipase and colipase are capable of promoting lipase mediated hydrolysis of 
triglyceride at the lipid interface in the presence of bile salts and phospholipid25. 
However under certain reaction conditions colipase was found to be more efficient at 
lipase activation than procolipase.
Insight into binding and activation of human pancreatic lipase (hPL) at a lipid interface 
has been achieved via crystallographic techniques. Resolution of the 3D-structure of 
hPL via X-ray crystallography revealed hPL to be a single chain glycoprotein of 449 
amino acids arranged as two domains connected by a hinge region26. Residues 1-336 
form the amino terminal domain26 typical of an a/p hydrolase fold27 with a dominant 
central parallel P sheet. Residues 337-449 form a carboxy terminal domain which 
subsequent studies of hPL crystallized with procolipase demonstrated to contain a 
binding site for a 1:1 stoichiometric complex of enzyme with cofactor28. In addition 
procolipase was observed to consist of three finger shaped regions with a significant
proportion of non-polar amino acids concentrated in the finger tips; these were 
proposed to provide a means of binding procolipase to the lipid interface28,29.
The amino terminal domain contains the active site which is a catalytic triad of the 
amino acid residues, Ser 152, Asp 176 and His 26326 with Ser 152 being the 
nucleophilic residue essential for catalysis30. The active site is covered by an 
amphipathic helix31 acting as a lid therefore conformational change of the enzyme is 
necessary to allow substrate contact with the active site. Rolling back of the lid 
uncovers the hydrophobic catalytic center and augments the hydrophobicity of the 
surface surrounding the active site by exposure of the nonpolar side of the lid31.
The 3-D structure of a hPL-procolipase complex, co-crystallized with mixed micelles 
of phosphatidylcholine and bile salt revealed further conformational changes in the 
enzyme-cofactor complex32. With phospholipid bound in the active site the position of 
the catalytic triad is unchanged although the surrounding environment is altered. Van 
der Waals bonds exist between a surface loop (35 loop) present over the active site 
and the lid when the enzyme is in the closed conformation. When the lid rolls back the 
35 loop folds onto the core of the protein rendering the active site serine accessible to 
solvent in the base of an hydrophobic canyon ideal for lipid substrate binding.
The same study32 illustrated that repositioning of the lid and 35 loop in hPL also 
results in creation of an electrophilic region (oxyanion hole) around the active site 
which acts to stabilize the negative charge generated during ester hydrolysis of the 
substrate. Further interaction also occurs between the N-terminal region of 
procolipase and the open conformation of the lipase lid via direct H-bonds giving 
increased stability to the hydrophobic surface around the active site in preparation for 
interaction with lipid interfaces. Chemical modification of a procolipase residue 
involved in these H-bonds resulted in loss of procolipase activity illustrating the 
importance of lid binding for functioning of the complex24. Deletions in the lid domain 
of hPL have given further support for involvement of the lid in interfacial binding and 
activation33. The bending angle between the C and N terminal domains of hPL has 
also been suggested to be important for positioning of the lid and subsequent catalytic 
activity34.
Crystallization of the hPL-colipase complex with an inhibitor of lipase, a Cn alkyl 
phosphate compound synthesized to mimic a triglyceride substrate, revealed
information regarding the possible interactions between substrate and enzyme35. The 
long hydrophobic Cn alkyl chain, taken to represent a fatty acid chain of a triglyceride 
molecule, was orientated in the hydrophobic groove of the active site with van der 
Waals contacts formed with the active site Ser 152. Interaction of the Cn alkyl chain 
was also observed with hydrophobic areas on the open lid near the rim of the active 
site. Assuming these results to be analogous to binding of a triglyceride molecule the 
remaining fatty acid chain was suggested to be positioned within the lipid layer thus 
enabling rapid removal of the lipolytic products.
The lid movement and consequent reorganization of pancreatic lipase upon lipid 
binding appears to have many functions, an interfacial lipid binding site is created, 
shape and access is given to the active site canyon, the oxyanion hole is stabilized and 
interaction with procolipase is strengthened32. The stimuli for opening the hPL lid is 
unknown35 and may simply occur in the presence of a lipid interface. Alternately hPL 
may exist in dynamic equilibrium between a closed and open form, the open 
conformation of which is stabilized in that conformation by contact with a lipid 
interface.
The sequence of events leading to the formation of the lipase-colipase-lipid complex is 
also unclear with possible binding of lipase with colipase in solution before adherence 
to the interface or via initial binding of colipase to the lipid interface acting as an 
anchor for subsequent lipase attachment. Both pathways have been postulated to exist 
by Lowe36 who suggested binding between colipase and the N-terminal of hPL to be a 
crucial factor in potentiating lipase activity. Further consideration of experimental 
evidence suggests that although binding of lipase and colipase is possible in solution, 
preliminary binding of colipase with the lipid interface may induce a conformational 
change increasing affinity of colipase for lipase37.
1.2.3 The physicochemical state of lipids during digestion.
The physicochemical state of aqueous upper intestinal contents is of importance in 
understanding the transport of lipolytic products from the emulsion surfaces to the 
enterocytes and in the context of the work here transport of drug molecules by the 
same means. Lipid emulsification mechanisms of the stomach have been suggested
7from results of an in vivo study to produce partially emulsified lipid droplets of 
between 1 to 100 pm diameter with the largest fraction sized in the range of 20 to 40 
pm17. An extension of the investigation revealed no further marked emulsification of 
dietary fat in the duodenum compared to the stomach which was proposed to be a 
result of limited mechanical shear forces despite the presence of excess amphiphiles38. 
Most dietary lipids were present in the human duodenum as emulsified droplets 1 to 
50 pm in size after 1 hour of digestion. Lipid droplets of the same size in the stomach 
and duodenum differed in lipid composition with the higher lipolytic activity in the 
duodenum reflected by neutral lipid depletion and duodenal droplet enrichment with 
lipolytic products, cholesterol and phospholipids38.
Accumulation of lipolytic products at the emulsion surface appears to be the first step 
in creation of the two separate phases suggested to exist (from in vitro39 and in vivo 
investigations40) together with emulsion droplets in postprandial duodenal contents. A 
model to explain the lipid phase states present throughout lipolysis40 is described 
below. Duodenal absorption of long chain fatty acids previously released from 
triglyceride by HGL activity stimulates ejection of pancreatic enzyme secretion8. 
Biliary lipids (bile salt and lecithin mixed micelles and cholesterol) are also released as 
bile from the gallbladder and rapidly become diluted in chyme from the stomach. 
Further rapid interfacial hydrolysis forms a multilamellar liquid crystalline bilayer at 
the surface of the emulsified lipid droplet which is comprised mainly of 
monoglycerides and fatty acids, with phospholipid, cholesterol and bile salts also 
present. Continued lipolytic activity shrinks the neutral lipid core of the droplet with 
the resultant high surface pressure releasing the liquid crystal bilayer as a multilamellar 
vesicle.
Layers from the multilamellar vesicles bud off and become solubilized by unsaturated 
bile salt micelles into unilamellar vesicles with hydrodynamic radii of between 400 to 
1200 A. The unilamellar vesicles are probably the initial phase in the process of 
lipolytic product dispersal, being comprised of aqueous mixed lipids saturated with 
bile salts. The structure of lipid aggregates in the small intestine thus depends on the 
mixed lipid to bile salt ratio as upon further bile salt incorporation into the unilamellar 
vesicles smaller intestinal mixed micelles are formed (hydrodynamic radii of 80 A).
The intestinal mixed micelles contain bile salts, long chain fatty acids, monoglycerides,
8cholesterol and phospholipids and act as a sink for lipolytic products under normal in 
vivo conditions.
Solubilization of lipolytic products (formed by the action of pancreatic lipase, 
phospholipase and cholesterol esterase) within intestinal mixed micelles increases their 
luminal solubility in addition to providing a means of diffusion to their site of 
absorption. Micelle formation is not required for absorption of short chain fatty acids 
as their high solubility in aqueous chyme41 enables these molecules to freely diffuse to 
the brush border membrane (BBM), although their hydrophilic nature does provide 
some resistance to their subsequent passage across42.
1.2.4 Lipid absorption.
The absorption of monoglycerides, medium and long chain fatty acids through the 
BBM of the intestinal mucosa occurs mainly from intestinal mixed micelles, although 
evidence suggests a certain amount of absorption is also possible from the unilamellar 
vesicular phase43. Absorption usually occurs by a process of passive diffusion due to 
the lipophilic nature of the products. However potential barriers to the passage of 
lipolytic products exist next to the BBM membrane42, namely the unstirred water layer 
(UWL) and intestinal mucus.
Dissociation of the lipolytic products from the vesicles and micelles is necessary 
before absorption44. Three models (reviewed by Thomson45) have been proposed to 
explain lipolytic product transfer from the micellar phase to the BBM. The collision 
model describes partitioning of the fatty acid directly from the micelle into the BBM 
of the enterocyte42. The other models involve a further step whereby fatty acids first 
partition into an intermediate aqueous phase. This is the UWL where fatty acids are 
soluble enough to diffuse across for absorption by passive transport, i.e. the 
“aqueous” model45.
Within the UWL acid microclimates are present adjacent to the BBM46. These have 
been suggested to be formed by mucus entrapment of hydrogen ions transported into 
the intestinal lumen by various types of antiporters47,48. If the intermediate aqueous 
phase is an acid microclimate, fatty acid uptake may occur via the “dissociation” 
model45. The decreased pH of the environment ensures fatty acids are unionized,
decreasing their solubility in micelles and enhancing partitioning into the BBM49. In 
addition low pH increases the critical micelle concentration (CMC) leading to further 
dissociation of micelles and fatty acid release50.
Although transport of fatty acids across the BBM into enterocytes has been thought 
to occur via passive diffusion51, evidence suggests absorption may be enhanced by the 
presence of a BBM fatty acid binding protein (FABPm)52. FABPm has been located on 
the outer surface of the enterocyte membrane and is thought to act as a medium and 
long chain fatty acid receptor53, possibly aiding lipid transport into the cell by acting 
as a translocase54.
Upon dissociation of the intestinal mixed micelles, the bile salt molecules diffuse back 
to the intestinal lumen to form new micelles which take up further lipolytic products 
until lipid absorption is complete. Some bile salts are then passively absorbed in the 
jejunum with the majority undergoing active resorption in the terminal ileum55 for 
transport to the liver via the enterohepatic circulation.
1.2.5 Cellular events and lymphatic transport.
Once inside the enterocyte long chain fatty acids and monoglycerides are transported 
through the cell cytoplasm to the endoplasmic reticulum. The mechanism for 
transportation is still unknown however intracellular fatty acid-binding proteins 
detected in enterocytes may be involved56. Reesterification of the lipolytic products 
into triglyceride then occurs via two possible pathways (reviewed by Tso7); the extent 
to which each pathway is utilized depending upon the lipid mixture absorbed. The 
monoglyceride pathway involves monoglyceride and free fatty acid together with the 
enzyme complex, triglyceride synthase, situated at the cytoplasmic surface of the 
endoplasmic reticulum57. When monoglyceride supply is low the a-glycerophosphate 
pathway converts absorbed fatty acids and endogenous glycerol into triglyceride 
within microsomes45.
The re-esterified triglyceride is utilized in the endomembrane system58 as the source of 
core lipid for the assembly of lipoproteins45, namely chylomicrons and very low 
density lipoproteins (VLDL). These are spherical complexes consisting of a 
triglyceride core surrounded by a coat of cholesterol, phospholipid and apoproteins.
Chylomicrons and VLDL stabilize lipid in the aqueous media of the cytoplasm and 
lower cellular concentration of lipid to maintain a concentration gradient for passive 
absorption. Eventually they migrate towards the basolateral membrane and are 
released by exocytosis into the intercellular space59. Passage of chylomicrons and 
VLDL through the lamina propria results in accumulation in the mesenteric lymph for 
final secretion via the thoracic duct into the systemic circulation60.
In the case of short and medium chain fatty acids (less than 12 carbon atoms) these in 
general do not undergo re-esterification into triglyceride and are passively absorbed 
along with glycerol directly into the portal blood61.
1.3 Influence of the lipid digestion cascade on drug absorption from 
lipid-based formulations.
The physiological stages of lipid processing may have a beneficial effect upon the 
absorption of a poorly-water soluble drug if activated by co-ingested lipid or lipid 
included in the formulation. Possible mechanisms by which stimulation of the lipid 
digestion cascade may improve drug bioavailability are discussed below:
1.3.1 Gastric emptying.
Chyme formed from a fatty meal contains some lipolytic products released by HGL 
activity, which upon entry into the duodenum, have been demonstrated to reduce the 
rate of gastric emptying62. This effect is possibly mediated by enhanced release of 
cholecystokinin, a polypeptide hormone known to be involved in slowing gastric 
emptying63. Physiologically a decreased rate of gastric emptying is advantageous to 
maximize energy obtained from ingested triglyceride, as rapid gastric emptying of fat 
has been demonstrated to diminish the efficiency of lipolysis64.
In terms of drug bioavailability the possible benefit of a reduction in gastric emptying 
rate is immediately evident, as increased gastric retention would prolong the drug 
absorption phase. Early work65 reported a twofold increase in bioavailability of 
micronized griseofulvin when administered to humans in a com oil in water emulsion 
over that obtained from an aqueous suspension and a tablet dosage form; comparable
experiments using rats66,67 also demonstrated improved bioavailability when drug was 
presented in a com oil in water emulsion. The improved bioavailability was suggested 
to be due to fatty acids released from digestion of the com oil acting to inhibit gastric 
emptying and thus decrease the rate of transfer of drug into the intestine65. Drug 
therefore would have more time to dissolve in the region of the intestine where 
absorption is likely to be most efficient.
1.3.2 Emulsification
The emulsification of a lipid formulation could be presumed to be beneficial due to the 
larger surface area available for drug release and enzymatic activity. Emulsification of 
a lipid formulation may be achieved by the normal physiological emulsification 
process already described, by dosage as a prepared emulsion or by inclusion of 
surfactants.
The classic studies using griseofulvin66 and phenytoin68 compared drug bioavailability 
from a com oil in water emulsion, a com oil suspension and an aqueous suspension. 
Control experiments demonstrated that differences achieved in drug absorption could 
not be attributed to solubility of the drugs at the time of dosing. For both dmgs 
bioavailability was highest from the prepared emulsion, although in the case of 
phenytoin both lipid formulations gave higher bioavailability than the aqueous 
suspension.
Comparison of these lipid formulations in terms of their initial emulsification status is 
complicated by the availability of com oil to lipase activity. The action of lipase may 
result in accumulation of lipolytic products upon the oil surface which could promote 
further emulsification and a consequent reduction in droplet size of both com oil 
based formulations. The increased drug plasma levels from the prepared emulsion 
compared to those from the com oil suspension nevertheless may be due to a 
difference in droplet size. The release of drug from the com oil suspension could be 
assumed to be delayed as digestion is necessary to reduce droplet size to that 
equivalent of the prepared emulsion.
When phenytoin was administered to rats in a sesame oil suspension and emulsion69 
the bioavailability and maximum plasma concentrations were not significantly different
between the two formulations, although the time to reach maximum plasma 
concentration (Cmax), was twice as long for the oil suspension. Compared to the 
aqueous suspension included in the study both oil based formulations gave an 
approximate 50 % increase in Cmax. This perhaps illustrates that although use of a 
crude prepared emulsion can increase absorption rate by avoiding the immediate need 
for emulsification, if sufficient time is available for digestion and absorption a simple 
suspension of drug in lipid can be equally effective as an emulsified formulation to 
enhance bioavailability for some drugs.
Inclusion of surfactants in a lipid formulation can further reduce droplet size, with 
creation of a fine dispersion upon release of the formulation into gastric fluid. The 
features, formulation and advantages of these systems, described as self emulsifying 
drug delivery systems (SEDDS), are discussed further in Chapter 5.
1.3.3 Digestion
If the lipid digestion cascade is to improve bioavailability of a drug, the lipid used in 
the formulation must be a suitable substrate for lipolytic enzymes. The advantage of 
digestible lipid has already been discussed with regards to emulsification mediated by 
lipolytic products. In addition lipolytic products would also have a stimulatory effect 
on gallbladder evacuation, causing bile release with a resultant increase in the 
concentration of bile salts and lecithin present. The surfactant properties of bile salts 
and lecithin may provide a further means of enhancing drug bioavailability by 
increasing the solubility of a drug through micellar solubilization; drug dissolution rate 
may also be increased due to a reduction in surface tension. Enhancement of the 
solubility and dissolution rate of hydrophobic drugs by bile salt and lecithin micelles 
and the possible mechanisms involved are addressed in Chapter 6 .
Drug bioavailability has previously been reported to be higher from formulations 
containing a digestible versus a non-digestible lipid70,71. The highly lipophilic 
compound, probucol, was presented to rats as a solution in long or medium chain 
triglyceride (MCT) and in a non-digestible lipid (liquid paraffin)72. The absorption of 
probucol was demonstrated to be dependent on the lipid vehicle, with no drug 
absorption detected when using liquid paraffin. This indicated that digestion was
required to transfer drug into the GI fluid and possibly micelles from which absorption 
was possible, rather than drug remaining partitioned in a non-digestible lipid until 
excretion.
Absorption of the poorly water-soluble drug SL-512 in rats was investigated73 using a 
digestible MCT formulation and a synthetic non-digestible lipid (MBLA). SL-512 
exhibited the same partitioning behaviour from both lipid vehicles into an aqueous 
solution however serum levels were 4-fold higher from the MCT formulation. 
Subsequent control experiments in the same study demonstrated the importance of 
lipid digestion to increase absorption of SL-512, possibly explained by digestion 
enhancing release of drug partitioned in the lipid.
Digestion of lipid in a formulation does not necessarily need to be rapid to improve 
drug absorption by the mechanisms described above. The rate and extent of lipid 
digestion is known to differ depending on the length and degree of saturation of the 
fatty acid chain, as well as the extent of esterification of the glycerol backbone1. 
Choice of a lipid susceptible to rapid lipolysis may in fact be disadvantageous as 
absorption of lipolytic products could occur before the drug has been solubilized into 
mixed micelles, leading to precipitation of drug in the GI fluid.
This has been demonstrated to a certain degree by examination of the bioavailability 
of penclomedine74, a poorly water-soluble cytotoxic agent, after intraduodenal 
administration to rats in various oil in water emulsions. Results showed an increase in 
bioavailability according to the lipid used in the formulation in the following order: 
MCT > long chain triglyceride (LCT) > non-digestible oil > short chain triglyceride 
(SCT) > aqueous suspension. Low bioavailability from the emulsion formed using the 
SCT, tributyrin, was proposed to be due to the rapid hydrolysis of tributyrin into 
water soluble products. The resulting lack of intestinal mixed micelles to solubilize 
drug and the rapid manner of drug release probably caused the drug to precipitate, 
hence little improvement in bioavailability was observed over than given by the 
aqueous suspension. Lower bioavailability of penclomedine from the LCT 
formulations compared to MCT formulations may be due to the slower rate of 
hydrolysis of LCT, with the main factor responsible for bioavailability from the LCT 
formulations being the ability of penclomedine to partition from the oil. The 
surprisingly high bioavailability of drug from the non-digestible formulation was also
suggested to be due to the same mechanism and illustrates the advantage of a 
dispersed formulation to increase drug partitioning into the aqueous GI fluid.
The advantage of using a digestible lipid for a formulation appears related to the 
physicochemical nature of the drug; a drug with a high partition coefficient would 
remain in the oil and therefore be more dependent upon digestion to enhance 
absorption. For a drug with a higher tendency to partition into the aqueous 
environment, simply presenting the drug in a readily dissolved state in a lipid- 
formulation, with good dispersion characteristics, may be sufficient to achieve higher 
bioavailability over that possible from a solid dosage form.
A further point for consideration is that a drug which does become solubilized 
through digestion will probably be partitioned within all phases created during the 
process, namely emulsion droplets, multilamellar and unilamellar vesicles and 
intestinal mixed micelles4. As digestion proceeds with time the relative proportions of 
the various phases will change accordingly, thus the absorption rate of drug from the 
final phases of lipid digestion may also be dependent upon the kinetics of the digestive 
process. This may perhaps explain why a longer period of time has been reported for 
drug to reach maximum plasma levels from a lipid-based formulation compared to an 
aqueous suspension, although eventually the lipid formulation has higher 
bioavailability.
1.3.4 Absorption
The presence of lipolytic products may influence the extent of hydrophobic drug 
absorption from the intestine in terms of drug transfer to the BBM and alteration in 
membrane permeability to the drug molecules75. The models already discussed for 
transfer of lipolytic products from the micellar phase to the BBM (section 1.2.4) may 
also apply to drug molecules sufficiently lipophilic to be solubilized within intestinal 
mixed micelles. These micelles are believed to solubilize high concentrations of 
hydrophobic drug and facilitate drug diffusion across the UWL to the BBM70. Upon 
breakdown of the micelle dissolved drug monomers are released in high concentration 
into the aqueous fluid surrounding the microvilli, ready for absorption across the 
BBM and subsequent transport into the bloodstream70. Micellar dissociation leading
to the release of drug in a readily absorbable form has been suggested to be promoted 
by absorption of bile salts in the distal portion of the small intestine76.
The UWL, with possible augmentation from the integral mucus layer has been 
suggested to be the main barrier to absorption of lipophilic drugs77'79 with restriction 
from the UWL reported to increase with drug hydrophobicity1. Recent work has 
demonstrated the ability of a single lysophospholipid molecule to seed aggregation of 
bile salt molecules at concentrations below their CMC80. The seeding of these 
aggregates appeared to be a non-specific hydrophobic mechanism therefore a suitable 
hydrophobic drug molecule may also be able to induce the same effect. The drug 
molecule would thus become surrounded by a small aggregation of bile salts with a 
subsequent increased transfer rate through the UWL. This proposed mechanism may 
perhaps play a role in hydrophobic drug absorption observed when bile salt 
concentration and lipolytic activity is low.
Although micellar solubilization may improve drug diffusion through the UWL, the 
subsequent release of lipolytic products upon dissociation of the micelle has been 
suggested to be disadvantageous to drug absorption. Contrary to increasing lipophilic 
drug bioavailability, the presence of fatty acid has been noted to restrict the 
absorption of griseofulvin; an effect which was explained by the ability of fatty acids 
to increase the thickness of the UWL and reduce intestinal blood flow81. Likewise 
extensive solubilization of drug in micelles may not always be beneficial in terms of 
bioavailability. Micellar solubilization of drug may result in a reduction in the rate of 
difliisivity compared to free drug molecules82. Retention of drug within micellar 
structures may also reduce the concentration of free drug available for absorption79,83. 
The normal process of lipid digestion and absorption has been suggested to impair the 
integrity of the intestinal epithelium on a regular basis, with the extent of damage 
increasing with fatty acid concentration84. Constituents of intestinal mixed micelles 
and other components likely to be present during digestion of a lipid-based 
formulation, i.e. fatty acids, bile salts, monoglycerides, lysolecithin and non-ionic 
surfactants have also been reported to increase membrane permeability85. In the case 
of lipolytic products this effect may be mediated by incorporation into the membrane, 
altering the configuration in such a manner that it becomes easier for drugs to 
permeate75. Enhanced membrane permeability due to lipid digestion is unlikely to
increase the bioavailability of hydrophobic drugs as transport across the membrane 
generally occurs by passive transcellular diffusion86. However the absorption of highly 
polar and / or high molecular weight drugs may be improved75.
Poelma et al79 examined the influence of mixed bile salt, lecithin and fatty acid 
micelles upon drug absorption in terms of rate of drug transfer across the UWL, 
(including integral mucus layer) and epithelial membrane. The absorption of a range of 
hydrophilic and lipophilic drugs, solubilized within the micellar solutions was assessed 
using a rat chronically isolated small intestinal loop. Any influence from the micellar 
systems on dissolution rate of the drug was thus eliminated. Micellar concentrations 
were selected to be physiologically representative. Overall results from the study 
indicated that mixed micelles did not have any beneficial effect upon transference of 
solubilized drug across the UWL or the epithelial membrane for all drugs tested. Lack 
of absorption enhancement for the hydrophilic drugs may perhaps be related to the 
low concentration of oleic acid used in this study (5 mM). To demonstrate membrane 
permeability Kvietys et al84 used higher oleic acid concentrations (10-40 mM) which 
they stated as typical of levels in the physiological fed state. The concentration of fatty 
acid present solely from digestion of a lipid-based formulation may not be sufficient to 
exert any influence by the mechanisms described above.
1.3.5 Lymphatic absorption of drugs.
The primary route of drug transport from the enterocyte into the systemic circulation 
is the portal vein although entry is also possible via the intestinal lymph. One of the 
functions of the lymphatic system is to drain fluid from extracellular tissue back into 
the vascular compartment. Within the GI tract the lymphatic system also provides a 
means of transport to the systemic circulation for lipophilic digestive products unable 
to disperse easily in the aqueous environment of blood, such as cholesterol87 and fat 
soluble vitamins88. Some highly lipophilic drugs also gain access to the systemic 
circulation via the lymphatics (as reviewed by Porter and Charman60), however for a 
drug to be transported by this route concurrent synthesis of the triglyceride core of 
chylomicrons is necessary. The triglyceride for chylomicron formation is synthesized 
from long chain fatty acids absorbed during normal lipid digestion89 therefore
ingestion of lipid followed by activation of the lipid digestion cascade could be 
presumed to enhance drug absorption via this route90.
Selective absorption into the lymph has been demonstrated for the pesticide DDT91 
and the drug probucol72, with evidence that co-administration of these compounds 
with lipid can enhance lymphatic absorption72,92 The extent of absorption was found 
to depend on the type of lipid vehicle, with LCT revealed to give the highest 
concentration of drug in the lymph when compared with administration in MCT and 
liquid paraffin. LCT was also found to be the most effective vehicle for increasing 
lymphatic transport of the retinoid, isotretinoin93. By selection of a LCT the 
subsequent absorption of long chain fatty acids into the enterocyte was postulated to 
stimulate the synthesis of chylomicrons and hence increase capacity of the lymph to 
transport lipophilic drug molecules. However limited drug uptake into the lymphatic 
system is also possible without lipid presence94 if drug is presented in a sufficiently 
solubilized form to enable drug absorption into the enterocyte. Absorption is then 
followed by transportation to the lymph in association with VLDL produced from 
endogenous lipids.
As the portal vein has a much higher flow rate than the lymph a selective uptake 
mechanism is required for lymphatic transport of drug to occur95. Methods to enhance 
drug absorption by the lymphatics have been widely investigated as this route has the 
advantages96 of avoidance of first pass metabolism, improved absorption of highly 
lipophilic drugs and sustained release to the systemic circulation. In addition drug 
targeting strategies to areas supplied by the lymph could be useful, such as cytotoxic 
drugs to prevent lymph metastasis and drug treatment of immune diseases.
Drug lipophilicity appears to be a major factor with regards to whether drug will be 
transported via the lymphatics and attempts have been made to promote lymphatic 
drug transport by using prodrugs with increased lipophilicity60. This can be brought 
about by forming an ester with a lipophilic molecule such as fatty acid or by designing 
the drug to closely resemble a triglyceride, phospholipid or glyceride to increase 
likelihood of drug incorporation into the lipoprotein synthetic pathway.
For a drug to undergo lymphatic transport to an extent where bioavailability is 
improved a log Pod value of >5 and triglyceride solubility of > 50 mg / ml has been
found to be beneficial97. These parameters are only a guideline and other factors are 
also relevant such as the metabolic pathway of the drug and chemical stability. 
Influence from the type of lipid formulation used to deliver the drug upon the extent 
of lymphatic drug transport has also been considered. LCT has already been 
mentioned as the lipid type most likely to promote lymphatic absorption however 
further advantage may be gained by using lipolytic products i.e. long chain fatty acid 
and monoglyceride90. This approach eliminates the lipolysis stage thus reducing time 
required to initiate chylomicron formation with a resultant decrease in time available 
for drug to be absorbed into the portal blood.
Three different lipid vehicles, formulated to represent the physical stages of lipid 
digestion, were investigated to assess the extent of lymphatic absorption of the highly 
lipophilic free base form of halofantrine98. Results showed absorption to be more 
efficient as formulation dispersion status increased (micellar > emulsion > solution). 
However the model used eliminated any effects from gastric emptying and 
emulsification and when these were reintroduced using a conscious rat model99 the 
type of dispersion had no effect upon the extent of halofantrine lymphatic uptake. 
Other evidence also suggests a role for in vivo bile mediated solubilization of drug to 
enhance transport by the lymph100. It therefore seems likely that as long as normal 
lipid processing can occur to reduce the lipid formulation to a micellar solution the 
long chain lipid used or the initial state of dispersion of the formulation will not 
influence the extent of drug lymphatic uptake.
1.4 Lipid-based formulations.
1.4.1 Stimulation of the lipid digestion cascade.
There is insufficient biological data available at present to be clear about the 
requirements of lipid formulations, although the studies already discussed in this 
chapter suggest the process of lipid digestion to be relevant. To develop a formulation 
which could benefit drug absorption via the various stages of physiological lipid 
processing it is necessary to know how much lipid is required to stimulate the lipid 
digestion cascade. Some of the early studies reporting increased bioavailability from
lipid-containing oral formulations were noted by Yamahira et al101 to use large lipid 
volumes in excess of that practical for clinical use. They suggested a lipid dose 
equivalent to a 0.5 ml capsule to enable reasonable comparison of experimental results 
with those possible clinically.
Investigation into the minimum amount of emulsified com oil necessary to maximize 
the uniformity and extent of absorption of griseofiilvin102 revealed a requirement of 4 
g of com oil contained within 10 g of an oil in water emulsion. These workers 
suggested drug absorption to be enhanced via a reduction in the gastric emptying rate 
and stimulation of gallbladder evacuation. Bioavailability of the poorly water-soluble 
steroid, danazol, from a hard gelatin capsule was noted to be increased three fold 
when given after a meal as opposed to dosage in the fasted state103. The use of a 
monoglyceride emulsion to administer the same dose of danazol increased plasma 
levels to those achieved when the capsule was given in the fed state. As bioavailability 
from the emulsion was independent of the presence or absence of food, a possible 
explanation is that the monoglyceride-based emulsion may have triggered a 
postprandial environment in the GI tract. The quantity of emulsion used to administer 
the dose of danazol was 30 g which is too large for use on a regular basis.
The large volume of lipid used in the above studies thus appears impractical from a 
pharmaceutical viewpoint, introducing problems of emulsion formulation and patient 
compliance with chronic usage. Further research is therefore required to assess if 
lower lipid volumes, suitable for encapsulation, could stimulate the lipid digestion 
cascade. However even if a significant proportion of lipid is found to be required, 
lipid-based formulations remain an option if the drug is needed only on a short term 
basis.
1 .4.2 Constituents of lipid-based formulations.
Various types of lipid-based formulations exist; from a simple solution or suspension 
of drug in lipid, through to emulsions and more complex self-emulsifying and 
microemulsion systems. Due to the limited solubility of some hydrophobic drugs in 
lipids and to increase formulation dispersibility, other components such as co-solvents 
and surfactants are frequently included in a lipid formulation. The influence of these
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constituents upon drug bioavailability may vary depending on the mechanism 
responsible for enhancement of drug absorption.
Certain surfactants have been demonstrated to render an otherwise digestible lipid 
unavailable to pancreatic lipase activity. When triglyceride is freely digested by lipase, 
drug preferentially partitioned in the lipid phase is proposed to be slowly released 
together with lipolytic products. The drug molecules and lipolytic products form a 
solubilized micellar phase with bile salts and lecithin which aids transport of drug to 
the site of absorption. A surfactant which prevents digestion would thus result in 
retention of drug in the lipid phase with an obvious disadvantage to drug 
bioavailability. Lack of or a reduction in the concentration of lipolytic products 
released could also decrease the solubilization capacity of the aqueous phase 
increasing the likelihood of precipitation of drug. The use of co-solvents in a 
formulation may also increase the possibility of drug precipitation upon release of the 
formulation into the aqueous GI fluid.
Surfactants have also been noted to increase the viscosity of GI fluid, a property 
shown mainly by polyethoxylated surfactants104. If surfactant concentration in a 
formulation was sufficient to mediate an increase in viscosity, drug absorption may be 
decreased due to a reduction in the diffusion rate of free drug molecules and micelles 
to the BBM; on the other hand drug absorption may be enhanced as an increase in 
viscosity may reduce the rate of gastric emptying.
When designing a formulation safety issues regarding the use of surfactants is a major 
consideration. Surfactants may be acutely damaging to the intestinal mucosa causing 
loss of epithelial cells from the surface, which although reversible, could in turn have a 
permeability enhancing effect on the intestinal membrane85. This may promote 
absorption of the surfactant molecules leading to possible toxicity through systemic 
mechanisms, in addition to increasing absorption of other non-related noxious 
materials in the GI tract.
Non-ionic surfactants are considered the least likely of surfactant types to induce 
toxicity. Several studies of homologous series of non-ionic surfactants105, 106 have 
revealed toxicity, (measured by lethality through systemic effects), to increase in line 
with the non-polar nature of a surfactant and, in general, ability to act as an intestinal 
permeability enhancer85. However damage to the intestinal mucosa induced by a non­
ionic surfactant, Triton X-100, has been demonstrated to undergo restitution after 
only one hour107. In addition the GI tract has several defense mechanisms to prevent 
local damage such as the intestinal mucous layer, increased intestinal motility and 
enzymes, gut flora and buffering systems85. These together with the restitution 
capability of the intestinal mucosa may well be sufficient to overcome any membrane 
erosion caused by inclusion of a surfactant in a lipid-based formulation, as long as 
intervals between dosage are sufficient to enable time for repair.
An understanding of the influence of surfactants on the process of lipolysis appears 
desirable when designing a lipid-based formulation. Knowledge of other possible in 
vivo effects from constituents used in the formulation may also provide a means to 
enhance drug bioavailability and avoid potential problems. The benefits and adverse 
effects of surfactants and co-solvents on drug bioavailability and other issues related 
to formulation of lipid-based systems are addressed further in Chapter 5.
1.5 Overview of the investigations included in this thesis.
Hydrophobic drugs when dosed in a conventional tablet can exhibit limited 
bioavailability. In general terms the work in this thesis was intended to strengthen the 
argument for presentation of drugs in a lipid-based formulation when the above 
situation is observed. The activity of lipase towards a triglyceride substrate is central 
to the main mechanism proposed to be responsible for the enhancement of drug 
bioavailability from lipid-based formulations. Interest was therefore focused on the 
behaviour of lipase towards triglyceride under various conditions and in the presence 
of substances likely to be included in a lipid-based formulation.
Chapter 2
An in vitro model taken to represent the digestion of triglyceride by lipase in the 
duodenum had previously been developed108 and was based on a titrimetric assay 
utilizing a stationary pH device (pH-stat). Chapter 2 involves examination and 
validation of various experimental conditions selected for use in the model, which is 
referred to throughout this thesis as ‘the standard pH-stat assay’.
Chapter 3
A decrease in the activity of lipase towards triglyceride had been observed108 when 
certain non-ionic surfactants were included in the assay. As surfactants are frequently 
used components of lipid-based formulations further knowledge regarding this 
phenomenon was desirable. Enzyme kinetic parameters can provide information 
regarding the mechanism by which enzyme activity is reduced when an inhibitory 
substance is present109. By determination of these parameters in the presence and 
absence of an inhibitory surfactant the mechanism by which surfactants are able to 
inhibit lipase may be revealed.
With this aim in view the activity of lipase towards triglyceride is quantified in 
Chapter 3 in terms of kinetic parameters, under conditions of the standard pH-stat 
assay. An attempt is also made to obtain the same parameters when a surfactant 
known to inhibit lipase activity is included in the assay system.
Chapter 4
Ideally a surfactant used in a lipid-based delivery system should fulfill the 
requirements of the formulation whilst having no influence on lipase activity. To 
enable selection of a surfactant which satisfies this criteria further knowledge 
regarding the behaviour of different non-ionic surfactant types towards lipase activity 
was required.
A range of non-ionic surfactant groups are screened for inhibitory behaviour towards 
lipase in Chapter 4 under conditions of the standard pH-stat assay. The results are 
analysed in relation to properties of the surfactants, namely the chemical structure and 
the HLB value, which describes the balance between the hydrophilic and lipophilic 
portions of a surfactant.
Chapter 5
The majority of surfactants tested in Chapter 4 decreased lipase activity under 
conditions of the assay, suggesting that a lipid-based formulation would probably 
include surfactants with some inhibitory behaviour towards lipase. Previous studies108 
had revealed certain surfactants with dominant lipophilic character were able to 
reduce the inhibition of lipase activity mediated by hydrophilic surfactants. This 
suggests a means by which a surfactant with inhibitory properties could be included in 
a formulation to achieve the level of dispersion required, in conjunction with a
lipophilic surfactant to overcome any consequential effect upon lipase. A range of 
lipophilic surfactants are screened in Chapter 5, using the standard pH-stat assay, for 
ability to overcome inhibition mediated by a hydrophilic surfactant.
Of considerable importance however is the relevance of lipase inhibition observed in 
vitro to the in vivo situation. To examine this aspect two lipid-based formulations of 
the same drug were designed to render one system digestible, when evaluated in vitro, 
and the other not. The development of these formulations is described in Chapter 5 
followed by a discussion of results from an in vivo study where the formulations were 
administered to dogs. The in vivo study was performed by a contractor110, m .
Chapter 6
The main mechanism by which lipid-based formulations improve the bioavailability of 
hydrophobic drugs has already been suggested to involve solubilization of drug in bile 
salt and lecithin micelles1. If these micelles are able to greatly increase the solubility of 
a poorly water-soluble drug, stimulation of the lipid digestion cascade, and hence 
release of bile at the time of dosing could led to improved bioavailability. In Chapter 6  
the extent to which solubilization may increase the solubility of a range of steroids 
was assessed under various conditions. The degree of solubility enhancement is 
examined in relation to the hydrophobic nature of the steroid, expressed via an 
experimentally determined parameter, log P hplc- 
Chapter 7
The overall aim to encourage the use of lipid-based delivery systems is somewhat 
inhibited by the need to develop these formulations on an individual basis for each 
drug. Inability to predict the level of bioavailability enhancement likely to be achieved 
is another negative factor. The work in Chapter 7 involves adaptation of an existing 
mathematical model112 which predicts the fraction of dose absorbed from a suspension 
formulation of a poorly water-soluble drug. The equations of the model were adapted 
to an emulsion system where drug is presented dissolved within lipid droplets. Results 
from the model are discussed in relation to which drugs and under what conditions an 
emulsion formulation may enhance bioavailability.
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Chapter 2 - An in vitro model of lipolysis (the standard pH-stat assay).
2.1 Introduction
The use of a pH-stat to monitor the progress of enzymatic hydrolytic reactions where 
protons are liberated is a well established technique113. In the specific case of the 
pancreatic enzyme lipase, a titrimetric assay utilizing a pH-stat has become a standard
1 1 / 1  l i emethod to determine the rate of substrate utilization ’ ’
Challis116 used a pH-stat to investigate the lipolysis of lipid-based self-emulsifying 
systems by lipase and the method was further developed and validated by other 
workers at R P Scherer108. Their method enabled the extent of digestion of a lipid- 
based formulation, in a physiologically representative reaction medium, to be followed 
with respect to time. Comparison between the rate of digestion of various 
formulations by lipase could thus be made. The conditions for the model in terms of 
temperature, ionic strength and pH were selected to represent the in vivo situation. 
The primary objective of the work described in this chapter was to examine and 
validate the conditions selected for use in the R P Scherer in vitro model. The effect 
of enzyme concentration and the pH of the reaction mixture on lipolysis of MCT by 
lipase were examined. An investigation was also performed to enable selection of a 
model triglyceride suitable for use throughout the study of lipolysis inhibition.
The set up, calibration, operation and maintenance of the pH-stat are described below, 
followed by an account of the methodology chosen for the in vitro model of lipolysis, 
referred to subsequently as the standard pH-stat assay. This assay procedure was used 
for all lipolysis experiments described in Chapters 3, 4 and 5. To help ensure validity 
of results obtained using the standard pH-stat assay several control experiments were 
also performed. These covered the issues of enzyme potency, substrate and enzyme 
stability, extent of triglyceride digestion and blank rates.
2.2 The standard pH-stat assay of lipolysis.
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General principles of the assay.
A pH-stat assembly enables the progress of a reaction to be followed at constant pH, 
hence the device is particularly suitable for quantitative determination of enzyme 
reaction rates. The pH-stat operates by monitoring the electrode potential (expressed 
as pH), during a chemical reaction. The device is preset to an end-point pH value 
which corresponds to the constant pH at which the reaction is required to take place. 
Initially the reaction mixture has the same potential as the end-point pH however 
when the chemical reaction is started protons are liberated or taken up, with a 
resultant change in the potential. The pH-stat restores the reaction mixture to the set 
end-point pH by automatic continuous titration with acid or alkali. During the course 
of a reaction the volume of titrant used can be recorded as a function of time to create 
a progress curve of the reaction for kinetic analysis.
Relation of the assay to lipase activity.
A pH-stat is ideally suited to follow the lipolysis of triglyceride as the multi-phasic 
turbid nature of the emulsion does not interfere with the nature of the assay. 
Triglyceride is digested by the enzyme, pancreatic lipase and if the lipolytic reaction 
proceeds to completion a triglyceride molecule is split by ester hydrolysis into one 
monoglyceride and two fatty acids. The fatty acids release protons with a resultant 
drop in the pH. The pH-stat then releases a known volume of alkali (sodium 
hydroxide) to maintain the end-point pH value. The moles of sodium hydroxide used 
can be equated with fatty acid liberated to determine the percentage of triglyceride 
digested throughout the course of the reaction.
Optimization of the assay.
To help ensure precision of results with this type of assay the stirring rate of the 
reaction mixture must be kept constant and the electrodes should be calibrated. 
Absorption of carbon dioxide needs to be kept to a minimum and leakage of titrant 
from the burette tip should not occur. Another possible complication with the method 
is the existence of an unknown liquid junction potential113. This is created by different
diffusion rates of potassium and chloride ions into the reaction mixture from saturated 
potassium chloride present in the calomel electrode. The effect of any resulting 
diffusion potential upon the potential measured by the pH-stat was assumed to be 
minimal and therefore disregarded. This assumption was justified by determination of 
the apparent reaction rate before enzyme addition, known as the blank rate.
It is important to correctly set up the titrator unit of the pH-stat to ensure that the rate 
of titrant addition is sufficient to maintain the end-point pH throughout the reaction. If 
settings are too slow delays may occur in titrant addition whereas rapid addition of 
titrant can result in overshooting the required end-point pH value. Factors which 
affect selection of an appropriate titration rate include concentration of titrant, buffer 
capacity and size of the sample. Titrant addition is controlled by the proportional band 
selector, which determines the volume of titrant added and the pause between 
additions. This selector is set to a pH span prior to the end-point pH value. When the 
reaction mixture shows a reading corresponding to the pH setting on the proportional 
band selector, titrant delivery is gradually reduced as the end-point pH is approached. 
The setting of the proportional band selector is normally chosen so a reduction in 
titrant delivery starts when approximately 90 % of titrant needed to reach the end­
point has already been added.
Preliminary experiments were performed to enable selection of the proportional band 
and titration speed settings. A titrant concentration of 1 M sodium hydroxide was 
found sufficient to ensure addition of a low volume to the reaction mixture thus 
minimizing dilution effects and possible reduction in reaction temperature. The buffer 
selected for use in the reaction mixture was tris-maleate which has the advantages of 
avoiding problems caused by other buffers such as calcium salt precipitation and 
absorbance of carbon dioxide. Tris-maleate can also be used over a pH range of 5.5 to 




Tris-maleate buffer at pH 6.5
Trizma®-maleate (tris-maleate) C^nN CV C^C^ 50 mM Sigma T3128
Sodium chloride NaCl 150 mM Sigma S9625
Calcium chloride dihydrate CaCl2*2H20  5 mM Sigma C3881
Sodium hydroxide NaOH 40 mM Fisons S/4880/60
Buffer was prepared by dissolving appropriate quantities of tris-maleate, sodium 
chloride and calcium chloride dihydrate in distilled water followed by addition of 
sodium hydroxide pellets to adjust to the required pH. As the pH of a buffer solution 
can vary significantly with temperature the buffer was brought up to experimental 
temperature before any final adjustments were made for volume and pH (using 1M 
NaOH solution).
Simulated bile solution
Taurodeoxycholic acid sodium salt 8  mM Sigma T0875
L-a-phosphatidylcholine 1.6 mM Sigma P9671
(60 % pure from fresh frozen egg yolk) 
to volume using tris-maleate buffer above.
The simulated bile solution was prepared daily to minimize degradation of 
components. Appropriate quantities of sodium taurodeoxycholate (bile salt) and 
phosphatidylcholine (lecithin) were dissolved in tris-maleate buffer using a heated 
magnetic stirrer. After preparation simulated bile solution was stored at 4°C until 
required.
Trielvcerides
Tributyrin Ci5H2606 Sigma T8626
Triolein C57H104O6 Sigma T7752
LCT (Soya bean oil) R P Scherer.
MCT (Fractionated coconut oil as Miglyol® 812) Hiils (UK) Ltd.
Additional materials Supplier / Code No.
Porcine pancreatin Sigma P I500
Porcine pancreatin BDH 39029
Anti-foam A (100 % active silicone polymer) Sigma A5633
Normadose hydrochloric acid 0.1 M Prolabo 32/051/605
Normadose sodium hydroxide solution 0.1 M Prolabo 32/067/600
Normadose sodium hydroxide solution 1 M Prolabo 32/066/606
Standard pH 7 phosphate buffer Fisons J/2850/17
Standard pH 4 phthalate buffer Fisons J/2820/17
Standard pH 9.2 borate buffer Fisons J/2870/15
2.2.2 Equipment 
The pH-stat assembly
Radiometer pH-stat system ETS822 comprising of PHM82 Standard pH Meter, 
TTT80 Titrator, ABU80 Autoburette, and TTA80 Titration Assembly with stirrer 
(No.847-714).
Glass indicating electrode (No.G2040C)
Calomel pH reference electrode (No.K4040C)
All from Radiometer Analytical A/S, Copenhagen, Denmark.
Gallencamp water bath 
B&T Circon pump
Water jacketed titration vessel (250 ml capacity)
The pH-stat was assembled in a stack system (from the top) of pH meter, titration 
assembly and auto burette with the stirrer unit holding the reaction vessel to the right.
The jacketed reaction vessel was connected via tubing to a pump unit contained in the 
water-bath. The pump allowed heated water to be circulated between the reaction 
vessel and the water bath. An integral thermoregulator on the water-bath maintained 
temperature with a separate thermometer suspended in the water bath to act as an 
external check.
Settings used for pH-stat assembly.
PHM82
Sensitivity left as set after calibration (± 1 % absolute)
Temperature 37°C





Accuracy imprecision of display value 0.005 ml







0.05 pH units (accuracy ± 5 %) 
pH-STAT
depressed (when end-point pH > reaction medium pH) 
set at pH 6.5 unless otherwise stated for experiment 
± 0.02 pH
Calibration of PHM82 standard pH meter.
To ensure accurate results from the pH meter a calibration procedure was necessary 
to check electrode function and response of the pH meter to the individual 
characteristics of each electrode. Calibration was performed on a daily basis before 
use of the pH-stat assembly for experimental work. The standard buffer solutions used
30
to calibrate the pH meter were selected according to the end-point pH of the assay. 
For an end-point pH below 7 buffer solutions of pH 4 and 7 were used, the pH 4 
buffer was replaced by a buffer of pH 9.2 when the end-point value was set at > pH 7. 
All pH measurements were taken at the same temperature as the experiments were to 
be performed (37°C) with the stirrer unit operational.
Calibration Procedure.
Electrodes were removed from storage solutions, rinsed with distilled water and 
located in the electrode head. With the pH meter sensitivity dial set at 100 % and the 
temperature dial to 37°C, the standard pH 7 buffer was left in the reaction vessel until 
a stable pH reading ( ± 0.01 pH units) had been displayed for 30 minutes. Using the 
buffer dial which alters parallel displacement the pH reading was adjusted to the 
manufacturers specified pH value at 37°C unless the correct reading was already 
shown. The pH was monitored for a further 15 minutes to ensure the reading 
remained stable, followed by rinsing of the vessel and electrodes with distilled water. 
The second buffer solution (pH 4 or 9.2, as appropriate) was placed in the vessel and 
left until a stable pH reading had been displayed for 15 minutes. If adjustment to the 
manufacturers specified value was necessary this was performed using the sensitivity 
dial which alters slope. A check was made to ensure the reading remained stable for 
15 minutes. If so the vessel and electrodes were rinsed with distilled water and the pH 
7 buffer solution was returned to the vessel. If the pH reading was within ± 0.01 pH 
units of the manufacturers specified value then calibration was complete. If the pH 
reading fell outside of these limits the whole procedure was repeated until results 
were within the specification.
2.2.3 Method for standard pH-stat assay.
The standard pH-stat assay described here was used for all lipolysis experiments; any 
modifications made to the assay for a particular investigation are noted under the 
corresponding description of the method.
Daily preliminary procedures.
Prior to starting the assay the burette unit was primed. Distilled water left in the 
burette for overnight storage was removed followed by flushing and refilling using 
titrant. This approach ensured no dilution of titrant and eliminated air bubbles. The 
titrant volume display was reset to commence from zero.
Pancreatin was weighed into 4 ml amber glass vials (fitted with Teflon lined rubber 
sealed lids), in amounts of 500 mg (+ 0.3 mg) and stored dry at 4°C until use. The 
required quantity of triglyceride was weighed into a vial of the same type as that used 
for pancreatin. If surfactant was also to be included in the experiment the triglyceride 
and surfactant were weighed into the same vial and thoroughly mixed. This technique 
will be referred to in future text as the premixed method.
For surfactants in a solid state at room temperature liquefaction was necessary to 
improve ease of handling and to aid dispersion into the reaction mixture. This was 
achieved by gentle heating of the complete storage container in a hot air cupboard 
until the surfactant was molten followed by thorough mixing to ensure homogeneity. 
After melting most surfactants remained in a liquid state after addition to triglyceride 
and were stored at 30°C until use. The above method was utilized for all surfactants 
listed in Chapters 3, 4 and 5 if solid / semi-solid at room temperature.
Assay procedure.
To start each assay 100 ml of simulated bile solution was required, the majority of 
which was placed in the reaction vessel. This was followed by the previously weighed 
sample of triglyceride or triglyceride with surfactant. The vial used to weigh the 
triglyceride was rinsed three times using the remaining simulated bile solution, with 
the rinsings added to the vessel followed by lOpl of anti-foam A to prevent foaming. 
Upon activation of the stirrer unit the reaction medium was left to equilibrate to 37°C 
(+ 0.5°C). When a stable pH reading had been shown for 10 minutes the mixture was 
titrated up to the end-point pH of 6.5, with a record made of the initial pH and titrant 
volume used. This step allowed adjustment for slight variations in starting pH values 
of the reaction mixture caused by different batches of simulated bile solution and 
properties of the triglyceride and surfactants.
32
Whilst the reaction mixture was reaching equilibrium temperature a vial of pancreatin 
was reconstituted by addition of 2 ml of distilled water. The resulting enzyme 
suspension was mixed by vortexing and left at 38°C for a pre-incubation period of 20 
minutes. Following this period the pancreatin was re-suspended and 1 ml of the 
resulting enzyme suspension was added to the reaction medium which initiated the 
assay. The titrator and electronic timer were started simultaneously at this stage. The 
volume of titrant used was recorded manually using the timer at intervals of 1 minute 
for the first twenty minutes followed by readings every 5 minutes for a further 40 
minutes.
Clean up and shut-down procedure.
To ensure no contamination occurred between assays the vessel underwent thorough 
washing to remove any remaining traces of enzyme and lipid using hot water and 
liquid detergent. The vessel was then rinsed with tap water four times followed by a 
final rinse using distilled water. Electrodes were cleaned by wiping with clinical tissue, 
followed by a distilled water rinse, and a final wipe with absolute alcohol 95 %. The 
reservoir was refilled with titrant.
If no further assays were to be performed during the same day the electrode head and 
stirrer were detached and scrubbed thoroughly using hot water and liquid detergent, 
followed by a distilled water rinse. The glass indicating electrode was placed in 
standard pH 4 buffer solution and the calomel pH reference electrode in a solution of 
saturated potassium chloride for overnight storage. The titrator reservoir was flushed 
twice using distilled water and then refilled with the same.
Processing of standard pH-stat assay results.
The assay gave readings of the volume of titrant used per unit time, which 
corresponded to protons released from fatty acid on a one to one molar basis. By 
assuming each triglyceride molecule underwent hydrolysis to form two fatty acids and 
a monoglyceride molecule, and that all free fatty acids were ionized, it was possible to 
determine the percentage of triglyceride digested out of the total initially present. For 
tributyrin the calculation was based on complete hydrolysis to three fatty acids and 
glycerol. Hydrolysis of tributyrin to completion was assumed as fatty acids with a
short chain length are known to be rapidly cleaved, especially in vitro in the presence 
of bile salts119.
To perform the calculations the initial weight of triglyceride used in each experiment 
was adjusted for purity, if known, followed by determination of the total fatty acid 
available for possible hydrolysis by lipase. The volume of sodium hydroxide titrant 
recorded at each time point was converted to the corresponding concentration of 
neutralized free fatty acids. The percentage of triglyceride digested out of the total 
initially present was then determined from the concentration of free fatty acids. The 
percentage of triglyceride digested or amount of fatty acid neutralized was plotted 
against time to produce a progress curve of lipase activity referred to in future text as 
a digestion profile.
2.3 Assessment of lipase activity of pancreatin.
The source of lipase used in the standard pH-stat assay was pancreatin obtained from 
porcine pancreas. Pancreatin contains lipase, the enzyme responsible for hydrolysis of 
triglyceride in the duodenum together with the required cofactor, colipase. Porcine 
pancreatin was selected as a substitute for human pancreatin as both porcine 
pancreatic lipase and colipase have been described as displaying a high degree of 
sequence homology to the human derived source30,120 with a similar pH-activity 
profile121.
Due to the crude, variable nature of pancreatin certain minimum standards of activity 
are set. For batch I to IQ of pancreatin used in this study the supplier specified a 
minimum lipase activity of at least to the United States Pharmacopoeia (USP) 
specification122. The supplier of batch IV pancreatin stated compliance with the 
British Pharmacopoeia (BP) 1968 standard for pancreatin123 which was based on 
assessment of pancreatin activity towards triacetin. Martindale124 provides a 
conversion factor for the BP 1968 standard to the BP 1980 standard. The USP and 
BP 1980 standards are both based on the rate of hydrolysis of olive oil and the 
potency of one USP unit is stated as approximately equivalent to the BP unit of lipase 
activity124. Based on these figures the minimum activity of batch IV pancreatin per mg
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is 6.15 units compared to batch I to ID pancreatin with a minimum activity of 2 units 
per mg.
As no information was available regarding maximum activity a more specific measure 
of lipase activity was required to ensure equivalence between batches of pancreatin 
used throughout this thesis. Pancreatin activity was thus assessed using a tributyrin 
substrate. Tributyrin is an ideal substrate to measure lipase activity41,125 as it yields 
completely ionized water-soluble products under alkaline conditions (pH 8 to 9).
Although tributyrin is hydrolyzed between two to ten times faster than long chain 
triglyceride a linear reaction rate is normally maintained for a sufficient time period to 
assess maximum activity. Tributyrin has additional advantages over long chain 
triglycerides in that it emulsifies spontaneously in dilute sodium chloride solution 
removing the need for emulsifier. Inhibition of lipase activity due to emulsifier at the 
substrate / water interface is thus avoided as is any interference from bile salts which 
can modify the pK values of essential ionizable groups on the enzyme and shift the 
optimum pH of lipase.
For each batch of pancreatin (batch I-IV), maximum lipase activity was assessed 
according to the procedure described below.
2.3.1 Method
Lipase activity of pancreatin was standardized titrimetrically at pH 8.5 and 25°C using 
a continuous pH-stat technique and a tributyrin emulsion (3.6 g tributyrin in 100 ml 
buffer containing 50 mM tris-maleate pH 8.5, 5 mM calcium chloride dihydrate and 
150 mM sodium chloride). The pancreatin was prepared as a suspension in distilled 
water (150 mg / 3 ml), mixed by vortexing and incubated for 20 minutes at 25°C 
followed by a second thorough mixing before use.
100 ml of tributyrin emulsion and 25 mg of pancreatin (0.5 ml of suspension) were 
used for each assay. These reagents were stirred continuously whilst the pH was 
maintained constant with 1 M sodium hydroxide. The volume of titrant used was 
recorded every 15 seconds for 12 minutes. The highest volume of titrant used over
four consecutive readings corresponded to the maximum catalytic potential of the 
enzyme per minute under conditions of the assay.
2.3.2 Results
The enzyme activity determined for each batch of pancreatin is shown in Table 2.1. 
One tributyrin unit (TBU) of lipase activity is defined as the liberation of one 
micromole of butyric acid from a substrate of tributyrin per minute under conditions 
of the assay. For the purpose of this work the specific activity of pancreatin (number 





Specific activity of pancreatin 
(Maximum No. of TBU 
per mg per minute).
I Sigma 13H0347 9.6
n Sigma 14H0877 obtained 10/95 8.0
Ha Sigma 14H0877 obtained 6/96 8.8
III Sigma 53H0442 8.0
IV BDH Not stated 9.2
Table 2.1 Specific activity determined for each batch of pancreatin used in the 
standard pH-stat assay.
A minimal difference in lipase activity was noted between pancreatin batches in terms 
of the number of TBU per mg of pancreatin however the significance of the parameter 
of TBU was unknown in relation to the rate of digestion of medium and long chain 
triglycerides intended for use in the standard pH-stat assay. To assess the difference 
between pancreatin batches when acting upon MCT (1 g) the standard pH-stat assay 
was performed using each batch of pancreatin. Results from this investigation are 
shown in Figure 4.8 (section 4.4.3) where the difference in activity between the 
various batches of pancreatin was concluded to be minimal.
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2.4 Selection of a triglyceride substrate.
The main criteria for selection of a triglyceride suitable for use in the standard pH-stat 
assay was availability to the hydrolytic activity of pancreatin. This was to ensure that 
any inhibition of enzyme activity due to the presence of surfactant could easily be 
detected. A preliminary investigation was performed to assess the availability of a 
range of triglycerides to hydrolysis by pancreatin. A known weight of triglyceride 
(approximately 0.45 g) was digested under conditions of the standard pH-stat assay 
for a period of 60 minutes. For certain triglycerides the digestions were replicated.
2.4.1 Results and discussion.
The quantity of triglyceride digested after 60 minutes is shown in Table 2.2 for each 







% total triglyceride 
digested
Tributyrin C4:0 99 302.4 98 (at 66 minutes)
Triolein Cl8:l 65 885.4 56, 54, 53, 61, 55.
LCT Cl8:i 25% 
Cl8:2 51%
- 870.86* 40, 38.
MCT C8 60 % 
Cio 40 %
99.7 503.6# 92, 90.
Table 2.2 Percentage of the total triglyceride digested within a 60 minute period, 
for a range of triglycerides.
* Calculated using average fatty acid composition for Soya bean oil126.
# Calculated using average fatty acid composition for Miglyol® 812127.
To enable comparison between experiments the results were expressed as a 
percentage of the total triglyceride present. The various triglycerides were assayed at 
equal weight therefore use of a percentage scale eliminated complications introduced 
by their different molecular weight values and hence molar concentrations.
From examination of Table 2.2 the MCT, fractionated coconut oil was chosen for 
further investigations due to adequate hydrolysis in the assay system, pharmaceutical 
acceptability, high standard of purity, low cost and availability with specified 
proportions of the component fatty acids.
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2.5 Effect of pH on enzyme activity.
In common with other enzymes lipase activity has been demonstrated to vary with 
pH121 j j je optimum pH for lipase activity will depend upon conditions of the reaction 
medium such as the concentration of bile salts128 and ionic strength129. A pH of 6.5 
was proposed for use with the standard pH-stat assay on the basis that it was typical 
of the fasting duodenal pH in healthy subjects130.
Determination of the optimum pH for pancreatin activity under conditions of the 
standard pH-stat assay would enable assessment of the degree of enzyme activity 
remaining at the chosen pH of 6.5. The maximum velocity of pancreatin activity 
towards a substrate of MCT was therefore assessed over a pH range of 5 to 9.
2.5.1 Method
A series of digestion profiles were performed under conditions of the standard pH-stat 
assay, using a substrate of 1 g of MCT. The end-point pH values used ranged from 5 
to 9 at 0.5 increments. Simulated bile solution for each experiment was prepared 
using tris-maleate buffer of a pH value corresponding to the particular reaction end­
point pH. This was achieved by preparing a concentrated solution of tris-maleate 
buffer with sodium hydroxide omitted. The buffer solution was then adjusted to the 
required pH by adding a sufficient quantity of dry sodium hydroxide and made up to 
volume. Before use simulated bile solution was equilibrated to 37°C and the pH 
rechecked to allow any final adjustments with 1 M sodium hydroxide solution if 
required.
2.5.2 Results and discussion.
A digestion profile of product formed, (expressed as millimoles of fatty acid released), 
with time was produced in duplicate for each end-point pH. The gradient of the initial 
linear portion of each digestion profile was used to determine the initial velocity of the 
reaction via linear regression, after ensuring no lag phase (described in section 3.3.3) 
was present at the start of the reaction.
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Figure 2.1 demonstrates the dependence of pancreatin activity on pH of the reaction 
mixture when hydrolyzing a substrate of MCT. The optimum pH for pancreatin 
activity under conditions of the standard pH-stat assay was approximately 7.5, 
indicated by the apparent maximum initial velocity observed of 0.345 mmol min'1 
(Figure 2.1). For a pH end-point of 6.5 the initial velocity fell to 0.19 mmol min"1 
which represents a 45 % reduction in enzyme activity compared to the apparent 
maximum possible.
When the digestion profiles were examined in terms of the percentage of MCT 
digested after 60 minutes (results not shown) this was also noted to vary with pH. For 
a pH of 6.5, 83 % of the total triglyceride present had been digested whereas at pH
7.5 this figure increased to 103 %. When using the optimum pH for pancreatin 
activity (pH 7.5) some triglyceride appears to have undergone complete hydrolysis to 
fatty acids and glycerol. This may be explained by the high rate of enzyme activity 
coupled with a high degree of emulsification conferred by the presence of bile salt. 
Although triglyceride hydrolysis has been stated as likely to proceed to completion in 
vitro, this situation would be unlikely in vivo due to mechanisms available for 
absorption of monoglycerides119.
Although the reaction kinetics of pancreatin are dependent upon pH, under conditions 
of the standard pH-stat assay (a pH of 6.5) pancreatin had sufficient activity to enable 
assessment of hydrolytic behaviour towards various substrates.
An explanation for the observed decrease in enzyme activity away from the optimum 
pH of 7.5 may involve change in the ionization status of ionic groups present in the 
enzyme or substrate117. If these ionic groups are not in the required ionic form, 
alteration in conformation of the active site, enzyme / substrate binding or catalytic 
ability may occur with a resultant decrease in enzyme activity or enzyme inactivation. 
In the case of porcine pancreatic lipase the catalytic triad of the active site of the 
enzyme is known to be composed of ionizable amino acid residues, serine, aspartic 
acid and histidine26. Early workers41 with porcine pancreatic lipase suggested a 
requirement for the histidine residue to be ionized in order to achieve the maximal rate 
of hydrolysis of tributyrin. They quoted a pKa value for histidine in their system of 5.8 
although the exact pKa values can be influenced by the environment of the enzyme.
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The pH of the environment in which an enzyme is present can cause irreversible 
enzyme inactivation and this is known to occur with porcine pancreatic lipase at pH 
values lower than 5131. As lipase activity in Figure 2.1 varies when pH is raised above 
5, the ionic state of residues in the active site is suggested as more likely to be 
responsible. This could be confirmed by further experimentation involving pre­
incubation of the enzyme for a period equal to the length of the assay at various pH 
values before commencing digestion at pH 7.5. If the reaction rate was reduced this 
would indicate pH related enzyme inactivation. However as the work described here 
was carried out to investigate the appropriate nature of the assay conditions rather 
than to characterize the enzyme this investigation was not performed.
A further consideration is the possible influence of the ionic strength of the buffer, 
(used to prepare the simulated bile solution), upon the pH activity profile (Figure 2.1). 
The tris-maleate buffer contained varying concentrations of sodium hydroxide to 
adjust the pH resulting in higher ionic strength for the more alkaline solutions. To 
correct for this each solution could have been brought to a constant ionic strength by 
adding the appropriate quantity of a neutral non-inhibitory salt, however this would 
have further altered reaction conditions from those of the standard pH-stat assay.
2.6 Selection of enzyme concentration.
For an enzyme reaction taking place in solution, the initial velocity of the reaction 
should be proportional to the enzyme concentration (Equation 2.1)109.
v = k\E \ Equation 2.1
If this is the case a linear relationship should be obtained which passes through the 
origin indicating zero activity at zero enzyme concentration. If the relationship 
deviates from linearity this is usually a result of the assay system although it can 
sometimes be due to a property of the enzyme132.
The relationship between pancreatin concentration and initial velocity was examined 
to ensure no interference was present from the standard pH-stat assay system. This 
approach also enabled the enzyme concentration selected for use in the standard pH-
stat assay (250 mg of pancreatin) to be examined in terms of initial velocity compared 
to that shown by higher quantities of pancreatin.
2.6.1 Method
A series of digestion profiles were produced under conditions of the standard pH-stat 
assay using a fixed substrate concentration of 1 g of MCT and varying concentrations 
of pancreatin. As a quantity o f250 mg of pancreatin had been proposed for use in the 
standard pH-stat assay, the enzyme concentrations chosen for use in this investigation 
spanned a range from 62.5 mg up to 500 mg. The enzyme suspension was prepared in 
the normal manner with adjustments for strength made by varying the volume of 
distilled water. This ensured minimal variation in the volume of enzyme suspension 
added to each assay (between 0.5 to 1.25 ml). The series of digestion profiles were 
performed for both batch I and II of pancreatin.
2.6.2 Results and discussion.
The initial velocity of each digestion profile was determined as described in section
2.5.2 and is shown as a function of enzyme concentration in Figure 2.2 for batch I and 
II of pancreatin. A linear relationship between initial velocity and pancreatin 
concentration was shown by batch II of pancreatin (r2 = 0.9985) if the result obtained 
using 500 mg of pancreatin was disregarded.
As the velocity of a reaction is known to vary with substrate concentration, the initial 
velocity should be determined from the gradient of the digestion profile when only 5 
% or less of the substrate has been used133. This approach ensures that initial velocity 
is a true value and not limited by substrate availability. For the high pancreatin 
concentration of 500 mg (batch n) 13.35 % of MCT had been utilized 2 minutes after 
commencing the assay. This reaction was too fast to enable accurate measurement of 
the true initial rate which probably accounts for deviation of this result from the linear 
relationship displayed by the lower enzyme concentrations.
The data obtained using batch I pancreatin indicated an apparent maximum initial 
velocity, first evident at an enzyme concentration o f250 mg (Figure 2.2). Non­
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linearity between initial velocity and concentration of batch I pancreatin may be due to 
error in determination of initial velocity. For profiles produced using batch I 
pancreatin intervals of 5 minutes were used to record titrant volumes which resulted 
in high substrate utilization (11 to 37 %) before the first volume was recorded. These 
readings were too widely spaced to give accurate results with substrate concentration 
probably limiting initial velocity. For profiles produced using batch II pancreatin 
titrant recordings were taken every minute for the first 20 minutes and thereafter 
every 5 minutes which appeared to reduce this source of experimental error.
When considering the suitability o f250 mg of pancreatin for use in the standard pH- 
stat assay, concentrations above 250 mg gave a faster initial rate of digestion. 
However the total percentage of triglyceride digested after 60 minutes remained the 
same with approximately 80 % digestion shown by both batches at concentrations of 
250 mg and above (results not shown). Therefore 250 mg of pancreatin was 
concluded to be appropriate for use in the standard pH-stat assay due to the smooth 
digestion profile produced which displayed the maximum extent of digestion possible 
at pH 6.5 within the 60 minute assay.
2.7 Stability of pancreatin and other assay components.
To ensure validity of results from the standard pH-stat assay, control experiments 
were performed to assess stability of all assay components throughout the duration of 
the assay.
2.7.1 Pancreatin
In the case of pancreatin, enzyme activity and stability was assessed with respect to 
time and in the presence of other assay components. To examine the intrinsic activity 
of pancreatin over the total assay period of 80 minutes pancreatin was reconstituted in 
the normal manner and then left for pre-incubation periods of 0,40 and 60 minutes 
instead of the usual 20 minute period. Immediately following the period of pre­
incubation the pancreatin solution was used to digest 1 g of MCT under conditions of 
the standard pH-stat assay.
To determine if any of the assay components affected enzyme stability, experiments 
were performed whereby instead of reconstituting the enzyme with distilled water as 
in the standard pH-stat assay, the enzyme was reconstituted using buffer, simulated 
bile solution and simulated bile solution mixed with a non-ionic surfactant 
(Cremophor 0.5 % w/v). The pancreatin solution was then pre-incubated for 20 
minutes and used to digest 1 g of MCT under conditions of the standard pH-stat 
assay.
Results and discussion.
The dependence of pancreatin activity on the duration of the pre-incubation period 
used for the pancreatin suspension is illustrated in Figure 2.3. Although the rate of 
digestion was slightly reduced as the pre-incubation period was increased, after 40 
minutes all profiles displayed a similar percentage of triglyceride digestion (Figure 
2.3).
When the time taken to digest a specified percentage of MCT was determined from 
the digestion profiles in Figure 2.3 and displayed as a function of pre-incubation time 
(Figure 2.4), the difference in time taken for digestion can be seen to be minimal. The 
results showed enzyme activity to be virtually unchanged when using a pre-incubation 
period of 20 minutes compared to the digestion rate when the pre-incubation stage 
was omitted (Figure 2.4).
The effect of reconstitution of pancreatin with solutions containing various assay 
components as opposed to the normal medium of distilled water is illustrated in 
Figure 2.5. The resulting digestion profiles (Figure 2.5) suggest close contact of 
enzyme solution during pre-incubation with buffer components, bile salts, lecithin and 
non-ionic surfactant did not inhibit subsequent pancreatin activity towards a substrate 
of MCT. This result could be used to support the assumption that pancreatin was also 
stable when in the presence of the same components in the bulk reaction vessel.
2.7.2 Substrate of MCT.
An investigation was designed to examine the stability of the substrate (MCT) and 
simulated bile solution when combined together over the total assay period. MCT (1
g) was mixed with simulated bile solution and left in the reaction vessel with the 
stirrer unit operational for 80 minutes to represent the pre-incubation period and 
duration of the assay. The reaction mixture was then digested under conditions of the 
standard pH-stat assay.
Results and discussion.
Figure 2.6 demonstrates the stability of MCT and simulated bile solution when 
combined and left for a period equivalent to the total duration of the assay before 
commencement of digestion. Pancreatin activity towards MCT which had undergone 
a prolonged stirring period of 80 minutes and the same substrate under conditions of 
the standard pH-stat assay was identical. The conclusion can therefore be drawn that 
MCT remains stable in the presence of simulated bile solution throughout the total 
assay period.
2.7.3 Extent of triglyceride digestion.
When digesting MCT (1 g) under conditions of the standard pH-stat assay the total 
percentage of triglyceride converted into monoglyceride and two fatty acids did not 
exceed 80 % (Figures 2.3, 2.5-6). The reason for this was unknown although enzyme 
activity or stability may decrease as the concentration of lipolytic products in the 
vessel is increased.
Bile salts and lecithin have been suggested to decrease fatty acid concentration within 
an in vitro system by solubilization of lipolytic products into mixed bile salt and 
lecithin micelles134. Failure to achieve total triglyceride digestion in the in vitro 
standard pH-stat assay may thus relate to insufficient concentrations of bile salt and 
lecithin in the simulated bile solution to solubilize all fatty acids released.
An investigation to determine if the concentration of bile salt and lecithin used in the 
standard pH-stat assay was limiting the extent of triglyceride digestion was therefore 
performed. Simulated bile solution was prepared in the normal manner to contain 
double (bile salt 16 mM, lecithin 3.2 mM) and half (bile salt 4 mM, lecithin 0.8 mM) 
the concentrations of bile salt and lecithin present in the standard simulated bile
solution. The resulting simulated bile solutions were then used to perform a digestion 
of 1 g of MCT under conditions of the standard pH-stat assay.
To determine if enzyme activity was reduced with time due to presence of lipolytic 
products in the reaction mixture 3g of MCT was digested under conditions of the 
standard pH-stat assay for 120 minutes. Fresh enzyme solution containing 250 mg of 
pancreatin (prepared in the normal manner) was added to the reaction mixture 120 
minutes after the start of the assay and then left to digest for a further 20 minutes.
Results and discussion.
From Figure 2.7 it can be seen that altering the concentrations of bile salt and lecithin 
present in simulated bile solution does not alter the extent of triglyceride digestion or 
the rate of pancreatin activity towards 1 g of MCT. This result suggests that bile salt 
concentration is not a limiting factor in the standard pH-stat assay in terms of 
desorption of lipolytic products from the interface and subsequent solubilization into 
micelles.
When using an increased quantity of MCT (3 g) only 52 % of the total triglyceride 
present was digested after 120 minutes (Figure 2.8). When fresh pancreatin (250 mg) 
was added to the reaction vessel 120 minutes after assay commencement a further 4 
% of triglyceride was digested over a 20 minute period.
From comparison with the usual total percentage of triglyceride digestion (80 %) 
achieved with 1 g of MCT, Figure 2.8 suggests that as substrate concentration is 
increased the total percentage of triglyceride digested is reduced. Lack of substrate is 
therefore not responsible for the decline in enzyme activity which also seems unlikely 
to be a result of enzyme degradation with time as fresh enzyme also showed reduced 
activity. The inhibition of further pancreatin activity towards the remaining 
triglyceride is probably a form of product inhibition caused by a higher fatty acid 
concentration in the vessel than is reached with 1 g of MCT.
A final point for consideration is the percentage of the liberated fatty acids in an 
ionized state at the pH of the reaction mixture. Only fatty acids in an ionized state will 
be available for detection by a titrimetric method, with the percentage of ionized fatty 
acid dependent upon fatty acid pK value. Long chain fatty acids have been noted to be 
incompletely ionized at slightly acidic pH values125 such as those found in the
duodenum and this is also likely to be the case for the medium chain fatty acids 
present in this system.
The pK value of long chain fatty acids has been demonstrated to decrease when 
calcium ion and ionic strength of the system was raised134. To increase the percentage 
of fatty acids ionized when titrated under conditions of the standard pH-stat assay the 
calcium ion concentration and / or ionic strength of the simulated bile solution could 
have been increased to depress pK values. However this approach was inappropriate 
due to the need to represent physiological conditions.
A correction factor could be used to determine the actual reaction rate from the pH- 
stat responses by calculation of the percentage of fatty acids ionized using the medium 
chain fatty acid pK value134. Determination of pK values under conditions of the 
standard pH-stat assay was not performed as results from digestion profiles were 
required for comparison of the influence of surfactants on digestion rather than 
absolute values of digestion. The adequate percentage of MCT digestion recorded (80 
% at pH 6.5) without the application of a correction factor was considered sufficient 
to make this comparison.
2.8 Investigation of blank rate.
A blank rate is the existence of an apparent rate of reaction within an assay system 
which is not due to the monitored reaction132. If the blank rate is significant its source 
needs to be understood and the extent quantified so that appropriate corrections can 
be made. In the case of the standard pH-stat assay, volume of titrant recorded should 
be directly related to release of fatty acid from triglyceride with no interference from a 
blank rate.
To examine the system for the existence of a blank rate the standard pH-stat assay 
was performed with various components eliminated in turn. These control 
experiments revealed a blank rate to occur only when enzyme was present in the 
system. Upon addition of pancreatin to tris-maleate buffer an immediate drop in pH 
was seen followed by no further release of titrant over a 60 minute period. The initial 
drop in pH was corrected within a couple of seconds by titration of 0.02 ml sodium 
hydroxide (1 M) and this volume remained constant for all experiments performed. A
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possible reason for the reaction rate detected could be acidity of the enzyme 
suspension or endogenous substrate material contained within it.
Upon addition of pancreatin to simulated bile solution a blank rate totalling 0.05 ml of 
sodium hydroxide 1 M occurred during the 60 minute assay which was slightly higher 
than the blank rate observed for pancreatin with tris-maleate buffer. This suggests a 
component of the simulated bile solution, most probably lecithin, to be responsible for 
the increase in blank rate. The knowledge that pure porcine pancreatic lipase, in the 
presence of bile salts, is able to hydrolyze the sn-1 ester bond of egg lecithin131 gives 
further weight to this theory.
Further experimentation revealed the blank rate to be constant therefore correction 
could be made by subtraction from the assay results. In the case of the kinetic studies 
performed in this work subtraction would be inappropriate as the blank rate obtained 
is part of the integral enzyme activity, thus to discount it would result in 
underestimation of the enzyme activity. For the non-kinetic work subtraction was also 
considered unnecessary due to the minimal and constant nature of the blank rate 
compared to the overall titrant volume recorded.
2.9 Conclusions
The standard pH-stat assay of lipolysis described in this chapter was considered 
suitable to determine the availability of triglyceride to lipase, present in the assay in 
the form of porcine pancreatin. The optimum pH for pancreatin activity under 
conditions of the assay was pH 7.5, although a value of 6.5 was used for the standard 
pH-stat assay as this was more representative of conditions in the duodenum. The 
percentage of MCT hydrolyzed by pancreatin under conditions of the standard pH- 
stat assay was sufficient to allow observation of possible inhibition of enzyme due to 
the presence of surfactants in future work.
Components of the assay system remained stable for an assay duration of 60 minutes. 
The concentration of bile salt and lecithin used in the simulated bile solution had little 
influence on the rate and extent of triglyceride digestion within the range tested. 
Distortion of results from the standard pH-stat assay due to blank rates were minimal





























Figure 2.1 Effect of pH on the initial velocity of pancreatin-catalysed 
digestion of MCT.
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Figure 2.2 Effect of pancreatin concentration on the initial velocity of 
pancreatin-catalysed digestion of MCT.
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Figure 2.3 Effect of pancreatin pre-incubation time on the rate and extent of
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Figure 2.4 Effect of pancreatin pre-incubation on time taken to digest a 
specified percentage of MCT.
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Figure 2.5 The effect of method used to reconstitute pancreatin on rate and extent 
of digestion of MCT.
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Figure 2.6 Stability of substrate and simulated bile solution throughout the 
duration of the standard pH-stat assay.
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□
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Figure 2.7 Influence of bile salt and lecithin concentration on the rate and extent of 
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Chapter 3 - Determination of the kinetic parameters Km and Vmax for pancreatin 
acting upon MCT alone and in the presence of the surfactant, Cremophor
RH40.
3.1 Introduction
Lipid-based formulations commonly include one or more surfactants to enhance 
dispersion of the formulation in the GI fluid. Certain surfactants have been found to 
be inhibitory towards pancreatin activity108; a property which could result in 
prevention of in vivo digestion of lipid in the formulation. As lipid digestion is 
proposed to be an important mechanism of enhanced hydrophobic drug bioavailability 
from lipid-based formulations1 use of surfactants which do not inhibit pancreatin is to 
be preferred. To enable avoidance of surfactants with potent properties of enzyme 
inhibition a means of classifying surfactants according to inhibitory behaviour in this 
respect would be advantageous.
Pancreatin activity towards a substrate of MCT can be characterized in terms of the 
kinetic parameters Km and Vmax. These parameters, derived from the Michaelis- 
Menten relationship135, describe the relationship between the initial velocity of 
pancreatin activity upon MCT and the concentration of MCT present. Km and Vmax 
are of a constant value for a particular enzyme acting under specified reaction 
conditions, therefore when a surfactant capable of interfering with pancreatin activity 
is included with MCT in the reaction system Km and Vmax values will change 
accordingly.
The change in parameter values reflects the altered relationship between initial 
velocity and MCT concentration due to the presence of an inhibitory surfactant. The 
effectiveness of the inhibitor can be defined by an inhibitor constant (ki)109. Therefore 
determination of ki values in vitro for each surfactant would provide guidance with 
regards to their likely inhibitory potency towards lipase in vivo. This information 
would be useful when selecting a surfactant for inclusion in a lipid-based formulation.
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A discussion of special factors for consideration when performing kinetic studies with 
an enzyme such as lipase, which acts at the interface of an insoluble substrate is given 
in section 3.1. Section 3.2 provides a description of the theoretical basis of the 
Michaelis-Menten relationship. This is followed by determination of the kinetic 
parameters Km and Vmax for pancreatin acting upon MCT under conditions of the pH- 
stat assay. The second stage of the investigation (section 3.3-3.6) involves an attempt 
to determine Km and Vmax when a non-ionic surfactant, (Cremophor RH40, referred to 
hereafter as Cremophor) known to inhibit pancreatin was included in the assay.
3.1.1 Kinetic studies involving enzymes which act at an interface.
When investigating the kinetic behaviour of lipase it is necessary to bear in mind that 
lipolysis occurs within a heterogeneous system whereas the concepts of enzyme 
kinetics are based on an homogeneous system. An homogeneous system is one in 
which the enzyme and substrate are freely soluble in an aqueous environment with 
enzyme specificity solely related to the chemical nature of the substrate.
Within a system where lipolysis is taking place a soluble enzyme acts upon an 
insoluble substrate at a lipid-water interface. The nature of lipolysis means that the 
specificity of the enzyme is related to the state of the substrate at the interface as well 
as the affinity of the active site of the enzyme for a single substrate molecule136. As 
binding of the enzyme to the interface is a separate step from the catalytic reaction 
classical Michaelis-Menten kinetics may not apply. Issues regarding the involvement 
of a lipid-water interface in the catalytic process of lipolysis have been subject to an 
extensive review by Brockman136, the main points of which are discussed in the 
following text.
In order for lipolysis to occur the substrate needs to be present at a concentration 
exceeding its solubility in the aqueous medium to create an interface. The interfacial 
area of substrate available for enzyme to bind is also relevant to the rate of lipolysis. 
This interfacial requirement of lipase may in fact be advantageous to enzyme activity 
as it helps to ensure enzyme and substrate accumulate together in high concentrations 
within a limited area for kinetic activity137.
The velocity of a lipolytic reaction would be expected to relate to the ratio of enzyme 
to substrate interfacial area rather than substrate concentration in the bulk reaction 
mixture. If the substrate concentration is expressed in units of area / volume lipase 
activity is related to the interfacial area available. However the situation is 
complicated by partitioning of substrate from the bulk substrate phase into the 
interface which in turn relates concentration at the interface back to that present in the 
bulk phase.
The concentration of triglyceride available at the interface for lipolysis has been 
reported to be as low as 2 to 5 % with the amount decreasing with time138. However 
as lipolysis continues the lipid core of the emulsion droplets helps to maintain a rapid 
equilibrium between lipid in the bulk and surface phase to ensure replenishment of 
interfacial triglyceride. Diglycerides will accumulate at the interface in preference to 
triglyceride due to their higher surface activity conferred by the free hydroxyl group, 
however these will quickly be removed by rapid hydrolysis.
For the work carried out in this study weight / volume units were selected to express 
substrate concentration as opposed to units which define the interfacial area. This was 
due to the selection of an emulsion formulation for the substrate. Measurements of 
interfacial area for an emulsion system are difficult to determine136 as are the lipid 
composition, lipid packing and surface pressure for such an interface139.
The intended examination of the effect of surfactants on the kinetic parameters of 
pancreatin also argues against the use of interfacial area as a parameter. The addition 
of surfactant to a reaction system would be expected to cause an apparent increase in 
interfacial area due to incorporation of some surfactant molecules into the lipid 
interface. The parameter of interfacial area would therefore no longer solely represent 
the substrate concentration136, hence comparison between kinetic parameters from 
substrates of MCT alone and in the presence of surfactant would not be possible.
3.1.2 Nature of the interface.
An interface which separates two bulk phases can be considered to be a two- 
dimensional surface known as the surface phase136. The surface phase will not be an 
homogeneous region and can coexist with other surface phases if more than two bulk
phases are present. Even a pure surface phase composed of a single component will 
not necessarily have all the molecules in the same conformation. When a surface phase 
has two or more components there are numerous modes of molecular interaction. The 
types of arrangements can range from immiscible to completely miscible, with changes 
in arrangement possible due to variations in the stoichiometry.
When the concept of surface phases is applied to a lipid-water interface it becomes 
evident that a lipid substrate presented as an emulsion will be composed of at least 
two distinct bulk phases140 with surface phases between. The substrate and enzyme 
will partition between the bulk and surface phases along with digestion products 
produced as the substrate starts to undergo lipolysis. As the reaction proceeds 
substrate, enzyme and digestion products will undergo partitioning between different 
bulk and surface phases and their position will change with respect to time.
Factors which may affect partitioning include changes in interfacial tension, lipid 
packing arrangements, substrate concentration and area of interface available to 
lipase, all of which are altered due to the generation of lipolytic products. Lipase itself 
in vitro will not be present in high enough concentration to have a significant physical 
effect on phase distribution.
The arrangement or conformational state of the substrate at the surface phase will 
influence substrate availability for lipolysis141 and hence affect the kinetic behaviour of 
lipase. Lipolysis may be limited to particular types of surface phases, have specific 
rates of activity for different surfaces or occur only at phase boundaries making 
reaction rates for lipolytic enzymes difficult to interpret.
3.1.3 Presentation of the substrate as an emulsion.
When investigating the kinetic activity of lipase the results will be influenced by the 
chosen experimental method as different techniques can alter physicochemical 
properties of the substrate and hence enzyme activity. For this work an indication of 
enzyme activity which could be related to the physiological situation was desired. 
Presentation of the triglyceride substrate as an emulsion allowed lipase to be in 
contact with substrate in a reaction mixture representative of in vivo conditions, as 
alimentary triglyceride upon ingestion forms a fat rich emulsion.
Under conditions of the standard pH-stat assay used in these kinetic studies the 
triglyceride is initially mechanically dispersed into simulated bile solution to produce a 
crude emulsion. Lecithin contained within simulated bile solution provides a degree of 
emulsification which is further enhanced by the digestion products released as lipolysis 
proceeds. The triglyceride therefore becomes increasingly emulsified over the course 
of the lipolysis reaction. This is similar to the in vivo situation where emulsion 
droplets have a core of non-polar lipids with a surface monolayer of amphiphiles. This 
monolayer usually consists of lipolytic products and phospholipids which create a 
mixed lipid film necessary to lower interfacial tension and prevent droplet 
aggregation. Bile salts are also present but these have little emulsification properties 
towards triglyceride142.
In addition to the close representation of in vivo conditions given by use of an 
emulsion, a further advantage is the large interfacial area an emulsion provides. The 
interfacial area is the major factor which will influence the observed kinetic activity of 
lipase143, regardless of different kinetic behaviour at various surface types. Providing 
sufficient interfacial area for all enzyme molecules to adsorb to the surface will result 
in determination of the maximal catalytic rate. The surfaces and stirrer of the reaction 
vessel also increase surface area available to lipase and may even enhance enzyme 
activity.
The special considerations necessary for kinetic studies involving lipase resulted in the 
following approach with regards to the methodology employed with this work. Due 
to the need for lipase to bind to a triglyceride interface before digestion can 
commence the triglyceride substrate was presented as an emulsion. This method of 
substrate presentation helps to maximize interfacial area available for lipase binding. 
The concentration of triglyceride present in each digestion performed was expressed 
in units of bulk concentration as these were easy to determine and not influenced by 
the presence of surfactant if included in the system.
3.1.4 Outline of this investigation.
With all the issues related to kinetic behaviour of lipase in mind a pragmatic approach 
was needed. It was decided in this study to investigate whether traditional enzyme 
kinetic equations could be applied to lipolysis of an emulsion system.
The study was designed to investigate the kinetic behaviour of pancreatin when 
digesting a MCT, (represented by Miglyol® 812), under conditions of the standard 
pH-stat assay. The behaviour of pancreatin was defined by determination of apparent 
values for the parameters, Km and Vmax. These parameters describe a hyperbolic 
relationship between initial velocity of an enzyme reaction and substrate concentration 
and are discussed further in section 3.2.
Inclusion of the surfactant Cremophor in the reaction system with MCT was known 
to inhibit pancreatin activity from preliminary studies. A further investigation was 
therefore designed to determine Km and Vmax values when Cremophor was included in 
the substrate emulsion. A knowledge of these apparent parameters was intended for 
further studies involving quantification of the potency of inhibition of various 
surfactants towards pancreatin.
The investigations carried out in this chapter are summarized below:
• Determination of Km and Vmax for pancreatin when acting upon MCT.
• An attempt to determine Km and Vmax for pancreatin when acting upon MCT in the 
presence of Cremophor. The experimental results were examined for information 
regarding the type of inhibition mediated by Cremophor.
• The effect of different batches of pancreatin on MCT hydrolysis in the presence of 
Cremophor.
• The effect on initial rate determinations of using 0.1 M NaOH as titrant in the 
standard pH-stat assay instead of the standard 1 M NaOH.
• The effect of the method of preparation used for the reaction mixture upon the rate 
of MCT hydrolysis.
3.1.5 Materials
As for Chapter 2 (section 2.2.1) plus
Cremophor RH40 (USP name-Polyoxyl 40 Hydrogenated Castor Oil)
Cremophor RH40 is a non-ionic surfactant described as a hydrogenated castor oil 
ethoxylate with a stated144 average of 45 ethoxy groups per molecule and a HLB 
value of between 14 to 16. The general structure for a castor oil ethoxylate is 
illustrated in section 4.8.
Cremophor RH40 is produced by reacting 45 moles ethylene oxide with one mole of 
hydrogenated castor oil. This results in a composite product with glyceryl 
polyethylene glycol oxystearate and fatty acid glycerol polyglycol esters comprising 
the hydrophobic portion. The hydrophilic part consists of polyethylene glycol (PEG) 
and glycerol ethoxylate.
3.2 Determination of the kinetic parameters, Km and Vmax for pancreatin 
acting upon MCT.
3.2.1 Introduction
The kinetic parameters Km and Vmax are useful to describe the properties of an 
enzyme catalysed reaction. They describe the shape of a rectangular hyperbola 
predicted by the Michaelis-Menten equation135 for a particular enzyme acting under 
specified reaction conditions.
The Michaelis-Menten equation (Equation 3.1) relates the rate of substrate utilization 
or product formation (v - hereafter referred to as velocity) of an enzyme reaction to 
the initial substrate concentration (5) present.
V mix S  .v = --------  Equation 3.1
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Km and Vmax are constants of this rectangular hyperbola relating velocity to substrate 
concentration. Vmax is the maximum velocity of the reaction when the substrate
concentration is saturating the enzyme. Km is the Michaelis constant describing the 
substrate concentration at which the reaction proceeds at half its maximum initial 
velocity. The following assumptions145 are made during the derivation of the 
Michaelis-Menten equation:
• The initial rate measurement is made in the steady state when the concentration of 
enzyme-substrate complex is unchanging.
• The rate of the reverse reaction is negligible during the initial rate measurement 
period.
• The formation of enzyme-substrate complex does not significantly deplete the 
concentration of free substrate.
If these assumptions are valid then the initial portion of the progress curve 
representing the enzyme reaction will exhibit linear behaviour. The gradient of the 
linear portion is taken to be the initial velocity. This ensures that a steady-state has 
been reached when velocity is measured and any reverse reaction is negligible. To 
ensure that formation of enzyme / substrate complex does not deplete the substrate 
concentration a check should be made to ensure velocity is linearly proportional to 
enzyme concentration. Linearity between velocity and enzyme concentration for 
pancreatin activity upon MCT has already been discussed and demonstrated in 
Chapter 2.
The aim of this work was to characterize pancreatin activity, (represented by the 
initial velocity of the enzyme), towards a substrate of MCT, in terms of and Vmax- 
Progress curves of digestion of MCT by pancreatin (hereafter referred to as digestion 
profiles) were performed over a range of substrate concentrations to obtain initial 
velocity measurements. These provide a means of assessing the compliance of 
pancreatin behaviour with the Michaelis-Menten relationship.
The initial velocity of the enzyme reaction was determined under conditions of the 
standard pH-stat assay. This is a direct continuous assay which has the advantage of 
allowing observation of the rate of product formation, namely fatty acid, with respect 
to time. A curve is normally obtained with an initial linear rate which eventually 
declines with time. Any non-linear behaviour at the beginning of the reaction would be
apparent from visualization of the digestion profile reducing error in the estimation of 
initial velocity. Decreased enzyme activity due to a reduction in substrate availability, 
the reaction reaching equilibrium, product inhibition or instability of assay 
components would also be evident.
3.2.2 Method
A series of fourteen digestion profiles of pancreatin acting upon MCT, over a 
concentration range of 2 to 71 mM, were produced under conditions of the standard 
pH-stat assay. To increase the range of the hyperbolic plot of v against s, the substrate 
concentrations were chosen to span at least five times the Km value.
The digestion profiles represented product formed, expressed in terms of fatty acid 
released in millimoles per unit volume, with respect to time. To obtain a measurement 
of initial velocity each digestion profile was inspected to ensure the initial portion was 
linear. The initial rate was then calculated from the gradient of the initial linear portion 
which normally occurred over the first five minutes from the start of digestion. 
Computerized linear regression was employed to calculate the gradient.
3.2.3 Calculation of Km and Vmax.
The initial velocity measurements obtained were used to produce a plot of v against 
v/s (Figure 3.1) known as an Eadie-Hofstee plot146,147. This linear arrangement of the 
Michaelis-Menten equation best reveals fit upon visual inspection between the data 
and a straight line in order to check if the equation applies148. The plot also allows 
qualitative examination of the extent of scatter which relates to accuracy of the assay 
method (representation of error with this plot is distorted making quantitative 
assessment of error difficult149).
Upon visual inspection of the Eadie-Hofstee plot (Figure 3.1), a linear relationship 
was seen to exist (r = -0.9593) between substrate concentration and initial velocity 
indicating that the Michaelis-Menten relationship was applicable despite the 
heterogeneity of the reaction mixture.
There are several methods available for calculation of Vmax and Km values using the 
experimental initial velocity data obtained. With this work two methods were 
selected, the direct linear plot150 and least-squares fit to a hyperbola151, both of which 
can be calculated by a computerized procedure. These methods are preferred to 
methods involving linear transformations of the Michaelis-Menten equation which 
require the use of suitable weighting for each data point.
3.2.3.1 The direct linear plot.
The direct linear plot is created by plotting the substrate concentration used, s, and 
initial velocity value, v, obtained from each digestion profile as an individual pair. The 
v value is plotted onto the vertical axis representing Vmax and the corresponding s 
value onto a negative horizontal Km axis. A straight line is then drawn between the 
two points and extrapolated into ‘Vmax, Km parameter space’.
The resulting straight lines obtained from each digestion profile should all intersect at 
the coordinates of the best fit Km, Vmax values if the data fits the Michaelis-Menten 
relationship exactly. Measuring errors present in experimental data result in different 
intersections being obtained, the coordinates of which each provide estimates of Km 
and Vmax- The median values of the intersection co-ordinates are taken to be the best 
fit Km and V ,^152.
The advantages145 of the direct linear plot include no requirement for a weighting 
scheme, the method is less sensitive to outliers than the least-squares fit method and 
confidence limits can be calculated for Km and Vmax- Only one assumption is made, 
that the error is as likely to be positive as negative.
Results
The s and v pairs obtained from the digestion profiles of pancreatin acting upon MCT 
were used to construct a direct linear plot (Figure 3.2) for illustration purposes. From 
Figure 3.2 a number of different intersections can be seen to occur due to 
measurement error in the data. A computer software package153 was used to calculate 
the coordinates of each intersection and thus determine best-fit median values of Km 
and Vmax- The resulting Km and Vmax values are shown in Table 3.1.
Visual inspection of the direct linear plot will not reveal if the data significantly 
deviates from Equation 3.1, however a qualitative check for deviation had already 
been made by means of the Eadie-Hofstee plot (Figure 3.1).
3.2.3.2Least-squares fit to a hyperbola.
This method involves a computerized least squares fit of a v against s hyperbola to 
experimental data points, resulting in best fit values of Km and Vmax and an estimate of 
their errors. To check assumptions made by the least squares fit method hundreds of 
points are necessary, however if justified the method gives marginally better estimates 
when compared with the more statistically robust direct linear plot.
The following assumptions145 are implicit when using least squares fit method for the 
statistical analysis of enzyme kinetic data:
• Random errors in replicate values of the measured velocity, v, follow a normal 
distribution.
• There is no error in the substrate concentration, s.
• The correct weights are known.
• Fluctuations in the>> values must be independent of any fluctuations in the x  values. 
Results
A curve fitting program154 was used to fit the experimental data from the digestion 
profiles of pancreatin acting upon MCT to Equation 3.1. The resulting fit of the data 
points to a v against s hyperbola is shown in Figure 3.3.
The Km and Vmax values determined by the least squares fit (Table 3.1) are based on 
the presence of a constant absolute measurement error in the data. The existence of 
this homogenous error is an inherent assumption of the least squares fit method which 
is not necessarily true for the data.
The data may exhibit systematic variation of standard deviation which is dependent on 
the value of v, known as constant relative error. Allowance for this heterogeneous 
error would be need to be made by application of additional weighting factors to the
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data. To do this a prohibitively large number of data points are required to confirm 








Direct linear 0.382 0.373 - 0.391 11.6 10.6-12.5
(68 % confidence (68 % confidence
limits) limits)
Least squares fit 0.375 0.008 10.8 0.77
to hyperbola (standard error) (standard error)




Table 3.1 Comparison of parameter values Km and Vmax (for pancreatin acting 
upon MCT) determined using different analytical methods.
3.2.4 Discussion
As expected, the direct linear method and the least squares fit to a hyperbola gave 
different estimates for Km and Vmax when calculated from the same experimental data 
set, however they agreed to within confidence intervals so the difference was not 
significant. In order to analyze this result further another least squares fit was 
performed with weighting applied to the data which presumed existence of a constant 
relative error.
The application of a constant relative error gave values for Km and Vmax (Table 3.1) 
which, when compared with values from the other two methods, were closest to those 
given by the more statistically robust direct linear method. This gave an indication that 
the data exhibits heterogeneous error, describing an increase in measurement error as 
velocity value increases.
Parameter values calculated from the direct linear plot were therefore considered to 
be the most reliable as this method has no requirement for a weighting scheme. This 
was combined with the fact that to use the least squares fit method with confidence 
many more data points were necessary to confirm the correct weighting scheme.
Support for accuracy of the data overall and confidence in the parameter values 
obtained from the direct linear plot and the least square fit is given by Cleland155. 
Cleland stated that reasonably precise estimates of Km and Vmax would have standard 
deviations of less than 10 % of the mean Km and Vmax values. This was found to be 
true for both methods as in the case of the direct linear plot the standard deviation in 
terms of the percent of the mean is 8.19 % for Km and 2.36 % for Vmax, and the values 
from the least squares fit method are 7.16 % for Km and 2.13 % for Vmax- 
The good fit of the experimental data to Equation 3.1 increased similarity of Km and 
Vmax values obtained via the two analytical methods. Therefore the choice of analytical 
method would probably not alter conclusions drawn from the use of Km and Vmax 
values in subsequent experiments.
3.2.5 Relevance of kinetic parameters to an enzyme which acts at an interface.
The v against s hyperbola (Figure 3.3) demonstrates the existence of a relationship 
between the initial velocity of the reaction and concentration of MCT present in the 
substrate emulsion. As substrate concentration is increased the enzyme eventually 
becomes saturated with substrate.
This result gives the impression that the Michaelis-Menten equation applies to the 
relationship between initial velocity of pancreatin and the concentration of MCT. 
However it has to be remembered that the Michaelis-Menten relationship is not 
directly applicable to the action of an enzyme upon an insoluble substrate. To explain 
the kinetics of a lipolytic enzyme acting at an interface, a model of two separate 
stages has been proposed resulting in a two-dimensional form of the Michaelis- 
Menten equation156. The first stage is an equilibrium to describe the reversible 
penetration of enzyme into the interface. Once penetration has occurred a second 
equilibrium exists for the catalytic interaction between a molecule of enzyme and a 
substrate molecule.
Various complications are involved in the interpretation of Km or Vmax determined in 
this study. The concentration of substrate was expressed as the total MCT present in 
the system. This resulted in a v against s hyperbola with s described as units of 
millimoles per unit volume. However the actual concentration of lipid available to the
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enzyme may not directly relate to the total lipid present. The quantity of lipid 
partitioned from the bulk into the surface phase or the emulsion droplet size and 
hence interfacial area may vary, limiting availability of substrate for enzyme 
adsorption. If this is the case kinetic parameters determined will reflect the adsorption 
of lipase to the interface and interfacial interaction rather than solely the rate of 
catalytic interaction between substrate and enzyme.
It has been stated that when utilizing an emulsion form of substrate for determination 
of kinetic parameters all experiments should be performed using the same substrate 
preparation due to the non-equilibrium nature of emulsion particles and differences in 
particle size distribution136. Under conditions of the pH-stat assay it is difficult to 
know how relevant variations in emulsion droplet size would be once lipolysis 
commenced. The simulated bile solution along with lipolytic products released will aid 
triglyceride emulsification. This, combined with the mechanical stirring action of the 
pH-stat, could result in emulsion droplets of uniform size irrespective of substrate 
concentration thus the effect on the kinetic parameters determined could be minimal. 
To ensure the degree of substrate dispersion does not affect Km or Vmax substrate 
concentration could be expressed in terms of interfacial area, however as already 
discussed interfacial area is difficult to determine for an emulsion system, particularly 
one which is constantly changing.
Regardless of the factor/s controlling the increase in enzyme velocity with substrate 
concentration, the relationship between the two appears to be of a consistent manner 
for pancreatin activity upon MCT under conditions of the standard pH-stat assay.
This gives support to the determined values of Km and Vmax for subsequent 
comparison with the same parameters measured in the presence of surfactant.
3.3 Investigation of the inhibition of pancreatin activity by the surfactant, 
Cremophor.
3.3.1 Introduction
Knowledge of the mechanism by which surfactants inhibit pancreatin activity may be 
useful to prevent inclusion of surfactants with this property in lipid-based
formulations. Preliminary experiments by colleagues at R P Scherer108 had revealed 
pancreatin activity to decrease towards a substrate of MCT in the presence of the 
surfactant, Cremophor. As the kinetic behaviour of pancreatin upon MCT (section 
3.2) exhibited apparent compliance with the Michaelis Menten equation an 
investigation was designed to examine whether this compliance still held when 
Cremophor was included in the system. If this was the case elucidation of the type and 
mechanism of inhibition shown by Cremophor towards pancreatin may be possible.
The use of the term inhibitor describes any substance which can reduce the velocity of 
an enzyme-catalysed reaction. Studies of the inhibition of enzyme activity can be 
useful to provide information regarding the specificity of an enzyme, the active site of 
an enzyme and / or kinetic mechanisms involved in the reaction117.
Inhibitors can be divided into two main types, irreversible and reversible151.
Irreversible inhibitors combine with the enzyme to cause eventual zero catalytic 
activity if present in excess to the enzyme concentration. Enzyme activity cannot be 
regenerated by removal of an irreversible inhibitor from the system. Irreversible 
inhibition is quantified in terms of the velocity of inhibition.
Reversible inhibitors exist in an equilibrium between free and bound state with the 
enzyme or enzyme-substrate complex. The effectiveness of a reversible inhibitor is 
expressed by the inhibitor constant (ki)109, which is a quantitative measure of the 
dissociation constant for the enzyme-inhibitor complex, ki can be useful to compare 
potency of different inhibitors when acting under specified conditions upon the same 
substrate.
Reversible inhibitors can be classified into three main types, competitive, non­
competitive and uncompetitive with partial inhibitors existing for each type109. Mixed 
inhibitors which exhibit a combination of the above types also exist. The types are 
classified according to the step in the catalytic pathway where the inhibitor acts. 
Distinction between the different types of inhibition can be achieved by graphical 
analysis although a definite classification on this basis alone is not always possible. A 
linear arrangement of the Michaelis Menten equation, the Lineweaver-Burk double 
reciprocal plot157 (1/v against 1/[S]) is normally chosen for this purpose. The effect of 
the presence of inhibitor on the plot of 1/v against 1/[S] can also be used for the
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determination of ki, however it is preferable to perform a least squares fit to the 
appropriate rate equation if known.
To classify the type of inhibition using the Lineweaver-Burk method, data needs to be 
collected for construction of several line plots of 1/v against 1/[S], with each plot 
made in the presence of a different fixed concentration of inhibitor158. All of the plots 
are then assembled on one set of axes. Determination of the type of inhibition is made 
on the basis of how the presence of the inhibitor effects the relationship between the 
line plots and the position of their intersections with relation to the axes.
If an inhibitor bound to an enzyme causes complete inhibition of a reversible nature 
the plot of 1/v against 1/[S] will be sufficient to identify the type of inhibition. Further 
information on partial inhibition may be revealed when gradients taken from the 
Lineweaver-Burk plot are shown against the fixed inhibitor concentration used109. For 
example in the presence of a partial inhibitor an enzyme will retain some catalytic 
activity when the inhibitor is bound. Gradients from the Lineweaver-Burk plot against 
inhibitor concentration will show hyperbolic behaviour indicating a partial inhibitor 
rather than the usual linear relationship seen with a complete inhibitor.
Further information on the type of inhibition can be gained by comparison of the 
kinetic parameters Km and Vmax obtained in the absence of an inhibitor, with those 
given by the identical enzyme reaction when inhibitor is present151. Competitive 
inhibitors increase the value of Km, which means that a higher substrate concentration 
is necessary to achieve half the velocity of Vmax which remains constant. Non­
competitive inhibitors reduce Vmax, the maximum velocity attainable, while Km is 
unchanged. Uncompetitive inhibitors decrease both Km and Vmax whilst mixed 
inhibitors can increase or decrease the value of either parameter.
The purpose of this work was to use the Lineweaver-Burk method to classify the type 
of inhibition displayed by Cremophor towards pancreatin activity upon MCT. In 
addition information regarding the site of inhibitory activity may become apparent. 
Quantification of the potency of inhibition of Cremophor towards pancreatin 
measured by the inhibitor constant, ki may also be possible.
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3.3.2 Method
Digestion profiles were produced to obtain five Lineweaver-Burk plots of 1/v against 
1/[S], with each plot produced in the presence of a different fixed concentration of 
Cremophor. Concentrations of MCT substrate (0.1 g, 0.25 g, 0.5 g, 0.75 g, 1 g, 1.5 g, 
2 g, 3 g and 4 g) for each Lineweaver-Burk plot were selected using Figure 3.3 as a 
guideline. A preliminary investigation of Cremophor inhibition of pancreatin activity 
towards MCT was performed (results not shown) to ensure the selected fixed 
Cremophor concentrations (0.01 g, 0.05 g, 0.1 g, 0.25 g and 0.5 g) gave varying 
degrees of inhibition.
A digestion profile was produced for each MCT concentration in the presence of each 
of the five Cremophor concentrations in turn. This resulted in the initial production of 
45 digestion profiles with some combinations being replicated later. Profiles were 
produced under conditions of the standard pH-stat assay with the titrant volume 
recorded every minute for a total period of twenty minutes.
3.3.3 Results
Determination of initial velocity.
To construct the 1/v against 1/[S] plots initial velocity measurements were required 
from each digestion profile. A visual inspection of the digestion profiles revealed that 
some profiles were exhibiting a lag phase. A lag phase is a term used to describe a 
slowly accelerating phase of enzyme activity which occurs at the beginning of the 
progress curve132. The lag phase is then followed by a phase of higher enzyme activity 
where the enzyme has reached the linear steady state. With the presence of a lag and 
steady state phase in the same digestion profile pancreatin can be said to be 
demonstrating biphasic kinetics109. Reasons for the appearance of a lag phase are 
discussed later in the text (section 3.3.6).
The presence of a lag phase introduced complications in relation to measurement of 
initial velocity. Some differences in the nature of the digestion profiles obtained in the 
presence of Cremophor are illustrated in Figure 3.4. For digestion profiles showing a 
definite lag and steady state phase followed by an approach towards equilibrium, (e.g.
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profile B, Figure 3.4), the initial rate can be determined from the steady state phase 
with reasonable accuracy. On some digestion profiles (e.g. profile D, Figure 3.4) the 
position where the lag phase finished and the steady state commenced was difficult to 
assess. In these cases the series of linear data points which exhibited the steepest 
gradient were used to calculate maximum enzyme velocity shown on the digestion 
profile.
The duration of the assay period was a further complication as a higher rate of 
enzyme activity may have been reached later in the profile if the assay had been 
continued for a longer period (e.g. profile C, Figure 3.4). Digestion profiles produced 
in the presence of high concentrations of Cremophor (e.g. 0.5 g) exhibited extensive 
suppression of enzyme activity (e.g. profile E, Figure 3.4). These profiles were 
suspected to be composed solely of a lag phase which had not been overcome within 
the 20 minute assay. In view of the linear nature of profiles of type E the initial 
velocity measurements were taken to be the gradient of the total profile.
For all digestion profiles the initial velocity measurements were calculated using linear 
regression on the selected titrant volumes. An attempt to overcome difficulties in 
initial rate determination due to presence of a lag phase could have been made by 
fitting each digestion profile to a rate equation for a given type of inhibition. However 
as the inhibition mechanism was not known and could not be hypothesized this was 
not possible.
The Lineweaver-Burk plot.
The initial velocity measurements determined were presented as individual 
Lineweaver-Burk plots of 1/v against 1/[S] for each fixed concentration of 
Cremophor (Figures 3.5 a-e). These plots (Figures 3.5 a-e) may be exhibiting a linear 
relationship between 1/v and 1/[S] although the scatter was too great to make a 
definite statement to this effect.
A criticism of the Lineweaver-Burk plot is that it gives undue weighting to the points 
obtained at low substrate concentrations (high 1/[S] values)158. This can result in 
concealment of a poor fit between data and a straight line if proper weighting is not 
applied to the points109. To illustrate this error bars for v of ± 0.01 mmol min'1 have 
been applied to the experimental data in Figure 3.5a to show the deficiencies of the
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plot. This is only a rough estimate of the error, not an accurate quantitative 
assessment of the experimental error. The positive error bars for high values of 1/[S] 
are not shown as they exceeded the scale of the graph.
Although the Lineweaver-Burk plot is not reliable for calculation of kinetic 
parameters, the plot was selected for this work to enable examination of trends due to 
the presence of an inhibitor. In view of the manner in which error is increased at high 
1/[S] values this needs to be bom in mind with regards to assessing linearity of the 
data. Further examination of the data in Figures 5.3 a-e when represented as separate 
v against s hyperbolas suggested the presence of Cremophor had altered the behaviour 
of pancreatin in such a manner that the enzyme kinetics were no longer related to the 
Michaelis-Menten equation.
Figures 3.5 a-e were combined onto a single Lineweaver-Burk plot (Figure 3.6) to 
enable examination of the relationship between data sets obtained using different 
Cremophor concentrations. The resulting combined Lineweaver-Burk plot (Figure 
3.6) did not exhibit a series of straight line plots which could be discussed with any 
confidence to provide information on the type of inhibition shown by Cremophor. Any 
relationship between the data sets was difficult to identify due to the large degree of 
scatter in the data.
There are several experimental reasons which may have caused pancreatin activity in 
Figure 3.6 to exhibit non-linear kinetics when in fact the enzyme may still be obeying 
the Michaelis-Menten equation. The contribution of the lag phase to error in initial 
velocity measurements has already been discussed. For some profiles initial velocity 
may not have been determined at steady state if the lag phase had not been overcome 
within the duration of the assay. Pancreatin has shown the ability to overcome 
inhibition from Cremophor with time (Figure 3.12c). In retrospect extension of the 
duration of the assay would probably have eliminated this source of error, by allowing 
measurement of the steady state reaction rate on profiles displaying a high degree of 
inhibition.
Another experimental influence which may have prevented pancreatin activity from 
exhibiting linear kinetics was the use of different batches of pancreatin for the 
digestion experiments. This situation was enforced by the supply of materials. An 
investigation into effects from the use of different batches of pancreatin is described in
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section 3.4. Although experimental error could have lead to scatter in Figure 3.6, the 
overall effect was felt unlikely to be sufficient to obscure an overall trend between the 
line plots if one existed.
3.3.4 Discussion
The inhibitory effect of Cremophor upon pancreatin activity could not be classified in 
terms of a particular type of inhibition using the Lineweaver-Burk method. This was 
due to non-compliance of pancreatin with the Michaelis-Menten equation when 
Cremophor was present or to experimental error in the results as already discussed. 
The manner in which Cremophor may be able to inhibit pancreatin is therefore 
discussed qualitatively below in terms of the three main types of inhibition117:
• Competitive inhibition
A competitive inhibitor competes with substrate for the same binding site upon free 
enzyme. Alternatively the inhibitor may bind at a different site to the substrate on the 
enzyme and cause a conformational change in the enzyme so that substrate can no 
longer bind to its normal binding site. This means the inhibitor would not necessarily 
have to resemble the substrate structure to display competitive kinetics.
The extent of competitive inhibition can be reduced by increasing the substrate 
concentration whilst inhibitor concentration remains fixed. If an increase in substrate 
concentration is able to reduce inhibition an increase in the Km value will be observed 
whilst Vmax remains the same when compared to kinetic parameters obtained in the 
absence of inhibitor.
There is evidence that non-ionic surfactants can inhibit the activity of lipase by binding 
in the active site of the enzyme. Crystallographic studies of porcine lipase and colipase 
with the non-ionic surfactant, tetraethylene glycol monooctyl ether (TGME) revealed 
a TGME molecule to be tightly bound to the active site pocket159. The non-ionic 
surfactant in this instance probably induced opening of the active site flap acting as a 
substrate analog. Further support for this is given by the observed reversible inhibition 
of tributyrin hydrolysis when TGME was included in the system.
Cremophor could also act as a competitive inhibitor by binding at the active site on 
lipase in the same manner as TGME or by interfering with the interfacial binding site 
on lipase or colipase; this may result in a conformational change of lipase or colipase 
with derogatory effects on enzyme activity.
Evidence to suggest that Cremophor acts as a competitive inhibitor would be the 
demonstration of identical values of Vmax when acting upon MCT alone and in the 
presence of Cremophor. This should be achieved solely by means of increasing the 
substrate concentration. In the absence of Cremophor V max is reached at a MCT 
concentration of 3.5 g. Unfortunately due to limitations of the assay system it was not 
possible to increase MCT concentrations to the higher levels necessary to reach Vmax 
in the presence of Cremophor.
• Non-competitive
A non-competitive inhibitor forms an inactive enzyme /substrate / inhibitor complex 
by binding at a site on the enzyme other than the substrate binding site. The inhibitor 
is also able to bind with the free enzyme whilst not altering binding of enzyme to 
substrate. For Cremophor to exhibit non-competitive inhibition an inactive complex of 
lipase or colipase with MCT and Cremophor would need to be formed. The resulting 
complex could not break down to release product or would break down at a slower 
rate than lipase with MCT if exhibiting partial non-competitive behaviour.
The effect of a non-competitive inhibitor cannot be overcome by increasing the 
substrate concentration as a proportion of enzyme remains in the inactive complex. As 
a result at a fixed concentration of inhibitor, the velocity of the reaction will be 
reduced by the same degree of inhibition, independent of the substrate concentration 
used. The effect of this on kinetic parameters is a decrease in Vmax whilst the Km value 
remains constant compared to the value in the absence of inhibitor.
To examine for changes in kinetic parameters due to the presence of Cremophor the 
experimental data obtained using 0.01 g of Cremophor (Figure 3.5 a) was selected. 
This data was chosen as when plotted as a v against s hyperbola (Figure 3.7) it 
displayed the least scatter when compared with the other Cremophor concentrations 
tested (Figure 3.5 b-e). The experimental data (Figure 3.7) was fitted to Equation 3.1 
via a computerized least squares fit of a v against s hyperbola to obtain estimates for
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Km and Vmax (Table 3.2). The least squares fit method was chosen instead of the direct 
linear plot as it allows visual examination of the deviation from Equation 3.1.
Although the parameters obtained exhibited a high degree of error they provided a 
qualitative indication that the presence of Cremophor decreased VmM by 
approximately one third compared to Vmax for MCT alone (Table 3.1), whilst the 
value of Km increased threefold compared to the Km for MCT alone (Table 3.1). The 
increase in the Km value tends to suggest that the mechanism of inhibition shown by 
Cremophor is not non-competitive.
• Uncompetitive
An uncompetitive inhibitor is unable to bind with free enzyme and can only bind 
reversibly with the enzyme / substrate complex causing it to become inactive. As the 
inhibitor is only able to bind with the enzyme / substrate complex the degree of 
inhibition increases in line with substrate concentration. This mechanism is considered 
rare in single substrate reactions and results in a decrease in Vmax and Km compared to 
the same parameters given in the absence of inhibitor.
For Cremophor to exhibit uncompetitive inhibition it would only be able to combine 
with a lipase / MCT complex probably with colipase also present and would not be 
able to bind with free lipase. From examination of Km and Vmax values (Table 3.2) 
obtained using 0.01 g of Cremophor an uncompetitive mechanism seems unlikely as 
Km increased compared to the value given in the absence of inhibitor.
Mixed inhibitors also exist which have an effect on both Vmax and Km. These can arise 
from several situations therefore it is not possible to give an explanation of the 
possible mechanisms involved.
From the above discussion, comparison of the kinetic parameters Km and Vmax for 
pancreatin activity upon MCT (Table 3.1) with those obtained in the presence 
Cremophor (Table 3.2) has indicated that non-competitive and uncompetitive 
mechanisms are unlikely. The definite increase seen in the Km value corresponds to the 
expected change in kinetic parameters for competitive inhibition. The Vmax value 
should be unchanged for a competitive inhibitor whereas with these results the Vmax 
value is decreased. A decreased Vmax value is to be expected as substrate
concentrations assayed in the presence of Cremophor were not increased above the 
levels tested for MCT alone. Without testing higher concentrations of substrate it is 
not possible to state that the maximum velocity had been reached. Therefore by 
comparison of the kinetic parameters Km and Vmax, Cremophor may be acting by way 
of a competitive mechanism or be exhibiting a mixed type of inhibition.
Degree of inhibition.
A distinction between the three main types of inhibition can be made by examination 
of a measurement known as the degree of inhibition117 over a range of substrate 
concentrations. The degree of inhibition relates initial velocity measurements from the 
same concentration of substrate in the presence and absence of an inhibitor.
A selection of digestion profiles of pancreatin activity towards MCT in the presence 
of Cremophor (0.01 g) are shown in Figure 3.8. The inhibitory effect of Cremophor 
on pancreatin activity towards MCT appears to diminish when the substrate 
concentration is increased. Figure 3.8 illustrates the monotonic increase in initial 
velocity with substrate concentration indicating increased enzyme activity. This does 
not necessarily imply that inhibition is being overcome as the increase in velocity may 
solely be due to the presence of an increased concentration of substrate.
The degree of inhibition enables enzyme activity to be examined in relation to 
substrate concentration and the inhibitory effect of Cremophor. Equation 3.2 
expresses the degree of inhibition as a percentage of uninhibited initial velocity, VVa.
Vi
V0/o=  — x 100 Equation 3.2
Vo
where
Vi = Initial velocity measured in the presence of inhibitor for fixed 
concentration of substrate.
V0 = Initial velocity measured in absence of inhibitor for the same fixed 
concentration of substrate.
Equation 3.2 was used to calculate Va/a for the initial velocity measurements in the 
combined Lineweaver-Burk plot (Figure 3.6). This was possible only for substrate 
concentrations where a corresponding uninhibited velocity measurement for MCT had 
been made in section 3.2. The resulting variation in V% with substrate concentration is 
shown in Figures 3.9 a-b where the data is grouped according to the concentration of 
Cremophor used.
To gain information regarding the type of inhibition shown by Cremophor from 
Figures 3.9 a-b a trend should be seen for each Cremophor concentration across the 
range of substrate concentrations. For a competitive inhibitor the degree of inhibition 
(expressed as V%) should decrease as substrate concentration is increased, for a non­
competitive inhibitor the V% should remain constant whereas for a uncompetitive 
inhibitor V% will increase with substrate concentration117.
A trend was not evident between V0/o and substrate concentration (Figures 3.9 a-b), 
due to the large degree of scatter in the results. It was therefore not possible to gain 
any further information regarding the type of inhibition shown by Cremophor using 
the parameter of the degree of inhibition. However all values of V% were at or below 
80 % indicating that in all cases Cremophor diminished the rate of enzyme activity in 
the steady state phase compared to the rate obtained using the same substrate 
concentration in the absence of Cremophor.
3.3.5 Conclusions
From this investigation into the inhibition of pancreatin activity by Cremophor it has 
not been possible to identify a particular type of inhibition. Results do however 
indicate that Cremophor is acting as a reversible rather than irreversible inhibitor. 
Evidence for this is supplied by comparison of digestion profiles for pancreatin acting 
upon MCT in the presence and absence of Cremophor. The presence of an identifiable 
lag phase on the digestion profile only occurs when Cremophor is included in the 
system.
Cremophor therefore appears to be responsible for inhibiting pancreatin activity in the 
early part of the digestion profile. As the lag phase is followed by a period of 
increased enzyme activity this indicates that inhibition is of a reversible nature. If the
inhibitor were irreversible enzyme activity would be completely lost upon binding with 
an inhibitor and the velocity would not be able to increase later on in the reaction.
A relationship between the concentration of inhibitor present and the extent of 
pancreatin inhibition at a fixed concentration of substrate has also been revealed. The 
effect of an increase in Cremophor concentration on digestion profiles obtained using 
a fixed substrate concentration (1 g MCT) is illustrated in Figure 3.10. The digestion 
profiles show a decrease in enzyme activity as concentration of inhibitor in the 
reaction mixture is raised.
To quantify this decrease in pancreatin activity the time taken to digest 2.5 % of MCT 
was calculated from each digestion profile. The resulting times are shown to increase 
with inhibitor concentration in Figure 3.11. For 2.5 % of MCT to be digested in the 
presence of 0.01 g of Cremophor takes 2 minutes whilst when Cremophor is raised to 
0.5 g the time is increased to 14 minutes.
In conclusion the only statements it is possible to make from this investigation is that 
Cremophor acts as a reversible inhibitor towards the digestion of MCT by pancreatin. 
Enzyme activity in the steady state phase was reduced by Cremophor in all cases 
compared to the rate when Cremophor was absent. Furthermore the extent to which 
enzyme activity is inhibited for a fixed substrate concentration increases with the 
amount of Cremophor present over the range of Cremophor concentrations tested.
3.3.6 Significance of the lag phase in relation to the mechanism of Cremophor 
inhibition.
The lag phase observed on digestion profiles of MCT in the presence of Cremophor 
may be a result of the assay method or be a feature of the enzyme-substrate reaction 
132. As the digestion profiles of pancreatin activity towards MCT alone did not show a 
measurable lag phase this argues against the cause being an artefact of the assay 
system.
The presence of Cremophor in the assay altered the nature of the majority of digestion 
profiles obtained, with the resultant curve indicating biphasic reaction kinetics. In 
general the duration of the lag phase increased with the proportion of Cremophor to
substrate present. Lag phases were observed which ranged from a minimum of one 
minute to a maximum of the total assay period of twenty minutes.
Lag phases in kinetic studies of lipolytic enzymes acting upon monolayers, micelles 
and emulsions have been a common observation131. A lag time, X/, the duration of 
which was found to be independent of enzyme concentration, has been described for 
pancreatic phospholipase A acting upon phospholipid systems of low lipid packing160. 
X/ was said to represent the rate limiting step of diffusion-controlled enzyme 
adsorption into the interface before a steady state was reached.
When the above observation is related to the studies performed here for pancreatin 
acting upon an emulsion system of MCT no observable lag time was present. The lack 
of a lag phase indicates that any delay in enzyme penetration into the interface of the 
triglyceride droplets is of a transitory nature and if present cannot be detected by the 
standard pH-stat assay. This may be due to the chosen conditions of the standard pH- 
stat assay in terms of pH, ionic strength and calcium ion concentration, all of which 
have been related to duration of the lag phase139,160.
The presence of a lag phase when Cremophor is included in the system suggests that 
Cremophor may have become incorporated into the interface of the triglyceride 
droplets or be present upon the interfacial surface. This could delay lipase or colipase 
adsorption to the interface to such an extent that the prolonged adsorption step is 
revealed by the assay as a lag phase.
Product activation is a common interpretation given to explain the lag phase seen 
when lipolytic enzymes act at a lipid / water interface131. This term describes the 
situation where products released from the lipolytic reaction such as fatty acids 
increase enzyme activity. The release of lipolytic products may increase enzyme 
activity by acting as amphiphiles to enhance substrate dispersion, or by increasing the 
substrate enzyme interaction through charge effects.
A further lag type, x /39 has been described as dependent in duration upon the rate of 
product accumulation at the lipid / water interface and enzyme concentration. x«* was 
observed from monolayer studies under conditions of high surface pressure which in 
turn relates to high lipid packing around triglyceride droplets. The duration of Xd was 
proposed to be dependent on the effect of product accumulation at the interface 
which subsequently alters colipase partitioning.
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The following theory of colipase partitioning139 relates product accumulation at the 
interface to increased interfacial colipase binding and hence an increased lipolytic rate. 
Colipase can partition between the bulk aqueous phase and the lipid / water interface. 
Before initiation of lipolysis the colipase partition coefficient will be constant for a 
fixed interfacial composition, with colipase preferentially partitioned into the aqueous 
bulk phase. As lipolysis proceeds the interfacial composition will change as lipolytic 
products start to accumulate and colipase partitioning into the lipid / water interface 
will increase. Fatty acids released by lipolysis have been suggested161,162 to form 
clusters of between 10 to 20 molecules which become stabilized by calcium ions to 
form fatty acid-calcium soaps at the interface. These clusters could change the charge 
properties of the surface and enhance colipase binding and hence hydrolytic rate. 
Further support to this theory was provided by inclusion of calcium ions and albumin 
in the system139. An increase in calcium ions which encourage fatty acid cluster 
formation decreased duration of x</, whilst addition of albumin, known to cause 
desorption of products from the interface, increased duration of id- 
Although the work described above was carried out using monolayer techniques 
biphasic kinetics have also been reported from in vitro studies using substrate in 
emulsion form163. The emulsion consisted of dietary LCT droplets surrounded by a 
phospholipid monolayer, the packing density of which creates a high surface pressure. 
The above situation is comparable to the in vitro studies performed with this work 
using the standard pH-stat assay where biphasic kinetics are seen when Cremophor is 
included in an emulsion of triglyceride and phospholipid.
The appearance of a lag phase in pancreatin activity when Cremophor is included with 
MCT may be explained by a combination of mechanisms involving diffusion- 
controlled enzyme adsorption into the interface and product activation. The lack of a 
measurable lag phase on digestion profiles of MCT alone indicate that under the 
conditions of the standard pH-stat assay colipase can rapidly adsorb to the triglyceride 
interface for fast initiation of hydrolysis. When Cremophor is added to the system the 
appearance of a lag phase could indicate Cremophor molecules incorporated into or 
layered on the interface are restricting adsorption of colipase. As some colipase 
eventually becomes bound to the interface the mechanism of product activation may 
start to play a part. The released lipolytic products would accumulate at the
triglyceride interface perhaps replacing some of the Cremophor molecules whilst at 
the same time enhancing colipase partitioning. The overall effect would be a sudden 
increase in hydrolytic rate leading to the biphasic kinetics observed.
This hypothesis would also explain why the duration of the lag phase was not always 
consistent for digestion profiles produced using identical concentrations of 
Cremophor and substrate. A particular combination or concentration of products at 
the interface can have a dramatic effect on colipase partitioning. This can produce a 
sudden large increase in the hydrolytic rate resulting in lack of a linear relationship 
between colipase binding and lipolytic product concentration139. The transitory nature 
of fatty acid clusters altering charge surface properties at the interface may also help 
to account for the erratic lag duration apparent between digestion profiles of 
comparable substrate and inhibitor concentration. An investigation of the duration of 
the lag phase in relation to enzyme, fatty acid and calcium ion concentrations may be a 
useful area to research for further insight into the inhibitory mechanism of 
Cremophor.
3.4 Investigation of the effect of different batches of pancreatin on the 
attempt to classify the type of inhibition shown by Cremophor.
3.4.1 Introduction
Whilst investigating the inhibition of pancreatin activity due to the presence of 
Cremophor it became necessary to replenish the stock of pancreatin. Upon receipt the 
new supply of pancreatin (batch II) was noted to be of a different batch number to 
that already in use (batch I). The new supply was assessed for activity towards 
tributyrin (section 2.3) which indicated comparable activity to the previous batch I 
therefore work continued using batch n.
Analysis of results from later work in Chapter 4 revealed enzyme activity towards 
identical MCT / surfactant mixtures to vary when a different batch of pancreatin was 
used for the digestion. Batch I of pancreatin exhibited higher activity than batch n. 
Both batch I and II of pancreatin had been employed in the study of Cremophor 
inhibition of pancreatin activity towards MCT. As results obtained using both batches
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had been analyzed together it was felt that the use of different enzyme batches may 
have been a contributory factor towards the large degree of scatter in the results 
obtained. A study was therefore designed to examine the inherent enzyme activity of 
each batch in terms of activity towards MCT / Cremophor mixtures.
3.4.2 Method
A series of experiments were designed to enable comparison between the different 
batches of pancreatin in terms of the extent of activity shown towards MCT / 
Cremophor mixtures. The batches of pancreatin to be tested were Sigma batch I, 
Sigma batch II (obtained 10/95), Sigma batch Ha (obtained 6/96) and a source of 
pancreatin from BDH (batch IV). Batch IV pancreatin was chosen as an example of 
an enzyme extract with stated higher minimum activity than the Sigma source.
The batch Ha pancreatin represented a fresh sample from the same lot number as 
batch II and was used in these experiments immediately upon receipt for comparison 
with results obtained from the original supply of batch H  This was to ensure no loss 
of activity had occurred to the original supply of batch II during use and storage in the 
laboratory. Further supplies of batch I pancreatin for this study were unavailable from 
Sigma, therefore as stock was exhausted data from digestions performed in section
3.3 were included for comparison when appropriate.
The investigation involved the digestion of MCT / Cremophor mixtures of varying 
proportions. The concentration of MCT was fixed at 1 g with the proportion of 
Cremophor ranging through 0.01 g, 0.05 g, 0.1 g, 0.25 g, 0.5 g and 1 g. Each 
combination was digested under conditions of the standard pH-stat assay using the 
batches of pancreatin available.
3.4.3 Results and discussion.
Digestion profiles of pancreatin activity towards the MCT / Cremophor mixtures were 
grouped in terms of the Cremophor concentration present. The digestion profiles 
illustrated the extent of digestion with time for the different batches of pancreatin 
tested (Figures 3.12 a-g). In general the results showed little difference in activity
between batch n  and batch Ha of pancreatin however batch I appeared to have higher 
activity towards the substrate than batch II in most cases. Batch IV pancreatin 
exhibited higher activity than the Sigma source. This was to be expected from the 
slightly higher quoted minimum standard of activity compared to that stated for the 
Sigma source. The extent of the increase in batch IV pancreatin activity compared to 
Sigma pancreatin decreased with the concentration of Cremophor present. Overall the 
digestion profiles in Figures 3.12 a-g did not show a great difference in activity 
between batches of Sigma pancreatin and could not give weight to a hypothesis that 
batch I was more active towards MCT / Cremophor mixtures than batch n.
This investigation had only covered a limited range of the concentrations of MCT and 
Cremophor used for the inhibition study involving Cremophor in section 3.3. An 
examination was therefore made of the initial velocity measurements displayed in the 
combined Lineweaver-Burk plot (Figure 3.6) in terms of the batch of pancreatin used. 
It was thought that these results may reveal further information regarding variability 
between the batches of pancreatin which was not apparent when assessing the 
digestion profiles of the selected combinations tested above.
To reexamine results from Figure 3.6 in terms of variation in activity between batches 
of pancreatin the initial velocity measurements were separated according to the batch 
of pancreatin used for the digestion. The data from each batch is represented as a 
hyperbolic plot of v against s, using separate plots for each fixed Cremophor 
concentration (Figure 3.13a {batch 1} and Figure 3.13b {batch II}).
The separation of results into batch of pancreatin used (Figures 3.13 a-b) indicated an 
apparent reduction of scatter within the batch II results compared to those given by 
batch I. This suggests that batch n  is more likely to give reproducible results than 
batch I when acting upon MCT and Cremophor mixtures. However the apparent 
reduction in the degree of scatter could be incidental as Figure 3.13 a and b do not 
represent the same number of data points for each Cremophor concentration.
In conclusion the large degree of scatter within the total results from the Cremophor 
inhibition study shown in Figure 3.6 was felt to be due mainly to the lag phase as 
already discussed, with a small influence from variation in activity between batches of 
pancreatin due to the crude nature of the enzyme extract.
The digestion profiles obtained from the experiments performed in this study were 
replicates of MCT and Cremophor combinations already digested for the investigation 
of the inhibitory behaviour of Cremophor (section 3.3). After treatment of the 
digestion profiles as described in section 3.3.3 the initial velocity measurements 
obtained were included on the combined Lineweaver-Burk plot (Figure 3.6); digestion 
profiles produced using batch Ha and IV of pancreatin were excluded.
Variation in enzyme activity between batches of pancreatin was not an issue for the 
experimental determination of the kinetic parameters Km and Vmax (section 3.2) as 
batch I was used to produce all of the digestion profiles.
3.5 An investigation of the effect on initial rate measurements of using 
0.1 M NaOH as titrant in the standard pH-stat assay.
3.5.1 Introduction
Throughout the study of inhibition of pancreatin activity due to Cremophor, a titrant 
concentration of 1 M NaOH had been used under conditions of the standard pH-stat 
assay to record the rate of enzyme activity. This provided fast neutralization of the 
protons released from fatty acids during the hydrolysis of triglyceride with minimal 
increase in volume of the reaction mixture over the duration of the assay.
The use of a high concentration of titrant may decrease assay sensitivity in terms of 
volume of titrant recorded with time. Addition of the lowest volume it is possible for 
the pH-stat to deliver could result in overshoot of the end point pH if reaction rate 
was sufficiently slow, although this had not been observed to occur from the pH of 
the reaction mixture displayed throughout each digestion. However the increased pH 
may have been rapidly compensated for by release of further protons from subsequent 
hydrolysis of triglyceride. The amount of NaOH added would therefore be correct but 
detail in the rate of titrant addition with time and hence the rate of reaction may be 
lost. The recorded titrant volume used to calculate initial velocity could therefore 
include titrant related to digestion occurring slightly later in the reaction.
An investigation was designed to examine whether a reduction in the concentration of 
titrant used could reduce scatter in the initial velocity values when fitted to Equation
3.1. This involved the production of a series of digestion profiles using 0.1 M NaOH 
as titrant. Initial velocity values obtained from these profiles and from replicate 
digestion profiles produced using 1 M NaOH as titrant were compared for compliance 
with the Michaelis-Menten equation.
3.5.2 Method
A series of digestion profiles representing pancreatin activity towards MCT in the 
presence of Cremophor were produced under conditions of the standard pH-stat 
assay. The Cremophor concentration was fixed at 0.01 g with substrate (MCT) 
concentration varying from 0.1 g to 2 g. The titrant used for the assay was a 
standardized solution of 0.1 M NaOH. The speed setting on the ABU 80 autoburette 
was increased to a capacity of 20 ml per minute to reduce any delay in reaction 
neutralization due to the increased volume of titrant used. All other settings remained 
as stated in section 2.2.2.
3.5.3 Results and discussion.
A lag phase was evident at the beginning of each digestion profile therefore initial 
velocity was calculated from the steepest gradient exhibited on the profile (as per 
section 3.3.3). Figure 3.14 illustrates the hyperbolic nature of the initial velocity 
values in relation to substrate concentration. A computerized least squares fit of a v 
against s hyperbola to the experimental data points (Figure 3.14) illustrates the 
apparent compliance of the data with Equation 3.1. This procedure also provided best 
fit values of Km and Vmax and an estimate of their errors, shown in Table 3.2.
Titrant Vmax Vmax Km Km
concentration (mmol min'1) standard error (mM) standard error
1 0 M NaOH 0.226 0.031 32.4 8.83
0.1 M NaOH 0.184 0.016 21.7 3.83
Table 3.2 Comparison of Km and Vmax values for pancreatin when acting upon MCT 
(in the presence of 0.01 g of Cremophor), determined using different 
concentrations of titrant.
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A reduction in titrant concentration from 1 M (Figure 3.7) to 0.1 M NaOH (Figure 
3.14) appears to have increased compliance of pancreatin behaviour with the 
Michaelis-Menten equation. This is shown by comparison of the standard errors for 
corresponding values of Km and Vmax (Table 3.2). The larger titrant volumes when 
using 0.1 M NaOH may have increased precision when determining the initial velocity 
by improving identification of the steady state phase.
The use of a low Cremophor concentration of 0.01 g has already been shown to 
exhibit closer compliance to the Michaelis-Menten equation compared to results using 
higher concentrations of Cremophor (Figure 3.5 a-e), probably due to the reduced 
degree of inhibition of pancreatin activity. It is debatable whether the use of 0.1 M 
NaOH as titrant would have increased compliance of pancreatin behaviour with the 
Michaelis-Menten equation for digestion profiles containing concentrations of 
Cremophor above 0.01 g. Although this was not tested higher Cremophor 
concentrations tended to cause greater distortion in the shape of digestion profiles 
which would not be altered by a higher titrant volume therefore identification of the 
steady state phase would still be subjective leading to error. Any deviation in 
pancreatin behaviour from the Michaelis-Menten equation is therefore proposed to be 
due to erratic enzyme activity resulting in distortion of the shape of the digestion 
profile rather than a problem with assay sensitivity.
3.6 Investigation of the effect of the method used for Cremophor addition 
(direct or premixed) to the assay upon subsequent activity of pancreatin.
3.6.1 Introduction
Preliminary investigations of the activity of pancreatin towards MCT in the presence 
of Cremophor had revealed different results according to the method used for 
preparation of the reaction mixture. When preparing the substrate of MCT and 
Cremophor the two components have to be incorporated into the simulated bile 
solution. This can be achieved in two ways, by addition of MCT and Cremophor 
individually or by use of a combined premixed form of the two as described in the 
method for the standard pH-stat assay (section 2.2.3).
85
When using an identical concentration of Cremophor the extent of digestion was 
observed to relate to the method used to prepare the substrate / surfactant mixture.
To investigate this phenomenon further a series of experiments were designed to 
quantify the change in inhibitory activity of Cremophor according to the method used 
to add the substrate and surfactant to the reaction mixture.
3.6.2 Method
Two methods of preparing the substrate / surfactant mixtures were investigated, the 
premixed method used in the standard pH-stat assay and the direct addition method. 
Substrate concentration was fixed at 1 g MCT to enable examination of the effect of 
varying the Cremophor concentration included in the reaction mixture. The quantity 
of Cremophor used ranged from 0.01 g in 12 stages up to 2 g, which resulted in 
twelve digestion profiles being obtained for each of the two methods.
For the premixed method Cremophor and MCT were combined and added to the 
reaction vessel as per the method described in the standard pH-stat assay (section 
2.2.3). The direct addition method involved addition of the Cremophor by weight 
directly into a beaker followed by some simulated bile solution. A magnetic stirrer 
was used to incorporate the Cremophor into the simulated bile solution. The resulting 
solution was placed in the reaction vessel followed by separate addition of the MCT. 
The assay was carried out in the same manner as the standard pH-stat assay from the 
stage of addition of MCT to the reaction vessel.
3.6.3 Results
The digestion profiles of percent triglyceride digested against time were grouped 
according to the method of substrate preparation used, direct addition of Cremophor 
into simulated bile solution (Figure 3.15) or premixed with MCT (Figure 3.16). This 
allowed examination of the ability of Cremophor to suppress lipolysis of MCT (1 g) in 
relation to the concentration of Cremophor present in the reaction mixture and the 
method of preparation used.
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From Figure 3.15 the inclusion of Cremophor via the direct addition method up to a 
concentration of 0.25 g had no effect upon triglyceride digestion when compared to 
the MCT control profile. However in the case of the premixed method (Figure 3.16) 
the profiles including Cremophor up to concentration of 0.25 g showed a decrease in 
the rate of digestion.
In the case of the premixed method, a Cremophor concentration of between 0.25 g 
and 0.5 g resulted in a dramatic decrease in extent of lipolysis with almost complete 
suppression reached with 1 g of Cremophor (Figure 3.16). Examination of the 
digestion profiles produced via the direct addition method revealed a gradual decrease 
in pancreatin activity with the use of Cremophor concentrations between 0.5 g and 
1.9 g, with a Cremophor concentration of 2 g necessary to almost completely 
suppress pancreatin activity (Figure 3.15).
The same concentration of Cremophor was therefore able to exhibit a different effect 
upon the activity of pancreatin according to the method used for Cremophor addition 
to the reaction vessel. When premixed with MCT, Cremophor was capable of a 
greater degree of pancreatin suppression than when added directly to the simulated 
bile solution.
3.6.4 Discussion
The difference in the inhibitory effect of Cremophor according to the method used to 
prepare the assay constituents is assumed to be due to the distribution of Cremophor 
within the reaction mixture, and reflect the non-equilibrium style of the reaction 
mixture. When Cremophor is added by the direct addition method it is possible that 
the Cremophor molecules remain in solution or aggregate together in a different phase 
to the lipid substrate. However when Cremophor is added by the premixed method 
lipid and Cremophor have definite contact from the start of the assay and may form a 
phase to which lipase and / or colipase find adsorption difficult or which water has 
trouble penetrating.
Workers investigating the inhibition of another lipolytic enzyme164, phospholipase C, 
by substrate analogs observed a long lag period in enzyme activity towards lecithin. 
However the lag phase did not occur if the substrate analogs were added after lecithin
hydrolysis had commenced. The initial binding of substrate to enzyme was proposed 
to result in an conformational change in the enzyme which increased enzyme affinity 
for the substrate. Inhibitory analogs present in the system before substrate hydrolysis 
commenced blocked the enzyme-substrate binding site, thus preventing a 
conformational change in the enzyme.
A similarity may be drawn between the above observation and the work performed in 
this investigation when using different methods of adding Cremophor to the assay.
The enhanced inhibitory action of Cremophor when mixed directly with MCT could 
be due to the increased proximity of Cremophor and MCT at the substrate interface. 
Enzyme orientated at the interface would be more likely to interact with the 
Cremophor or Cremophor may restrict binding of lipase or colipase to the MCT. The 
quantity of enzyme able to bind with MCT would therefore be reduced initially 
resulting in depressed lipolytic activity.
In the case of Cremophor mixed directly into the simulated bile solution there is less 
opportunity for Cremophor to come into contact with the substrate surface or enzyme 
at the beginning of the reaction, as it immediately undergoes dilution in the aqueous 
milieu. A higher concentration of Cremophor would therefore be necessary to 
increase interaction of Cremophor with MCT and enzyme to produce the same degree 
of inhibition as given by the premixed method.
3.7 Conclusions
The quantitative investigation of pancreatin activity towards MCT indicated an 
apparent compliance of kinetic behaviour with the Michaelis-Menten equation 
(Equation 3.1). This allowed determination of the kinetic parameters Km and Vmax for 
pancreatin when acting upon MCT under conditions of the standard pH-stat assay. 
The values of Km and Vmax are apparent due to complications involved with the 
parameter of substrate concentration. The relationship between initial velocity of 
pancreatin activity towards MCT and substrate concentration may equally be 
reflecting a relationship between another parameter dependent on bulk substrate 
concentration. These parameters could include substrate availability at the interface, 
lipid packing density and conformation of the lipid at the interface.
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For this study substrate was presented in emulsion form to increase representation of 
the physiological situation and provide maximum interfacial area of substrate. If the 
interfacial area is not present in excess to the concentration of enzyme used, initial 
velocity measurements and hence the values of Km and Vmax will be related to the 
increase in interfacial area with substrate concentration rather than the catalytic step. 
Information as to the physical state of the substrate in terms of availability to 
pancreatin and concentration of the substrate at the interface could increase the 
understanding of lipolysis kinetics further, however the values of Km and Vmax 
determined relate to the particular reaction conditions used in the standard pH-stat 
assay. These values were considered sufficient for use as a comparative measure of 
pancreatin activity for subsequent investigations involving inclusion of a surfactant 
with inhibitory properties within the same reaction system.
The surfactant, Cremophor, a known inhibitor of pancreatin activity towards MCT, 
was chosen to investigate inhibition of pancreatin activity by surfactants. The study 
revealed a change in the kinetic behaviour of pancreatin as a lag phase was observed 
when Cremophor was present in the system. The inhibition observed was examined by 
production of Lineweaver-Burk plots (1/v against 1/[S]) in the presence of different 
concentrations of Cremophor, by comparison of the kinetic parameters Km and Vmax 
with those from MCT alone and through the use of the parameter of the degree of 
inhibition.
A linear relationship between 1/v against 1/[S] indicates compliance of enzyme kinetic 
behaviour with the Michaelis-Menten equation and is necessary to enable information 
regarding the mechanism of inhibition to be obtained from the Lineweaver-Burk plot. 
As a linear relationship between 1/v against 1/[S] could not be established from the 
experimental data it was not possible to determine if pancreatin obeyed the Michaelis- 
Menten equation in the presence of Cremophor, although for the plot produced in the 
presence of the lowest concentration of Cremophor linear behaviour appeared likely. 
Lack of linearity may have been a result of experimental error introduced by the lag 
phase at the beginning of the digestion profiles (which complicated the measurement 
of initial velocity) or from the use of different batches of pancreatin. Scatter in the 
data prevented identification of a definite mechanism for Cremophor inhibition of 
pancreatin. A conclusion could be drawn however that Cremophor was acting as a
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reversible inhibitor due to the ability of enzyme to exhibit increased activity after the 
initial lag phase.
Possible mechanisms responsible for the inhibitory effect displayed by Cremophor can 
however be discussed from various traits in pancreatin kinetic behaviour revealed 
during the investigation. There are several sites at which Cremophor may act within 
the reaction pathway in order to produce a reduction in pancreatin activity, namely at 
the site of the lipid interface or at the binding site of the enzyme.
A study was made of different preparation methods for MCT and Cremophor 
mixtures before inclusion in the assay system. This revealed a higher inhibitory effect 
was given by Cremophor if premixed with MCT before addition to the aqueous 
medium of the reaction system. As this method increases direct contact between 
substrate and Cremophor, evidence is thus provided for the inhibitory action of 
Cremophor to be mainly related to its presence at the lipid interface rather than on the 
solution state of the enzyme.
At the interface Cremophor may form a layer over the MCT molecules or become 
incorporated into the interface. If Cremophor is presumed to form a mixed interface 
with MCT the resulting composite interface may have decreased susceptibility to 
enzymatic binding and attack than the free substrate resulting in a decreased reaction 
rate. The inclusion of Cremophor into the interface could also slow down pancreatin 
activity through an effect of substrate dilution. Alternatively the presence of 
Cremophor on the surface of the interface could prevent or slow down the process of 
enzyme adsorption by steric hindrance.
It is possible that Cremophor is interacting with colipase or lipase at the lipid or other 
binding sites on the enzyme. Lipase may have a high affinity to bind with Cremophor 
as a substrate analog whereupon binding is followed by slow hydrolysis of Cremophor 
relieving the inhibition with time. This theory would account for the existence of the 
lag phase which increases in duration with Cremophor concentration, as initially more 
enzyme would be bound in the complex form unavailable to act upon the natural 
substrate.
An increase in enzyme activity with time allows proposals of mechanisms by which 
inhibition due to Cremophor may be relieved. As lipolysis slowly proceeds the 
products released such as fatty acids and monoglycerides may act to remove
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Cremophor from the system by forming a complex. Alternatively they may enhance 
enzyme binding by increasing colipase partitioning into the interface. Cremophor itself 
may gradually change phases leaving the substrate more available for hydrolysis. If the 
phase transition is abrupt kinetic behaviour of the enzyme will change dramatically if 
the physical state of the substrate is the factor limiting lipolysis.
In summary this study has revealed that Cremophor is acting as a reversible inhibitor 
with the suppression of pancreatin activity increased when a method involving close 
contact between Cremophor and substrate is used for assay preparation. This suggests 
the inhibitory mechanism of Cremophor is related mainly to the lipid interface, with 
the lag phase representing a delay in the initial adsorption of enzyme to substrate due 
to Cremophor altering the physical state of the substrate.
Cremophor does not completely prevent all enzyme / lipid binding as a limited amount 
of lipid hydrolysis is seen to occur during the lag phase. The released lipolytic 
products may accumulate at the triglyceride interface to enhance colipase partitioning 
into the interface, displacing some of the Cremophor molecules in the process. This 
mechanism known as product activation has the overall effect of a sudden increase in 
hydrolytic rate leading to the biphasic kinetics seen.
As Cremophor could be decreasing pancreatin activity through a combination of 
effects this would explain the lack of a linear relationship between initial velocity and 
substrate concentration. The kinetic data obtained from this study is too complex for 
determination of the inhibitory mechanism of Cremophor to be possible via the 
methods used. Scatter in the results, although in some part due to experimental error, 
may also be related to the erratic kinetic behaviour of lipase resulting from rapid phase 
distribution changes of substrate, surfactant and enzyme within the system. The 
composite nature of Cremophor may also increase the discontinuity at the interface 
and thus differences in kinetic activity.
Relevance in vivo.
The standard pH-stat assay has been used throughout this investigation as an in vitro 
model of lipolysis. A point for consideration is that kinetic behaviour of lipase can 
vary tremendously with small changes in reaction conditions136. This investigation has 
demonstrated a rapid change in kinetic behaviour by the sudden end of the lag phase
followed by rapid activity on some digestion profiles. The reason for the end of the 
lag phase is unknown therefore lipase may act towards the same substrate / surfactant 
combination under dynamic in vivo conditions quite differently. However it is 
reasonable to conclude that a substance acting as an inhibitor in vitro is likely to 
exhibit an inhibitory effect, if not to the same degree, in vivo.
The concept of accumulation of lipolytic products at the interface increasing colipase 
partitioning and hence lipolytic activity can also be related to the physiological 
situation139. When dietary triglycerides reach the duodenum they have already been 
partially hydrolyzed in the stomach by human gastric lipase. The lipolytic products 
released are already available to enhance binding of colipase and thus facilitate 
lipolysis in the small intestine. This may lead to any surfactant-mediated inhibition 
being overcome in vivo before the formulation has reached the duodenum. However 
for a highly inhibitory surfactant the lag phase in vivo may be greater than the GI 
transit time of the formulation thus preventing drug release from a lipid-based 



















Figure 3.1 A linear arrangement of the Michaelis-Menten equation 
(Eadie-Hofstee plot v versus v/s).
Goodness of fit between experimental data and a straight line provides 
evidence for compliance with the Michaelis-Menten equation).
—  Linear regression fit 
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Figure 3.2 Direct linear plot for the digestion of MCT by pancreatin.
This plot illustrates the direct linear method, and are 
determined from the best fit median values of the intercepts.
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Figure 3.3 Computerized least squares fit of a v against 5 hyperbola 
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Figure 3.4 Illustration of differences in the nature of the digestion profiles produced by 
pancreatin when hydrolysing MCT in the presence of Cremophor.
A - Typical profile for MCT
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Figure 3.5a The 1/v versus 1/[S] plot for the hydrolysis of MCT
by pancreatin in the presence of Cremophor (10 mg).




S  Error bars for v of 0.01 mmol min*1 are shown only to 
illustrate the deficiencies of the Lineweaver-Burk plot.
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Figure 3.5b The 1/v versus 1/[S] plot for the hydrolysis of MCT 























Figure 3.5c The 1/v versus 1/[S] plot for the hydrolysis of MCT 
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Figure 3.5d The 1/v versus 1/[S] plot for the hydrolysis of MCT 
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Figure 3.5e The 1/v versus 1/[S] plot for the hydrolysis of MCT
by pancreatin in the presence of Cremophor (500 mg).
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Figure 3.6 The combined 1/v versus 1/[S] plot for the hydrolysis of MCT by 
pancreatin in the presence of different fixed concentrations of Cremophor.
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Figure 3.7 Computerized least squares fit of a v against S hyperbola to experimental data 
from the hydrolysis of MCT by pancreatin in the presence of Cremophor (10 mg).
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Figure 3.8 The effect of an increase in substrate concentration on pancreatin activity 
in the presence of a fixed concentration of Cremophor (10 mg).
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Figure 3.9a Comparison of uninhibited initial velocity (V%) as a function of substrate
concentration in the presence of different fixed concentrations of Cremophor.
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Figure 3.9b Comparison of uninhibited initial velocity (K/o) as a function of substrate 
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Figure 3.10 The effect of an increase in Cremophor concentration on pancreatin activity 
towards a fixed concentration of substrate (MCT 1 g).
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Figure 3.11 Time taken to digest 2.5 % of substrate (MCT 1 g) in the presence of different 





















Figure 3.12(a-d) Comparison of enzyme activity shown by different batches of pancreatin
towards a substrate o f :
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Figure 3.12(e-g) Comparison of enzyme activity shown by different batches of pancreatin
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Figure 3.13a The combined v versus [S] plot for the hy drolysis of MCT by pancreatin 
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Figure 3.13b The combined v versus [S] plot for the hydrolysis of MCT by pancreatin 
(Batch II) in the presence of different fixed concentrations of Cremophor.
0.16-1
0 .1 4 -
0 .12 -
0 . 10 -
0 .0 8 -
0 .0 6 -
0 .0 4 -
0 .0 2 -
0 . 0 0 -
-0.02
Cremophor 
■  10 mg 
O 50 mg 
A 100 mg 
▼ 250 mg 
□ 500 mg |




” 1 1 1 1 1 1 1 1 1 1









Figure 3.14 Computerized least squares fit of a v against S hyperbola to experimental 
data from the hydrolysis of MCT by pancreatin in the presence of Cremophor (10 mg) 
using 0.1 M NaOH as titrant.
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Figure 3.15 Digestion profiles of MCT (1 g) in the presence of Cremophor 
when added to the assay system via the direct addition method.
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Figure 3.16 Digestion profiles of MCT (1 g) in the presence of Cremophor 
when added to the assay system via the premixed method.
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Chapter 4 - Inhibition of pancreatin activity towards MCT by non-ionic 
surfactants: A structure-activity study.
4.1 Introduction
The non-ionic surfactant, Cremophor was shown to depress the rate of digestion of 
MCT by pancreatin under conditions of the standard pH-stat assay in Chapter 3. 
Information as to which non-ionic surfactant types are likely to inhibit pancreatin 
activity would be useful so their use in lipid-based formulations could be avoided.
This is desirable due to the suspected role of lipid digestion in enhancement of the 
bioavailability of hydrophobic drugs from lipid-based formulations.
Pancreatin acts at the interface of a lipid / water system therefore accumulation of 
surfactant at the interface could alter enzyme activity. The features of a surfactant 
which were expected to affect the activity of pancreatin were the chemical structure 
and the balance between the hydrophilic and lipophilic properties of a surfactant. If a 
relationship was found to exist between a particular surfactant property and potency 
of inhibition towards pancreatin this may provide further information regarding the 
mechanism by which non-ionic surfactants inhibit pancreatin activity.
4.1.1 Characteristics of surfactants.
Surface active agents, commonly known as surfactants, are molecules comprised of 
two distinct regions165. One of the regions is hydrophobic and consists of hydrocarbon 
chain or ring systems with saturated or unsaturated bonds. The other region is 
hydrophilic, and may contain an ionized group which confers an electrical charge on 
the surfactant molecule.
Surfactants where the hydrophilic moiety consists of polyoxyethylene chains or 
hydroxyl groups have no residual electrical charge on the molecule hence they are 
known as non-ionic. Non-ionic surfactants are preferred for pharmaceutical purposes 
due to their reduced toxicity compared to other surfactant groups and lack of 
sensitivity to other components likely to be present in a lipid-based formulation165. All
investigations and discussion of surfactant behaviour in this thesis relates to the non­
ionic group.
As a surfactant has two moieties, one of which has affinity for the solvent whilst the 
other does not, the conferred dual nature of the molecule is described as 
amphipathy166. It is the amphipathic nature of surfactants which is responsible for their 
tendency to accumulate at the surface boundary between two phases. This ultimately 
can lead to surface activity at liquid / liquid or liquid / air interfaces, micellization and 
solubilization.
4.1.2 The hydrophile-lipophile balance (HLB) of a surfactant.
As the behaviour of surfactants is highly dependent on the respective influence from 
their hydrophilic and lipophilic moieties* various methods have been devised to 
quantify the balance between the two. The HLB number method, devised in 1949 by 
Griffin167, has been widely adopted as an empirical method of representing the balance 
between the hydrophilic and lipophilic content of a surfactant molecule. Griffin later 
adapted the concept168 into a series of equations which enable calculation of surfactant 
HLB numbers using analytical or composition data.
Equation 4. I168 is commonly used to determine the HLB number for polyhydric 
alcohol fatty acid esters for which saponification numbers can be obtained analytically.
HLB = 20^1 -  Equation 4.1
where S = Saponification number of the ester.
A = Acid number of the fatty acid which is defined as the number of mg of 
KOH required to neutralize 1 g of fatty acid.
If saponification data is unavailable or difficult to obtain, Equation 4.2168 allows 
calculation of the surfactant HLB value from compositional data if the hydrophilic 
surfactant moiety consists of polyhydric alcohol and oxyethylene groups.
E + PHLB = —-— Equation 4.2
where E  = The percentage by weight of the surfactant molecule made up by 
oxyethylene chains.
P = The percentage by weight of the surfactant molecule made up by 
polyhydric alcohol groups. This term is disregarded if the hydrophilic 
portion of the surfactant molecule consists solely of oxyethylene.
Another method developed by Shinoda et al169 involves determination of the phase 
inversion temperature (PIT). The PIT is defined as the temperature at which the 
hydrophilic and lipophilic properties of the surfactant balance at the interface and 
maximum solubilization of oil occurs170. Whereas the HLB number remains constant 
for a particular surfactant as it is assigned via surfactant structure, the PIT is a 
characteristic property of the emulsion system. The PIT will therefore alter to reflect 
changes in the behaviour of a particular surfactant due to influences from the emulsion 
system such as ionic strength, temperature, structural modifications of the surfactant 
molecule, other additives in the system, and nature of the oil phase171.
Although the HLB number provides no information regarding influence from the 
environment upon behaviour of the surfactant, it is widely used to select surfactants 
suitable for a particular purpose such as emulsification, solubilization or detergency. 
For non-ionic surfactants the HLB number ranges from 0 to 20 on an arbitrary 
scale165. The lower numbers on the scale (0 to 5) represent surfactants with high 
lipophilicity which can be used as water in oil emulsifiers and antifoaming agents.
HLB numbers in the range of 7 to 16 approximately are oil in water emulsifiers with 
HLB values from 13 to 17 indicating surfactants with detergent properties.
Surfactants with HLB values from 17 upwards are very hydrophilic and act as 
solubilising agents.
4.1.3 Influence of the HLB value of a surfactant on emulsion systems.
The ability of a surfactant to emulsify a system of water and oil is related to the 
interfacial film of surfactant formed at the phase boundary. To achieve a minimum
free energy state the hydrophobic portion of the surfactant becomes orientated in the 
oil phase165. The accumulation of surfactant molecules at the interface chemically 
changes the nature of the interface, in addition to replacing some of the water 
molecules previously present. The resulting mixed interface has reduced 
intermolecular attraction and therefore a lower surface tension which enhances 
emulsion formation165.
The type of emulsion formed, emulsion stability and orientation of the surfactant 
molecule in the interface is dependent on the HLB of a surfactant. As the 
polyoxyethylene chain is lengthened through a homologous surfactant series, 
hydrophilic character and the HLB number of the surfactant increases. At high HLB 
values the hydrophilic moiety of the surfactant dominates surfactant character with 
strong hydration forces between water and the polyoxyethylene chain171. This highly 
hydrated interfacial film results in a convex curvature of the interface towards water 
giving the surfactant properties of an oil in water emulsifier. Surfactants with a short 
polyoxyethylene chain exhibit low hydration effects, the interface has a concave 
curvature towards water and the surfactant acts as a water in oil emulsifier. At 
intermediate HLB values between the two states the degree of hydration will result in 
an interface with little curvature and at this point the HLB is said to be balanced. 
Surfactants with different HLB values will have varying effects on surface tension and 
thus ease of emulsification. If the hydrocarbon portion is extended through a 
homologous surfactant series, surface tension will be reduced promoting 
emulsification whereas if the hydrophilic region is enlarged the opposite effect is
_ 1 6 5seen
The HLB value of a surfactant also provides information on the likely phase behaviour 
of any surfactant not adsorbed at the interface. A surfactant where the lipophilic 
moiety is dominant (as indicated by a low HLB) will tend to dissolve in the non-polar 
phase of an emulsion whereas a predominantly hydrophilic surfactant would partition 
into the water phase. If the surfactant exhibits low solubility in both oil and water this 
will tend to result in formation of a separate surfactant phase in the system171.
In terms of emulsions the properties of the interfacial film will determine the ease of 
emulsion formation whereas the stability of the emulsion is dependent upon interfacial 
tension172 although other factors such as steric stabilization are also involved. As the
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degree of surfactant ethoxylation will affect properties of the interface, an emulsion 
produced from an identical oil and water mixture will have different characteristics 
depending on HLB value of the surfactant used.
4.1.4 Outline of this investigation.
This investigation covers several aspects of the inhibition of pancreatin activity 
towards MCT by non-ionic surfactants. Non-ionic surfactants are ideal for 
investigation of the effect of surfactant polarity (expressed by the HLB value) on 
pancreatin activity, as HLB can be increased through a homologous series of 
surfactants solely by lengthening the polyoxyethylene chain. Pancreatin activity was 
therefore able to be assessed in the presence of surfactants covering a wide range of 
HLB values without alteration in the basic chemical structure of the surfactant used.
A series of nonylphenol ethoxylated surfactants (NPEs) were initially employed to 
establish if a relationship existed between the HLB value of a surfactant and potency 
of inhibition shown towards pancreatin (sections 4.2 to 4.5). The toxicity profile of 
NPEs means they are unsuitable for pharmaceutical purposes, as their small size 
allows ease of penetration and disruption of lipid membranes. However they were 
considered ideal for the above investigation due to the large number of commercial 
materials available, covering a wide range of HLB values.
The study was then extended to involve homologous series of non-ionic surfactants 
generally considered suitable for pharmaceutical applications (sections 4.6 to 4.12). 
This was to determine whether the degree of ethoxylation of a surfactant was the sole 
influence regarding potency of inhibition or if the chemical structure of the surfactant 
hydrophobe was also relevant. The number of surfactants available in each series was 
limited which placed a restriction on the HLB values investigated. However sufficient 
surfactants were obtained to enable comparison of the extent of inhibition seen with 
results from the NPEs.
Section 4.13 describes an attempt to characterize the degree of ethoxylation for a 
range of surfactants included in the inhibition study, using cloud point and *H NMR 
analysis. This was to examine the accuracy of the extent of surfactant ethoxylation 
quoted by the manufacturer.
I l l
4.1.5 Materials
As for Chapters 2 and 3 with the addition of nonylphenol (Aldrich 29,085-8) and the 
industrial non-ionic surfactants used in this study which have been grouped into the 
classes described below:
• Alcohol ethoxylates (nonylphenol ethoxylates and linear alcohol ethoxylates)
• Castor oil ethoxylates and hydrogenated castor oil ethoxylates
• Sorbitan esters
• Ethoxylated esters (polyethoxylated sorbitan esters and polyglycolyzed glycerides)
The non-ionic surfactants are listed in their respective series together with the 
manufacturers specification for each product. The ethoxylation number represents the 
number of moles of ethylene oxide reacted with one mole of the respective surfactant 
hydrophobe; it is usually equivalent to the average number of ethoxy groups present 
in the polyoxyethylene chain or the average number of ethoxy groups distributed 
across various ethoxylation sites on the molecule. The HLB value quoted for each 
surfactant has been obtained from the manufacturers data sheet, or if not available 
from this source was calculated from the ethoxylation number via Equation 4.2.
Nonylphenol ethoxylated surfactants




































Linear alcohol ethoxylated surfactants
Series Alkyl chain Ethoxylation number
Brij
30 lauryl (Cl2.-o) 4
35 lauryl (Cl2:0) 23



























Series Alkyl chain Ethoxylation
56 cetyl (C16.0) 10
58 cetyl (Ci6:o) 20
72 stearyl (Ci8:0) 2
76 stearyl (Ci8:o) 10
78 stearyl (Ci8:o) 20
92 oleyl (Ci8;i) 2
96 oleyl (Ci8:i) 10
98 oleyl (Ci8:i) 20
Lutensol
A03 synthetic Ci3:o - Cis;o 3
A08 synthetic Ci3:o - Ci5:o 8
AO10 synthetic Ci3:o - C15.0 10
AT11 fatty alcohol Ci6:0 - Ci8:o 11
A012 synthetic Ci3:o - Ci5:o 12













































1 monolaurate (C i2:o) 8.6
2 monopalmitate (C i6:o) 6.7
3 monostearate (Cl8:o) 4.7
4 monooleate (C 18:l) 4.3
41 tristearate (Ci8:o) 2.1
43 sesquioleate (Ci8:l) 3.7
45 trioleate (Ci8:l) 1.8
Span
65 tristearate (Ci8:o) 2.1
Polvethoxvlated sorbitan esters
Series Ethoxylation number HLB number
Crillet
1 monolaurate (C i2.-o) 20 16.7
2 monopalmitate (Ci6:o) 20 15.6
3 monostearate /—■
v
p 00 © 20 14.9
4 monooleate (C 18;1) 20 15.0
11 monolaurate (C 12.0) 4 13.3
35 tristearate r“*
\ n t—• 00 © 20 10.5
41 monooleate (C 18;I) 5 10.0
45 trioleate (Cl*:l) 20 11.0
Tween
65 tristearate (Cl8:o) 20 10.5
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The Polvglvcolvzed Glycerides
Labrafil M-1944CS Apricot kernel oil PEG-6 complex 
main fatty acid: oleic (Ci8:i) 
Labrafil M-2125CS Com oil PEG-6 complex
main fatty acid: linoleic (Ci8:2) 
Labrafil WL 2609BS Com oil PEG-8 complex
main fatty acid: linoleic (Ci8:2) 
Labrafac CM 10 Polyglycolyzed Cs-Cio glycerides






Labrasol Glyceryl caprylate / caprate and PEG-8
caprylate / caprate
main fatty acid: caprylic-capric 14.0
Address of suppliers
Aldrich, New Rd, Gillingham, Dorset, SP8 4XT.
Surfactants were kindly donated by:
Alfa Chemicals Ltd., Arc House, Binfield, Bracknell, RG42 4PZ (Labrafac, Labrasol, 
Labrafil series).
BASF United Kingdom Ltd., Cheadle, SK8 6QG (Cremophor RH40, Lutensol 
series).
Cargo Fleet Chemical Co. Ltd., Eaglescliffe, Stockton (Synperonic series).
Croda Chemicals Ltd., Snaith, Goole, DN14 9AA (Etocas, Croduret, Crill, Crillet 
series).
Diamond Shamrock Process Chemicals Ltd., Eccles, M30 OBH (Ethylan series). 
Dow Chemical Company Ltd., Hounslow, TW5 9QY (Dowfax series).
Hoechst UK Ltd., Hounslow, TW4 6JH (Arkopal series).
Hiils (UK) Ltd., Matrix House, Milton Keynes, MK9 1NJ (Miglyol® 812).
R P Scherer Ltd., Blagrove, Swindon, SN5 8YS (Soya bean oil).
Stepan Europe., St. James Court, Warrington, WA4 6PS (Neobee M20).
Surfachem Ltd., Thirsk Row, Leeds, LSI 4DP (Brij, Span, Tween series).
Unichema International, Bebington, Wirral, L62 4UF (Priolene).
4.2 Investigation of the inhibition of pancreatin activity by nonylphenol
ethoxylated surfactants.
4.2.1 Preliminary investigations.
Nonylphenol ethoxylated surfactants (NPEs) are a class of alcohol ethoxylated 
surfactants formed by an alkaline catalysed reaction between ethylene oxide and the 
phenol hydrogen upon nonylphenol:
The ethoxy group added on may react with another molecule of ethylene oxide and so 
on to form a chain of varying length. The subscript n represents the ethoxylation 
number, which for future discussion of NPEs is taken to be identical to the number of 
ethoxy groups in the polyoxyethylene chain.
Preliminary investigations were necessary to establish if pancreatin activity towards a 
substrate of MCT was inhibited by NPEs. By increasing the degree of ethoxylation of 
the NPEs tested, the extent of pancreatin inhibition could then be examined in terms 
of the HLB value of the surfactant.
It was also necessary to establish concentrations of MCT and surfactant for use in the 
assay. Ideally concentrations were required which revealed the potency of inhibition 
of the surfactant whilst representing appropriate concentrations of surfactant and 
triglyceride likely to be included in a lipid-based formulation.
4.2.2 Method
O -H O—(CH2CH20)n H
(CH2)8-CH3 (CH2)8-CH3
The standard pH-stat assay (section 2.2) was employed to assess pancreatin activity 
towards MCT in the presence of NPEs. NPEs with ethoxy groups of 2, 4, 5, 6, 7, 7.5, 
10, and 12 (Dowfax series) were selected for use in this study. Batches of MCT
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containing NPEs at 10, 20 and 50 % w/w were prepared for each surfactant by the 
premixed method. For digestions where NPEs were present at a concentration of 10 
or 20 % w/w 500 mg masses of MCT / surfactant mixture were used for each assay; 
this mass was increased to 2 g when the surfactant concentration was raised to 50 % 
w/w. Digestion profiles of pancreatin activity upon the MCT / surfactant mixtures were 
produced under conditions of the standard pH-stat assay, with titrant volumes 
recorded at intervals of five minutes over a period of one hour.
4.2.3 Results
Digestion profiles for MCT in the presence of NPEs at 10 and 20 % w/w (with respect 
to MCTT
The activity of pancreatin towards MCT in the presence of NPEs at 10 % w/w 
concentration (with respect to MCT) is shown in Figure 4.1. The digestion profiles 
are represented as line plots to aid interpretation although data was available only at 5 
minute intervals. A digestion profile for the same concentration of MCT produced 
under identical experimental conditions is included in Figure 4.1 as a control. Figure
4.1 shows that inclusion of surfactant at a concentration of 10 % w/w did not appear to 
inhibit pancreatin activity towards MCT.
Upon increasing the concentration of surfactant to 20 % w/w (with respect to MCT) 
examination of the resulting digestion profiles in Figure 4.2 suggested some 
suppression of pancreatin activity. This is evident from comparison of the total 
triglyceride digested upon completion of the assay. The MCT control profile reached 
90 % digestion after 60 minutes. When the nonylphenol ethoxylated surfactant with a 
chain of two ethoxy groups (2-NPE) was included in the reaction mixture, the total of 
MCT digested was reduced to 83 % over the same assay period. For the other ethoxy 
chain lengths tested the total percentage of MCT digested was between 83 and 90 %. 
There was no evidence of a reduced enzyme reaction rate at steady state due to 
inclusion of NPEs (Figure 4.2).
The effect of NPEs at a concentration of 20 % w/w did not influence digestion of MCT 
sufficiently to demonstrate definite inhibition of enzyme activity or to enable 
examination of a relationship between pancreatin activity and ethoxy chain length of 
the surfactant.
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Digestion profiles for MCT in the presence of NPEs at 50 % w/w (with respect to 
MCTV
The digestion profiles of MCT in the presence of NPEs at 50 % w/w are illustrated in 
Figure 4.3a (ethoxy chain lengths 0 to 6) and Figure 4.3b (ethoxy chain lengths 6 to 
12). A control profile of MCT (1 g) digested under identical conditions is included in 
Figure 4.3 to represent pancreatin activity in an uninhibited system.
All digestion profiles containing NPEs at 50 % w/w (with respect to MCT) showed 
suppression of pancreatin activity compared to the control MCT profile (Figure 4.3 a- 
b). NPEs with ethoxy chain lengths from 4 to 7.5 suppressed pancreatin activity, as 
shown by the decreased percentage of MCT digested at the end of the assay 
compared to the control. However the shape of these profiles were similar to the 
MCT control profile (Figure 4.3 a-b), with no evidence of a lag phase. For 10-NPE a 
lag phase occurred at the beginning of the profile followed by a surge in enzyme 
activity; the same pattern in a more pronounced form was shown in the presence of 
12-NPE (Figure 4.3b).
Figure 4.3 a includes a digestion profile for MCT in the presence of nonylphenol. This 
profile demonstrated that extensive suppression of MCT digestion can be caused by 
the nonylphenol moiety without ethoxylation. The highly lipophilic 2-NPE (Figure 
4.3a) exhibited a pattern of enzyme suppression similar in character to nonylphenol 
however inhibition was partially overcome 35 minutes into the assay.
Overall the inclusion of 50 % w/w surfactant (with respect to MCT) in the assay system 
suggested the existence of a relationship between the activity of pancreatin towards 
MCT and the degree of surfactant ethoxylation. This in turn inferred a possible 
correlation between the potency of inhibition of a surfactant and its HLB value. 
Figures 4.3 a-b also demonstrated that the quantity and ratio of MCT (1 g) to 
surfactant (1 g) used within the assay was sufficient to reveal varying extents of 
inhibitory activity from the surfactants tested. Therefore for all future digestions 
performed in Chapter 4, MCT to surfactant concentration was maintained at 50 % w/w 
(with respect to MCT) using a mixture of 1 g of MCT and 1 g of surfactant in each 
case. These quantities are also of a level likely to be found in a lipid-based formulation 
for oral administration.
4.3 Investigation of the relationship between inhibition of pancreatin activity
by NPEs and surfactant HLB value.
Investigations in section 4.2 had indicated an apparent relationship between pancreatin 
activity towards MCT and the degree of ethoxylation of NPEs. However only a 
limited range of NPEs had been examined covering ethoxy chain lengths from 2 to 12. 
In order to examine this suspected relationship further, an additional twenty NPEs 
from various manufacturers (listed in section 4.1.6) were obtained with ethoxy chain 
lengths from two to thirty. This enabled the potency of inhibition of NPEs to be 
examined across a wide range of HLB values.
4.3.1 Method
Digestion profiles of MCT were produced in the presence of each surfactant to assess 
the extent of pancreatin activity. Each digestion involved 1 g of MCT and 1 g of 
nonylphenol ethoxylated surfactant, premixed prior to digestion under conditions of 
the standard pH-stat assay. Titrant volume was recorded every 5 minutes over the 60 
minute assay.
Due to long delays in obtaining some of the NPEs the experimental work for this 
investigation was divided into two stages. The surfactants readily available were used 
early in the study (Stage A of the study). At a later date digestion profiles were 
produced using the remaining NPEs (Stage B of the study).
4.3.2 Results 
Stage A
The digestion profiles in Stage A of the investigation were produced using NPEs with 
HLB values ranging from 0 to 17. The effect of the NPEs upon pancreatin activity 
was seen to vary greatly. This is demonstrated by comparison of the amount of 
triglyceride digested five minutes after commencement of the assay (between 0.5 to 
26 % of the total MCT present), and upon completion of the sixty minute assay 
(between 13 to 80 % of the total MCT present).
Due to the large number of surfactants tested, a method other than direct comparison 
of digestion profiles was required to allow examination of the relationship between 
pancreatin activity and surfactant HLB value. The parameter selected for this purpose 
was the time taken for pancreatin to convert a specified percentage of triglyceride (t%) 
to monoglyceride and two fatty acids.
The t% value does not represent a fundamental kinetic parameter of pancreatin activity 
or a particular inhibitory mechanism but is used solely to compare the efficiency of 
pancreatin digestion of MCT within the standard pH-stat assay. A general parameter 
of this type was required due to the wide variation in levels of inhibition. t% allowed 
the relationship between inhibition of lipolysis and surfactant HLB value to be 
examined for a large number of surfactants in a manner independent of complications 
involved when comparing digestion profiles of a non uniform shape.
As the extent of digestion differed considerably between profiles, it was necessary to 
compare various t% values. A range of to/o values (2.5, 5, 10, 25 and 50 %) were 
therefore calculated from each digestion profile to enable determination of the \% 
value common to most profiles. Calculation of t% was achieved by linear interpolation 
between the two data points either side of the required percentage of digestion on the 
profile.
In combination the tio % and t25 % parameters were found to represent the complete 
range of NPEs tested in Stage A and provided a means of graphical presentation of 
the inhibitory properties of surfactants towards pancreatin. High t% values indicated 
potent inhibitors as pancreatin activity was depressed whereas low t% values 
represented rapid enzyme digestion of MCT and thus surfactants with weak inhibitory 
properties.
Figure 4.4 illustrates the relationship between the selected to/o parameter and surfactant 
HLB value for NPEs tested in Stage A. For surfactants with HLB values up to eleven 
t25 % decreased towards a minimum at HLB 11 (Figure 4.4). This suggested a loss of 
potency of inhibition with decreased surfactant lipophilicity. Between HLB values of 
12 to 15 a sharp rise in tio % and t25 % can be seen as surfactants become more 
inhibitory towards pancreatin reaching an apparent maximum inhibitory HLB value of 
approximately 15 (Figure 4.4). With HLB values of 16 and above inhibition appeared
to decline although only three surfactants were available for testing in this range 
(Figure 4.4).
Stage B
Upon receipt of the remaining surfactants required for the study digestion profiles 
were produced in the same manner as for Stage A. For some profiles in Stage A, a 
high percentage of MCT had been digested when the first titrant volume was recorded 
5 minutes after the start of the assay. Frequency of titrant volume recordings were 
thus increased in Stage B to improve accuracy of the linear interpolation. Titrant 
volumes were recorded every minute for the first twenty minutes of the assay 
followed by every 5 minutes for a further forty minutes.
Calculation of t»/o (2.5, 5,10, 25 and 50 %) was made from each digestion profile, 
where data allowed, in the same manner as described in Stage A. Examination of the 
resulting values revealed t2.5 % and ts % to represent the complete range of NPEs tested 
in Stage B and these are shown in Figure 4.5 as a function of the HLB value of the 
surfactant. Upon examination of the relationship between t% and HLB value (Figure 
4.5) the same trend was seen as already described for the surfactants tested in Stage A 
(Figure 4.4).
The sharp increase in potency of inhibition seen for NPEs with HLB values from 10 to 
15 in Figure 4.5 was examined further by means of a log / linear plot. Figure 4.6 
demonstrates an exponential relationship between t2.5 % and the HLB value of NPEs. 
This indicates a monotonic increase in the potency of inhibition of NPEs according to 
the number of ethoxy groups present, when in the HLB range of 10 to 15.
Comparison of results from Stage A and B of the investigation revealed NPEs with 
similar HLB values to have a greater inhibitory effect upon pancreatin activity in 
Stage B than when tested in Stage A. This effect is illustrated in Figure 4.7 which 
demonstrates that digestion on profiles from Stage B was slower to proceed, hence 
values of t25 % are increased when compared to a surfactant with the same HLB value 
used in Stage A. Control experiments to recheck operation of the pH-stat, stability of 
the assay components and NPEs revealed the explanation for this behaviour involved 
the batch of pancreatin used for the digestion.
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4.4 Investigation of the susceptibility of pancreatin to the inhibitory 
properties of nonylphenol ethoxylated surfactants.
4.4.1 Introduction
The difference in susceptibility of pancreatin to the inhibitory properties of NPEs with 
the same HLB value appeared to be related to the batch of pancreatin used for the 
digestion (section 4.3.2). Batch I used in Stage A being less susceptible to inhibition 
mediated by NPEs than batch II used in Stage B. However only the magnitude of the 
inhibitory effect was altered, with the relationship between t% and surfactant HLB 
value remaining the same (Figures 4.4 / 4.5).
When the activity of batch I and II of pancreatin had been assessed using a substrate 
of tributyrin (section 2.3), both batches had been observed to have a similar rate of 
hydrolytic activity. Likewise an investigation in Chapter 3 had not demonstrated 
conclusively that batch I was more active towards MCT in the presence of 
Cremophor than batch n.
Although repeatability of results had been demonstrated when using the same batch of 
pancreatin to digest MCT / nonylphenol ethoxylated surfactant mixtures, repeatability 
had not been examined between batches. An investigation was thus designed to 
examine further the inhibition of pancreatin by NPEs to ensure conclusions from the 
inhibition study were not specific to a particular batch of pancreatin.
The surfactants chosen for the investigation were 10-NPE and 12-NPE (Dowfax 
series). These were selected as they had HLB values in the region where, in Figure 
4.7, the difference in enzymatic activity between the two batches was most 
pronounced. In addition each batch of pancreatin was also used to produce a 
digestion profile of MCT. This was to ensure any difference in pancreatin activity was 
due solely to inclusion of NPEs in the reaction mixture.
4.4.2 Method
Digestion profiles using 1 g of MCT as substrate were produced to determine the 
activity of batch I and II of pancreatin in an uninhibited system. In addition batch Ha
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and batch IV of pancreatin were included in this study for the same reasons as stated 
in Chapter 3. Digestion profiles were also produced using the same batches of 
pancreatin acting upon a substrate of MCT (1 g) premixed with 1 g of surfactant (10 
or 12-NPE).
All digestion profiles were produced under conditions of the standard pH-stat assay. 
Titrant volume was recorded every minute for the first twenty minutes followed by 
every 5 minutes for the remainder of the one hour assay. In the case of batch I 
pancreatin, due to lack of enzyme, data from Stage A of the investigation was 
included for comparison. In this case titrant volumes had been recorded at 5 minute 
intervals over the one hour assay period.
4.4.3 Results
The activity of each batch of pancreatin towards 1 g of MCT is shown in Figure 4.8. 
Little difference was seen between the profiles from batches I, n  and Ila although 
batch I appeared to have slightly higher activity towards the substrate (Figure 4.8). 
Batch IV of pancreatin had the highest rate of enzyme activity towards MCT (Figure 
4.8) as expected from the higher standard of minimum activity stated by the 
manufacturer. No difference was seen between the batches of pancreatin in terms of 
total triglyceride digested at the end of the assay which varied between 82 to 84 %. 
Figures 4.9 and 4.10 illustrate how the presence of 10 and 12-NPE respectively 
caused an alteration in enzyme activity towards MCT, the magnitude of which varied 
according to the batch of pancreatin used. When compared with the virtually identical 
activity observed between batches when digesting MCT alone, (Figure 4.8) inclusion 
of surfactant revealed the enhanced ability of certain batches of pancreatin to 
overcome inhibitory effects.
In the presence of surfactant, digestion profiles from all batches of pancreatin 
exhibited a lag phase (which was considerable for batch II pancreatin) followed by a 
period of enzyme activity at steady state (Figures 4.9-4.10). The rate of enzyme 
activity at steady state appeared to be diminished compared to the rate shown on the 
uninhibited MCT profiles (Figure 4.8). To quantify this change in pancreatin activity
use was made of the parameter V%. described in Chapter 3 (Equation 3.2) as the 
degree of inhibition.
Vi
V0/o=  — x 100 Equation 3.2
Vo
where
Vo = Reaction rate shown by pancreatin at steady state towards 1 g of MCT.
V  = Reaction rate shown by the same batch of pancreatin at steady state
towards MCT (1 g) in presence of nonylphenol ethoxylated surfactant (1 g).
V% was calculated using Equation 3.2 to describe enzyme reaction rate at steady state 
in the presence of NPEs as a percentage of the uninhibited rate shown towards MCT. 
The enzyme reaction rate towards MCT, Vo, was determined from the linear portion 
of each digestion profile in Figure 4.8 by means of linear regression. Calculation of 
enzyme reaction rate in the presence of 10-NPE, Vi io-npe, and 12-NPE, Vi 12-npe, was 
determined in the same manner as for Vo from profiles in Figure 4.9 and Figure 4.10 
respectively, where data allowed. The resulting values are shown in Table 4.1 













I 5.94 3.84 65 3.19 54
n 4.86 3.17 65 2.62 54
Ila 4.90 3.27 67 - -
IV 8.31 6.77 81 4.47 54
Table 4.1 Comparison of reaction rates shown at steady state by each batch of 
pancreatin towards a substrate of MCT in the presence and absence of 
nonylphenol ethoxylated surfactants.
In all cases y% confirmed that the presence of NPEs decreased enzyme activity at 
steady state compared to the activity shown by the same batch of pancreatin towards 
MCT alone (Table 4.1). All batches of pancreatin tested showed a r% of 54 % in the 
presence of 12-NPE, therefore enzyme activity towards the same substrate had been 
reduced by 46 % irrespective of the inherent activity of the pancreatin used (Table
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4.1). Considered in isolation this result suggested V0/o to be a constant value relative 
to the surfactant used. However when results from the less inhibitory surfactant, 10- 
NPE were examined, an increased value of r% was shown by batch IV of pancreatin 
(Table 4.1). Further data was therefore required to examine if V% was of a variable or 
constant nature with respect to the degree of ethoxylation of a surfactant.
4.4.4 Relationship between the decrease in pancreatin activity at steady state 
( V0/o) and the degree of ethoxylation of NPEs.
Introduction
The presence of surfactant was noted in section 4.4.3 to reduce enzyme activity at 
steady state (represented by *%), however it was not known if the extent of this 
reduction was related to the degree of ethoxylation of the surfactant and / or the batch 
of pancreatin used. To examine further the influence of the degree of ethoxylation of 
NPEs on the activity of pancreatin (batch I and II) in terms of r*. a study was 
designed which involved fifteen NPEs with ethoxylation numbers from 0 to 30 
(Dowfax and Arkopal series).
Digestion profiles were produced in the presence of each surfactant in same manner as 
described for Stage B (section 4.3.2) using batch n  of pancreatin. Profiles had already 
been obtained in the presence of the same surfactants using batch I of pancreatin in 
Stage A. This enabled comparison of activity between the two batches in the presence 
of the same surfactant.
Results
When pancreatin activity was quantified at steady state using Equation 3.2, V% values 
for batch I and II of pancreatin did not appear to differ in the presence of the same 
surfactant. However was noted to vary with the degree of ethoxylation of the 
surfactant. This variation in r% is shown in Table 4.2 in terms of the length of the 
ethoxy chain and corresponding HLB value of the surfactant tested.
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Table 4.2 Relationship between pancreatin activity at steady state, ( V% ) 
and the degree of ethoxylation of the surfactant present.
The relationship shown in Table 4.2 between the percent of the uninhibited reaction 
rate remaining in the presence of surfactant, (represented by V0/o) and the HLB value 
of the surfactant reflects the trend seen in Figure 4.4. For surfactants with a HLB 
value of 0 to 11 V% slowly increased representing decreasing inhibitory effect. V0/o 
fell in value for surfactants with HLB values between 12 and 14, indicating increased 
inhibition of pancreatin activity. The highly ethoxylated surfactant with a HLB of 17 
also showed extensive inhibition of enzyme activity at steady state. However the 
severe inhibition caused by surfactants with HLB values between 14 and 16 is not 
reflected in Table 4.2 as these surfactants extended the lag phase to such an extent 
that pancreatin did not reach steady state within the one hour assay.
In summary the parameter of has shown NPEs to cause a reduction in enzyme 
activity at steady state. The results suggest the extent of this reduction is related to 
the degree of ethoxylation of the surfactant and appears unaffected by the batch of 
pancreatin used.
The duration of the lag phase on each digestion profile used to obtain y% was 
measured and is illustrated in Figure 4.11 as a function of the HLB value of the 
surfactant present. From a HLB of 10 profiles produced using batch II pancreatin 
exhibited a longer lag phase than profiles produced using batch I pancreatin (Figure 
4.11); the extent of this difference increased from a HLB value of 10 up to 15. 
Inhibition of pancreatin activity by NPEs therefore appears to be mediated mainly by 
an extension of the lag phase with some reduction in enzyme reaction rate at steady 
state. For both the lag phase and y% the extent of the inhibition is related to the
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degree of ethoxylation of the surfactant. Results suggest the inter-batch variation in 
susceptibility of pancreatin to inhibitory effects of NPEs is related only to a reaction 
occurring during the lag phase.#
4.4.5 Discussion regarding the variation in susceptibility of pancreatin to inhibitory 
effects of alcohol ethoxylated surfactants.
The difference in susceptibility of various batches of pancreatin to the inhibitory 
effects of alcohol ethoxylated surfactants appears related to the initial stages of 
triglyceride digestion. Interestingly enzyme activity at steady state, although reduced 
in the presence of surfactants, was virtually unchanged between batches of pancreatin. 
When pancreatin acts upon a substrate of MCT under conditions of the standard pH- 
stat assay enzyme activity reaches steady state immediately. This occurs despite the 
supramicellar concentration of bile salt in the simulated bile solution which would be 
expected to inactivate lipase by causing displacement of the enzyme from the lipid 
interface173. However colipase present in pancreatin may overcome any desorbing 
activity of bile salts173 resulting in immediate lipase activity, possibly by acting as an 
anchor for lipase to bind to the substrate174.
The process of colipase binding to the lipid substrate has been suggested to occur via 
hydrogen bonding with ester linkages in the lipid substrate20. The hydrogen bonds 
have been reported to be easily disrupted by non-ionic surfactants20 and octylphenol 
ethoxylate has been demonstrated to displace colipase from the lipid substrate 
interface173. Tensioactive agents, such as non-ionic surfactants, have also been stated 
to mediate inhibition of lipase by affecting the interfacial quality of the substrate175.
In the work presented here pancreatin has demonstrated the ability to overcome the 
initial lag phase caused by the presence of alcohol ethoxylated surfactants or 
Cremophor (section 3.4), although the time taken to reach steady state did vary. This 
initial inhibition of enzyme activity upon commencement of the assay may be a direct
^Susceptibility of pancreatin to the inhibitory properties of linear alcohol ethoxvlates.
Digestion profiles of MCT produced in the presence of LAEs (Lutensol AO series) were also 
performed using batch I and II of pancreatin. The resulting profiles from batch II exhibited an 
extended lag phase compared to profiles including the same surfactant digested by batch I. This 
indicates that batch I and II of pancreatin exhibit different activity regardless of the type of alcohol 
ethoxylated surfactant present.
result of surfactant altering the quality of the substrate interface. Colipase, whilst able 
to overcome any desorption of lipase due to bile salts in the reaction milieu, may be 
unable to immediately overcome effects from the surfactant molecules.
Surfactant molecules could initially be assumed to accumulate at the lipid interface 
blocking adsorption of colipase, possibly by steric hindrance or interference with 
hydrogen bonding between colipase and triglyceride substrate. Eventually binding of 
some colipase would allow limited lipolysis to proceed. The resulting accumulation of 
lipolytic products at the interface would thus promote further colipase binding and 
increase enzymatic activity to steady state; this suggests the colipase partitioning 
theory already proposed for Cremophor also applies to inhibition mediated by other 
non-ionic surfactant types.
Studies by other workers gives support to the above hypothesis that colipase rather 
than lipase is responsible for overcoming inhibition from non-ionic surfactants. 
Colipase has been shown to activate lipase in the presence of substrate interfaces to 
which lipase cannot bind alone176. The addition of colipase in increasing amounts to a 
detergent inhibited system has also been demonstrated to eventually abolish the lag 
phase177.
If the ability of colipase to restore lipase activity is related to length of the lag phase, 
the duration of the lag phase must reflect efficiency of the colipase. For this study 
using MCT / nonylphenol ethoxylated surfactant mixtures digestion profiles from 
batch I pancreatin had a shorter lag phase compared to batch II (Figure 4.11). This 
infers that batch I pancreatin contains colipase with higher activity than batch II.
The literature goes some way to supporting this assumption as the structure of 
colipase has been found to be related to the duration of the lag phase. Colipase 
isolated from porcine pancreatic glands can vary in the number of amino-acid residues 
present in the peptide chain. Proteolysis at the N-terminal will result in conversion of 
procolipase (colipase-101) to the more active colipase-96 form20. When acting upon a 
substrate of phosphatidylcholine stabilized triglyceride emulsion colipase-96 can 
overcome lag times at 100 times lower concentrations than procolipase178. In addition 
cleavage of colipase-96 at the C-terminal end to colipase-85 reduced lag time further 
by a factor of six23.
Several factors could be responsible for the difference in duration of the lag phase 
between batch I and n  pancreatin if colipase is proposed to be the cause. Both 
batches could contain the same form or forms of colipase in identical proportions 
however the concentration of colipase in the bulk enzyme extract may be different. 
Alternately the form of colipase may be different due to the crude nature of the 
material rendering batch I more efficient at adsorption to the lipid interface in the 
presence of non-ionic surfactants. Unfortunately no information was available from 
the manufacturer or literature regarding the possible form or concentration of colipase 
present in the pancreatin used in this series of experiments.
No discernible difference in activity was evident between batch I and II of pancreatin 
when acting upon MCT in the absence of non-ionic surfactants. This tends to suggest 
the concentrations or proportions of colipase present in each batch were adequate to 
overcome any influence upon enzyme binding from bile salts or lecithin. The 
difference between batch I and II of pancreatin only became apparent when the 
interface was affected by surfactant molecules to such a degree as to make binding of 
colipase difficult.
Further work to investigate this phenomenon could include the use of pure lipase in 
the assay system with subsequent addition of known forms of colipase to the reaction 
mixture. This would establish which form of colipase is particularly efficient at 
overcoming the lag phase. Another approach could involve increasing the 
concentration of pancreatin used in the assay. This may establish if differences in the 
ability to overcome the lag phase between batches was solely related to concentration 
of colipase in the bulk extract, rather than the form of colipase present.
As the simulated bile solution used in the standard pH-stat assay contained calcium, 
upon addition of trypsin any colipase present should be cleaved to the more efficient 
colipase-8523. If extent of colipase cleavage is the limiting factor this approach should 
result in lag phases of the same duration for both batches of pancreatin used.
4.5 A hypothesis to explain the relationship between the HLB value of NPEs 
and the extent of inhibition of pancreatin activity.
NPEs have an inhibitory effect on the activity of pancreatin towards MCT. The extent 
of the inhibition appears to be related to the HLB value of the surfactant. The same 
relationship between HLB value of NPEs and potency of inhibition towards 
pancreatin activity was demonstrated by the various parameters of t>/o (Figures 4.4 &
4.5), duration of the lag phase (Figure 4.11), and V% (Table 4.2).
Examination of t% revealed that within a HLB range of 10 to 15 (ethoxylation number 
of 5 to 15) the potency of inhibition of NPEs increased exponentially with the extent 
of surfactant ethoxylation (Figure 4.6). Surfactants with a HLB value of 
approximately 15 had maximum inhibitory effect represented by a lag phase which 
lasted for the duration of the assay, however as illustrated in Figure 4.10 these long 
lag periods can be overcome if the assay period is extended. As the degree of 
ethoxylation of the surfactant, and hence the hydrophilic character is increased above 
a HLB of 15 the potency of inhibition shown by the surfactant declines.
Digestion profiles produced in the presence of NPEs with dominant lipophilic 
character (ethoxy chain lengths < 5) showed suppression of enzyme reaction rate at 
steady state without evidence of a lag phase. Digestion profiles with nonylphenol 
present also inhibited pancreatin by reduction of enzyme reaction rate with no lag 
phase present. A further characteristic of profiles produced in the presence of 
lipophilic surfactants was a reduction in the amount of MCT digested at end of the 
assay compared to the MCT control.
From the above discussion alteration in the activity of pancreatin by NPEs appears 
related to the degree of ethoxylation of the surfactant and hence surfactant 
hydrophile-lipophile balance. This may perhaps be explained by consideration of the 
behaviour of NPEs at a lipid-water interface. The orientation of nonylphenol 
ethoxylated surfactant molecules at an oil-water interface has been suggested to vary 
depending upon length of the ethoxy chain, as represented in Figure 4.12 below170.
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Figure 4.12 The state of orientation of NPEs with different numbers of ethoxy 
groups at an oil-water interface. (Reproduced from reference170.)
For NPEs with high lipophilic character the surfactant molecule is represented as 
completely partitioned into the oil phase (Figure 4.12). As the number of ethoxy 
groups in the chain is increased from 5 through to 8 the hydrophilic ethoxy chain 
gradually penetrates into the aqueous phase until only the nonylphenol moiety remains 
in the oil. Additional ethoxylation after this point results in the ethoxy chain adopting 
a meander form in the water with the hydrocarbon group also penetrating further into 
the aqueous phase.
In the standard pH-stat assay triglyceride droplets, probably with associated lecithin, 
are dispersed in an aqueous reaction mixture as an oil in water emulsion. The 
nonylphenol ethoxylated surfactant molecules are assumed to be located mainly at the 
interface between the triglyceride droplet and the aqueous environment. If the 
surfactant molecules adopt a similar conformation as illustrated in Figure 4.12 
according to the length of their ethoxy chain, a mechanism to explain the change in 
their inhibitory effects with HLB can be proposed.
Nonylphenol and NPEs with ethoxy chain lengths below 5 have dominant lipophilic 
character. From Figure 4.12 the highly lipophilic nature of these surfactants would 
result in the complete molecule being partitioned into the triglyceride droplet. The 
lipase and colipase would still be able to bind and start digestion immediately as
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demonstrated by the lack of a lag phase at the beginning of the digestion profiles 
produced in the presence of these surfactants. Penetration of the surfactant completely 
into the oil may cause a substrate dilution effect by acting as inert spacers, resulting in 
less triglyceride available at the interface for lipase to act upon. This is analogous to 
the concept of substrate dilution used in lipolytic enzyme kinetic studies where a lipid 
or detergent molecule known not to be a substrate for the enzyme is introduced into
-  179the system .
The digestion profiles support the substrate dilution theory by exhibiting decreased 
enzyme activity at steady state and a reduction in the extent of triglyceride digestion 
achieved within the assay period. In addition little difference was seen between 
digestion profiles produced in the presence of these surfactants when using different 
batches of pancreatin. This could be explained by assuming binding of colipase to 
substrate experiences little disruption as some triglyceride is still immediately 
available, therefore colipase with higher activity is not necessary.
For NPEs with chains containing from 5 to 15 ethoxy groups the potency of inhibition 
increases with the degree of ethoxylation of the surfactant. Chains composed of 6 to 8 
ethoxy groups will start to form an oxyethylene mantle around the lipid droplet 
restricting access of colipase to the interface and thus delaying enzyme adsorption. As 
the ethoxy chain is increased to 9 groups and above the mantle will become harder to 
penetrate as the ethoxy chain adopts a meander form. This accounts well for the 
increase in duration of the lag phase with the degree of ethoxylation of the surfactant, 
reflecting restricted colipase binding to substrate. It also illustrates the dependence of 
lipase activity on the ability of colipase to overcome the presence of surfactant, thus 
revealing the advantage of colipase with higher activity.
The potency of inhibition of NPEs with ethoxy chain lengths of above 15 starts to 
diminish as hydrophilic character of the surfactant is increased by lengthening of the 
ethoxy chain. Figure 4.12 illustrates how partitioning of the nonylphenol moiety 
further into the aqueous reaction system is likely due to the dominant hydrophilic 
character of the molecule. These highly hydrophilic surfactants may show reduced 
inhibition due to preferential partitioning of the surfactant from the lipid interface into 
the aqueous reaction medium. This would result in enhanced colipase binding to the 
lipid interface and a subsequent increase in the rate and extent of MCT lipolysis.
4.6 Investigation to determine the effect of various types of non-ionic 
surfactants on pancreatin activity towards MCT.
The aim of this investigation was twofold, to determine if the relationship between 
HLB value and the potency of inhibition demonstrated by NPEs held for other non­
ionic surfactants suitable for use in pharmaceutical formulations. Secondly to examine 
for a relationship between the potency of inhibition and chemical structure of 
surfactants to gain further information regarding the mechanism of inhibition. 
Although alcohol ethoxylated surfactants are not suitable for oral administration the 
linear alcohol ethoxylated surfactants (LAEs) were included in this study for 
comparison with results from the NPEs due to simplicity of their chemical structure. 
The potency of inhibition of LAEs was examined in relation to HLB value and the 
length of the alcohol derived linear alkyl chain (section 4.7).
The castor oil ethoxylates, sorbitan esters, polyethoxylated sorbitan esters and 
polyglycolized glycerides were selected as examples of surfactant types which might 
be considered for pharmaceutical use. These groups of surfactants covered a wide 
range of HLB values however the number of surfactants available in each group was 
limited. Each group of pharmaceutically acceptable surfactants is discussed 
individually in terms of inhibition of pancreatin activity in relation to their chemical 
structure and HLB values in sections 4.8 to 4.10.
The following method was used to assess pancreatin activity towards MCT in the 
presence of each surfactant in turn (listed according to type in section 4.1.6). A 
digestion profile was produced for each surfactant under conditions of the standard 
pH-stat assay, with 1 g of MCT and 1 g of surfactant used for each digestion. The 
titrant volume was recorded every minute for the first 20 minutes, followed by 
recordings at 5 minute intervals for the remaining 40 minutes of the assay. Batch II 
pancreatin was used for all digestions performed. The resulting profiles are discussed 
under the relevant surfactant group heading.
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4.7 Linear alcohol ethoxylated surfactants.
The purpose of this study was to examine the ability of linear alcohol ethoxylates 
(LAEs) to inhibit pancreatin activity towards MCT. Any inhibitory effect observed 
due to LAEs was intended for comparison with results already obtained from the 
NPEs. Nonylphenol had been demonstrated in section 4.2.3 to have an inhibitory 
effect upon pancreatin therefore the inhibition mediated by NPEs may also be due in 
part to influence from the nonylphenol moiety. As the linear alcohol ethoxylates do 
not possess an aromatic moiety, any inhibitory activity observed could be attributed 
only to the linear alkyl chain and / or the ethoxy chain.
LAEs are generally made by addition of ethylene oxide to alcohol using KOH 
catalysis. Formation of the ethoxylate occurs in the same manner as for the NPEs, 
with a reaction between the hydrogen of the alcohol group and ethylene oxide. The 
final product of ethoxylation is represented by the following formula:
CH3(CH2)x (CH2CH20)nH
where x + 1 = The number of carbons present in the linear alkyl chain, 
n = The ethoxylation number.
Two main series of LAEs were obtained for testing, the Lutensol AO series ( C 1 3 - C 1 5  
alkyl chain) and the Brij series. The alcohol moiety of the Lutensol AO series is 
produced synthetically by the oxo process; a method which converts olefin 
hydrocarbon vapors into aldehyde followed by hydrogenation to alcohol. The Brij and 
Lutensol AT series (mixed C16-18 alkyl chain) are described as comprised of fatty 
alcohols, obtained from natural fats and wax containing substances.
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The formulae of the alcohols used for the alkyl chain of the Brij surfactants are listed 
below:
LAEs with ethoxylation numbers of 3, 8, 10, 12 (Lutensol AO series), 11 (Lutensol 
AT series) and 2, 4, 10, 20 and 23 (Brij series) were tested for inhibitory activity 
towards pancreatin by production of digestion profiles as described in section 4.6.
4.7.1 Ability of LAEs to inhibit pancreatin.
The digestion profiles produced using the Brij and Lutensol AO series of LAEs are 
shown in Figures 4.13 and 4.14 respectively, with the ethoxylation number and HLB 
value indicated for each surfactant. Comparison of the control MCT profile with 
digestion profiles produced in the presence of LAEs revealed all surfactants tested to 
have an inhibitory effect upon pancreatin activity (Figure 4.13 and 4.14).
The rate of MCT digestion during the first 20 minutes of the assay decreased as the 
number of ethoxy groups increased from 2 to 10 inclusively (HLB 4.9 to 13.5) 
(Figure 4.13 and 4.14). For LAEs with > 10 ethoxy groups (HLB of 14.3 and above) 
the inhibitory effect of LAEs on pancreatin activity lessened (Figure 4.13 and 4.14).
4.7.2 Comparison of the potency of inhibition of LAEs and NPEs in terms of the 
ethoxylation number of the surfactants.
To compare the potency of inhibition shown by LAEs and NPEs towards pancreatin, 
digestion profiles were grouped according to the ethoxylation number of the 
surfactants. Digestion profiles from surfactants with the same number of ethoxy 
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oleyl alcohol CH3(CH2)7CH=CH(CH2)7CH2OH






All alcohol ethoxylated surfactants with 2 ethoxy groups (Figure 4.15a) caused a 
similar decrease in rate and final extent of MCT digestion compared to the control, 
irrespective of the alcohol moiety present. A difference was noted in the shape of the 
digestion profiles as a smooth curve was observed in the presence of LAEs, as 
opposed to the two stage digestion profile shown by 2-NPE (Figure 4.15a).
Figure 4.15b revealed higher inhibitory activity towards pancreatin from a LAE with 
an ethoxylation number of 4 (4-LAE) compared to 4-NPE. The 4-LAE inhibited 
pancreatin to almost the same extent as 7-NPE (Figure 4.15b). Likewise the profiles 
produced in the presence of 10-LAE also showed greater inhibition of pancreatin 
activity than 10-NPE (Figure 4.15c). In the case of 10-LAEi6;o the extent of 
pancreatin inhibition was equivalent to that shown by the 12-NPE profile (Figure 
4.15c). Comparison of digestion profiles produced in the presence of 3 and 8-LAE 
also exhibited higher inhibitory activity towards pancreatin than NPEs with the same 
number of ethoxy groups (results not shown).
LAEs with ethoxylation numbers from 3 up to 10 inclusively therefore appear to be 
more efficient inhibitors of pancreatin activity when compared to NPEs with identical 
ethoxylation numbers. However in the case of the highly ethoxylated 20 and 23-LAE 
surfactants with HLB values of > 15 the reverse situation is seen, with the LAEs 
having a reduced inhibitory effect compared to 20 and 23-NPE (Figure 4.15d). This 
effect also occurred for a LAE with an ethoxylation number of 12 (HLB of 14.3) 
which exhibited less inhibition than 12-NPE (Figure 4.15c).
4.7.3 Comparison of the potency of inhibition of LAEs and NPEs in relation to 
surfactant HLB value.
To demonstrate the potency of inhibition of LAEs and NPEs in terms of HLB value, 
the time taken for pancreatin to digest 2.5 % of MCT, t2.5 % for both groups of 
surfactants is shown in Figure 4.16. A relationship can be seen between surfactant 
HLB value and t2.5 % for the LAEs which closely resembles the general trend shown by 
the NPEs (described in section 4.3.2).
For the LAEs with HLB values in the range of 10 to 13 inhibition increases steeply 
(Figure 4.16). The inhibitory effect reaches an apparent maximum at a HLB value of
13 (corresponding to an 11-LAE) compared to the apparent maximum value of 15 
shown by NPEs (corresponding to a 15-NPE). Figure 4.16 also reveals a sharp 
reduction in inhibition as the HLB increases above 13 for LAEs which follows the 
pattern shown by NPEs, although for LAEs the decrease starts at a lower HLB value.
4.7.4 Influence of the alkyl chain of LAEs on inhibition of pancreatin activity.
Digestion profiles in Figures 4.15a-d were examined to determine if the length of the 
linear alkyl chain influenced the extent of inhibition of pancreatin by LAEs. 
Comparisons were made between digestion profiles from surfactants with alkyl chains 
of Ci2:o Ci6:o, Ci8:0, Ci8:i (Brij series), a C i6-i8 mixture (Lutensol AT series), and a C13- 
15 mixture (Lutensol AO series).
The Ci6:o surfactants with 2 and 10 ethoxy groups had slightly increased inhibitory 
behaviour compared to the Ci8:o and Ci8:i chains with the same ethoxylation number 
(Figures 4.15a and c). However for highly ethoxylated LAEs the reverse situation was 
seen, as the 20-LAEi6:o exhibited less inhibition of pancreatin than the Cis chain 
equivalents (Figures 4.15d).
Investigation of the effect of a mixed C16-18 chain (1 I-LAE16-18) (Figure 4.15c) could 
not be determined as another 11-LAE was not available for comparison. Likewise no 
conclusion could be drawn regarding a difference in inhibitory behaviour between the 
fatty alcohol derived hydrocarbon chains (Ci6:o, Ci8:o, Ci8:i, Ci6-is) and the synthetic 
alcohol derived chain (C13-15) due to the small number of C 13.15 surfactants available. 
However a direct comparison was possible for the surfactants with an ethoxy chain 
length of 10, where less inhibition was seen from the C13-15 than the longer alkyl chain 
equivalents (Figure 4.15c). The existence of a double bond in the Ci8:i chain appears 
to confer an increase in potency of inhibition when compared to the saturated Ci8:o 
chain with the same extent of ethoxylation in Figures 4.15a, c and d.
4.7.5 Mechanism proposed to explain the inhibitory effect of LAEs on pancreatin 
activity.
The mechanism of inhibition proposed to explain the effect of NPEs on pancreatin 
activity involved the position of the lipophilic and hydrophilic moieties of the 
surfactant when partitioned into the lipid interface. If orientation of the linear alcohol 
ethoxylated surfactant molecule at the interface is also related to potency of inhibition 
towards pancreatin, results from this study can possibly be explained.
The LAEs exhibited higher inhibitory activity towards pancreatin than NPEs with the 
same ethoxylation number up to a HLB of approximately 13, thereafter as surfactant 
hydrophilic character was increased the NPEs had higher inhibitory activity. The 
difference in inhibitory activity between the two groups of alcohol ethoxylated 
surfactants may relate to the partitioning behaviour of the hydrocarbon moiety of the 
surfactant into the lipid interface.
The linear alkyl chain of LAEs has higher hydrophobic character than the nonylphenol 
moiety of NPEs and could therefore be assumed to provide the most efficient anchor 
for a surfactant molecule into the lipid interface. However as the hydrophilic nature of 
the surfactant is increased by more extensive ethoxylation the LAEs become less 
inhibitory than NPEs, inferring the NPEs to be more efficiently retained within the 
lipid interface. The mechanism behind this result may be due to the short, fluid alkyl 
chain on nonylphenol making the molecule easier to dissolve in the core of the lipid 
droplet, compared to the straight hydrocarbon chain of LAEs.
The same reasoning can also be related to the stronger inhibitory action of LAEs 
compared to NPEs with the same extent of ethoxylation below a HLB value of 13.
The more efficient partitioning of the nonylphenol component in lipid could draw the 
surfactant further into the lipid droplet leaving less ethoxy groups at the interface 
relative to an LAE with comparable ethoxylation. The LAEs would then have a higher 
proportion of the ethoxy chain at the surface to mediate more effective inhibition of 
pancreatin via hydrophilic effects.
Insufficient surfactants were available to enable any conclusions to be drawn with 
regards to influence from the hydrocarbon chain of LAEs on inhibition of pancreatin 
activity. Varying the length of the alkyl chain by two carbons did change the potency
of inhibition exhibited by LAEs with the same ethoxylation number. However the 
difference remained minimal and related to the altered HLB value of the surfactant. 
The presence of a double bond in the alkyl chain did appear to increase inhibition, 
possibly by enhancing flexibility of the alkyl chain and thus partitioning into lipid.
4.8 Castor oil ethoxylated surfactants
(including hydrogenated castor oil ethoxylates).
The ethoxylated forms of castor oil are widely used in pharmaceutical preparations as 
solubilisers, dispersants, emulsifiers and emollients. Two series of ethoxylated castor 
oil derivatives were obtained for testing, the Etocas series (castor oil ethoxylates) and 
the Croduret series (hydrogenated castor oil ethoxylates). Hydrogenation of the 
carbon to carbon double bond in castor oil forms the Croduret series, which have 
greater chemical stability compared to the castor oil ethoxylated surfactants. The 
general formula of a castor oil ethoxylated surfactant180 is shown below:
The number of moles of ethylene oxide reacted per mole of castor oil is the sum of x, 
y and z, which in turn is expressed as the ethoxylation number.
The castor oil ethoxylates (Etocas and Croduret series) were assessed for potency of 
inhibition towards pancreatin activity by production of digestion profiles, as described 
in section 4.6. Results were examined in relation to the HLB value of the surfactants. 
The Croduret series, by comparison with Etocas surfactants, enabled examination for 
alteration in inhibitory activity due to hydrogenation of the double bond in castor oil. 
An attempt was also made to determine the HLB value of the surfactant Cremophor, 
also a hydrogenated castor oil ethoxylate, used extensively in Chapter 3.
4.8.1 Results and discussion
Figures 4.17 and 4.18 illustrate the digestion profiles produced using the Etocas and 
Croduret surfactants respectively, with the ethoxylation number and HLB value 
indicated for each surfactant. From comparison of the digestion profiles with the 
control, all castor oil ethoxylated surfactants markedly reduced pancreatin activity 
towards MCT (Figures 4.17-4.18).
Surfactants with a high degree of ethoxylation (HLB range 12.7 to 14.7) almost 
completely suppressed pancreatin activity throughout the hour assay (Figures 4.17- 
4.18). However if the assay had continued for a longer period, ranking of the 
surfactants in terms of potency of inhibition may have been possible from comparison 
of the duration of the lag phase. At HLB values above 14.7 inhibition started to 
decline within the assay period (i.e. Etocas-100 with a HLB of 16.5) (Figure 4.17). 
The surfactants with a low extent of ethoxylation, (Etocas-5 and Croduret-7) have 
HLB values of 3.9 and 5 respectively, and thus high lipophilic character. Both of these 
surfactants had a greater inhibitory effect on pancreatin activity than alcohol 
ethoxylates with the same number of ethoxy groups (comparison not shown). A 
possible explanation for their higher inhibitoiy effect may be due to strong attractive 
forces between the substantial castor oil component and MCT. Resultant adsorption 
of the hydrophobic castor oil moiety of the surfactant to the lipid interface could 
restrict binding of enzyme to the substrate, if surfactant concentration was sufficient 
to cover all of the interface.
Etocas-10 with a HLB value of 6.3 showed less inhibition (Figure 4.17) than 10-NPE 
/ LAE surfactants (Figure 4.15c). The reduced inhibitory effect from the same number 
of ethoxy groups may be due to the manner of their distribution on the surfactant 
molecule. The castor oil molecule has three sites where ethoxylation is most likely to 
occur (on the hydroxyl groups), with a possibility of ethoxylation also at the site of 
the three carbonyl groups. In the case of alcohol ethoxylates all the ethoxy groups 
form a single chain upon one site. Therefore if inhibitory effect is due to a barrier 
formed by ethoxy groups at the lipid interface, the castor oil ethoxylates would 
require a higher degree of ethoxylation to build up the length of the ethoxy chains,
and thus reach the same inhibitory effect as an alcohol ethoxylate with a lower 
ethoxylation number.
Some evidence of this was shown upon comparison of the potency of inhibition of 
Etocas and Croduret surfactants with that of the NPEs, using the time taken for 
pancreatin to digest 2.5 % of MCT, t2.5 %. Figure 4.19 illustrates the relationship 
between t2.5 % and HLB value for the castor oil derived surfactants, which can be seen 
to resemble the trend exhibited by the NPEs (also shown). Of those examined, the 
castor oil ethoxylate with the highest inhibitory effect had a HLB of approximately 14 
and an ethoxylation number of 50; the most inhibitory NPE had an ethoxylation and 
HLB number of 15 (Figure 4.19). The surfactants have similar HLB values despite the 
wide difference in ethoxylation number, as the castor oil ethoxylates require extensive 
ethoxylation to offset influence from the high molecular weight lipophilic castor oil 
component of the surfactant.
The effect of hydrogenation of castor oil on inhibition of pancreatin activity was 
examined by comparison of Etocas and Croduret surfactants with identical 
ethoxylation numbers, 40 and 60. No difference in potency of inhibition was evident 
between digestion profiles of Etocas-40 and Croduret-40 whereas when 60 ethoxy 
groups were present, Etocas-60 was less inhibitory. These conclusions were drawn 
from examination of the profiles shown in Figures 4.17 and 4.18 using a larger scale. 
Etocas-60 and Croduret-60 both have a HLB value of 14.7 which appears to be near 
the HLB region where the potency of inhibition towards pancreatin starts to decline 
due to high hydrophilic character of the surfactant. The difference between profiles 
was small and hence may be due to experimental variation. Alternatively Croduret-60 
may have retained potency of inhibition more efficiently than Etocas-60 due to 
increased molecular stability conferred by hydrogenation, however further data would 
be necessary to support this suggestion.
4.8.2 Examination of the potency of inhibition of Cremophor in relation to other
castor oil derived ethoxylated surfactants.
Cremophor, a hydrogenated castor oil ethoxylate with an ethoxylation number of 45, 
was used in Chapter 3 to investigate the type of inhibition shown by non-ionic 
surfactants towards pancreatin activity. From subsequent work in this chapter the 
extent to which non-ionic surfactants inhibit pancreatin appears to be related to the 
HLB value of the surfactant. The HLB value of 14 to 16 stated for Cremophor in the 
product data sheet was in an area where Etocas and Croduret surfactants started to 
lose inhibition as hydrophilic character increased.
Personal communication with the manufacturer did not provide further information 
regarding a more precise HLB value for Cremophor. The potency of inhibition of the 
Etocas and Croduret surfactants appeared to be related to their HLB value. Using this 
relationship an attempt was made to determine a narrower HLB range for Cremophor 
and to assess the potency of inhibition of Cremophor in relation to other castor oil 
ethoxylated surfactants.
A digestion profile of MCT in the presence of Cremophor was produced under 
identical conditions to those used for the Etocas and Croduret series. The resulting 
profile was similar to the profiles from the Etocas and Croduret surfactants with 
ethoxylation numbers of 40 to 60. Enzyme activity in the presence of Cremophor was 
revealed to be almost completely suppressed throughout the hour assay, with total 
MCT digested not exceeding 3.5 % (data not shown).
The tz 5 % value from the digestion profile of Cremophor is represented in Figure 4.19 
across a HLB range of 13.6 to 14.7. This HLB range was calculated for Cremophor 
using analytically determined saponification values stated in the product data sheet 
and Equation 4.1. The ricinoleic acid number181 of 187.98 was used for the calculation 
as ricinoleic acid constitutes 90 % of the fatty acids in castor oil182. From 
compositional data of Cremophor a further HLB value of 13.6 was calculated via 
Equation 4.2 which fell within the same range given by Equation 4.1.
The trend between tzs % and HLB value for the Etocas / Croduret surfactants exhibits 
considerable scatter and could not be used with confidence to determine a HLB value 
for Cremophor. The position of tzs % from Cremophor (Figure 4.19) in relation
to tzs % from other castor oil derived surfactants suggests Cremophor to have a HLB 
value of approximately 14.5, which falls within the range specified by the data sheet 
and calculated via Equation 4.1. Figure 4.19 also reveals that Cremophor is not as 
inhibitory towards pancreatin as some of the other castor oil derived surfactants or 
NPEs examined.
4.9 Sorbitan esters and polyethoxylated sorbitan esters.
The sorbitan esters and the polyethoxylated sorbitan esters (PSEs) have become well 
established surfactants due to their low toxicity and wide range of applications in the 
pharmaceutical and food industry165. The sorbitan esters are effective water in oil 
emulsifiers and can act as wetting and dispersing agents for powders in lipophilic 
systems. When ethoxylated these surfactants display properties of oil in water 
emulsification and solubilization. The popularity of sorbitan esters and PSEs is due in 
part to the ease with which the two types can be combined to achieve the degree of 
emulsification required for a particular oil in water system.
Sorbitan esters are produced by the dehydration of sorbitol, to form a cyclic ether.
The resulting anhydrous sorbitol has four alcohol groups remaining which are capable 
of undergoing esterification. Esterification can occur solely with fatty acids to form 
sorbitan esters or with fatty acids and ethylene oxide resulting in PSEs. The sorbitan 
esters and PSEs are described in terms of their degree of esterification with fatty acid, 
for example if only one alcohol group on the sorbitan moiety is esterified with fatty 
acid the surfactant is known as a monoester. The sorbitan esters and PSEs used in this 
study are monoesters or polyesters formed using one of the following fatty acids:
Common names Structural Formula Referred to in text as:
lauric acid CH3(CH2)ioCOOH (Ci2:o)
palmitic acid CH3(CH2)i4COOH (Ci6:o)
stearic acid CH3(CH2)i6COOH (Cig:o)
oleic acid CH3(CH2)7CH=CH(CH2)7COOH (Ci8:i)
The general formula for a sorbitan monoester and a polyethoxylated sorbitan 
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where R = the alkyl group of the fatty acid.
x +y + z -  the total number of moles of ethylene oxide (= to the ethoxylation
The ethoxy groups of a polyethoxylated sorbitan ester (PSE) will be distributed on the 
x, y  and z positions shown in the diagram in the case of monoesters or all upon one 
position for triesters, although some literature sources85, 165 suggest ethoxylation is 
also possible on the carbonyl groups of the fatty acids. Personal communication with 
Croda, the supplier of the majority of the sorbitan derived surfactants used in this 
study, confirmed ethoxylation was possible on the carbonyl group of the fatty acids 
for their products, although ethoxylation on the hydroxyl groups was favoured.
Sorbitan esters are classified as non-ionic surfactants, as although they are mainly 
dominated in character by the lipophilic fatty acid chains, a weak hydrophilic influence 
is conferred by the sorbitan moiety. The fatty acid chains give sorbitan esters high 
solubility in lipophilic systems which increases with the extent of fatty acid 
esterification. This is reflected in their HLB values which decrease from the 
monoesters down to the triesters.
The sorbitan esters (Crill and Span series) and the PSEs (Crillets and Tween series) 
were assessed for potency of inhibition towards pancreatin activity by production of 
digestion profiles, as described in section 4.6. Results were examined in relation to the 
ethoxylation number and HLB value of the surfactants (which ranged from 1.8 to 
16.7); the extent of fatty acid esterification and the nature of the fatty acid component 
of the surfactant was also considered.
number) reacted with one mole of sorbitan ester to form PSEs.
4.9.1 Results and discussion
Figure 4.20 illustrates digestion profiles produced in the presence of sorbitan 
monoesters and their counterparts with an ethoxylation number o f20 (20-PSEs). 
Sorbitan monoesters generally caused a slight depression in enzyme activity at steady 
state, with total MCT digested after one hour marginally decreased compared to the 
control (Figure 4.20).
The digestion profiles from the 20-PSEs exhibited significant suppression of 
pancreatin activity, shown as an extended lag phase; in addition less than 25 % of the 
total MCT available was digested within the one hour assay (Figure 4.20). 
Comparison of results in Figure 4.20 suggest ethoxylation is responsible for the 
extensive inhibitory activity of 20-PSEs towards pancreatin.
A trend between the length of the fatty acid chain and potency of inhibition was not 
apparent from profiles in Figure 4.20, however for both sorbitan monoesters and 20- 
PSEs the Ci8:i chain had a higher inhibitory effect than the Ci8:o chain. This is in 
agreement with results from the LAEs, where Ci8:i consistently showed increased 
inhibition compared to Ci8:o (Figure 4.15a, c & d).
Figure 4.21 illustrates digestion profiles from the complete series of PSEs tested. 
Inhibitory activity was noted to increase with the extent of ethoxylation of the PSEs, 
however the trend appeared random relative to the HLB values of the surfactants. A 
lag phase which lasted for the total duration of the assay occurred in the presence of 
Ci8:o and C i8:i 20-PSEs (monoesters) (Figure 4.21) with a HLB value of 
approximately 15. The same potency of inhibition was shown by the Ci8:o and C i8:i 
20-PSEs (triesters) at a lower HLB value of 10 to 11 (Figure 4.21).
For a polyethoxylated sorbitan triester to exhibit the same HLB value as a 
polyethoxylated sorbitan monoester with an identical fatty acid chain, the triester 
requires a higher degree of ethoxylation to offset the lipophilicity conferred by the 
two additional fatty acid chains. To illustrate this point the C is:i 5-PSE (monoester) 
with only 5 ethoxy groups has a HLB of 10 whereas the C is:i triester with a HLB of 
11 has 20 ethoxy groups. Digestion profiles produced in the presence of both 
surfactants are shown in Figure 4.21 where despite similar hydrophile / lipophile 
balance within the molecule, the triester is more inhibitory towards pancreatin.
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Several reasons may be responsible for this effect. A triester may be a more efficient 
inhibitor than a monoester with the same HLB value due to the higher number of 
ethoxy groups available to form a more effective ethoxy barrier at the lipid interface. 
Alternately the additional fatty acids could enhance inhibition by promoting stronger 
hydrophobic binding between the surfactant and lipid interface, thus blocking access 
of pancreatin to substrate. Finally the larger size of the triester surfactant molecule 
may be involved by preventing enzyme / substrate binding via spatial effects.
Evidence for the existence of a lipophilic mechanism of inhibition is given by 
comparison of the potency of inhibition shown by the non-ethoxylated sorbitan 
triesters (Ci8:o and Ci8:i) and their monoester counterparts (Figure 4.22). The 
increased inhibitory effect of the triesters is solely due to raised surfactant lipophilicity 
from the additional fatty acids. The pattern of inhibition from these lipophilic 
surfactants involves a decrease in both enzyme activity at steady state and total MCT 
digested at the end of the assay. The reduction in pancreatin activity does not show 
the characteristic lag phase seen with inhibition from ethoxylated surfactants (e.g. 
Figure 4.21, C i8:i 5-PSE).
The conclusion from these comparisons is that the extent of inhibition of pancreatin 
activity may be related to the degree of ethoxylation and the lipophilic character of the 
surfactant. These two influences may act either in combination (as proposed in section
4.5) or independently depending on the structure of the surfactant. When assessing 
results from these sorbitan derived surfactants any influence on inhibition of 
pancreatin from the hydrophilic sorbitan ring was considered unlikely, other than 
through general spatial obstruction to enzyme binding.
4.10 Polyglycolized Glycerides.
Polyglycolized glycerides are ethoxylated esters made by an alcoholysis reaction of 
natural oils with polyethylene glycols. The polyglycolized glycerides have many 
pharmaceutical applications, however of particular interest to this study is their 
proposed ability to improve the bioavailability of hydrophobic drugs when 
administered orally184. The amphiphilic nature of the polyglycolized glycerides is 
suggested to enable formation of oil in water dispersions, miscible with cholesterol,
triglycerides and phospholipids present in the GI fluid. In addition a polyglycolized 
glyceride oil, Labrasol included in this study has been described as exhibiting good 
solvent capabilities and emulsification properties to aid formation of emulsions and 
microemulsions. The polyglycolized glycerides have the added advantage of solubility 
in vegetable oils and compatibility with gelatin capsule shells.
From the above description polyglycolized glycerides appear particularly suited for 
use in lipid-based formulations for hydrophobic drugs. Inhibition of pancreatin activity 
by these surfactants may therefore be especially relevant in terms of enhancement of 
the bioavailability of drugs via lipolysis. The polyglycolized glycerides (Labrafil series 
(Cig complex with PEG), Labrafac (Cg-Cio + PEG 400) and Labrasol (Cg-Cio + PEG 
8)) were assessed for potency of inhibition towards pancreatin activity by production 
of digestion profiles, as described in section 4.6.
4.10.1 Results and discussion
Figure 4.23 illustrates digestion profiles produced in the presence of each 
polyglycolized glyceride. The medium chain polyglycolized glycerides (Cg:io) had little 
influence upon pancreatin activity, although a lag phase of short duration was seen 
with the 8-PEG version.
The long chain polyglycolized glycerides (6-PEG Cig:i and Cig^) depressed pancreatin 
activity at steady state with a decrease in total MCT digested upon completion of the 
assay compared to the control. The Cig:2 8-PEG showed similar behaviour with the 
introduction of a short lag phase, probably due to higher hydrophilic character 
compared to the 6-PEG variants.
The inhibition of pancreatin activity by the Cig:i and Cig:2 polyglycolized glycerides 
followed the same trend with HLB value as seen with the other surfactant groups 
already discussed. This may be due to the fact that the long chain polyglycolized 
glycerides are composed of natural oil in a complex with PEG. On the other hand the 
medium chain polyglycolized glycerides (Cg:io) showed little inhibition relative to their 
HLB numbers of 10 and 14, values which for other surfactant classes resulted in 
extensive enzyme inhibition. This may be a result of the composite nature of these 
products.
The polyglycolized glyceride (Cs:io) is present with free glycerides and probably free 
polyethylene glycol as well. As the surfactant is added to the assay by weight the 
mixture of constituents will have reduced the concentration of inhibitory substance 
present within the reaction system. Free polyethylene glycol would be expected to 
partition into the aqueous phase. More importantly the free medium chain glycerides 
could be assumed to be available at the lipid interface for hydrolysis by pancreatin and 
to enhance binding of colipase according to the colipase partitioning theory. This may 
explain the short lag phase seen, and a final extent of triglyceride digestion equivalent 
to that shown by the MCT control.
4.11 Influence of surfactant chemical structure upon inhibition of pancreatin.
The above investigation (section 4.7-4.10) has provided evidence to suggest that the 
chemical structure of the surfactant, in addition to the HLB value, was related to the 
potency of inhibition of a surfactant. The pattern of inhibition shown across a 
digestion profile had a particular character depending upon whether the lipophilic or 
hydrophilic moiety of the surfactant was dominant. This in turn suggested inhibition to 
be mediated by different mechanisms.
Potency of inhibition ofNPEs was proposed to relate to partitioning of the surfactant 
molecule into the lipid interface and extensive inhibition was seen when the ethoxy 
chain was long enough to adopt a meander form. The resulting ethoxy mantle created 
around the lipid droplet could prevent enzyme binding by spatial and possibly 
detergent mediated effects.
The partitioning behaviour of the hydrophobic moiety of the alcohol ethoxylates into 
the lipid interface was proposed to be responsible for difference in inhibitory activity 
between NPEs and LAEs with similar ethoxylation numbers. The aromatic 
hydrophobe ofNPEs was suggested to increase retention of surfactant within the lipid 
interface compared to the linear alkyl chain of LAEs.
The high potency of inhibition demonstrated by the castor oil ethoxylates was 
suggested to relate to the extensive hydrophobic castor oil component. In all cases 
digestion profiles from the castor oil ethoxylates displayed a lag phase indicating an 
initial delay in enzyme activity. Interestingly existence of a lag phase for lipophilic
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members of a surfactant series was peculiar to the castor oil ethoxylates. All lipophilic 
members of the other surfactant groups tested did not exhibit a lag phase but 
suppressed enzyme activity across the whole digestion profile. Suppression of enzyme 
activity across the whole profile has been proposed to be a result of incorporation of 
surfactant molecules into the interface, where they effectively dilute the concentration 
of substrate available at the interface. The large size of the castor oil component and 
the close proximity of the ethoxylation sites to the fatty acid chains may prevent 
integration of these surfactants into the triglyceride interface. Instead a surfactant 
layer may be formed upon the MCT surface thus preventing initial enzyme / substrate 
binding resulting in a lag phase.
The number of sites of ethoxylation on a surfactant molecule may also be relevant to 
the extent of inhibition. If an identical number of ethoxy groups are distributed over 
several positions on a molecule as opposed to forming a single chain on one site 
reduced inhibition may be expected. This would be due to the longer single chain 
being able to protrude further from the lipophilic moiety of the surfactant, forming a 
more effective ethoxy mantle than several shorter chains. Further surfactants were 
required to test this hypothesis.
Comparison of sorbitan mono and triesters demonstrated that an increase in lipophilic 
character of the surfactant increased potency of inhibition. The same triester displayed 
a further enhancement in potency of inhibition when ethoxylated. This inferred that 
hydrophilic inhibition from ethoxylation and substrate dilution from the lipophilic 
moiety can occur at the same time to increase inhibition of pancreatin. This alone 
cannot however be taken as definite evidence of combined lipophilic and hydrophilic 
inhibitory mechanisms as results may simply be reflecting spatial obstruction from the 
larger surfactant structure to enzyme / substrate binding.
4.12 Conclusions from the investigation of inhibition of pancreatin activity by 
non-ionic surfactants.
From these investigations of various groups of non-ionic surfactants it is clear that 
under conditions of the standard pH-stat assay a relationship exists between the 
hydrophile-lipophile balance of a surfactant and the ability of the surfactant to inhibit
pancreatin activity towards MCT. At low HLB values surfactants have been proposed 
to inhibit pancreatin via lipophilic effects whereas when HLB is increased by 
ethoxylation hydrophilic inhibitory mechanisms may come into play. However the 
results suggest HLB not to be the only factor involved, as the structure of the 
hydrophobe also appears to have an influential effect on the potency of inhibition 
shown by a surfactant. In general for surfactants with the same extent of ethoxylation, 
inhibitory effect appears to increase with the size of the hydrophobic moiety.
It could be argued that the overall size of the surfactant molecule when present at the 
lipid-water interface may alone be sufficient to inhibit lipase purely by preventing 
access of colipase to the substrate. The altered nature of the digestion profiles 
according to HLB value of the surfactant however tends to suggest the situation is 
more complex. For surfactants with dominant hydrophilic character the effect upon 
digestion of MCT is to delay initial enzyme activity as indicated by a lag phase on the 
digestion profile. The lag phase is subsequently overcome after a variable period of 
time which tends to increase with the hydrophilic character of the surfactant. 
Conversely the lipophilic surfactants from all groups, except the castor oil ethoxylates, 
decreased enzyme activity at steady state without evidence of a lag phase. Inhibition 
in this case was proposed not to be mediated by surface activity but to relate to a 
substrate dilution effect with surfactant molecules acting as inert spacers, reducing 
triglyceride concentration available at the interface for hydrolysis.
Lipophilic surfactants also tended to cause a reduction in the percentage of 
triglyceride digested upon completion of the assay compared to that shown by the 
MCT control. This may be a result of low HLB surfactants forming two phases of 
droplets, one of which is rich in surfactant. Any MCT incorporated in this phase could 
be expected to be held in a form unavailable to pancreatin, thus explaining the reduced 
level of triglyceride digestion observed at the end of the profile.
Throughout this study the mechanism of inhibition has been related to surfactants 
altering the availability of the substrate to the enzyme. A further point to remember is 
that MCT / surfactant emulsion systems could be expected to have different interfacial 
areas depending upon the HLB value of the surfactant, which could also influence 
pancreatin activity to some extent. The possibility of surfactant monomers in solution 
having a direct influence on the catalytic properties of lipase also cannot be ignored;
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some detergent molecules have been observed in crystallographic studies35 to locate at 
the entrance of the active site of lipase, bound to the hydrophobic part of the lid. In 
discussions throughout this chapter it has been assumed that digestion recorded 
related directly to pancreatin activity towards MCT. However as demonstrated by 
data in Chapter 5 certain surfactants are also available to digestion by pancreatin. 
Further experimentation would enable assessment of the extent to which this may 
have contributed to the results.
4.12.1 Relevance of findings to the use of surfactants within formulations.
This investigation has provided some guidance regarding selection of a surfactant for 
a lipid-based formulation in terms of minimizing possible inhibition of pancreatin 
activity:
• Surfactant series
For a surfactant series potency of inhibition can be predicted to some degree by 
testing a few surfactants spread across the HLB range. For example, results from the 
castor oil ethoxylates indicate that all members of the series have substantial inhibitory 
properties, irrespective of HLB value. This suggests the use of a castor oil based 
surfactant is best avoided.
• Minimum inhibitory HLB value within a surfactant series
Through a homologous series of surfactants, as the degree of ethoxylation is increased 
a point is reached where the hydrophilic and lipophilic moieties of the surfactant 
balance for a particular emulsion system. The degree of hydration of the interfacial 
film at this balance point brings the curvature of the adsorbed monolayer to near zero, 
the oil-water interfacial tension is at a minimum and the resulting oil in water emulsion 
exhibits maximum stability170.
From investigation of the NPEs, Figure 4.4 shows inhibition of pancreatin activity to 
be at its lowest at a HLB value of approximately 11, which corresponds to the 
surfactant, 6-NPE. This surfactant may possess low lipophilic influence, in 
combination with an ethoxy chain too short to mediate inhibitory activity. Another
possibility is that 6-NPE may be the member of the surfactant series where the 
hydrophilic and lipophilic moieties of the surfactant are most evenly balanced at the 
interface under conditions of the standard pH-stat assay. The emulsion thus formed 
with 6-NPE, from the discussion above, would be expected to have a low interfacial 
tension. Lipase has already been shown to be prevented from binding to lipid due to 
high interfacial pressure and colipase was proposed to overcome this inhibition by 
increasing the interfacial pressure at which lipase could bind176. A surfactant capable 
of reducing interfacial tension could thus be assumed to promote lipase binding, hence 
inhibitory effects from the surfactant would be reduced.
If the same behaviour was shown through a series of surfactants suitable for use in a 
lipid-based formulation, the surfactant showing the lowest potency of inhibition could 
be chosen. A possible disadvantage of this approach is the need to assess several 
members of a particular surfactant series, across a wide range of HLB values, to 
enable detection of the HLB value where surfactant is most evenly balanced at the 
interface and thus least inhibitory.
• Length of the ethoxy chain
Results from the alcohol ethoxylated surfactants have shown that when the 
hydrophilic moiety of the surfactant was dominant, the potency of inhibition of the 
surfactant rapidly increased with each additional ethoxy group (Figure 4.6). Use of a 
surfactant with the shortest ethoxy chain possible, (and the properties required for the 
lipid-based formulation), would appear prudent in terms of minimization of 
interference with pancreatin activity.
These guidelines may lead to selection of the surfactant least likely to impede enzyme 
activity however the surfactant chosen on this basis may not provide the 
emulsification properties required by the lipid-based formulation. An interesting field 
to investigate would be the inhibitory capability of surfactant combinations such as 
mixtures of sorbitan esters with the polyethoxylated variants, which when combined 
enable selection of any HLB value.
4.13 Physicochemical characterization of surfactants.
The non-ionic surfactants utilized in this chapter were commercial surfactants known 
to be of variable composition. During the manufacturing process the addition of 
ethylene oxide to the hydrophobic moiety of the surfactant usually results in a Poisson 
distribution of the length of the ethoxy chains185. The properties of the surfactant 
material produced will therefore be dependent on the average extent of ethoxylation. 
HLB values used in this investigation for correlation with potency of surfactant 
inhibitory behaviour were based upon the ethoxylation number stated by the 
manufacturer. This number should be representative of the mean number of ethoxy 
groups on the surfactant molecule. To validate the HLB values used to compare the 
behaviour of surfactants, the mean degree of ethoxylation was determined for the 
majority of the alcohol ethoxylated surfactants included in the study. This was 
achieved using the techniques of cloud point determination and NMR.
4.13.1 Determination of cloud point temperature.
When an ethoxylated non-ionic surfactant is dissolved in water, solubility of the 
surfactant relies upon interactions between the hydrophilic ethoxy chain and water. If 
the temperature of the solution is gradually increased hydration forces between the 
ethoxy chain and water weaken, with a consequent reduction in solubility171. 
Eventually a temperature is reached at which the hydrophilic forces are no longer 
sufficient to maintain solubility of the surfactant in water and cloudiness is seen due to 
separation of the solution into two phases. The term cloud point185 is used to describe 
the temperature at which this cloudiness occurs.
The cloud point temperature closely reflects the extent of ethoxylation of a surfactant 
and for materials with the same hydrophobe correlation between cloud point and 
ethoxy group content is quite precise185. Due to this statement of precision between 
cloud point and the degree of surfactant ethoxylation, cloud point determination was 
attempted for selected NPEs (Dowfax, Arkopal and Lutensol AP series) and LAEs 
(Lutensol AO and AT series) used in the inhibition study.
Method
For each surfactant a 1 % w/v solution was prepared using distilled water at 4°C. After 
thorough mixing a description was taken of the resulting surfactant and water 
mixture. Stirring was maintained as the integral heating element of the magnetic stirrer 
gradually increased the temperature of the solution. Temperature was indicated by a 
thermometer suspended within the solution.
Temperature was recorded when slight clouding was first observed and again upon 
definite clouding which tended to occur suddenly. To aid determination of clouding a 
black background was used behind the solution.
Results
The temperature of definite clouding was taken to represent cloud point temperature 
under the experimental conditions used. The temperature when clouding was first 
observed allowed ranking of surfactants which exhibited identical cloud point 
temperatures.
According to the above definitions the NPEs and LAEs tested were listed in 
ascending order of cloud point temperature (Table 4.3). The results enabled ranking 
of surfactants with manufacturer quoted HLB values of 12 to 15 inclusively, in terms 
of degree of ethoxylation. It was not possible to determine cloud points for 
surfactants stated to have chain lengths of between 2 and 7 ethoxy groups as these 
surfactants were not soluble in an aqueous system. However using the principle that 
surfactants with less ethoxy groups display characteristics of higher lipophilicity, the 
description of the surfactant solution at 4°C (Table 4.3) served to rank the 
surfactants. Surfactants ranked in this manner showed increased dispersibility in an 
aqueous system as the ethoxylation number specified by the manufacturer increased. 
The solutions of highly hydrophilic NPEs with an ethoxylation number stated by the 
manufacturer of 20 and above remained clear upon boiling. This result gave support 
to the stated length of the ethoxy chains, as clouding is known not to occur below the 
boiling point of water when ethylene oxide constitutes > 75 % of the surfactant 
molecule185. The surfactants tested must therefore have a minimum of 15 ethoxy 
groups as with any less the ethoxy chain would not exceed 75 % of the total 
composition of a nonylphenol ethoxylated surfactant molecule.
Overall the cloud point temperatures supported the ethoxylation number stated by the 
manufacturer. The only exceptions were 7.5-NPE which the experimental cloud point 
indicated to be closer to an average of 8 ethoxy groups and 15-NPE, the cloud point 
of which suggested a lower extent of ethoxylation.
The cloud point determinations have thus given increased confidence in the HLB 
values calculated from the ethoxylation numbers stated by the manufacturer and hence 
in the correlation between potency of inhibition of the surfactant and HLB value.
Surfactant











Solution appearance at 4°C
2-NPE (Dowfax) 5.7 2.0 Large oily droplets
4-NPE (Dowfax) 8.9 4.0 Coarse dispersion
4-NPE (Arkopal) 8.9 3.5 Fine, white dispersion
5-NPE (Dowfax) 10.0 5.0 Fine, white dispersion
6-NPE (Dowfax) 10.9 6.0 Fine, white dispersion
6-NPE (Arkopal) 10.9 5.5 Hazy, white suspension
7-NPE (Dowfax) 11.7 7.0 Hazy, white suspension
8-NPE (Arkopal) 12.3 8.0 16 Clear solution
7.5 -NPE (Dowfax) 12.0 8.0 17 Clear solution
10-NPE (Dowfax) 13.3 9.5 55 Clear solution
10-NPE (Arkopal) 13.3 10.0 63 Clear solution
11-NPE (Arkopal) 13.8 11.0 70 Clear solution
12-NPE (Dowfax) 14.1 11.5 77 Clear solution
15-NPE (Arkopal) 15.0 13.5 92 Clear solution
14-NPE (Lutensol) 14.7 14.0 96 Clear solution
20-NPE (Lutensol) 16.0 19.0 >99 Clear solution
23-NPE (Arkopal) 16.4 21.0 >99 Clear solution


























87 Clear solution, clouding first 
observed at 79°C
Table 4.3 Characterization of the degree of ethoxylation of alcohol ethoxylated 
surfactants via cloud point temperatures and *H NMR spectroscopy.
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4.13.2 NMR analysis
NMR (NMR) provides a method for identification of the number of protons 
present within a surfactant molecule in terms of their chemical environment, thus 
enabling prediction or confirmation of surfactant structure. NMR is commonly 
employed for studies of alcohol ethoxylated surfactants to determine the ratio of alkyl 
to ethoxy protons185. NMR spectrometry was thus applied to the alcohol ethoxylates 
for which cloud point determinations had been attempted, as an additional method to 
investigate the length of the surfactant ethoxy chain.
Method
A NMR spectrum was produced for each surfactant listed in Table 4.3 using one of 
the spectrometers listed below:
Jeol JNM EX400 Fourier Transform Nuclear Magnetic Resonance Spectrometer at an 
observation frequency of 399.78 MHz.
Jeol JNM GX270 Fourier Transform Nuclear Magnetic Resonance Spectrometer at 
an observation frequency o f270.16 MHz.
For each surfactant tested approximately 20 mg of sample was dissolved in 3 ml of 
CDC13 and checked to ensure no insoluble impurities were present. The surfactant 
sample solution was then introduced into precision ground tubes of 5 mm internal 
diameter to a depth of approximately 2 cm. NMR spectra were taken at a temperature 
of 22°C using tetramethylsilane as an internal reference compound.
Interpretation of spectra
Tables186 specifying expected chemical shift values for XH protons within a specific 
chemical environment were used to assign the signals to molecular structure; the !H 













suspended HDO -4 .7
Aromatic H 6-9
Table 4.4 NMR chemical shifts186 for proton indicated in bold.
R = alkyl group, Ar = aryl group. Values will normally be within 0.2 ppm 
unless electronic or anisotropic effects from other groups are strong186.
The nonvlphenol ethoxylated surfactants.
A typical !H NMR spectrum of a nonylphenol ethoxylated surfactant (obtained from a 
10-NPE sample) in C D C I 3  is shown in Figure 4.24 with assignments from chemical 
shift values in Table 4.4 indicated. Upon the spectra from all NPEs tested signals were 
exhibited in three regions, 7.2-6.8 ppm, 4.1-3.6 ppm and 1.6-0.5 ppm. The aromatic 
protons resonate in the 7 ppm region (peaks i and h) whilst the signals at 4.1-3.6 ppm 
(peaks e, f, and g) were proposed to be due to the ethoxy protons. The signals 
between the chemical shift values of 1.6 and 0.5 ppm (peaks a, b, and c) were 
assigned to the alkyl protons.
A NMR spectrum of nonylphenol was used to further verify that the resonance seen at 
1.6 to 0.5 ppm related to the alkyl protons. Nonylphenol produced signals only within 
the alkyl region (1.6 to 0.5 ppm) and the aromatic region (7.2-6.8 ppm) confirming 
the position of resonance predicted for ethoxy protons (4.1-3.6 ppm) upon the spectra 
of the NPEs. Nonylphenol exhibited the same resonance pattern as NPEs in the region 
of 1.6 to 0.5 ppm although the intensities of the peaks were altered, suggesting 
nonylphenol to have a different branched form of the nine carbon alkyl chain 
compared to the NPEs.
Ethoxy group protons
The ethoxy protons have already been assigned to signals in the 4.1 to 3.6 ppm 
region. In each spectrum a major peak was evident at 3.6 ppm (peak e) which
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increased in intensity when spectra from surfactants with longer ethoxy chains were 
compared. As this peak represented the extent of surfactant ethoxylation a means of 
calibrating the corresponding integral trace was required.
Calibration was achieved by use of two multiplets (peaks f  and g) shifted downfield 
(at approximately 4.1 and 3.85 ppm) to the major ethoxy peak. These multiplets were 
due to the protons from the ethoxy group adjacent to the aromatic ring. The signals 
from these protons were separated from the major ethoxy peak due to a deshielding 
effect from the aromatic ring known as n bond anisotropy187.
Determination of the mean degree of ethoxylation of each nonylphenol ethoxylated 
surfactant was thus approached by measurement of the integral trace step for peak f  
known to correspond to two protons. Division of the millimeter value for one proton 
into the variable peak e trace gave the number of ethoxy protons present. The four 
ethoxy protons represented by peaks f  and g were added to this figure and the total 
divided by four to determine the complete number of ethoxy groups present on the 
surfactant.
The calibration procedure was repeated for each spectrum as the integral trace is 
spectrum specific. The results were expressed to the nearest half ethoxy group and are 
shown in Table 4.3.
Alkyl protons
An attempt was made to confirm the identity of the alkyl chain using the NMR 
spectra. The number of alkyl protons present was determined from the three step 
integral trace above peaks a, b, and c (1.6 and 0.5 ppm) using the same calibration 
measurement employed to predict the number of ethoxy groups from peak e. For all 
NPEs examined the signal at 1.6 to 0.5 ppm confirmed the existence of 19 protons 
(error ± 1 proton) which corresponded to a nine carbon chain.
From chemical shift values (Table 4.4) the assumption can be made that peak a relates 
to methyl protons, peak b to methylene protons and peak c to methine protons. From 
comparison of the relative intensities of these peaks all spectra appear to exhibit an 
approximate proton ratio of 9(CH3):8(CH2):2(CH). The high proportion of methyl 
protons therefore suggests branching of the alkyl chain.
Commercial nonylphenol surfactants are described in the literature as typically 
containing a branched form of the alkyl chain. The chain does not tend to differ in
terms of molecular weight but as it is usually formed from a propylene trimer a 
mixture of isomers is possible185. The NMR results suggest all NPEs tested in this 
study have a branched chain structure, a possible arrangement for which is shown in 
Figure 4.24.
The hydroxyl proton
The chemical shift value of the hydroxyl proton attached to the terminal ethoxy group 
can vary between 0.5 and 4.5 ppm and may be represented on the spectrum in a 
broadened form, depending on sample concentration and hydrogen bonding186. To 
confirm the resonance position of the hydroxyl proton several spectra from NPEs and 
LAEs were repeated after shaking the sample with D20. This is expected to result in 
the exchange of the hydroxyl protons present for deuterium causing disappearance of 
the OH signal.
In each case the result of the deuterium shake was to remove the broad bump seen 
between 2 to 3 ppm on spectra from NPEs (e.g. Figure 4.24, peak d) and LAEs. A 
further signal was seen to occur at 4.8 ppm corresponding to HDO. This test 
therefore confirmed the position of the hydroxyl proton, allowing subsequent 
adjustment of the predicted number of alkyl protons if the integral also included the 
resonance area of the hydroxyl proton.
The linear alcohol ethoxylates
A typical NMR spectrum of a linear alcohol ethoxylated surfactant (obtained from 
an 11-LAE sample) in CDC13 is shown in Figure 4.25 with assignments from chemical 
shift values in Table 4.4 indicated. The spectra from the LAEs exhibited signals within 
two regions, 3.3 to 3.8 ppm and 1.6 to 0.8 ppm. The ethoxy protons were all 
proposed to be represented by peak f  (3.7 ppm) whilst the alkyl protons were 
represented by peaks a, b and c in the region of 1.6 to 0.8 ppm.
The triplet signal at 3.4 ppm (peak e) was due to the terminal methylene before the 
start of the ethoxy chain187. As this peak was known to represent 2 protons the 
measurement in millimeters of the corresponding step of the integral trace was used to 
determine the number of protons in the ethoxy and alkyl regions. If the integral trace 
above peak e was not well defined upon a particular spectrum the integral trace above 
the preterminal methylene at 1.6 ppm (peak c) provided an alternative means of
calibration. Each spectrum was produced in duplicate as sharp integrals were not 
always achieved.
The number of ethoxy groups predicted via the NMR data for each LAE tested 
corresponded to the value quoted by the manufacturer and results are shown in Table 
4.3. The alkyl chain of the LAEs tested was quoted by the manufacturer as being 
comprised of between 13 to 15 carbons for the Lutensol AO series and 16 to 18 for 
the Lutensol AT series. The NMR spectra indicated the mean length of the alkyl chain 
(Table 4.3), which for each LAE tested fell within the range specified by the 
manufacturer. In terms of the structure of the alkyl chain the spectra were not able to 
confirm this due to distortion of the integral above the methyl signal. However LAEs 
are made from alcohol starting material which is normally linear185 and the integral 
step ratios on the NMR spectra did not suggest a branched structure.
Conclusions from NMR spectroscopy.
In general the NMR spectra indicated the mean length of the ethoxy chain to be 
identical to the ethoxylation number stated by the manufacturer. However for nine 
NPEs tested NMR data did not agree with the values quoted by the manufacturer, 
although the results only differed between 0.5 to 2 ethoxy groups. For all but one of 
these surfactants the number of ethoxy groups predicted by NMR was lower than the 
manufacturer value. This is not surprising given the fact that NMR determines the 
mean length of the ethoxy chain whereas the ethoxylation number represents the 
number of moles of ethylene oxide reacted with one mole of the alcohol.
The NMR spectra were able to confirm the mean number of carbons in the alkyl chain 
of the alcohol ethoxylates. In addition NPEs appeared to have a branched alkyl chain 
structure whereas spectra from LAEs suggested a linear chain.
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4.14 Relationship between results from surfactant characterization and 
potency of inhibition shown by the NPEs.
The proposed relationship between surfactant HLB value and inhibitory behaviour of 
alcohol ethoxylated surfactants towards pancreatin had been based upon the 
ethoxylation number stated by the manufacturer, which was assumed to be equivalent 
to the mean length of the ethoxy chain. As the NMR data had revealed certain 
surfactants to have a different number of ethoxy groups compared to the ethoxylation 
number quoted by the manufacturer, Equation 4.2 was used to calculate a HLB value 
which reflected the length of the ethoxy chain determined by NMR.
To examine whether the correlation between potency of inhibition and HLB value had 
been affected by these discrepancies in the assumed degree of ethoxylation, use was 
made of the parameter X%. The time taken to reach 5 % MCT digestion (t5 %) in the 
presence ofNPEs was represented as a function of surfactant HLB value determined 
via the ethoxylation number quoted by the manufacturer (Figure 4.26a) and from the 
mean length of the ethoxy chain from the NMR data (Figure 4.26b).
From examination of Figure 4.26 a and b it was evident that the relationship between 
potency of inhibition and surfactant HLB value from the NMR data (Figure 4.26b) 
exhibited less scatter than when HLB values calculated from data supplied by the 
manufacturer were used (Figure 4.26a). This result gave further confirmation of the 
proposed correlation between surfactant HLB value and inhibitory behaviour ofNPEs 
towards pancreatin. In addition the correlation gave further weight to the NMR 

















Figure 4.1 Comparison of pancreatin activity towards MCT (450 mg) in the presence
of 10 % w/w (with respect to MCT) NPEs with ethoxylation numbers from 2 to 12.
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Figure 4.2 Comparison of pancreatin activity towards MCT (400 mg) in the presence 
of 20 % w/w (with respect to MCT) NPEs with ethoxylation numbers from 2 to 12.
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Figure 4.3a Comparison of pancreatin activity towards MCT (1 g) in the presence
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Figure 4.3b Comparison of pancreatin activity towards MCT (1 g) in the presence 
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Figure 4.4110 % and % as a function of surfactant HLB value 
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Figure 4 . 5 % and t, % as a function of surfactant HLB value 
for NPEs examined in Stage B of the investigation.
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Figure 4.6 The exponential relationship between t^ % and surfactant HLB values from 
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Figure 4.7 Comparison of t^ % as a function of surfactant HLB value for NPEs 
























Figure 4.8 Digestion profiles of MCT (1 g) illustrating the activity of different 
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Figure 4.9 Digestion profiles of MCT (1 g) in the presence of 10-NPE illustrating 
the susceptibility of different batches of pancreatin to inhibition by the surfactant.
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Figure 4.10 Digestion profiles of MCT (1 g) in the presence of 12-NPE illustrating the 
susceptibility of different batches of pancreatin to inhibition by the surfactant.
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Figure 4.11 Duration of the lag phase as a function of surfactant HLB value when using 













































Figure 4.13 Comparison of pancreatin activity towards MCT (1 g) in
the presence of LAEs (1 g) (Brij Series).
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Figure 4.14 Comparison of pancreatin activity towards MCT (1 g) in 
the presence of LAEs (1 g) (Lutensol AO Series).
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Figure 4.15a Comparison of pancreatin activity towards MCT (1 g) in the presence
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Figure 4.15b Comparison of pancreatin activity towards MCT (1 g) in the presence 
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Figure 4.15c Comparison of pancreatin activity towards MCT (1 g) in the presence
of alcohol ethoxylated surfactants (1 g) with ethoxylation numbers from 10 to 12.
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Figure 4 .15d Comparison of pancreatin activity towards MCT (1 g) in the presence 
of alcohol ethoxylated surfactants (1 g) with ethoxylation numbers of 20 and 23.
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Figure 4.16 ^ 5 % as a function of surfactant HLB value for nonylphenol ethoxylated 
surfactants (NPEs) and linear alcohol ethoxylated surfactants (LAEs).

























Figure 4.17 Comparison of pancreatin activity towards MCT (1 g) in the presence
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Figure 4.18 Comparison of pancreatin activity towards MCT (1 g) in the presence 
of hydrogenated castor oil ethoxylates (1 g) (Croduret series).
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Figure 4 . 1 9 % as a function of surfactant HLB value for NPEs and 
castor oil ethoxylated surfactants (Etocas and Croduret series).
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Figure 4.20 Comparison of pancreatin activity towards MCT (1 g) in the presence
of sorbitan monoesters (1 g) and PSEs (1 g) with an ethoxy lation number of 20.
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Figure 4.21 Comparison of pancreatin activity towards MCT (1 g) in the presence 
of PSEs (1 g) with varying extents of ethoxy lation and fatty acid esterification.
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Figure 4.22 Comparison of pancreatin activity towards MCT (1 g) in the presence
of soibitan esters (1 g) with 1 (mono), 1.5 (sesquio) and 3 (tri) fatty acids.
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Figure 4.23 Comparison of pancreatin activity towards MCT (1 g) in the presence 
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Figure 4.24 A typical 'H NMR (399.78 MHz) spectrum of a nonylphenol ethoxylated 
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Figure 4.25 A typical !H NMR (270.16 MHz) spectrum of a linear alcohol ethoxylated 
surfactant (sample 11-LAE) in CDC13 with assignments indicated.
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Figure 4.26a t, % as a function of surfactant HLB value for NPEs using HLB values
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Figure 4.26b t5 % as a function of surfactant HLB value for NPEs using HLB values 
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Chapter 5 - Issues related to the inclusion of non-ionic surfactants in lipid-based
formulations.
5.1 Introduction
At present there are few examples of lipid-based formulations in common usage, 
despite the suggested advantages of this approach to the bioavailability of 
hydrophobic drugs1. Several reasons have led to this situation, not least of which are 
of a commercial nature. To produce a lipid-based formulation specialized machinery 
and expertise is required, possibly involving the need for a contractor, whereas these 
are normally available in house for conventional tablet formulations. A lipid-based 
system generally requires development on an individual basis for each drug which may 
be time consuming and costly. Lack of models to test the efficacy of the formulation 
and sparse knowledge regarding stability, in vivo processing and physiological effects 
of lipid-based formulations has also restricted their usage1.
Lipid-based formulations have been proposed to confer an advantage to hydrophobic 
drug absorption by several mechanisms (see section 1.3), most of which relate to the 
ability of pancreatic lipase to digest lipid in the formulation. Digestion is suggested to 
gradually release drug, previously partitioned in the lipid phase, into the GI fluid 
together with digestion products. These products, in combination with physiological 
amphipathic molecules and any surfactant present, could form a solubilizing phase in 
which drug may remain in a dissolved state until absorption. In addition digestion 
could improve dispersion of the lipid-based formulation, thus providing a higher 
surface area for drug release.
In an effort to overcome issues such as poor solubility of drugs in simple lipid 
solutions or to improve the initial dispersion of lipid in GI fluid, lipid-based 
formulations may contain surfactants and co-solvents. These excipients could have an 
adverse effect on drug bioavailability from a lipid-based formulation. Possible 
problems involve alteration in the physical state of the drug upon release from the 
formulation or the availability of the formulation to lipolytic enzymes. The 
experimental work in this chapter was thus performed to investigate the influence of 
surfactants on drug bioavailability from lipid-based formulations.
5.1.1 Self-emulsifying drug delivery systems (SEDDS).
Formulation of SEDDS
Although presentation of a hydrophobic drug dissolved within a lipid-based 
formulation could be advantageous, the success of this approach may depend upon 
the dispersibility of the formulation when administered. Ideally the formulation would 
be a self-emulsifying drug delivery system. SEDDS are isotropic mixtures of oil, 
surfactant, drug and possibly co-solvent which form fine oil in water emulsions in 
aqueous media under conditions of limited agitation, similar to those encountered in 
the GI tract188. The large interfacial area of the excellent dispersion formed by 
SEDDS upon release into the gastric fluid promotes diffusion of dissolved drug from 
the oily droplets into the surrounding aqueous environment. The drug is therefore 
presented in a state ready for rapid absorption.
SEDDS have certain advantages over the use of conventional lipid-based formulations 
such as emulsions. Emulsions are inherently difficult to formulate with high stability 
characteristics, give poor dosage precision and usually require a high volume to dose 
ratio1. Formulation of a SEDDS with a high solvent capacity for a drug provides a 
low volume dosage form which may be encapsulated within a hard or soft gelatin 
shell. The resulting physically stable unit dosage form has the advantages of 
containing a known concentration of drug in a form acceptable to the patient.
The mechanism by which SEDDS spontaneously emulsify has been widely 
investigated, with the conclusion that in order to achieve self-emulsification ultra low 
interfacial tension and / or interfacial disruption is required188. Early investigations 
suggested the speed of emulsification was related to the formation of a liquid crystal 
phase at the interface upon initial dilution of the oil / surfactant mixture with water189. 
Further support for this has been given by the observation of a relationship between 
good self-emulsification and the formation of a low viscosity liquid crystalline phase 
upon addition of a small amount of water to an oil / surfactant mixture190. Self- 
emulsification was suggested to be a result of dynamic formation of liquid crystalline 
units at the interface promoting further water penetration into the oily phase down 
aqueous channels. The resulting increase in surface pressure would lead to interfacial 
disruption and dispersion of the oil as droplets into the bulk aqueous phase190. The
relatively insoluble nature of surfactant in water would indicate surfactant is likely to 
remain in contact with the oil or disperse as a separate emulsion phase188.
An alternative mechanism of self-emulsification, described as ‘diffusion and 
stranding’, has been suggested for SEDDS which include a co-solvent188. Rapid 
migration of co-solvent from the formulation into the bulk aqueous phase is proposed 
to carry and solubilize some of the water insoluble material from the formulation with 
it in the process. Upon depletion of co-solvent any remaining oil from the formulation 
would disperse into droplets.
In theory the use of SEDDS for oral administration of hydrophobic drugs would 
appear advantageous however few exist; a significant limitation to their use being the 
effort involved in optimization of a SEDDS. An ideal SEDDS should disperse into an 
emulsion consisting of droplets < 5 pm in diameter, to reduce the diffusion path of the 
drug from the droplet191. In addition the polarity of the droplets, which is determined 
by the surfactant present, should promote partitioning of the drug into the aqueous 
phase191. The optimum polarity value for drug release will be related to the oil / water 
partition coefficient of the drug.
The literature provides some guidelines to aid formulation of a SEDDS. Particle size 
determination and phase diagrams are recommended to maximize self-emulsification 
and minimize the diameter of the droplets formed. These parameters are temperature 
dependent, therefore assessment should be performed at the intended temperature of 
use i.e. 37°C. A simple combination of MCT with an ethoxylated non-ionic surfactant 
comprising > 25 % of the formulation can produce a SEDDS188. The HLB value of 
the selected surfactant or blend of surfactants (a blend tends to produce a more stable 
system), should be between 8 to 18 for an oil in water microemulsion. The choice of 
surfactant is limited by toxicity profiles, however previous assessment of the self- 
emulsifying behaviour of a range of non-ionic surfactants revealed unsaturated ester 
based surfactants to be more effective dispersants in combination with MCT than 
saturated ether based equivalents190. Oleates with a HLB value of approximately 11 
formed superior dispersions, which was proposed to be due to the fluidity of the 
oleate chains in these surfactant molecules190. Polyglycolyzed glycerides have also 
been demonstrated to be efficient emulsifiers for SEDDS191. A recent study192 stated 
that the use of a surfactant with a HLB value in the range of 10 to 15 will optimize
self-emulsification, especially if in combination with a co-emulsifier such as a medium 
chain (Cg-Cio) monoglyceride. Other excipients used to formulate lipid 
microemulsions have been listed by Constantinides193.
The choice of surfactant can have an impact on the release of drug from a SEDDS by 
affecting solubilization capacity, a property maximized by the use of hydrophobic 
surfactants which do not migrate. However to raise the solubility of drug in a SEDDS 
a hydrophilic surfactant or co-solvent may be required. This can be counterproductive 
in terms of improving drug dissolution as the hydrophilic material may rapid diffuse 
(via the ‘diffusion and stranding’ mechanism) from the SEDDS into the aqueous 
phase. Precipitation of the drug may then occur, especially if the drug has a low log P 
(i.e. 2-3)188.
In more general terms liquid formulations of SEDDS are to be preferred over waxy 
pastes as they are easier to assess in terms of the morphology of the drug188. The 
number of excipients is best kept to a minimum as with all formulations. Even a slight 
alteration in the final formulation of a SEDDS (such as addition of co-solvent and / or 
drug194,195) can result in the loss of self-emulsifying behaviour. This is due to the 
sensitivity of self-emulsification to the oil / surfactant ratio. In some cases inclusion of 
drug can be advantageous resulting in a decrease in droplet diameter1. Formulation of 
SEDDS is discussed more fully in a recent review by Pouton188.
Bioavailability of drugs from SEDDS.
The profile of SEDDS as a possible delivery method has been raised by the use of 
microemulsions for delivery of the peptide, cyclosporin A (cyclosporin)195. The 
pharmacokinetics of cyclosporin, a highly lipophilic polypeptide of fungal origin, have 
been reported as widely variable when administered by the oral route196 and altered 
absorption has been related to the presence of bile, food and the formulation used197. 
The original formulation used by Sandoz for cyclosporin, (Sandimmune®) consists of 
oil and alcohol in combination with polyglycolyzed glycerides and is available as a 
solution and encapsulated in soft gelatin capsules193. It is described as a self- 
emulsifying system although in vitro tests reveal a crude emulsion198. When 
Sandimmune® solution was administered to rats as per dosage directions (median 
droplet diameter 4 pm) or after homogenization (median droplet diameter 2 pm) the
homogenized form increased blood levels nearly 2-fold. This suggested that the 
bioavailability of cyclosporin from an emulsion could be improved by reducing the 
size of the emulsion droplets198.
An absolute bioavailability of around 30 % has been stated for Sandimmune® although 
this value has been reported to vary from 7 to 90 %196. Sandimmune Neoral®
(Neoral), described as a microemulsion pre-concentrate, was therefore developed in 
an attempt to optimize the bioavailability of cyclosporin. Neoral is composed of lipids 
(com oil mono-, di- and triglycerides), surfactant (polyoxyl-40 hydrogenated castor 
oil), hydrophilic co-solvent (propylene glycol) and antioxidant (DL-tocopherol). Upon 
dilution of Neoral in the GI fluid a monophasic oil in water microemulsion is readily 
produced199.
Comparison of the bioavailability of cyclosporin from the Sandimmune® and Neoral 
formulations has revealed the presence of fat200 or bile201 to increase bioavailability 
from the Sandimmune® capsule. Bioavailability from Neoral capsules was much less 
sensitive to the presence of fat, although in the case of bile a minimal dependence was 
indicated. These results suggest the coarse emulsion formed by Sandimmune® 
requires further dispersion via the in vivo mechanisms of lipid processing whereas the 
Neoral microemulsion has inherent dispersion characteristics mainly unaffected by the 
physiological environment.
Neoral is now generally the preferred formulation of cyclosporin due to a reduction in 
inter and intra-patient variation, thus providing a more consistent plasma 
concentration with time profile compared to Sandimmune®202. Neoral has also been 
demonstrated to exhibit linear pharmacokinetics203, which provides a means of dosage 
titration with increased accuracy when compared to the original Sandimmune® 
formulation.
Further in vivo studies are required to demonstrate the efficacy of SEDDS in humans. 
Some evidence of the potential ability of SEDDS to improve drug bioavailability 
above levels shown by other delivery systems has been provided by animal studies. A 
SEDDS formulation (comprised of MCT and non-ionic surfactant) and a PEG 600 
solution formulation were employed to administer a lipophilic anti-viral compound 
(Win 54954) to beagle dogs204. Absolute bioavailability did not differ between the two 
formulations due to substantial first pass metabolism however plasma profiles from
the SEDDS displayed more consistent absorption with time. This was proposed to be 
a function of the inherent solubilization and high quality dispersion produced by 
SEDDS rather than a feature of the lipid component or use of a solution dosage form; 
a conclusion based also upon the erratic plasma profiles obtained for the same drug 
when administered in a soybean oil solution.
Four different formulations (a tablet, a suspension, a PEG 600 solution and a SEDDS) 
of a benzodiazepine derivative, (L-365 260) with low aqueous solubility were 
administered to dogs205. The SEDDS and PEG formulations both increased relative 
bioavailability and Cma* values to levels 7 to 8 times higher than those shown by the 
formulations where L-365 260 was not dissolved. For L-365 260 bioavailability 
appeared to be improved by a formulation which eliminated the dissolution stage. A 
further study compared the bioavailability of a highly lipophilic naphthalene derivative, 
Ro-150778 from three different formulations (a SEDDS, a PEG 400 solution and a 
tablet)191. When these were administered to non-fasted dogs the SEDDS gave four 
times the relative bioavailability of the PEG solution which in turn was 15-fold greater 
than the tablet.
These results illustrate that for a drug with limited aqueous solubility it is 
advantageous to use a formulation where the drug is in solution, such as a PEG 
solution or a SEDDS, thus enabling avoidance of the dissolution stage. When the 
aqueous solubility of a drug is very low, drug may precipitate upon release of a PEG 
solution into the aqueous environment of the GI tract. The same effect would not be 
expected from SEDDS as these have the capacity to solubilize drug and hold it in a 
dissolved form within the aqueous environment. A further advantage of SEDDS is 
their tendency to give more reproducible plasma profiles than seen with PEG 
solutions. This could possibly be accounted for by the rapid dispersion and gastric 
emptying of the formulation in the GI tract. The resulting high drug plasma levels 
likely to be achieved shortly after dosage of a SEDDS will require consideration if the 
drug in question has a narrow therapeutic index188.
Overall the use of SEDDS appears advantageous to enhance the bioavailability of 
poorly water-soluble drugs, whether solely by avoidance of the dissolution stage or in 
combination with solubilization and rapid dispersion.
5.1.2 Outline of this investigation.
SEDDS have excellent dispersion behaviour which removes the need for digestion to 
enhance solubilization of drug. This is not the case for the lipid-based formulations 
previously discussed in this thesis, which appear reliant upon the lipid digestion 
cascade (a process also known as lipolysis) to enhance bioavailability of drug. For 
these formulations digestion can release drug from the lipid phase into a solubilized 
phase formed from the components of bile and lipolytic products.
Digestion of these lipid-based formulations and subsequent release of drug from the 
lipid will be enhanced if the surface area of the lipid droplets is increased. This is 
frequently accomplished by the use of a mixture of hydrophilic surfactant (classified 
here as a HLB of > 10) with lipophilic surfactant (HLB < 10). The lipophilic 
surfactant is necessary to initiate crude emulsification of the oil allowing the 
hydrophilic surfactant to produce a fine and uniform oil in water emulsion. Drug 
absorption from emulsions of this nature is thought likely to be faster and more 
consistent compared to a situation where drug is concentrated within large oil 
droplets.
However inclusion of surfactants within a lipid-based formulation could be 
disadvantageous due to the ability of many non-ionic surfactants to inhibit digestion of 
lipid (as demonstrated by in vitro studies in Chapter 4). This chapter aims to examine 
further the influence of surfactants upon digestion of lipid-based formulations. In 
general terms the aim was to develop two lipid-based formulations. One of the 
formulations was to be available for digestion by pancreatin whereas the other was 
not. The difference in the availability of the two formulations to pancreatin was to be 
brought about by the informed selection of surfactants for inclusion in the 
formulations. The whole procedure was to be performed for two different drugs. The 
resulting formulations were intended for an in vivo study to determine if inhibition of 
lipid digestion by surfactants would impair drug bioavailability.
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All experimental work described in this chapter was performed during a period of 
secondment at R P Scherer at their premises in Swindon. The overall intention was to 
investigate whether the observations reported in Chapters 3 and 4 were general 
phenomena which could lead to intellectual property of general significance. Prior to 
commencing this work the following statements represented the available knowledge:
• Natural lipolysis of triglyceride within the GI tract can enhance the dissolution rate 
of a hydrophobic drug co-administered with triglyceride.
• Evidence from in vitro studies demonstrated the addition of a hydrophilic 
surfactant to triglyceride can in some cases totally inhibit lipolysis.
• The inhibition of lipolysis due to hydrophilic surfactants can be significantly 
reduced by certain lipophilic surfactants.
The preliminary investigations in this chapter (sections 5.2-5.3) were designed to 
assess a range of excipients, namely non-ionic surfactants, available for use in lipid- 
based formulations. Knowledge gained was to be employed to develop several lipid- 
based formulations. These formulations were required to test the virtues of a new 
class of lipid delivery systems, described below as consisting of:
1. A hydrophobic drug
2. A medium or long chain triglyceride capable of undergoing digestion in the 
presence of pancreatic lipase under in vivo conditions. The triglyceride was 
intended to be a solvent for the drug in addition to providing a source of lipolytic 
products upon digestion.
3. A hydrophilic surfactant or mixture of hydrophilic surfactants able to disperse the 
triglyceride upon in vivo administration. These are expected to inhibit the in vivo 
lipolysis of triglyceride.
4. A lipophilic surfactant or mixture of lipophilic surfactants capable of reducing 
inhibition of lipolysis due to the hydrophilic surfactant. Lipophilic surfactants 
preferred for this purpose being fatty acids and mono and / or di-glycerides of fatty 
acids.
In vivo tests were planned to compare drug bioavailability from such a formulation 
described above, with bioavailability from a similar system unable to undergo lipolysis. 
In addition it was proposed that both lipid-based formulations were to be compared 
with a current marketed product of the drug in question.
Two drugs were selected for the investigation on the basis of high hydrophobicity and 
poor absorption from conventional solid dosage forms due to dissolution rate 
limitation. These were fenofibrate, a broad spectrum lipid-modulating agent and 
cinnarizine, an antihistamine commonly used for vestibular disorders and motion 
sickness. The objective was to develop two formulations for each drug which were 
identical apart from the identity of the lipophilic surfactant used. The lipophilic 
surfactants were to be selected in order that one formulation was able to undergo 
lipolysis whereas the other was not.
The lipid-based formulations required for the in vivo tests were made to the following 
specifications. The final unit dosage form was to be a soft gelatin capsule containing a 
total 1 g of formulation. The formulation was to be comprised of drug within a lipid / 
surfactant carrier system. The intended composition of the formulation is described 
below with points 2 to 5 referring to the carrier system:
1. A drug (between 0.1-50 % w/w of the final formulation)
2. A triglyceride to comprise 10-90 % w/w (preferably 25-45 %) of the formulation. A 
percentage of the triglyceride may be replaced with a digestible lipophilic 
surfactant.
3. A hydrophilic surfactant to comprise 10-60 % w/w (preferably 30-45 %) of the 
formulation at a concentration which gave adequate dispersion and also 
substantially inhibited in vivo lipolysis of the triglyceride.
4. A hydrophilic solvent to comprise 0.1-20 % w/w of the formulation, if required, to 
increase drug solubility.
5. A lipophilic surfactant to comprise 5-60 % w/w (preferably 20-40 %) of the 
formulation:
For the lipolysing carrier system
A lipophilic surfactant capable of substantially reducing the inhibitory 
effect of the hydrophilic surfactant.
For the non-lipolvsing carrier system
A lipophilic surfactant unable to overcome the inhibitory effect of the 
hydrophilic surfactant.
The remainder of this chapter describes the stages involved in development of these 
formulations for fenofibrate and cinnarizine, followed by their evaluation under in vitro 
and in vivo conditions.
Section 5.2 describes the assessment of a range of lipophilic surfactants for ability to 
reactivate pancreatin activity within a previously non-lipolysing system (comprised of 
a digestible triglyceride and a hydrophilic surfactant). This approach provided basic 
information to aid development of the formulations by identifying surfactants capable 
of reactivation of lipolysis. Investigations in section 5.3 assessed the solubility of the 
drugs within possible formulation constituents and enabled selection of possible 
combinations of excipients exhibiting miscibility and suitable characteristics of self- 
dispersion.
Results from these preliminary investigations enabled selection of promising 
formulations (section 5.4) which underwent assessment and modification to ensure 
compliance with specifications for lipolysing and non-lipolysing formulations. 
Following selection of the lipolysing and non-lipolysing formulations, in vitro models 
representing gastric dispersion and digestion in the duodenum were used to assess 
drug release from the respective formulations (section 5.5). Finally the formulations 
were prepared for in vivo testing by a contractor. The in vivo results are discussed in 
section 5.6.
5.1.3 Materials
In addition to materials listed in Chapters 2 and 3 
Hydrophilic Surfactants
Trade name Description______________________HLB
Crillet 1 20-ethoxy sorbitan monolaurate 16.7
Crillet 2 20-ethoxy sorbitan monopalmitate 15.6
Crillet 4 20-ethoxy sorbitan mono-oleate 15.0
Lipophilic Surfactants
Trade name Description______________________ HLB
Etocas-5 5-ethoxy castor oil ethoxylate 3.9
Imwitor 375 Glyceryl citrate/lactate/linoleate/oleate N/A
Imwitor 988 Caprylic/capric glycerides N/A
Lauroglycol Propyleneglycol monolaurate 4-5
Maisine 35-1 Glycerol mono-oleate 4
Marlowet R11 11 -ethoxy castor oil ethoxylate 6.8
Neobee M20 Propylene glycol dicaprylate (65 %)
/caprate (35 %) 10
Plurol oleique Polyglyceryl-6-dioleate 10
Priolene 6930 Ci4-C20 fatty acids (69-75 % oleic acid) N/A
Span 20 5571 Sorbitan monolaurate 8.6









Alfa Chemicals Ltd. 
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(N/A = HLB value not available)
Other materials
Ethanol absolute (HPLC grade) E-0665 Fisons
Capricacid 99 % n-decanoic free acid C l875 Sigma
Caprylicacid 99 % n-octanoic free acid C2875 Sigma
Monocaprate 1-monodecanoyl-rac-glycerol (Cio:o) M2140 Sigma
Monocapiylate 1-monocapryloyl-rac-glycerol (C8:o) M2265 Sigma
Monoolein 1-monooleoyl-rac-glycerol (Ci8:o,[cis]-9) M7765 Sigma











(Address of suppliers listed in Chapter 4)
5.2 Study of the apparent ability of lipophilic non-ionic surfactants to 
reactivate pancreatin activity.
Experimentation by colleagues at R P Scherer108 had indicated that inclusion of 
lipophilic surfactants within a system where digestion of triglyceride was inhibited by 
hydrophilic surfactant allowed pancreatin activity to proceed. This observation 
suggested that the presence of lipophilic surfactant changed the nature of the reaction 
system so as to allow pancreatin to hydrolyze the triglyceride substrate.
Certain lipophilic surfactants inherently contain as part of their composition partial 
products of triglyceride digestion. This fact, in combination with the proposal that 
lipolytic products released during digestion may be able to reactivate a surfactant 
inhibited system, (see section 3.3.6), immediately suggests a possible mechanism for 
the above observation.
In the following study several different classes of non-ionic lipophilic surfactants were 
examined for the ability to reactivate pancreatin activity towards MCT in a system 
inhibited by hydrophilic surfactant. Information thus obtained was subsequently 
compared with the ability of pancreatin to utilize the lipophilic surfactants as 
substrate. This approach was taken to enable the measured reactivation of lipolysis to 
be related to the digestion of triglyceride and / or the lipophilic surfactant for the 
purpose of elucidation of the mechanism of reactivation.
5.2.1 Investigation of the ability of pancreatin to hydrolyze lipophilic surfactants.
A range of non-ionic surfactants with dominant lipophilic character (HLB< 10) were 
selected to undergo the standard pH-stat assay of lipolysis (section 2.2) in the absence 
of triglyceride. This was to determine if pancreatin could utilize the surfactants as 
substrate and if so to what extent.
Method
A digestion profile was produced (in duplicate) for each surfactant listed in section 
5.1.3 under conditions of the standard pH-stat assay. In each case 1 g of surfactant 
was added to simulated bile solution and stirred well before commencement of the
assay. Titrant volume was recorded at intervals of 10 minutes over an assay duration 
of 120 minutes. The digestion profiles represent the quantity of alkali required to 
neutralize digestion products released from the surfactant by pancreatin against time.
Results
Digestion profiles of each lipophilic surfactant are shown in Figures 5. la-b together 
with a control profile of MCT (1 g). This was included for comparison of titrant 
volumes from surfactant with levels obtained when using a natural triglyceride 
substrate. The duplicate digestion profiles of each surfactant were almost identical in 
all cases therefore each surfactant is represented by a typical profile in Figures 5. la-b. 
Background pancreatin activity in the absence of triglyceride was known to occur 
within the standard pH-stat assay (section 2.8) due to enzyme activity upon lecithin, a 
component of simulated bile solution. It was therefore necessary to ensure the 
digestion recorded on each profile did not include any enzyme activity due to the 
presence of lecithin.
To enable subtraction of the blank rate due to lecithin from each lipophilic surfactant 
profile, a blank digestion profile of pancreatin acting upon simulated bile solution was 
performed in duplicate. Titrant recordings were taken at identical time intervals to 
those used for the lipophilic surfactants. A typical blank rate profile of simulated bile 
solution was selected for subsequent subtraction from each lipophilic surfactant 
profile and the MCT profile before their representation in Figures 5. la-b. This 
approach allowed any enzyme activity which may not be due to digestion of surfactant 
to be discounted. The blank rate profile used is illustrated in Figures 5. la-b for 
comparison.
Digestion profiles from the surfactants were then divided according to whether the 
rate of digestion shown on the profile exceeded that shown by the simulated bile 
solution blank profile for the complete assay period. Figure 5.1a includes digestion 
profiles from surfactants which displayed a rate of digestion below the blank profile 
for at least part of the assay period. Surfactants illustrating an extent of digestion 
above the blank profile throughout the total assay period are illustrated in Figure 5. lb. 
The digestion profiles from the ethoxylated castor oil surfactants, Etocas-5 and 
Marlowet R11 (Marlowet) shown in Figure 5.1a exhibited negative values after
deduction of the blank profile. This result suggested that digestion of lecithin present 
in the assay system was inhibited in addition to the surfactant being unavailable to 
pancreatin as a substrate.
The sorbitan monoesters (Figure 5.1a) have been digested to a limited extent, the C12 
version (Span 20) appearing to be more available to pancreatin than the Cis:i (Span 
80) version. From the structure of these surfactants (section 4.9) it could be suggested 
that pancreatin is acting by cleavage of fatty acid from the sorbitan moiety.
A limited extent of digestion was also exhibited on the digestion profile of Plurol 
oleique (Figure 5.1a). This surfactant is described as a polyglyceryl ester of polymer 
units, each of which is composed of six glycerol molecules incorporating a Ci8:i di­
glyceride. Cleavage of the Cis:i fatty acids from the di-glyceride would appear to be 
the site of hydrolytic activity of pancreatin upon Plurol oleique.
The digestion profile of oleic acid (Priolene) showed slight digestion (Figure 5.1a) 
over the two hour assay period. This is difficult to explain but may relate to the purity 
of the oleic acid source used, described by the manufacturer as a C14-20 fatty acid with 
an oleic acid content of 69 - 75 %. No further information was available regarding 
other possible contaminants.
The profiles of the propylene glycol esters (Neobee M20 (Neobee) and Lauroglycol) 
showed significant digestion demonstrating that fatty acid esterified onto a propylene 
glycol backbone is readily available for hydrolysis by pancreatin (Figure 5.1b). 
Lauroglycol, a C12 monoester showed less digestion than Neobee, a Cg/io diester, 
which is to be expected due to the higher number of fatty acids available per molecule 
of Neobee. The shorter fatty acid chain may also be easier for pancreatin to hydrolyze. 
Further evidence for increased hydrolysis with shorter fatty acid chains is given by the 
results from Maisine (Figure 5.1b), a Cig:i monoglyceride. This surfactant exhibited 
less digestion than the Cn propylene glycol monoester, despite the natural glyceryl 
substrate backbone.
Highest digestion was shown by Imwitor 988, a partial glyceride of Cg-io described as 
consisting of 50 % monoglyceride, 40 % diglyceride and 6 % triglyceride (Figure 
5.1b). This result was to be expected as Imwitor 988 contains the natural substrate of 
pancreatin together with partial digestion products.
Imwitor 375 is a partially neutralized ester of mono and diglycerides of linoleate 
(Ci8:2) and oleate (Ci8:i) with citric and lactic acid. It contains 20 % of both mono and 
diglycerides (fatty acid chains of oleate and linoleate) and less than 2 % triglyceride 
with the remaining 58 % being composed of complex esters with citric and lactic acid. 
From the low rate of digestion seen (Figure 5. lb) the citric and lactic acid esters are 
probably unavailable to pancreatin activity, with the longer chain Cis fatty acids 
possibly slower to digest than the Cs-io of Imwitor 988.
Overall the results in Figures 5. la-b demonstrate the castor oil ethoxylates to be 
unavailable for lipolysis by pancreatin. The extent to which the other surfactants were 
digested appeared to depend upon the number of ester bonds per molecule with fatty 
acids. The chain length of the fatty acid may also be involved with results from the 
surfactants with medium chain fatty acids indicating higher availability to pancreatin 
than the long chain equivalents. A noticeable influence due to the nature of the ester 
backbone, i e propylene glycol, glyceryl or polyglyceryl was not observed.
5.2.2 Quantification of the reactivation of pancreatin activity by lipophilic 
surfactants.
To quantify the ability of lipophilic surfactants to reactivate pancreatin activity when 
incorporated in a previously inhibited system comprised of MCT and a hydrophilic 
surfactant, a non-lipolysing model of triglyceride digestion was required.
Cremophor at a concentration of 1 g was already known to efficiently inhibit 
pancreatin activity towards 1 g of MCT (Figure 3.12a) when digested under 
conditions of the standard pH-stat assay. In addition a digestion profile of Cremophor 
(1 g) had demonstrated the inability of pancreatin to digest the surfactant (results not 
shown). Cremophor (1 g) was therefore considered ideal in combination with MCT (1 
g) to create a model of a non-lipolysing system, with both substrate and surfactant 
virtually unavailable for lipolysis.
Each lipophilic surfactant tested in section 5.2.1 was included within the non- 
lipolysing model of triglyceride digestion. The reactivation of lipolysis observed is 
discussed in terms of the percentage of total lipolytic activity which could be related 
directly to digestion of the triglyceride.
Method
Digestion profiles were produced (in duplicate) under conditions of the standard pH- 
stat assay for each lipophilic surfactant when included in the non-lipolysing model. 
Substrate and surfactant mixtures were prepared by directly weighing 1 g of MCT, lg 
of Cremophor and 1 g of the lipophilic surfactant under examination into the same 
glass vial. The three constituents were mixed by vortexing to ensure homogeneity 
before addition to the simulated bile solution.
Titrant volume was recorded at intervals of 10 minutes over an assay duration of 120 
minutes. The digestion profiles represented the volume of titrant necessary to 
neutralize digestion products released with time.
Results
The resulting digestion profiles were classified into two groups depending upon 
whether the extent of digestion in the presence of lipophilic surfactant exceeded or 
was less than that shown by the non-lipolysing model.
The lipophilic surfactants unable to reactivate lipolysis within the two hour assay 
period were the castor oil ethoxylates (Etocas-5 and Marlowet), propylene glycol 
esters (Lauroglycol and Neobee) and a polyglyceryl ester (Plurol oleique). The 
digestion profiles from these surfactants were below that shown by the non-lipolysing 
model and are not illustrated.
An explanation of the inability of these surfactants to reactivate lipolysis may involve 
the structure of the surfactant. The castor oil ethoxylates have already been 
demonstrated in Chapter 4 to be inhibitory towards pancreatin, irrespective of 
ethoxylation number, and in Figure 5. la  to be unavailable for digestion by pancreatin. 
It is likely that these low ethoxylated castor oils have increased the non-lipolysing 
layer upon the triglyceride droplets preventing lipolysis.
The situation is different for the propylene glycol esters which when digested alone 
were available for hydrolysis by pancreatin (Figure 5.1b). Cremophor and triglyceride 
present in the system has in some manner rendered the propylene glycol esters 
inaccessible to pancreatin. They may be partitioned in the core of the lipid droplets 
with MCT, shielded from pancreatin activity by an outer hydrophilic layer of 
Cremophor.
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The digestion profiles from the lipophilic surfactants capable of reactivating 
pancreatin activity in the non-lipolysing model are shown in Figure 5.2. Also shown is 
the profile from the non-lipolysing model and a control profile of MCT (1 g), for 
comparison of the extent of reactivation achieved. The surfactants capable of 
reactivating lipolysis, to varying extents, included the sorbitan monoesters (Span 80, 
Span 20), oleic acid (Priolene), monoglyceride (Maisine) and the partial glycerides 
(Imwitor 988 and 375). Only Imwitor 988 gave a digestion profile which showed a 
rate and extent of digestion similar to the MCT control profile (Figure 5.2).
The ability of surfactants composed of partial triglyceride digestion products 
(Maisine, Priolene and Imwitor) to reactivate enzyme activity in the non-lipolysing 
model may be explained by the following hypothesis. When the MCT and surfactants 
are added to the simulated bile solution the digestion products inherent in the 
surfactant could be assumed to accumulate at the interface of the MCT droplets, in 
the same manner as would occur during normal lipolysis due to their physicochemical 
characteristics. The result of this could be an increase in colipase partitioning (see 
section 3.3.6) into the interface, with a consequent increase in lipase bound to the 
substrate. Enzymatic activity would increase, further lipolytic products would 
accumulate and eventually ‘bud off the lipid droplet, clearing away some of the 
Cremophor molecules in the process.
The C12 sorbitan monoester (Span 20) showed a surprising ability to reactivate 
lipolysis (Figure 5.2) compared to the availability of this surfactant to pancreatin 
activity when digested alone (Figure 5.1a). There was a lag period of approximately 
50 minutes before inhibition from Cremophor was overcome and then lipolysis 
proceeded at a rapid rate. Initial hydrolysis of the sorbitan-fatty acid ester bond may 
be responsible for overcoming inhibition by providing a source of lipolytic products. 
The lag phase may reflect the difficulty with which pancreatin hydrolyzes Span 20.
The Ci8:i sorbitan monoester (Span 80), was much less effective at reactivating 
pancreatin activity compared to Span 20 (Figure 5.2). The increase in the length of 
the fatty acid chain increases the lipophilicity of the material. The presence of a double 
bond in the fatty acid chain has already been suggested to enhance the ability of 
surfactant to partition into lipid compared to saturated equivalents (section 4.7.5).
The combined influence of these properties has probably resulted in Span 80
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partitioning into the lipid interface to an extent where the fatty acid ester bond is 
unavailable to surface activity from pancreatin. The limited concentration of fatty 
acids released may lead to a higher rate of enzyme activity with time however within 
the assay period of 120 minutes the effect of Span 80 is negligible compared to the 
other surfactants illustrated (Figure 5.2).
Overall these results tend to suggest that reactivation of lipolysis is due to partial 
digestion products, present as part of the composition of the lipophilic surfactant or 
released from the surfactant by the hydrolytic activity of pancreatin. If pancreatin 
activity is necessary to release digestion products from the lipophilic surfactant a lag 
phase is seen on the profiles. This phase probably relates to the time taken for 
digestion products to increase to a level where colipase partitioning into the interface 
is enhanced.
Further explanations for the reactivation of lipolysis may involve alteration in the 
nature of the emulsion system upon addition of lipophilic surfactant to the non- 
lipolysing model. The addition of a lipophilic surfactant which combines well with 
MCT to the non-lipolysing model may result in a higher interfacial area. The 
proportion of Cremophor present may no longer be sufficient to form a barrier over 
the whole interfacial area, thus allowing some initial hydrolysis to occur.
Addition of a lipophilic surfactant to the non-lipolysing model will change the HLB of 
the system, which may in turn affect the nature of the emulsion. This could result in 
dissociation of Cremophor from the triglyceride and subsequent reactivation of 
pancreatin activity due to exposure of the lipid interface. Further surfactants need to 
be tested to determine if a relationship exists between the HLB value of a lipophilic 
surfactant and the degree of reactivation achieved.
5.2.3 How much of the apparent reactivation of enzyme activity in the non- 
lipolysing model is due to digestion of MCT ?
Lipophilic surfactants have been proposed to reactivate digestion within the non- 
lipolysing model by increasing the accessibility of triglyceride substrate to pancreatin. 
The lipolysis recorded (Figure 5.2) could however be due to pancreatin activity upon
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a variety of substrates present in the reaction mixture. These include triglyceride, 
Cremophor, lipophilic surfactant and lecithin within the simulated bile solution. 
Contribution to the profiles in Figure 5.2 from the digestion of Cremophor and 
lecithin was thought unlikely, as a digestion profile of Cremophor with the blank rate 
due to lecithin removed consisted of negative values across the whole profile. For this 
reason the simulated bile solution blank profile was not subtracted from the digestion 
profiles in Figure 5.2. Thus by elimination, digestion within the reactivated non- 
lipolysing model could be due only to pancreatin activity upon the MCT substrate and 
/ or the lipophilic surfactant.
In most cases the lipophilic surfactants able to reactivate lipolysis were surfactants 
which included partial digestion products of triglyceride (Maisine, Priolene, Imwitor 
375 and 988). It would not therefore be surprising if the additional digestion seen was 
a result of hydrolysis of the lipophilic surfactant by pancreatin.
To determine the proportion of reactivated lipolysis which could be attributed to 
pancreatin activity upon MCT, the lipophilic surfactant profiles (Figures 5. la-b) were 
compared with profiles from the same surfactant when included in the non-lipolysing 
model. The profiles were compared by examination of the total volume of titrant used 
upon completion of the assay. The total volume of titrant recorded on the digestion 
profile of the lipophilic surfactant alone was converted into a percentage of the total 
volume of titrant recorded from the same surfactant included in the non-lipolysing 
model. This approach gave the percentage of reactivated digestion which could be 





Description of surfactant % of reactivated digestion 
attributable solely to 
digestion of MCT
Priolene Oleic acid 93
Span 20 C12 sorbitan monolaurate 91
Imwitor 375 Glyceryl citrate/lactate 
/linoleate/oleate
89
Maisine Glycerol mono-oleate 80
Span 80 Ci8:i sorbitan mono-oleate 69
Imwitor 988 Caprylic/capric glycerides 44
Table 5.1 Percentage of reactivated pancreatin activity which could be 
attributed solely to digestion of MCT.
From Table 5.1 the presence of oleic acid in the non-lipolysing model increased the 
extent of digestion of MCT to higher levels than those shown by the other lipophilic 
surfactants listed, however all of the surfactants increased digestion to a level above 
that shown when the same surfactant was digested alone. The percentage of 
reactivated digestion is described as that attributable solely to the digestion of MCT. 
This is based on the assumption that the lipophilic surfactant is digested to the same 
extent when present alone as in the non-lipolysing model. However this is not 
necessarily the case as the propylene glycol and polyglyceryl classes of surfactants 
(section 5.2.2) have been demonstrated to be less available to pancreatin in the non- 
lipolysing model. Likewise it is not possible to be certain that the model would not 
increase the extent to which a lipophilic surfactant is digested.
To investigate further the possible source of digestion recorded in these reactivated 
systems a series of experiments were performed to compare the extent of digestion of 
MCT and Imwitor 988 when digested together and individually. Separate digestion 
profiles were produced under the conditions of the standard pH-stat assay for MCT (1 
g), Imwitor 988 (1 g), MCT (1 g) combined with Imwitor 988 (1 g) and MCT (1 g), 
Imwitor 988 (1 g) and Cremophor (1 g) (i.e. the reactivated non-lipolysing model).
All of the resulting profiles are displayed in Figure 5.3 with the same information 
shown for Imwitor 375 in Figure 5.4.
From examination of Figure 5.3 it can be seen that the amount of digestion which 
occurred upon individual digestion of MCT and Imwitor 988 was not additive when 
the two were digested in combination. This suggests that the presence of Imwitor 988
as an emulsifier with MCT makes one or both substrates less available to pancreatin 
than when simply dispersed alone in simulated bile solution. Alternately the effect 
could be a result of the high level of digestion products released (as indicated by the 
final titrant volume of 4.5 ml). The concentration of bile salt available in the in vitro 
model may have been insufficient to solubilize and effectively remove the digestion 
products from the system. This may have inhibited further enzyme activity; a situation 
which would not occur if the same combination was digested in vivo.
When the same series of experiments were repeated for Imwitor 375, (a partial 
glyceride less available for hydrolysis than the 988 version) the MCT and Imwitor 
combination was digested to the same extent as the reactivated non-lipolysing model 
(Figure 5.4). However for both profiles the rate and extent of digestion was lower 
than that seen when the same quantity of MCT was digested alone. This suggests that 
the presence of Imwitor 375 resulted in MCT being less available to pancreatin. 
Accumulation of digestion products was probably not responsible for this effect as 
higher titrant volumes were recorded for MCT when digested alone. A possible 
explanation could involve the formation of a complex, unavailable to pancreatin 
activity, between MCT and the glycerol citric and lactic acid esters of Imwitor 375. 
These experiments did not provide any further information regarding the proportion 
of reactivation which may be due to MCT digestion. However in the case of Imwitor 
375 the amount of MCT and Imwitor digested in the non-lipolysing model reached 
the same extent as the same quantities with no Cremophor present, confirming that all 
of the inhibitory effect due to Cremophor was eventually overcome.
5.3 Preliminary considerations necessary for formulation of the lipid-based 
systems.
The preliminary investigations contained in this section were designed to rationalize 
selection of possible combinations of the three main components of the lipid-based 
formulations. These components were to be a triglyceride, a hydrophilic surfactant 
known to be inhibitory towards pancreatin activity upon triglyceride and a lipophilic 
surfactant. The lipophilic surfactant may or may not be able to overcome the said
inhibition depending upon the specification of the formulation in terms of lipolysing 
behaviour.
The solubility of fenofibrate and cinnarizine in various micellar solutions of 
triglyceride digestion products and surfactants was to be determined. This was to 
enable selection of components for the formulation which were most beneficial in 
terms of enhancing solubility of the drugs, both within the formulation and the 
presumed solubilized phase in vivo. In addition various combinations of triglyceride, 
hydrophilic and lipophilic surfactants, described as formulations, were to be assessed 
for miscibility and ease of dispersion; both important characteristics of the final 
formulation.
5.3.1 Drug solubility in micellar solutions.
Assessment of drug solubility in various micellar solutions was intended to enable 
selection of formulation constituents favourable to drug dissolution. If the triglyceride 
and surfactants selected enhanced drug solubility this may be advantageous upon 
release of the formulation from the capsule into the stomach. The drug would be less 
likely to precipitate upon release into the aqueous gastric fluid, thus remaining 
partitioned in the lipid and / or dissolved in a solubilized phase formed by the 
formulation ready for absorption.
The solubility of fenofibrate and cinnarizine was determined in micellar solutions of 
triglyceride digestion products and selected surfactants. In each case the micellar 
solutions were prepared in simulated bile solution to increase representation of the 
possible solution formed upon release of the formulation into the intestine. 
Appropriate combinations of monoglycerides and fatty acids were used to represent 
long and medium chain triglyceride digestion products. If the solubility of a drug was 
shown to be improved by either long or medium chain products this would indicate 
which type of triglyceride to select for use in the formulation. The lipolytic products 
released upon digestion of triglyceride in the formulation would then have a high 
solubilization potential for the particular drug.
Method
The solubility of fenofibrate and cinnarizine was determined in the following micellar 
solutions:
Micellar solution
• Long chain lipolytic products 
to represent soya bean oil 
( oleic acid 11 mM, monoolein 5 mM)
• Medium chain lipolytic products 
to represent fractionated coconut oil 
( caprylic acid 11 mM, monocaprylate 5 mM,
capric acid 7 mM, monocaprate 3.5 mM)
• Cremophor
• Crillet 4
• Simulated bile solution
• Tris-maleate buffer pH 6.5
The simulated bile solution and Tris-maleate buffer were prepared as per formulas 
given in section 2.2.1. To prepare the remaining solutions the appropriate quantities 
of constituents for each solution were added to simulated bile solution followed by 
processing in an ultrasonic bath at 37°C for 1 hour to ensure homogeneity. Each 
solution was then adjusted to pH 7.5 using a pH-stat and titrant of 1 M NaOH or 0.1 
M HC1 as appropriate.
Saturated solutions of drug were prepared in triplicate for each solution and left to 
reach equilibrium solubility in an ultrasonic bath for 1 hour at 37°C. The solutions 
were mixed by vortexing and 2 ml of the resulting suspension passed though a filter 
(Whatman P.V.D.F 13mm Syringe filters, 0.2 pm Cat. No. 6779-1302) to remove any 
drug not dissolved; the first 0.5 ml of filtrate being discarded to allow for any drug- 
filter binding which may occur.
The concentration of drug dissolved in the resulting filtrate was determined via a high- 
performance liquid chromatographic (HPLC) method developed and performed for
Total concentration 
0.5 % w/v
0.5 % 7 V
0.5 % 7 V 
0.5 % 7 V
each drug by the analytical division of R P Scherer. Sample solutions underwent 
HPLC analysis within a 24 hour period of preparation.
Results
The mean solubility of fenofibrate and cinnarizine in each solution is represented in 
Figures 5.5a and b respectively (with the standard deviation from 3 replicates 
indicated). All of the micellar solutions can be seen to have increased drug solubility 
levels above those shown in the buffer solution, included to represent aqueous 
solubility.
Figures 5.5a-b show both drugs to be preferentially soluble in the long chain rather 
than the medium chain lipolytic product solution. Fenofibrate and cinnarizine 
exhibited higher solubility in the micellar solutions of surfactants than in the medium 
chain lipolytic product micelles, with highest solubility overall determined in the 
Cremophor solution. Both drugs were soluble within the simulated bile solution 
whereas solubility within buffer could not be determined with accuracy due to the 
trace concentrations present.
Overall the results demonstrate the same pattern of solubility enhancement of 
fenofibrate and cinnarizine across the range of micellar solutions tested. For 
cinnarizine solubility values varied widely from zero up to 29 pg / ml whereas 
fenofibrate exhibited a narrower solubility range from zero to 6.5 pg / ml. Careful 
selection of constituents would appear prudent when devising the formulations for 
fenofibrate, to aid enhancement of the extremely low drug solubility. Choice of 
constituents for the formulations of cinnarizine could be considered to be less critical.
5.3.2 Miscibility Studies upon potential formulations.
204
Knowledge of the behaviour of triglyceride, hydrophilic and lipophilic surfactant when 
combined together was necessary to aid selection of a formulation which remained 
miscible after encapsulation within a soft gelatin capsule. Any phase separation of 
constituents after the encapsulation stage could result in drug recrystallization and 
thus the addition of a drug dissolution stage upon release of the formulation from the 
capsule.
To examine the miscibility of triglyceride, hydrophilic and lipophilic surfactant when 
present in different proportions, use was made of a three-component phase diagram. 
Each of the axes on the diagram represented the percentage contributed to the 
formulation by each of the three constituents. The effect of varying the proportions of 
constituents present upon the miscibility of the formulation could thus be examined. 
Eight combinations of triglyceride, hydrophilic and lipophilic surfactant were selected 
to provide a wide range of possible formulations, necessary as ideally the lipid-based 
formulation for each drug was to contain different constituents to widen the scope of 
any intellectual property which resulted from the study. Comparison of the different 
combinations was also intended to reveal effects from a particular constituent in terms 
of ease of dispersion and miscibility.
The possible formulations contained either Crillet 4, a polyethoxylated sorbitan mono- 
oleate or the hydrogenated castor oil ethoxylate, Cremophor, as the source of 
hydrophilic surfactant, both of which were known to be efficient inhibitors of 
pancreatin. The triglyceride chosen was either fractionated coconut oil (FCO) 
representing a medium chain triglyceride or soya bean oil (SBO) as an example of a 
long chain triglyceride.
Several different lipophilic surfactants already demonstrated (section 5.2.2) to be 
capable of reactivating lipolysis were used, oleic acid, Maisine (glycerol mono-oleate) 
and Imwitor 988 (caprylic/capric glycerides), with the latter two also tested in 
combination. A co-solvent, such as ethanol could be necessary to increase the 
solubility of drug in the final formulation, therefore examination for any possible 
influence from ethanol upon miscibility was also made for certain formulations.
Method





A Crillet 4 SBO Imwitor 988
B Crillet 4 FCO Maisine 35-1
C Crillet 4 FCO Imwitor 988/Maisine (1:1)
D Crillet 4 SBO Imwitor 988/Maisine (1:1)
E Cremophor SBO Oleic acid
F Cremophor FCO Oleic acid
G Crillet 4 SBO Oleic acid
H Crillet 4 FCO Oleic acid
Table 5.2 Combinations of triglyceride, hydrophilic and lipophilic surfactant selected 
as possible formulations.
Points were selected evenly distributed across a triangular phase diagram. Each point 
represented a possible formulation, the percentage of triglyceride, hydrophilic and 
lipophilic surfactant present within that formulation being specified by the 
corresponding axes.
For each point the quantities of triglyceride, hydrophilic and lipophilic surfactant 
necessary to produce 5 g of formulation were weighed into the same 20 ml clear glass 
vial (accuracy + 0.02g of target weight for each constituent). The mixture was mixed 
by vortexing and the vial was then left to stand at room temperature for 7 days after 
which time an assessment was made in terms of phase separation.
If the mixture of constituents formed a continuous phase throughout the vial the 
formulation was classified as miscible whereas vials which displayed two or more 
phases were described as immiscible. Maisine at room temperature was not a clear 
solution therefore when incorporated with other formulation constituents white 
specks were seen throughout the formulation. Although it would be possible to 
remove these particles by centrifugation, for this study they were not considered to 
constitute a phase separation when assessing the formulations for construction of the 
phase diagrams.
For each vial of formulations A to D where no phase separation was evident after 7 
days, absolute ethanol (0.5 ml) was added to the formulation resulting in an
approximate ethanol concentration of 9 % v/w. This represented the maximum 
concentration of co-solvent likely to be used in a formulation as higher concentrations 
can start to impair the soft gelatin shell. After addition of ethanol the formulations 
were again thoroughly mixed by vortexing and left to stand for 2 days before 
reassessment of miscibility status.
Results
For formulations A to H the results are illustrated upon individual phase diagrams 
(Figures 5.6 a-h). The diagrams indicate the phase state of the formulation when 
triglyceride, lipophilic and hydrophilic surfactant are present in varying proportions.
Hydrophilic surfactant
From inspection of the phase diagrams (Figures 5.6 e-f) formulations containing the 
hydrophilic surfactant Cremophor exhibited poor miscibility, irrespective of the type 
of triglyceride present. The viscosity of the resulting opaque formulations increased in 
line with proportion of Cremophor present. The oleic acid was observed to be layered 
upon the surface of the formulation. Formulations E and F containing Cremophor 
were thus discarded from the study due to the exhibited immiscibility. Their opaque 
nature was a further disadvantage as this would have prevented visual examination to 
determine if drug was dissolved.
Formulations containing Crillet 4 (Figures 5.6 a-d, g & h) gave superior results in 
terms of miscibility compared to Cremophor. In the case of these formulations when 
immiscibility was observed it appeared to relate to the type and concentration of 
triglyceride present (see below). Crillet 4 was thus indicated to be the preferred choice 
of hydrophilic surfactant for use in the final formulations.
Triglyceride
Considered as pairs, formulations C and D and G and H are identical except for the 
source of triglyceride. Formulation C (Figure 5.6c) remained miscible until FCO 
concentration was raised to 80 % whereas formulation D (Figure 5.6d) exhibited loss 
of miscibility at a SBO concentration of as low as 20 %.
The same behaviour was reflected by formulations G and H where formulation G 
(Figure 5.6g) exhibited loss of miscibility at a SBO concentration of 60 % whereas 
formulation H remained miscible up to a FCO concentration of 80 % (Figure 5.6h). 
These results suggest the use of FCO rather than SBO will improve the formulation 
when miscibility is difficult to achieve.
Lipophilic surfactant
For formulations containing FCO and Crillet 4 the choice of lipophilic surfactant had 
no influence upon miscibility (Figures 5.6 b, c, & h). When comparing formulations 
composed of the less miscible SBO with Crillet 4 (Figures 5.6 a, d, & g) the choice of 
lipophilic surfactant could improve miscibility. From the combinations tested inclusion 
of oleic acid (Figure 5.6g) allowed formulation of miscible systems at higher SBO 
concentrations than Imwitor or Maisine (Figures 5.6 a & d).
Absolute ethanol
Results from addition of absolute ethanol to formulations A to D had little effect upon 
phase behaviour. However the solubility of Maisine did improve in the presence of 
ethanol, with concentrations of up to 40 % being completely dissolved. Ethanol also 
promoted miscibility of a formulation when FCO was the source of triglyceride; the 
previously immiscible formulations B and C containing 80 % FCO became miscible 
upon addition of ethanol. Due to the lack of adverse effects from inclusion of ethanol 
in formulations A to D it was not felt necessary to examine the effect of ethanol on 
formulations E to H at this stage.
5.3.3 Assessment of ease of dispersion of potential formulations.
Ideally to maximize drug absorption the formulations chosen were required to form a 
fine, uniform emulsion upon release from the capsule. This was to increase the 
likelihood of even drug dispersion throughout the gastric fluid, with promotion of 
rapid and consistent gastric emptying into the small intestine. In addition both the 
lipolysing and non-lipolysing formulations were required to form a dispersion similar 
in quality, to ensure fair comparison in the in vivo study.
For all formulations which exhibited miscibility upon the phase diagrams (Figures 5.6 
a-h), characterization of the ease of dispersion was performed using the simulated 
gastric dispersion model. This model was intended to represent the dispersion formed 
upon release of the formulation into the aqueous gastric fluid in the stomach.
Method
To prepare Formulations A to H for characterization in terms of ease of dispersion, 1 
g (+ 0.02 g) of the formulation mixture was encapsulated into an air fill soft gelatin 
capsule (17.5 tube 2A) and heat sealed.
The simulated gastric dispersion model involved allowing lg of encapsulated 
formulation to emulsify for 30 minutes in 100 ml of simulated gastric fluid (0.34 M 
NaCl in 0.1 M HC1) contained in a 500 ml round bottomed flask. Agitation to 
simulate stomach movement was provided by an overhead stirrer. This slowly rotated 
the flask (30 r.p.m) within a water bath held at 37°C.
After 30 minutes the resulting solution was examined in the flask under a bright 
electric light source. Using the appearance of scattered light, the emulsion formed was 
characterized according to the grades listed in Table 5.3.
Grade Dispersion Emulsion characteristics
A Excellent Translucent micro-emulsion which may be optically clear 
(droplet diameter 0.01-0.1 pm) or bluish haze (0.1-0.2 pm).
B Good A uniform emulsion, slightly opaque, grey or white in 
colour, possibly with a bluish tint.
C Crude A non-uniform emulsion with a highly opaque appearance. 
Trace of residual oil may be present at the surface.
D Poor Large globules of non-emulsified oil with a significant 
amount of oil present at the surface.
Table 5.3 Description of emulsion characteristics used to score the efficiency of 
dispersion.
Results
The dispersion grade exhibited by each formulation (A-H) was marked inside the 
miscibility symbol corresponding to that formulation on the relevant phase diagram 
(Figures 5.6 a-h). From inspection of the phase diagrams (Figures 5.6 a-h) 
formulations which differed only in the triglyceride present (FCO or SBO) exhibited
the same dispersion grade when all of the constituents were present in identical 
proportions. Therefore the type of triglyceride used in a formulation did not affect the 
ease of dispersion.
Figures 5.6 a-d revealed the influence of lipophilic surfactant upon dispersion of the 
formulation. Imwitor gave an equal or improved dispersion compared to its use in 
combination with Maisine or results shown by Maisine alone. Use of oleic acid in a 
formulation (Figures 5.6 e-h) resulted in the worst dispersion behaviour of all those 
tested.
5.3.4 Conclusions of the preliminary investigations.
The above investigations provided valuable information to aid selection of 
constituents for the lipid-based formulations. Fenofibrate exhibited very low aqueous 
solubility in the micellar solutions of digestion products and surfactants. Therefore 
careful selection of constituents for the formulations of fenofibrate was required to 
maximize the solubility of the drug.
The medium chain triglyceride, FCO was more likely to form a miscible system than 
the long chain triglyceride, SBO if the concentration of triglyceride was above 40 %. 
Interestingly the choice of triglyceride did not appear to affect the ease of dispersion. 
The choice of lipophilic surfactant in general did not affect miscibility however oleic 
acid was able to produce a miscible system with higher concentrations of SBO than 
other lipophilic surfactants tested. Conversely oleic acid was the least efficient 
lipophilic surfactant of those tested in terms of creating a good quality dispersion, 
with Imwitor 988 giving superior results in this respect. Miscible formulations were 
difficult to achieve with Cremophor therefore Crillet 4 was the preferred choice of 
hydrophilic surfactant for all formulations. Inclusion of ethanol had minimal impact 
upon miscibility of a formulation.
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5.4 Development of lipolysing and non-lipolysing lipid-based formulations.
For each of the drugs (fenofibrate and cinnarizine) two formulations were required, 
both of which were to consist of triglyceride, hydrophilic and lipophilic surfactant, 
possibly in combination with a co-solvent for the drug. The constituents were to be 
present within the percentage limitations described in section 5.1.2. The lipolysing and 
non-lipolysing formulations for the same drug were to be identical in all respects, 
differing only in the lipophilic surfactant present and the resultant lipolysing 
characteristics.
The lipolysing formulation was required to comply with the conditions of digestion 
Profile m  described below, whereas the non-lipolysing formulation was required to 
comply with the conditions of Profile IV.
Specifications for the lipolysing behaviour of the final formulations.
Profile I The triglyceride alone in the quantity present in 2 g of final formulation.
Profile II The triglyceride in combination with the hydrophilic surfactant thoroughly 
mixed before addition to the reaction medium in the quantities present in 2 g of final 
formulation. For the hydrophilic surfactant to be classified as substantially inhibiting 
lipolysis, Profile II should exhibit a 50 % reduction in fatty acid production after one 
hour of digestion compared to Profile I.
Profile in  The triglyceride in combination with hydrophilic and lipophilic surfactant 
thoroughly mixed before addition to the reaction medium in the quantities present in 2 
g of final formulation. For the lipophilic surfactant to fulfil the description of 
overcoming inhibitory effects of the hydrophilic surfactant, Profile m  should exhibit 
at least 50 % of the fatty acid production shown by Profile I after one hour of 
digestion.
Profile IV The triglyceride in combination with hydrophilic and lipophilic surfactant 
thoroughly mixed before addition to the reaction medium in the quantities present in 2
g of final formulation. For the lipophilic surfactant to fulfil the description of unable to 
overcome inhibitory effects of the hydrophilic surfactant, Profile IV should not exceed 
the extent of digestion exhibited by Profile H
Profiles I-IV were to be performed under conditions of the standard pH-stat assay, at 
a pH of 7.5, for a period of 60 minutes.
5.4.1 Development of the final formulations for fenofibrate.
Ideally to increase the scope of any intellectual property resulting from the study one 
of the drugs was to have a formulation containing long chain triglyceride with the 
other a medium chain triglyceride. As the micellar solubility studies had already 
demonstrated poor solubility of fenofibrate when compared to cinnarizine, and higher 
solubility of both drugs in long chain digestion products, it was felt that fenofibrate 
would benefit most from formulation within a long chain triglyceride (SBO) system. 
Examination of phase diagrams from formulations containing SBO (Figures 5.6 a, d,
& g) revealed Formulation A (containing SBO, Crillet 4 and Imwitor 988) to give the 
best dispersion when the three constituents were present in approximately equal 
percentages. As a possible lipolysing formulation 20 % of SBO with 40 % each of 
Crillet 4 and Imwitor 988 was selected (referred to in future discussion as formulation 
Al). This selection was made on the basis of compliance with proportions of 
constituents specified in section 5.1.2, in addition to good dispersion behaviour and 
miscibility which was independent of the presence of ethanol at a concentration of 9 
% v/w.
To ensure formulation Al complied with the requirements for a lipolysing 
formulation, a series of digestion profiles (Profiles I, II and HI) were produced as 
described in section 5.4. A digestion profile of the quantity of SBO present within 2 g 
of formulation Al (Profile I) is shown in Figure 5.7 together with the digestion profile 
from 2 g of formulation Al (Profile ID). In addition a profile of SBO and Crillet 4 
(Profile II) illustrates the ability of Crillet 4 to inhibit the digestion of SBO.
From examination of Figure 5.7 the addition of Crillet 4 to SBO resulted in an 80 % 
reduction in fatty acid production after one hour of digestion compared to Profile I.
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This was well within the requirements for Profile II which only specified a 50 % 
reduction. In terms of the ability of the lipophilic surfactant to overcome the inhibitory 
effects of Crillet 4, Profile IE (Figure 5.7) demonstrated that inclusion of Imwitor 
resulted in a 414 % increase in fatty acid production after one hour of digestion 
compared to Profile I. This result exceeded the minimum 50 % reactivation specified 
for Profile IE and is a consequence of Imwitor 988 providing another source of 
substrate in addition to SBO. These profiles (Figure 5.7) therefore demonstrated the 
suitability of formulation Al for the lipolysing formulation of fenofibrate.
The non-lipolysing formulation needed to contain the same quantities of SBO and 
Crillet 4 as formulation Al, with Imwitor 988 substituted with a lipophilic surfactant 
unable to reactivate lipolysis. Five lipophilic surfactants (Etocas-5, Lauroglycol, 
Marlowet, Neobee and Plurol oleique), demonstrated in section 5.2.2 as unable to 
reactivate the non-lipolysing model, were selected as possible surfactants for use in 
the non-lipolysing formulation of fenofibrate.
By substitution of the quantity of Imwitor 988 present in formulation Al with each 
one of the lipophilic surfactants (listed above) in turn, five formulations were 
prepared. Upon assessment for miscibility as per section 5.3.2, all remained miscible 
after 7 days and upon inclusion of 9 % v/w ethanol, except for the formulations 
containing Neobee and Marlowet which were discarded from the study.
The remaining three formulations were tested for lipolysing characteristics by 
production of a digestion profile (Profile IV) using 2 g of formulation. The resulting 
profiles revealed formulations containing Plurol oleique and Etocas-5 to fulfil the 
definition of a non-lipolysing formulation by restricting the degree of lipolysis to that 
shown by Profile E or below (Profile IV of Plurol oleique is illustrated in Figure 5.7). 
A final decision between the use of Plurol oleique or Etocas-5 in the non-lipolysing 
formulation was not taken at this stage (see section 5.4.2).
5.4.2 Dissolution of fenofibrate in the final formulations.
A concentration of 5 % w/w fenofibrate was required in the final formulations for use in 
the in vivo study. It was also necessary for fenofibrate to be well within the solubility 
limit of the drug in each formulation to reduce the risk of drug recrystallization after
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encapsulation. Upon addition of fenofibrate at 5 % w/w to formulation Al and the non- 
lipolysing formulations containing Plurol oleique or Etocas-5 the drug dissolved, but 
only with processing in an ultrasonic bath.
As the drug had not dissolved instantly the use of a co-solvent to raise the solubility of 
fenofibrate within the formulations was investigated. Ethanol up to a concentration of
7.5 % w/w did not significantly improve drug solubility therefore a short chain 
triglyceride, triacetin, was also included in the formulation to act as an additional co­
solvent. A combination of 12.5 % w/w triacetin and 7.5 % w/w ethanol was found to 
enable 5 % w/w of fenofibrate to dissolve easily, with the additional advantage of a 
reduction in the viscosity of the formulations to improve ease of handling.
Any consequences from the presence of co-solvent and drug on miscibility and 
dispersion of the formulations were unknown, therefore ease of dispersion was 
assessed as per section 5.3.3. The inclusion of drug and co-solvents decreased the 
quality of dispersion given by formulation Al from grade B to C. The non-lipolysing 
formulation containing Etocas-5 produced a dispersion classified as grade B with 
visible aggregates, presumably of lipophilic material evident. The non-lipolysing 
formulation containing Plurol oleique produced a fine emulsion with some large 
spherical droplets, classified as a grade C dispersion. The non-lipolysing formulation 
containing Plurol oleique was felt to be preferable to Etocas-5 due to lack of 
agglomerations in the dispersion which could restrict the availability of drug.
Miscibility status was checked by encapsulating 1 g of the final formulations into soft 
gelatin capsules followed by heat sealing. Three capsules were prepared for each 
formulation and left undisturbed at room temperature for 48 hours (the proposed 
period between manufacturer and in vivo dosage). Phase separation did not occur in 
any of the capsules. The lipolysing and non-lipolysing formulations developed for 
fenofibrate therefore met the requirements for use in the in vivo study. Their final 
formulas are listed below:
Fenofibrate Formulations
Lipolvsine % w/w Non-lipolvsine % w/w
Soya bean oil 16 Soya bean oil 16
Crillet 4 32 Crillet 4 32
Imwitor 988 32 Plurol oleique 32
Triacetin 12.5 Triacetin 12.5
Ethanol 7.5 Ethanol 7.5
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5.4.3 Development of the final formulations for cinnarizine.
The formulations developed for cinnarizine were to contain a medium chain 
triglyceride (FCO), for the reasons already discussed. The lipophilic surfactant of 
choice was oleic acid to enable demonstration of reactivation of lipolysis by a 
surfactant which is virtually unavailable to pancreatin as a substrate. In addition oleic 
acid was already known to have a high solvent capacity for cinnarizine206 which may 
remove any requirements for a co-solvent.
Formulation H (Figure 5.6 h) was therefore selected as a possible lipolysing 
formulation with proportions of 20 % FCO, 40 % oleic acid and 40 % Crillet 4 
(referred to in future discussion as formulation HI). Assessment of the lipolysing 
behaviour of formulation HI by production of profiles I, II and HI (results not 
illustrated) revealed Profile HI to exhibit only 42 % of the fatty acid production 
shown by Profile I after one hour of digestion. As the requirement of Profile IE is a 
minimum of 50 % reactivation of lipolysis, oleic acid could not be classified as 
overcoming the inhibitory effects of Crillet 4 in formulation HI.
The formulation was then manipulated in terms of the percentage of the constituents 
present and the surfactants used in an attempt to increase the extent to which lipolysis 
was reactivated. The results of this approach are shown in Table 5.4.
Composition of the formulation (%) Percent
Triglyceride Hydrophilic Lipophilic surfactant(s) reactivation of
(FCO) surfactant lipolysis
20 40 (Crillet 4) 40 (oleic acid) 42
30 25 (Crillet 4) 45 (oleic acid) 44
35 20 (Crillet 4) 45 (oleic acid) 39
20 40 (Crillet 1) 40 (oleic acid) 52
30 25 (Crillet 2) 45 (oleic acid) 35
30 25 (Crillet 4) 35 (oleic acid) 10 (Imwitor 988) 60
25 25 (Crillet 4) 35 (oleic acid) 15 (Imwitor 988) 76
Table 5.4 Lipolysis shown by Profile EE as a percentage of lipolysis shown by the 
same quantity of triglyceride in Profile I.
Table 5.4 illustrates that oleic acid within formulation H was not able to reactivate 
lipolysis to the percentage required (50 %) when tested in the proportions stated. 
Upon increasing the proportion of FCO present from 20 to 35 % in formulation H the
percentage of reactivated lipolysis remained within the same range. The accumulation 
of digestion products in combination with oleic acid may be responsible for inhibiting 
further pancreatin activity, rather than the presence of the hydrophilic surfactant.
To examine the ability of oleic acid to reactivate lipolysis in the presence of a different 
inhibitory hydrophilic surfactant Crillet 4, a Cig.i 20-ethoxy sorbitan monoester used 
in formulation H was substituted with Crillet 1 (C12 20-ethoxy sorbitan monoester) 
and Crillet 2 (Ci6 20-ethoxy sorbitan monoester) in turn. Crillet 1 and 2 were selected 
as previous work (Figure 4.20) had already demonstrated these surfactants to be 
slightly less inhibitory towards pancreatin activity upon a FCO substrate than Crillet 4. 
The use of Crillet 1 was found to increase reactivation of lipolysis to 52 % which met 
the specification of Profile HI, however this was still considered to be too close to the 
minimum requirement.
By replacing a percentage of oleic acid with Imwitor 988 the reactivation of lipolysis 
increased to 76 % when using proportions of 25 % FCO, 25 % Crillet 4, 35 % oleic 
acid and 15 % Imwitor. This combination was considered suitable for the lipolysing 
formulation of cinnarizine as the observed reactivation of lipolysis exceeded the 50 % 
requirement, whilst still demonstrating the reactivation capabilities of oleic acid. 
Profiles I, II and in  in Figure 5.8 illustrate compliance of the formulation selected for 
cinnarizine with the specifications for a lipolysing formulation.
The non-lipolysing formulation of cinnarizine was to contain 25 % FCO and 25 % of 
Crillet 4 with the remainder of the formulation comprised of a lipophilic surfactant 
unable to reactivate lipolysis. Each of the following lipophilic surfactants (Etocas-5, 
Lauroglycol, Marlowet, Neobee and Plurol oleique) were substituted in the place of 
oleic acid and Imwitor 988 resulting in five potential formulations. When these were 
tested for miscibility as described in section 5.3.2, the formulation containing Neobee 
exhibited phase separation and was subsequently eliminated from the study. The 
lipolysing characteristics of the remaining formulations were assessed in turn by the 
production of a digestion profile (Profile TV). Marlowet was the only lipophilic 
surfactant which restricted lipolysis of the formulation to the degree shown by Profile 
II or below, and hence was selected for use in the non-lipolysing formulation of 
cinnarizine. Profile IV of the formulation containing Marlowet is illustrated in Figure 
5.8 to demonstrate compliance with the requirements for a non-lipolysing formulation.
5.4.4 Dissolution of cinnarizine in the final formulations.
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Dosage specifications of the in vivo study required the formulations of cinnarizine to 
contain drug at a concentration of 1.5 % w/w. Upon addition of cinnarizine to both the 
lipolysing and non-lipolysing formulations at the stated concentration no problems 
were encountered with solubility, eliminating any requirement for a co-solvent.
A final check for miscibility and ease of dispersion of the two formulations was 
necessary to ensure inclusion of drug had not altered these properties. The miscibility 
of each formulation was checked as described in section 5.4.2 and phase separation 
was not observed in any of the prepared capsules over a 48 hour period.
The ease of dispersion of the two formulations with drug included was determined by 
the method described in section 5.3.3. The lipolysing formulation gave an adequate 
fine emulsion with oil droplets on the surface, classified as grade C whereas the non- 
lipolysing formulation produced an excellent dispersion classified as grade A. 
Although ideally both formulations were required to exhibit the same quality of 
dispersion, time constraints prevented the search for an alternative to Marlowet. 
Hence the final formulations selected for cinnarizine are as listed below:
Cinnarizine Formulations
Lipolysing % WL  Non-lipolvsing % w/w
Fractionated coconut oil 25 Fractionated coconut oil 25
Crillet 4 25 Crillet 4 25
Oleic acid 35 Marlowet R ll 50
Imwitor 988 15
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5.5 In vitro assessment of the formulations of fenofibrate and cinnarizine 
used in the in vivo study.
The analytical tests described in the following text were performed using the final 
formulations of fenofibrate and cinnarizine. The investigations were designed to 
examine the rate of release of drug from the formulations in vitro for comparison with 
results from the in vivo study. The results recorded in Tables 5.5-5.7 were determined 
by the analytical division of R P Scherer via HPLC within a 24 hour period from 
preparation of the sample.
5.5.1 The simulated gastric dispersion model.
The simulated gastric dispersion model was used to assess the rate of drug release 
from each formulation when the final unit dosage form was introduced into an 
aqueous environment. The concentration of drug dissolved in the simulated gastric 
fluid with time was determined. This enabled prediction of the possible proportion of 
drug dissolved in vivo upon release of the formulation into the gastric fluid in the 
stomach.
Method
The final formulation as used in the in vivo study was prepared and encapsulated into 
gelatin airfil capsules in quantities of 1 g. Simulated gastric fluid (100 ml) in a 500 ml 
round bottomed flask was slowly rotated (30 r.p.m.) by an overhead stirrer, whilst the 
temperature was maintained at 37°C. Two capsules of formulation were 
simultaneously added to the flask, which was then left to rotate for 60 minutes.
Thirty and 60 minutes after commencing the experiment a 2 ml sample was removed 
from the flask for analysis of the concentration of drug dissolved. The experiment was 
repeated in duplicate for each formulation.
Results
The results from the simulated gastric dispersion model for both formulations of 
fenofibrate and cinnarizine are shown in Table 5.5.
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Drug in dissolved form / %
Fenofibrate formulations Cinnarizine formulations
Sample Time 
(minutes)
Lipolysing Non-lipolysing Lipolysing Non-lipolysing
30 85,91 24, 57 90, 93 94, 104
60 89, 101 60, 65 86, 93 98, 103
Table 5.5 Concentration of drug dissolved in the simulated gastric dispersion model 
as a percentage of the total drug present within the final formulations.
Results from the simulated gastric dispersions illustrate that both drugs are able to 
dissolve within a solution formed by simulated gastric fluid and constituents of the 
formulation. For all formulations a high percentage of drug dissolution occurred 
within 30 minutes of addition of the capsules to the fluid, the exception being the non- 
lipolysing formulation of fenofibrate. Results from this formulation suggest that 
constituents of the formulation are unable to form a solubilized phase to hold the total 
drug present in solution. Drug not dissolved may have precipitated in the aqueous 
solution or be preferentially partitioned in the lipid / surfactant droplets of the 
formulation.
5.5.2 The simulated intestinal digestion model.
The simulated intestinal digestion model represented digestion of the formulation 
within the small intestine. An increase in the concentration of drug dissolved in the 
simulated bile solution with time would indicate that lipolysis was releasing drug from 
the formulation in a state available for absorption. This model was considered more 
representative of the situation in the small intestine than the standard pH-stat assay 
due to the reduced agitation rate of the reaction mixture.
Method
Fenofibrate
Using the same apparatus as for the simulated gastric dispersion model, 100 ml of 
simulated bile solution (pH 7.5) with 10 pi anti-foam A was equilibrated to 37°C.
Pancreatin (250 mg), prepared as for the standard pH-stat assay, was added to the 
flask and allowed to distribute throughout the solution. Upon addition of 2 g of 
formulation to the flask, digestion commenced. A 2 ml sample was removed from the 
flask for analysis of the concentration of drug dissolved at 0 (before formulation 
addition), 30, 60, and 120 minutes. The experiment was repeated in duplicate for each 
formulation.
Cinnarizine
The method described for fenofibrate was adapted for cinnarizine as the solubility of 
this drug was known to vary with pH. The experiment was performed as described 
above and the digestion left to proceed for the required period of time (30, 60 or 120 
minutes) at which point the reaction mixture was transferred to the pH-stat and back- 
titrated to pH 7.5. A 2 ml sample was immediately removed for analysis of the 
concentration of drug dissolved. This method therefore involved a separate digestion 
experiment to obtain each sample. The whole experiment was repeated in duplicate 
for each formulation.
Results
Results from the simulated intestinal digestion model for both formulations of 
fenofibrate and cinnarizine are shown in Table 5.6.
Drug in dissolved form / %
Fenofibrate formulations Cinnarizine formulations
Sample Time 
(minutes)
Lipolysing Non-lipolysing Lipolysing Non-lipolysing
30 83, 88 29, 64 ND 97
60 91,93 37,51 ND 97
120 90,91 39, 52 ND 96, 100
Table 5.6 Concentration of drug dissolved in the simulated intestinal digestion 
model as a percentage of the total drug present within the final 
formulations. (ND = Not determined).
Results from the simulated intestinal digestion model reflect the solubility of drug at 
various time intervals throughout a slow digestion. The same pattern was seen as for 
the gastric dispersion experiments, with high levels of drug solubility from the 30
minute sample onwards except from the non-lipolysing formulation of fenofibrate.
The lipolysing formulation of cinnarizine could not be analysed as the viscosity of the 
sample prevented analysis by HPLC.
5.5.3 Effect of digestion mixture and filtration upon the assay of dissolved drug.
The sample solutions from the simulated gastric dispersion and intestinal digestion 
models were complex mixtures of drug, the formulation, components from the 
simulated gastric fluid or bile solution and other possible constituents in the reaction 
mixture.
To ensure that all of the drug dissolved within the complex sample solution was 
available for analysis via the HPLC method used, a control experiment was devised. 
The control experiment involved digestion of the final formulation under conditions of 
the standard pH-stat assay with drug omitted. A known concentration of dissolved 
drug was added to two samples of the resulting digestion reaction medium. One of 
these samples was filtered before analysis by HPLC whilst the other was not.
This approach enabled examination of the availability of drug for assay by HPLC 
when present within the complex digestion mixture. In addition an assessment was 
also possible to determine if the process of filtration, necessary for the HPLC assay, 
reduced the concentration of drug detected through drug binding to the filter (despite 
the standard precaution taken of discarding the first 0.5 ml of filtrate).
Method
Each formulation was digested under conditions of the standard pH-stat assay using 2 
g of the final formulation with drug omitted in each case. The assay was performed at 
a pH of 7.5 for a period of two hours. Upon completion of the assay two 1 ml 
samples of reaction mixture were removed. One ml of standard drug solution 
(fenofibrate 0.1 % w/v or cinnarizine 0.03 % w/v as appropriate) was then added to 
each sample. One of the samples was filtered through a 0.2 pm filter (discarding the 
first 0.5 ml of filtrate) before HPLC analysis to determine the concentration of drug 
dissolved whereas the other was not.
Results
Results from the above experiment are shown in Table 5.7 for the four formulations.
Fenofibrate formulations Cinnarizine formulations
Sample Lipolysing Non-lipolysing Lipolysing Non-lipolysing
Unfiltered 98, 100 97, 100 106 95
Filtered 94 94 100 108
Table 5.7 Percentage of standard drug solution available for HPLC analysis when 
combined with digestion components pre and post filtration.
The results shown in Table 5.7 suggest that the majority of drug present is available 
for assay when in the presence of components created by digestion of the final lipid- 
based formulations. It could not be stated that filtration decreased the concentration 
of drug determined when compared to the corresponding unfiltered sample. This 
suggests that any alteration in results obtained via HPLC due to drug binding to the 
filter was insignificant when the precaution of discarding the initial filtrate was taken.
5.5.4 Conclusions of in vitro assessment of the final formulations.
The high levels of drug solubility determined in the simulated gastric dispersion model 
suggests digestion of these formulations is not required to release the drug in a 
dissolved form into the surrounding aqueous media. It could be proposed that the fine 
dispersions promote drug diffusion from the lipid droplets and the solubilization phase 
formed by the constituents of the formulation is able to hold drug in solution.
The non-lipolysing formulation of fenofibrate appears in some manner to prevent drug 
dissolution in aqueous fluid. It seems possible that drug is preferentially partitioned 
into droplets formed from the formulation. The observation of droplets at the surface 
and bottom of the flask during assessment of the dispersion formed by the non- 
lipolysing formulation of fenofibrate gives some support to this supposition.
Additional evidence for preferential partitioning of fenofibrate into droplets of the 
lipid-based formulation is provided by the results in Table 5.7. The high solubility of 
fenofibrate when added in a dissolved form to the digested formulation (Table 5.7) 
suggests that drug dissolution is only impeded if drug is already within the 
formulation.
As the overall intended purpose of this investigation was to demonstrate the 
advantage of a lipolysing versus a non-lipolysing formulation the results from these in 
vitro evaluations were not promising. The lipolysing formulations should have 
demonstrated minimal drug dissolution within the gastric fluid with the majority of 
drug remaining partitioned in the lipid formulation. Upon digestion the concentration 
of drug dissolved in the reaction mixture should have increased with time representing 
the advantage of digestion to release drug previously partitioned in the lipid phase. 
Drug in the non-lipolysing formulations would ideally dissolve to the same extent in 
the gastric dispersion as seen from the lipolysing system with no subsequent increase 
in the concentration of drug dissolved in the digestion model.
As far as could be determined the non-lipolysing formulation of fenofibrate was the 
only formulation behaving as intended in vitro with a significant proportion of drug 
remaining partitioned in the formulation unavailable for release by lipolysis.
5.6 Comparative pharmacokinetics of the fenofibrate and cinnarizine 
lipid-based formulations from the in vivo study.
The in vivo study described below was commissioned by R P Scherer and carried out 
in entirety by Coming Hazleton207. An outline of the study and results have been 
included within this chapter to assess the influence of the lipolysing and non-lipolysing 
lipid-based formulations (developed in section 5.4) upon drug bioavailability.
The overall intention of the study was to provide support for formulation of 
hydrophobic drugs in digestible lipid systems, by demonstration of improved 
bioavailability compared to that obtained from conventional oral dosage forms.
The study was thus designed to compare the pharmacokinetics of cinnarizine and 
fenofibrate from three formulations containing the same dose of drug. The 
formulations to be examined were the current marketed product and the lipolysing 
and non-lipolysing lipid-based formulations developed in section 5.4.
To enable quantification of drug bioavailability the pharmacokinetic parameters of 
maximum plasma concentration (Cmax), the time of maximum concentration (W ), and 
the area under the curve (AUC0-24) were used. Cmax and W  were determined by visual
inspection of the pharmacokinetic profiles whereas AUC0-24 was quantified 
computationally.
The study design used was a randomised three way balanced cross-over in six male 
beagle dogs, with three dosing intervals separated by a 14 day washout period. The 
dogs were an appropriate model as capsules could be administered in the same 




The three formulations examined in the study are listed below:
Formulation A One capsule (hard gelatin capsule shell) containing 100 mg of 
fenofibrate in powder form (Lipantil®).
Formulation B Two capsules each containing 50 mg of fenofibrate in 1 g of the 
lipolysing formulation.
Formulation C Two capsules each containing 50 mg of fenofibrate in 1 g of the non- 
lipolysing formulation.
After each dosing 11 plasma samples were taken from the dogs over a 24 hour period 
and the concentration of fenofibrate in the plasma was assayed via HPLC with 
ultraviolet detection.
Cinnarizine
The three formulations examined in the study are listed below:
Formulation A Two tablets each containing 15 mg of cinnarizine (Stugeron®). 
Formulation B Two capsules each containing 15 mg of cinnarizine in 1 g of the 
lipolysing formulation.
Formulation C Two capsules each containing 15 mg of cinnarizine in 1 g of the non- 
lipolysing formulation.
After each dosing 11 plasma samples were taken from the dogs over a 24 hour period 




The mean plasma concentrations of fenofibrate determined for each formulation are 
illustrated in Figure 5.9 (up to 10 hours post-dose) and Table 5.8 summarizes the 








Cmax (MS ! ml) 11.03 5.64 5.38
tmax (h) 1.3 1.7 1.8
AUCo-24 (ugh / ml) 34.14 34.94 28.99
Table 5.8 Mean pharmacokinetic parameters from the fenofibrate in vivo study, 
(reproduced from reference110). * n = 5 data sets
Coming Hazleton concluded that all formulations demonstrated similar tmax values 
(Table 5.8). Formulation A had a Cmax value twice that of either formulation B or C. 
However this was not reflected in the comparative bioavailability of the formulations 
(from the AUCo-24 values), which was similar for all three formulations (Table 5.8).
Cinnarizine
The mean plasma concentrations of cinnarizine determined for each formulation are 
illustrated in Figure 5.10 (up to 10 hours post-dose) and Table 5.9 summarizes the 








Cmax (ng / ml) 94.49 165.36 100.02
tmax (h) 1.3 1.6 1.8
AUCo-24 (ng.h / ml) 406.07 667.73 451.51
Table 5.9 Mean pharmacokinetic parameters from the cinnarizine in vivo study, 
(reproduced from reference111). * n = 4 data sets.
Coming Hazleton summarized the results from the cinnarizine study as follows; all 
three formulations had similar times to Cmax (Table 5.9). Formulation B had a Cmax 
value which was 60 % greater than that shown by formulations A and C (Table 5.9).
The Cmax values were also reflected by the A U C o - 2 4  (Table 5.9). Therefore formulation 
B was stated to have the highest maximum plasma concentration and bioavailability of 
the three formulations tested, based on A U C  values from 0 to 24 hours.
5.6.1 Discussion of results from the in vivo study.
Fenofibrate
The mean plasma concentrations of fenofibrate (Figure 5.9) showed no difference in 
bioavailability between the three formulations tested, with the highest Cmax value 
recorded from the proprietary capsule. The in vitro assessment of the same lipid- 
based formulations of fenofibrate had demonstrated poor dissolution of fenofibrate 
upon release of the non-lipolysing system into gastric fluid, when compared to results 
from the lipolysing formulation (Table 5.5). This was proposed to be due to drug 
remaining partitioned within droplets of the formulation. The difference in dissolution 
behaviour between the two lipid-based formulations was not reflected by the results 
from the in vivo study.
As the same bioavailability was achieved from the two lipid-based formulations in 
vivo this suggests the non-lipolysing characteristics of formulation C may have been 
overcome by physiological mechanisms, thus allowing digestion to release drug 
partitioned in the lipid droplets. Alternatively bioavailability from both formulations 
may have been influenced by an unknown mechanism. The lipid-based formulations of 
fenofibrate contained a high concentration of co-solvents, which are known to 
undergo rapid dilution upon release into aqueous fluid188. This could result in 
precipitation of the drug, and thus a restriction to bioavailability from both 
formulations by addition of a drug dissolution stage. The in vitro assessments do not 
support this proposed mechanism as no restriction to drug solubility was noted for the 
lipolysing formulation in gastric fluid (Table 5.5), although this could possibly be due 
to the fact that the co-solvents were still present within the closed system.
The proportion of hydrophilic components within the formulations of fenofibrate was 
high, with 52 % of the formulation comprised of hydrophilic surfactant and co­
solvents compared to 25 % for the cinnarizine systems. High concentrations of 
hydrophilic surfactant have been suggested to result in the solubilization and
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entrapment of poorly water-soluble drugs within the micelles thus formed,192 reducing 
levels of drug absorption. In any event it is clear that formulation within a lipolysing 
system was in the case of fenofibrate ineffective in terms of improving drug 
bioavailability over that from a formulation which exhibited non-lipolysing behaviour 
in vitro.
Cinnarizine
In the case of cinnarizine the mean plasma concentration of the lipolysing formulation 
was raised compared to the non-lipolysing formulation and the proprietary tablet 
(Figure 5.10). This difference could not be accounted for by the in vitro model of 
gastric dispersion, which demonstrated both cinnarizine lipid-based formulations to be 
equally effective with regards to holding the majority of drug present in a dissolved 
state in aqueous fluid (Table 5.5).
In vitro tests also suggested lipid digestion was not required to release cinnarizine 
from the non-lipolysing system (Table 5.5), therefore the reduced bioavailability from 
this formulation may possibly relate to differences between the constituents of the 
formulations. The oleic acid and Imwitor 988 surfactant within the lipolysing 
formulation are or contain natural digestion products. These may promote the 
formation of intestinal mixed micelles upon entry into the intestine, which 
subsequently solubilize drug and aid transport to the microvilli for absorption. The 
non-lipolysing formulation contains no such products and may initially release drug in 
a dissolved state as a result of the excellent dispersion behaviour shown by this 
formulation in vitro (section 5.4.4). If drug is not absorbed rapidly, upon further 
dilution of the solubilized phase with GI fluid, precipitation of the drug may be 
expected thus accounting for the reduced bioavailability.
The benefit to drug bioavailability conferred by lipid-based formulations able to form 
a fine dispersion upon release into gastric fluid has been demonstrated by a similar in 
vivo study designed by R P Scherer208. Using the same study design as for fenofibrate 
and cinnarizine above, two lipid-based formulations were compared with a proprietary 
solid oily suspension, with each formulation containing 100 mg of progesterone. The 
lipid formulations were SEDDS which were able to undergo lipolysis within the
standard pH-stat assay. Figure 5.11 illustrates the mean plasma profile from each 
formulation. The benefit to bioavailability of the lipolysing SEDDS was evident from 
the 8 to 10 fold increase in Cmax and 5 to 7 fold increase in AUCo-24 compared to the 
proprietary oral solid dosage form.
5.7 Conclusions
Care needs to be exercised when utilizing lipophilic and hydrophilic surfactants to 
improve the dispersion of a lipid-based formulation. Inclusion of certain hydrophilic 
surfactants may prevent lipolysis of a lipid-based formulation. However the use of a 
lipophilic surfactant in the same formulation may be able to overcome the inhibitory 
effect of the hydrophilic surfactant upon lipolytic enzymes. Only certain lipophilic 
surfactants have the ability to do this, with effective reactivation of lipolysis appearing 
to relate to the production of lipolytic products, which may in turn promote colipase 
partitioning at the interface. In any event lipophilic surfactants containing partial 
digestion products as part of their composition are a good first choice for a 
formulation. Not only have these proved highly successful in this work at reactivating 
lipolysis but they are also devoid of toxicity problems if one based solely upon natural 
triglyceride digestion products is selected.
The formulation exercise described within this chapter highlights the complexity of 
formulating a lipid-based system and tends to suggest that for the near future 
development of a universal lipid-based formulation for hydrophobic drugs is remote. 
Careful selection of constituents for the formulation to maximize drug solubility 
within the system and hopefully to avoid the use of co-solvents (which may lead to 
subsequent precipitation of drug) is essential and peculiar to each drug.
The issue of bioavailability enhancement through administration of drug in a lipolysing 
as opposed to a non-lipolysing system (when assessed in vitro) remains unclear. 
Results from the in vivo study discussed in this chapter are difficult to interpret due to 
variations between the formulations such as quality of dispersion and the use of co­
solvents. In vitro assessments of the formulations did not relate directly to the in vivo 
bioavailability data obtained. Although improved bioavailability from a lipid-based 
formulation able to undergo lipolysis is unproven, it may be prudent to develop lipid-
228




































































Figure 5. la Digestion profiles of lipophilic surfactants (1 g) which displayed a digestion 
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Figure 5. lb Digestion profiles of lipophilic surfactants (1 g) for which the extent of 
digestion exceeded the simulated bile blank profile for the total duration of the assay.
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Figure 5.3 Digestion profiles to illustrate the variation in liberation of acidic components 
when various constituents of the non-lipolysing model (and Imwitor 988) were present. 
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Figure 5.4 Digestion profiles to illustrate the variation in liberation of acidic components 
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Figure 5.5a Solubility o f Fenofibrate determined in specified micellar solutions, 
(standard deviation from 3 replicates).
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Figure 5.5b Solubility o f Cinnarizine determined in specified micellar solutions, 
(standard deviation from 3 replicates).
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O  = miscible system
■  = immiscible system
Dispersion Grades
A = Excellent 
B = Good 
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M  Percentage Soya bean oil (Triglyceride source)
Figure 5.6 (a) Ternary Phase Diagram for Formulation A displaying miscibility 
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—  Percentage Fractionated coconut oil (Triglyceride source)
Figure 5.6 (b) Ternary Phase Diagram for Formulation B displaying miscibility 
and score for dispersion for systems of various composition.
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O  = miscible system
■  = immiscible system
Dispersion Grades
A = Excellent 
B = Good 
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Figure 5.6 (c) Ternary Phase Diagram for Formulation C displaying miscibility 
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Figure 5.6 (d) Ternary Phase Diagram for Formulation D displaying miscibility 
and score for dispersion for systems of various composition.
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Q  = miscible system
■  = immiscible system
Dispersion Grades
A = Excellent 
B = Good 
C = Crude 
D = Poor
80 70 60 SO 40 30 20 10
^  - ■" Percentage Soya bean oil (Triglyceride source)
Figure 5.6 (e) Ternary Phase Diagram for Formulation E displaying miscibility 
and score for dispersion for systems of various composition.
£
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M  Percentage Fractionated coconut oil (Triglyceride source)
Figure 5.6 (f) Ternary Phase Diagram for Formulation F displaying miscibility 
and score for dispersion for systems of various composition.
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o = niiscible system
■  = immiscible system
Dispersion Grades
A = Excellent 
B = Good 
C = Crude 
D = Poor
£
90 80 70 60 50 40 30 20 10
A   Percentage Soya bean oil (Triglyceride source)
Figure 5.6 (g) Ternary Phase Diagram for Formulation G displaying miscibility 
and score for dispersion for systems of various composition.
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Figure 5.6 (h) Ternary Phase Diagram for Formulation H displaying miscibility 






























Figure 5.7 Digestion profiles to demonstrate compliance o f the Fenofibrate 




Figure 5.8 Digestion profiles to demonstrate compliance o f the Cinnarizine 
formulations with the lipolysing criteria specified by Profiles I to IV.
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Figure 5.9 The mean plasma concentrations of Fenofibrate (pg / ml) 
determined for each formulation. (Reproduced from reference110).
— ■ — Formulation A-Proprietaiy Capsule 
—O —  Formulation B-Lipolysing lipid formulation 
(sd denoted -Ve for clarity)
•  Formulation C-Non-lipolysing lipid formulation




Figure 5.10 The mean plasma concentrations of Cinnarizine (ng/ml) determined 
for each formulation. (Reproduced from reference111).
■ —  Formulation A-Proprietaiy Tablet 
(sd denoted as -*ve for clarity)
—O—  Formulation B-Lipolysing lipid formulation 
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Figure 5.11 The mean plasma concentrations of Progesterone (ng/ml) 
determined for each formulation. (Reproduced from reference208).
■ —  Formulation A - Proprietary solid oily suspension 
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Chapter 6 - Solubility enhancement of steroidal compounds in micellar solutions
of physiological surfactants.
6.1 Introduction
The bioavailability of drugs with poor aqueous solubility has in some cases been 
notably improved upon administration with or after food4. This infers that processes 
stimulated during the digestion of food may in some way enhance drug levels in the 
blood. Hydrophobic drugs are normally readily absorbed across the GI membrane 
however their slow dissolution in aqueous GI fluid may be the rate limiting step with 
regards to bioavailability.
A major change which occurs in the duodenum upon ingestion of food is the release 
of biliary secretions containing bile salts and phospholipids (predominantly lecithin8), 
in high concentrations with cholesterol. Both bile salts and lecithin possess surfactant 
properties which may enhance the dissolution rate of hydrophobic drugs via the 
possible mechanisms of wetting and solubilization.
The presence of physiological surfactants in the GI fluid could increase the wettability 
of the surface of a drug with a resultant increase in the dissolution rate. The 
wettability of a solid is expressed by the contact angle between a solid surface and a 
liquid165. A contact angle close to zero will result in liquid spontaneously wetting the 
solid, whereas values of 90° or greater prevent liquid penetration into the capillary 
pores of a powder and tend to inhibit wetting209. Some hydrophobic drugs 
agglomerate upon fine particle size reduction. In this case the shape of the resultant 
powder aggregate and pore size, in addition to contact angle, will influence the ability 
of liquid to penetrate the powder capillary and wet the solid surface210. Physiological 
surfactants may increase the dissolution rate by reducing the interfacial tension 
between the surface of the drug and GI fluid. The contact angle will thus be 
decreased, increasing wettability of the drug and the effective surface area of the drug 
available for dissolution104.
An increase in the aqueous solubility of a drug may also increase the dissolution rate. 
Although solubility of a drug is an intrinsic characteristic it can be enhanced by a 
mechanism known as solubilization. This has been defined as ca particular mode of 
bringing into solution substances that are otherwise insoluble in a given medium,
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involving the previous presence of a colloidal solution whose particles take up and 
incorporate within or upon themselves the otherwise insoluble material’211. The 
monomers of surfactants (when present above the CMC) tend to aggregate together 
to form micelles, which are capable of rapid breakdown and reformation. Within the 
micellar structures the insoluble material becomes incorporated and is said to be 
solubilized.
From the 1960’s literature reports of the ability of bile salts to improve drug 
solubility, dissolution rate and absorption have been published. In vitro experiments 
by Bates et al demonstrated an increase in the dissolution rate212 and solubility213 of 
the poorly water-soluble drugs griseofiilvin and hexoestrol when in the presence of 
bile salts. They suggested this effect was due to solubilization of drug within bile salt 
micelles. In vivo results from Meli et al214, using comparisons between bile duct- 
cannulated rats and control animals, revealed the presence of endogenous bile to 
enhance the absorption rate of ethynylestradiol 3-cyclopentyl ether from the small 
intestine. Absorption of the poorly water-soluble drug, sulfadiazine was compared 
using rat in situ intestinal loops under various conditions of bile flow215. An increase 
in absorption was observed when bile flow was enhanced. The view that this was 
probably due to increased drug solubility via micellar solubilization was supported by 
a concurrent in vitro solubility study.
In an attempt to discern the mechanism by which bile salt can enhance drug 
dissolution rate, Miyazaki et al216 examined the effect of bile salt on the in vitro 
dissolution of indomethacin and phenylbutazone. Results indicated that the enhanced 
dissolution of the two drugs, both of which have poor aqueous solubility, was 
mediated by two different effects related to the presence of bile salts. Enhanced 
dissolution of indomethacin was suggested to be due to increased solubility via 
micellar solubilization, whereas for phenylbutazone wetting effects may have been 
responsible by increasing the effective surface area of the drug.
Bakatselou et al217 also carried out an in vitro investigation to elucidate the 
mechanisms by which bile salts caused improved dissolution of five steroids. They 
examined wetting, solubilization and diffusivity, separately for each steroid, over a 
range of bile salt concentrations. The mechanism of dissolution enhancement was
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concluded to vary depending on the individual compound, even when the steroids 
were structurally related. However for the most hydrophobic compound tested, 
danazol, the main mechanism of dissolution enhancement was concluded by the 
authors to be solubilization, whereas for the others wetting effects predominated.
The above in vitro studies only examined the effect of bile salts on drug solubility and 
dissolution rate. The influence of lecithin also deserves consideration for a closer 
representation of in vivo conditions. Lysolecithin, the product of phospholipase A 
activity upon lecithin in the duodenum, enhanced dissolution rates and solubilization 
of hexestrol, dienestrol and griseofulvin in vitro219. Although it is a natural 
progression to simulate in vivo conditions by including lecithin with bile salts, several 
workers have gone a stage further by including products of triglyceride digestion 
within micellar systems. This may be a better representation of intestinal mixed 
micelles formed in the lumen of the fed gut.
The formation of bile salt and lecithin mixed micelles in bile has also been studied 
widely in an attempt to elucidate further the mechanisms by which solubilization may 
occur. Upon storage in the gallbladder bile becomes concentrated resulting in mixed 
aggregates in the form of vesicles or micelles. Small219 originally described the 
structure of bile salt / lecithin mixed micelles as disc-shaped bimolecular leaflets of 
lecithin surrounded on their hydrophobic parts by bile salt molecules. The mixed disk 
model was later proposed by Mazer et al220 where the disc shaped micelle was 
described as comprised of a lecithin bilayer interspersed at a constant ratio with 
hydrogen bonded bile salt dimers. Further bile salt molecules were thought to be 
arranged as a layer on the outer micelle surface to prevent contact between the 
lecithin hydrocarbon chains and water. Cholesterol and cholesterol ester was 
suggested to be incorporated within the lecithin bilayer.
Although this model became widely accepted several studies using different analytical 
techniques have suggested the mixed micelles to have a flexible, cylindrical 
structure221'224 with a radius of approximately 27 A221,224 A recent theoretical 
model225 to describe the solubilization of phospholipid bilayers by micelle forming 
surfactants also concluded that cylindrical micelles were the most probable structures 
resulting from aggregation.
The core shell model224 proposes these cylindrical micelles to have a central core 
comprised of the lecithin tails arranged radially about the micelle axis, with the 
cylinder ends capped by bile salts. The micelle perimeter described as the shell 
includes the lecithin headgroups, bile salt molecules and water of hydration if present. 
These cylindrical micelles are expected to be formed close to the micellar phase limit 
in coexistence with premicellar bile salt / lecithin vesicles226.
Micelles comprised solely of bile salt molecules are associated via hydrophobic 
interactions between the bile salt hydrophobic faces and by hydrogen bonding of 
hydroxyl groups. This is possible due to the amphipathic nature of bile salt molecules, 
which have a side with dominant hydrophobic character and a hydrophilic face formed 
from hydroxyl groups and a short hydrophilic tail227. These bile salt micelles have been 
reported to have aggregation numbers of approximately 10 and a mean radii of 
approximately 10 A227,228. Recent studies confirmed the radius and described a trimer 
of three bile salt molecules as constituting the building unit of the micellar 7/1 helical
, , 229,230structure ’ .
The average human bile salt concentration has been reported to range from 10 to 20 
mM in the fed and from 4 to 6 mM in the fasted state231. Throughout the 
investigations described in this chapter, (with the exception of section 6.4) a bile salt 
concentration of 15 mM was selected as an average representation of in vivo 
conditions in the fed state. This concentration is also above the CMC of 2.5 mM 
quoted for sodium taurodeoxycholate80, the bile salt used throughout this 
investigation. Although direct comparison of CMC values is complicated by 
dependency upon experimental parameters, other workers have reported the CMC of 
bile salt to decrease upon addition of monoglyceride and / or lecithin80,82,210,2325 233 to 
the system. It is therefore a fair assumption that the concentrations of bile salt, lecithin 
and triglyceride digestion products used throughout this work resulted in micellar 
solutions.
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6.1.1 Outline of this investigation.
The aim of this study was to assess the influence of the major physiological 
surfactants present in the intestine, namely bile salt and lecithin, upon the solubility of 
a range of steroids in vitro. An enhancement in the solubility of these drugs would 
indicate a possible increase in their dissolution rate, if administered in the fed state 
when the level of bile is at its highest.
The solubility values determined were expressed in terms of the extent of solubility 
enhancement (S/S0), defined to be the solubility in micellar solution as a fraction of 
the intrinsic solubility in water. Intrinsic aqueous solubility (S0) of the steroids was 
determined in Sorensens phosphate buffer at pH 7 and the results are shown in Table
6 . 1.
Solubility enhancement was assessed for a range of steroids in relation to:
1. The concentration of bile salt / lecithin (3:1 ratio) mixed micellar solution over a 
concentration range of 0 to 15 mM bile salt.
2. The hydrophobic nature of the steroid, expressed via an experimentally 
determined log P h p l c  value. A range of ten steroids with varying hydrophobic 
character were selected for use however log Poet values quoted differed or were 
not available for all of the steroids chosen. An apparent partition coefficient for 
each steroid was therefore determined (log P h p l c )  using reverse phase high- 
performance liquid chromatography (RP-HPLC) as described in section 6.10.
3. The ratio of bile salt to lecithin used in the mixed micellar solution.
4. The inclusion of typical products of triglyceride digestion with bile salt to form 
a mixed lipid / bile salt micellar solution. This approach was taken to increase 
representation of the physiological fed state.
6.2 Materials
Steroids
All obtained from Sigma (Poole) and used without further purification
Steroid Code Mean &Ajnax (nm) 
(litres mole' 1 
cm'1)
Standard error 
as % of mean s
Intrinsic aqueous 
solubility (SG) 
(mg ml' 1 / x 1 0 '3)
Ethynylestradiol E-4876 8 281  = 2175 8 . 0 0 10.96
Hydrocortisone H-4001 8247 = 20050 0.36 619.88
Hydrocortisone
acetate
H-4126 8 2 4 7  = 21767 3.59 8.36
Hydrocortisone
butyrate
H-5270 8246 = 20040 2.46 63.74
Hydrocortisone
caprylate
H-6259 8 2 4 6  = 17052 2.18 1.82
Hydrocortisone
valerate
H-5395 8 2 4 6  = 19839 4.32 17.12
Progesterone P-0130 8 2 4 4  = 18752 2.57 0.92
Testosterone T-1500 8 2 4 7  = 18318 1.89 12.29
Testosterone
acetate
T-1625 8242 = 16897 6.78 0.15
Testosterone
enanthate
T-3006 8240 = 16988 2.78 1.28
Table 6.1 Molar absorption coefficient, 8 at stated A^ ax and intrinsic aqueous 
solubility, SG of each steroid listed.









































Sorensens phosphate buffer at pH 7
For 1 litre: Code Supplier
392 ml Potassium dihydrogen orthophosphate P-4800 Fisons
(K H JO J \ 5M
608 ml di-Sodium hydrogen orthophosphate dihydrate S-4450 Fisons
(NajHPCVHsO) \ 5 M
4.41 lg Sodium chloride (Nad) S-9625 Sigma
Other materials
Code Supplier
Sodium taurodeoxycholate T-0875 Sigma
L-a-Phosphatidylcholine (99 % pure from fresh egg yolk) P-3556 Sigma
Chloroform (HPLC grade) C-4966 Fisons
Ethanol absolute (HPLC grade) E-0665 Fisons
Methanol (HPLC grade) M-4056 Fisons
1-Monoolein M-7765 Sigma
Oleic acid 0-3879 Sigma
Sodium taurodeoxvcholate 
referred to in text as "bile salt"
OH
N -C H ^ -C H r-S -O  Na
HO
Phosphatidylcholine 
referred to in text as "lecithin"
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6.3 Method
6.3.1 Preparation of miceUar solutions.
A single bile salt (sodium taurodeoxycholate) was selected for use in the micellar 
solutions to simplify identification of ultraviolet absorbance due to bile salt during 
analysis of samples. Bile salt micellar solution was prepared by dissolving the 
appropriate quantity of bile salt in Sorensens phosphate buffer at pH 7. The mixed 
micellar solution consisted of bile salt (sodium taurodeoxycholate) and lecithin (L-a- 
phosphatidylcholine) at a ratio of 3:1 in the same buffer. Throughout this work the 
mixed micellar concentration (expressed in units of mM) refers to the bile salt 
concentration, with lecithin also present at one third of the bile salt concentration 
unless otherwise stated.
To prepare the mixed micellar solution appropriate quantities of bile salt and lecithin 
were dissolved in 20 ml of solvent comprised of methanol and chloroform at a ratio of 
2:3. The resultant clear solution was placed in a 500 ml Buchi flask and the solvent 
drawn off using a rotary evaporator (Buchi Rotavapor R110). The flask was then 
attached to a vacuum line overnight to ensure removal of any remaining chloroform. 
The resultant clear film of bile salt and lecithin remaining on the flask surface was 
subsequently dissolved in an appropriate volume of buffer to give the concentration of 
bile salt / lecithin mixed micellar solution required.
6.3.2 Determination of steroid solubility in aqueous and micellar systems.
To determine the solubility of the steroids in buffer, bile salt micellar solution and bile 
salt / lecithin mixed micellar solution, excess steroid was added to approximately 3 ml 
of potential solvent in a 4 ml capacity clear glass vial with a Teflon lined rubber sealed 
cap. Each solution was mixed by vortexing (Fisons Whirlimixer) upon addition of 
steroid to give a saturated suspension, with three replicates prepared for each 
solution. Vials were placed in a horizontal position to keep drug moving throughout 
the solution and left for 72 hours in a shaking incubator (New Brunswick Scientific
Controlled Environment Incubator Shaker) set at 150 r.p.m., 37°C. After this
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equilibration period drug not dissolved was removed from the solution by filtration 
through a 0.2 pm filter (Acrodisc® non-sterile filters 25 mm, Code no.4496) and the 
resulting filtrate was retained for assay.
Quantitative determination of the concentration of steroid dissolved in the filtrate was 
achieved via an ultraviolet spectroscopic method. A double beam instrument (Perkin- 
Elmer Lambda 3 UV/VIS Spectrophotometer) capable of automatic scanning over a 
specified wavelength range (200 to 320 nm for this work) was employed.
Absorbance due to bile salt occurred in the same area as the wavelength of maximum 
absorption (A ^) for the steroids. The spectrophotometer was able to automatically 
subtract the background absorption due to bile salt from the sample scan up to a bile 
salt concentration of 6 mM. Dilution of filtrate with buffer was necessary when higher 
concentrations of bile salt were present. To ensure accurate removal of absorption 
due to bile salt, the micellar solutions used in the sample and blank needed to be from 
the same batch and treated in the same manner with regards to dilution. A scan of the 
blank as a final check ensured complete subtraction of solvent effects from the sample 
scan throughout the wavelength range of interest.
The absorption reading for each sample was taken at the Amax for the steroid. Dilution 
of filtrate was performed if steroid in the sample gave an absorbance reading above
0.8, as accuracy for spectrophotometric detection peaks in the range of 0.2 to 0.7234. 
To convert the absorbance reading obtained from each sample into the concentration 
of steroid dissolved, use was made of the Beer-Lambert Law (Equation 6.1)234 which 
describes the relationship between the absorbance of a solution and concentration.
£ = —; Equation 6.1
cl
where s = The molar absorption coefficient (i.e. absorbance of a molar solution at 
Aroax in a 1 cm path length cell).
A = absorption at Amax 
c = molar concentration 
/ = path length of cell
For each sample the concentration of steroid dissolved was calculated via Equation
6.1 using the absorbance reading, A from the sample and the respective molar 
absorption coefficient, s shown in section 6.2. Determination of 8 is discussed below.
6.3.3 Determination of the molar absorption coefficient, 8 for each steroid.
The following method was used to determine 8 for each steroid listed in section 6.2. A 
standard solution of steroid in ethanol was used to perform a 1:99 dilution into mixed 
micellar solution (5 mM). The standard solution was prepared so that the dilution 
produced a micellar solution with an absorption reading of approximately 0.5, the 
region close to maximum spectrophotometric accuracy234. The use of a 5 mM 
concentration of mixed micellar solution enabled drug to remain dissolved, whilst 
assay was still possible without prior dilution of the solution.
The absorption reading at the A**x was obtained and used to calculate 8 via Equation
6.1. Three replicates were performed for each solution and the average value of 8 was 
determined for each steroid. The resultant values are shown in section 6.2 and were 
subsequently used in Equation 6.1 to calculate the concentration of steroid dissolved 
in all assay samples.
6 is known to vary with wavelength however the A^ ax for each steroid listed in section
6.2 had been demonstrated235 to remain constant ± 1 nm across a range of mixed 
micellar solutions with concentrations from 1 to 15 mM. This justified the use of a 
single 8 value (determined in 5 mM mixed micelle solution) for all assay samples with 
micellar concentrations within this range.
6.4 Influence of the concentration of bile salt / lecithin mixed micellar 
solution on the extent of solubilization of steroids.
This study was designed to examine if the extent of solubility enhancement shown by 
the steroids was related to the concentration of bile salt and lecithin mixed micelles in 
the dissolution media. The solubility of hydrocortisone acetate, hydrocortisone 
caprylate and progesterone was assessed in buffer and 1, 2,4, 6, 8, 10, 12, and 15 
mM bile salt / lecithin mixed micellar solution as described in section 6.3.2. The
solutions were left for an equilibration period of 24 hours before filtration and 
subsequent determination of the concentration of steroid dissolved.
6.4.1 Results and discussion.
Figure 6.1 demonstrates the change in solubility enhancement (S/S0) as a function of 
bile salt / lecithin mixed micelle concentration expressed in terms of the concentration 
of the bile salt. Error bars are the standard error of three replicates.
Hydrocortisone acetate and hydrocortisone caprylate (Figure 6.1) show a general 
trend of increased solubility with an apparent maximum reached at a micellar 
concentration of 8 mM, although variation across each set of three replicates made 
this inconclusive. In the case of progesterone a monotonic increase in steroid 
solubility across the complete range of micellar concentrations was exhibited (Figure 
6.1) which probably can be attributed to solubilization of progesterone within the 
mixed micelles.
Experimental error could possibly account for some variability in the hydrocortisone 
acetate and hydrocortisone caprylate results. The solubility enhancement ratio 
determined at the 15 mM bile salt concentration was compared with the S/S0 from an 
identical experiment where the equilibration time was extended to 72 hours. With an 
extended period of equilibration an overall increase was seen in the values obtained. 
The magnitude of the increase (125 % for hydrocortisone acetate, 39 % for 
hydrocortisone caprylate and a mere 5 % for progesterone) may explain 
inconsistencies seen for hydrocortisone acetate and hydrocortisone caprylate in Figure
6.1, and as a consequence all future experiments were left to equilibrate for 72 hours. 
Several studies have demonstrated a linear increase in steroid solubility with bile salt 
concentration when the CMC of bile salt was exceeded217,236'239. Although the results 
obtained here (Figure 6.1) have shown a general trend of increased solubility with 
concentration of the mixed micelles the relationship was not linear, even above the 
bile salt CMC of 2.5 mM. This may be due to the experimental procedure used as 
previously discussed, however another point for consideration is the influence of 
lecithin upon solubilization of steroids as the studies quoted above involved bile salt 
micelles.
An investigation233 examining the solubility of hydrocortisone in the presence of bile 
salt / lecithin (ratio of 4:1) mixed micellar solution reported a linear increase in 
solubility for bile salt concentrations in the range of 4 to 15 mM. However an 
extensive study of the solubility of diazepam232 in bile salt / lecithin mixed micellar 
solution over a wide range of ratios and concentration demonstrated that whilst the 
solubility increase was linear with bile salt alone, the presence of lecithin over the 
same bile salt concentration range resulted in negative deviation. Results from these 
two studies suggest the existence of a linear relationship between solubility of drug 
and the concentration of bile salt and lecithin micelles may be more sensitive to 
physicochemical properties of the drug than when using bile salt micelles. The 
presence of lecithin may introduce a different mechanism of solubility enhancement.
6.5 Influence of the hydrophobicity of steroids on micellar enhancement of 
steroid solubility.
The hydrophobicity of a drug is an important parameter in the relationship between 
dissolution rate and bioavailability of a drug when administered by the oral route.
Thus an increase in the aqueous solubility of a drug via micellar solubilization could 
provide a means of increasing dissolution rate and eventual bioavailability as already 
discussed.
A series of steroids were employed to compare the influence of drug hydrophobicity 
(represented by log P h f l c )  upon the extent of steroid solubilization within aqueous 
micellar solutions. The solubility of each steroid listed in section 6.2 was assessed in 
buffer, bile salt micellar solution (15 mM) and bile salt / lecithin mixed micellar 
solution (15 mM) using the method described in section 6.3.2.
6.5.1 Results and discussion.
Figure 6.2 illustrates the mean solubility enhancement (S/S0) of each steroid as a 
function of steroid hydrophobicity, represented by the parameter of log P h p l c  
(determined in section 6.10). The extent of solubility enhancement in both bile salt and 
mixed micellar solutions (Figure 6.2) increased with steroid hydrophobicity. This
relationship could be predicted as the tendency of a drug to partition within a non­
polar phase (the environment of the micelle in this instance) as opposed to remaining 
in the aqueous phase will increase in line with hydrophobicity of a drug.
The observation of a relationship between the extent of solubility enhancement within 
surfactant solutions and the hydrophobic nature of the solubilizate has commonly been 
reported240. For example a study by Collett et al241 examined the partitioning 
behaviour of a series of substituted benzoic acids into polysorbate 20 micelles as a 
function of the hydrophobicity of their substituent groups. A linear relationship 
between the extent of solubilization into micelles and the hydrophobic nature of the 
substituent groups was taken as an indication that the compounds were solubilized 
into the lipophilic regions of micelles. In the specific case of steroids Tomida et al242 
established a linear relationship between log Poet and the extent of solubilization within 
polyoxyethylene lauryl ether micelles for 19 steroids. The correlation was found to 
improve when the steroids were divided and analysed as separate groups depending 
upon the presence of a fluorine atom in the molecule.
Indeed the suggested relationship between hydrophobicity of the solubilizate and the 
extent of solubilization has recently been used by Mithani et al239 to develop a model 
for prediction of the extent of solubilization of poorly water-soluble drugs in bile salt 
micelles. The model uses the drug parameters of log Poet and aqueous solubility. 
Development of the model involved determination of the solubility of 6 steroids in 
water and bile salt micellar solution (15mM). This information was used to calculate 
the solubilization ratio (SR) (Equation 6.2), described as the ratio of the solubilization 
capacity of bile salt for the drug to the solubilization capacity of water for the drug.
SR = Equation 6.2
SCaq 4
where
SCbs = solubilization capacity of the bile salt micelles (moles drug / moles bile 
salt)
SCaq = solubilization capacity of water (moles drug / moles water)
The results239 showed a linear correlation (Equation 6.3) between log SR and log P 
for the 6 steroids plus a further 5 drugs, despite the lack of similarity between the 
structure of the drugs, although log P values of the drugs used did not exceed 4.6.
log SR = 2.09 + 0.64 log P ?  = 0.951 Equation 6 J 239
The S/So ratio for each steroid in bile salt, displayed in Figure 6.2, was converted into 
a log SR value to enable comparison of results from this investigation with those of 
Mithani et al239. Figure 6.3 illustrates spread of the resultant log SR values around the 
model of Mithani (Equation 6.3). The linear correlation between log SR values from 
Figure 6.2 and log Phplc is expressed in Equation 6.4 for steroids with log Phplc 
values < 5.
log SR = 2.18 + 0.72 log P r2 = 0.82 Equation 6.4
Although experimental conditions differed between the two sets of results in that a 
different bile salt was used, sodium taurocholate for Mithani’s investigation and 
sodium taurodeoxycholate in this work, the data presented here supports the model of 
Mithani. For drugs with a log P > 5 the linear relationship does not appear to hold 
although this may be a result of experimental error in determination of the very high 
log Phplc values.
The hydrophobic character of a drug appears to be a major influence upon the extent 
of solubilization although other physicochemical characteristics of a drug may also be 
involved. Discrepancy between the over prediction and actual solubility of diazepam 
and phenytoin in bile salt micellar solution239 using the model of Mithani provides 
some support to this suggestion.
The molar volume of the solubilizate has been considered in the past to be an 
influence upon the degree of solubilization on the basis that volume within the micelle 
for solubilizate is limited. An early study243 demonstrated inverse proportionality 
between the volume of hydrocarbons solubilized and molar volume in potassium 
laurate micelles. However the same relationship does not seem to have been 
substantiated using bile salt micelles. Miyazaki et al244 when investigating the
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preferential solubilization in bile salt micelles of indomethacin compared with the 
more lipophilic compound phenylbutazone, concluded molar volume not to be a 
significant factor. In fact the chemical structure of phenylbutazone was deemed to be 
of importance with suggested negative repulsive forces between the drug and bile salt. 
Molecular shape of a drug is another possible influential factor on the extent of 
solubilization of drug in bile salt micelles. The extent of solubilization of steroidal 
drugs in various micellar solutions has been discussed by Sjoblom and Ekwall245 in 
terms of molecular structure, mainly in relation to the hydrophilicity of the substituent 
at position 17.
21
Steroid nucleus to illustrate ring numbering reproduced from reference245.
Although results indicated higher solubilization to occur with increased substituent 
hydrophilicity, later work led Sjoblom246 to state that micellar solubility is determined 
by the structure of the steroid molecule as a whole, based on the following criteria:
1. Hydrophilic substituents do not unconditionally increase micellar solubility, as 
orientation of the steroid in the micelle may depend on balance of 
hydrophilicity between rings AB and CD (see structure above).
2. Position of the hydrophilic substituent is important.
3. Suitable hydrocarbon substituents increase solubility in the micelle.
The dominant substituent on the steroid frame in terms of solubilization enhancement 
may thus have influence with regards to orientation of the steroid molecule in the 
micelle. Micellar solubilization has been proposed to occur by three mechanisms247, 
incorporation of solubilizate into the hydrocarbon core of the micelle, orientation of 
the solubilizate into the palisade layer of the micelle in the same manner as the
surfactant, or by solubilizate adsorption onto the micelle surface. Early studies 
involving space filling models236 demonstrated the possibility of the steroid, 19- 
nortestosterone being solubilized within the micelle interior. Slightly later work 
involving NMR237 suggested the solubilization mechanism of testosterone involved 
complex association of bile salt and steroid molecules to form mixed micelles.
The most likely mechanism by which steroids are solubilized in bile salt micellar 
solution appears to be via orientation into the palisade layer of the micelle, with polar 
functional groups on the steroid frame maintaining some contact with the aqueous 
surroundings. Cai et al248 determined an activity coefficient value to quantify 
intermolecular interactions of steroid with solvent (water, bile salt and mixed bile salt / 
lecithin micellar solution). When using water as the solvent the activity coefficient was 
noted to differ between the steroids investigated. The activity coefficient decreased 
with increasing numbers of hydroxyl groups on the steroids and reflected their 
respective positions and hence ability to hydrogen bond with solvent. The same 
pattern was seen for the micellar solutions, albeit with reduced activity coefficient 
values due to the more favourable hydrophobic environment of the micellar solution. 
Demonstration of the same pattern suggests polar interactions between steroid and 
solvent still occur to a certain degree in micellar solution and hence total 
incorporation of the steroid molecule within the micelle interior is questionable.
In the case of the steroids examined in this investigation the position or nature of 
functional groups on the steroid frame appears to have altered the solubilization 
enhancement of steroids with similar hydrophobicity. The hydrocortisone esters, 
despite a general trend of increasing solubilization with lipophilic character, did not 
become solubilized to the same degree as other steroids tested with similar log P h p l c  
values (Figure 6.4). From examination of steroid structures illustrated in section 6.2 
the hydrocortisone esters differ mainly in the possession of a hydroxyl group at 
position 11, and also at position 17 together with a carbonyl group. The hydroxyl 
groups may result in orientation of the hydrocortisone steroid frame near the 
periphery of the micelle palisade layer due to preferential hydrogen bonding. Polar and 
hydroxyl groups on the bile salt and steroid may form H-bonds with the solvent and 
dominate over van der Waal forces between the steroid frame and hydrophobic areas
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of the bile salt and lecithin molecules. This may result in a less efficient arrangement 
of the steroid frame within the micelle structure and hence decreased solubilization.
For the testosterone series when the length of the hydrocarbon side chain was 
increased from 2 carbons on testosterone acetate (log P h p l c  4.71) to 7 on testosterone 
enanthate (log P h p l c  9.05) the extent of solubilization increased in bile salt / lecithin 
micelles but fell slightly in bile salt micelles (Figure 6.2). The decreased solubilization 
in the bile salt micellar solution did not reflect the increase in hydrophobicity of the 
drug and may perhaps be explained by spatial restriction within the micelle area. The 
smaller bile salt micelles may allow solubilization of a finite number of steroid nuclei, 
with the bulky hydrophobic side chain of testosterone enanthate restricting further 
solubilization. The longer side chain could be folding into the hydrophobic region of 
the micelle leaving less space for incorporation of further testosterone nuclei which 
the larger bile salt / lecithin micelle is able to accommodate.
6.6 Influence of lecithin on the solubilization of steroids by bile salt
micelles.
The correlation between steroid hydrophobicity and extent of solubilization appears to 
be mainly unaffected by the presence of lecithin, as bile salt micellar solution and bile 
salt / lecithin mixed micellar solution had similar solubilizing effects for the steroids 
tested (Figure 6.2); marginal differences were apparent between results from the two 
solutions but no obvious trend was evident to explain these.
The correlation (Figure 6.2) had been demonstrated when using a bile salt to lecithin 
ratio of 3:1, selected to represent intermediate conditions found in the small intestine. 
The ratio in healthy human subjects has been reported to range from 2.5:1 up to 
5: l 249. To further examine the influence of lecithin upon solubilization enhancement of 
steroids, a study was performed using a wider range of possible physiological bile salt 
to lecithin ratios.
Solutions were prepared as per section 6.3.1 to produce bile salt / lecithin mixed 
micellar solutions with the following ratios: 10:1, 5:1, 3:1 and 2:1, with the bile salt 
concentration fixed at 15 mM in each case. The solubility of progesterone and
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testosterone acetate was determined in each of the above solutions using the method 
described in section 6.3.2.
6.6.1 Results and discussion.
Figures 6.5 & 6.6 illustrate the dependency of mean solubility enhancement (S/SD) on 
the bile salt to lecithin ratio of mixed micellar solution for progesterone and 
testosterone acetate respectively. For both drugs solubility enhancement increased as 
the proportion of lecithin to bile salt in the mixed micellar solution was raised. Bile 
salt micelles were equal to or more effective in terms of solubility enhancement than 
bile salt / lecithin mixed micelles up to a ratio of 3:1.
Rosoflf et al232 carried out a similar investigation of the solubilization of diazepam (log 
P » 3250) in bile salt / lecithin mixed micelles with identical ratios (10:1, 5:1, 3:1 and 
2:1) to those tested above. These workers also reported the solubilization capacity of 
a mixed micellar solution for diazepam to increase with the proportion of lecithin 
present. The results were proposed to be a consequence of increased micellar volume, 
based on a study by Shankland251 which demonstrated (via molecular weight 
determination) the size of a mixed micelle to increase with the lecithin to bile salt 
ratio. Micelles with a low ratio of lecithin to bile salt would therefore have a smaller 
volume and reduced capacity to solubilize diazepam than larger micelles with a higher 
proportion of lecithin. Sufficient lecithin is necessary to produce a bile salt / lecithin 
mixed micellar system with no pure bile salt micelles remaining228. However an 
increase in lecithin above this concentration should not increase the micelle radius 
assuming the core shell model is correct, as the cylinder radius is determined largely 
by the length of the lecithin tail221.
Rosoff et al232 also stated that within the physiological concentration range of bile (<
40 mM), mixed micelle formation with any ratio of lecithin always resulted in an 
increase in diazepam solubility above the concentration in bile salt alone. This 
conflicts with results from these investigations possibly reflecting the dependence of 
solubilization upon physicochemical characteristics of individual drugs.
A later study233 examining the ability of lecithin, in a 1:4 ratio with bile salt, to modify 
the mechanism of dissolution for hydrocortisone demonstrated a marginal increase in
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solubility in the mixed micellar system compared to bile salt alone. The initial 
dissolution rates indicated inclusion of lecithin strongly suppressed the ability of bile 
salt to wet the hydrocortisone powder, with increased dissolution mediated through 
solubilization effects from lecithin. Two other steroids, betamethasone and danazol 
were also studied82 to examine the effect of bile salt and lecithin (4:1 ratio) on 
dissolution rate. For both drugs inclusion of lecithin increased solubility compared to 
the value in bile salt alone (15 mM), with the highly lipophilic danazol (log P 4.53) 
showing a solubility value at least 5 times higher. The large increase in the solubility 
of danazol was suggested to reflect the ability of the danazol molecule to enlarge the 
diameter of the bile salt / lecithin micelles and promote swelling resulting in higher 
aggregation numbers than usual.
Unlike danazol82, testosterone acetate in this study did not exhibit a dramatic increase 
in solubility when lecithin was included with bile salt (Figure 6.6). This was despite 
the use of the same concentration of bile salt in both studies and the similar log P 
values of the drugs (4.85 cf. 4.53). The extended ring structure of danazol82, closer in 
resemblance to taurocholate than testosterone acetate, may aid efficient integration 
with bile salt in the perimeter of the bile salt / lecithin micelle structure. Consequently 
higher solubilization may be possible than with a conventional steroid frame, 
regardless of lipophilic character of the solubilizate.
6.7 Influence of triglyceride digestion products upon enhancement of the
solubility of steroids by bile salt micelles.
To improve representation of micelles likely to be formed in the physiological fed 
state, typical products of triglyceride digestion, namely fatty acids and monoglyceride, 
were added to the bile salt and bile salt / lecithin micellar solutions. The resultant bile 
salt / mixed lipid micelles would thus provide a closer indication of the solubility 
enhancement of steroids likely to be achieved in vivo within intestinal mixed micelles. 
The molarity of the lipolytic products included in the micellar solution was based on 
complete digestion of a minimal quantity of triglyceride (0.5 % w/v). Oleic acid and 2- 
monoolein (ratio 2:1) were selected as representative of typical lipolytic products
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formed by in vivo digestion of a common dietary triglyceride, glycerol trioleate. For 
economic reasons 2-monoolein was substituted in this investigation by 1-monoolein. 
The bile salt / mixed lipid micellar solution was prepared in the same manner as 
described for the bile salt / lecithin mixed micellar solution (section 6.3.1) with 0.283 
mM of 1-monoolein and 0.565 mM of oleic acid added to the chloroform / methanol 
solvent at the same time as the bile salt. Upon addition of buffer to the lipolytic 
products and bile salt (15 mM) a clear micellar solution was produced. However the 
same components with inclusion of lecithin (5 mM or 1 mM) produced turbid 
solutions which were discarded from the study as unsuitable for assay using an 
ultraviolet technique.
The solubility of hydrocortisone acetate, hydrocortisone valerate, progesterone and 
testosterone acetate was determined in the 15 mM bile salt / mixed lipid (monoolein & 
oleic acid) micellar solution using the method described in section 6.3.2.
6.7.1 Results and discussion.
Figure 6.7 illustrates the mean solubility enhancement in bile salt / mixed lipid micellar 
solution, bile salt / lecithin mixed micellar solution and bile salt micellar solution for 
the steroids indicated. The mixed lipid / bile salt micelles significantly increased 
solubility enhancement for three out of the four steroids examined. Lipid inclusion did 
not increase the solubility enhancement of hydrocortisone acetate above that 
determined in the presence of lecithin.
The extent to which mixed lipid micellar solution enhanced solubility (relative to the 
other micellar solutions tested) appeared to increase with the log P of the drug, 
although the range of steroids tested was not wide enough to confirm this. The mixed 
lipid micelles could be assumed to be more lipophilic than the bile salt / lecithin 
micelles, with the bile salt micelles the least lipophilic. The enhancement of solubility 
may therefore be explained by increased partitioning of the steroids with higher 
hydrophobicity into the more lipophilic micelles.
An investigation into the effect of bile salt / fatty acid micelles on the extent of 
solubilization of the lipophilic drugs, griseofulvin, dantrolene and ketoconazole 
revealed solubilization to increase in line with drug hydrophobicity79. As with this
work when the results (of dantrolene) were compared with the extent of solubilization 
in bile salt / lecithin mixed micelles, the bile salt / fatty acid micelles had the greater 
effect. For clofazimine, described as a highly lipophilic drug, mixed bile salt / fatty 
acid micelles increased drug solubility compared to solubility achieved in bile salt 
micelles252. To some extent these results are conflicting with those from Luner et al253 
who stated that solubilization of gemfibrozil within bile salt / lecithin micelles was 
additionally enhanced by the presence of monoglyceride and unaffected by fatty acid 
salts.
The mechanism by which addition of lipolytic products to bile salt micelles enhances 
drug solubility may involve the larger size of the bile salt / mixed lipid micelle allowing 
incorporation of an increased number of drug molecules. Alternatively a different 
mechanism of solubilization may be occurring whereby, due to the more hydrophobic 
nature of the micelle, drug molecules are also able to partition into the hydrophobic 
interior rather than undergoing specific orientation in the palisade layer.
Interestingly for the least hydrophobic drug tested in this investigation, hydrocortisone 
acetate, solubility enhancement was reduced slightly compared to results using the bile 
salt / lecithin micellar solution (Figure 6.7). When an early study210 noted solubility of 
the poorly water-soluble drug, hexestrol to decrease in intestinal bile salt mixture 
upon incorporation of lipid additives, the workers proposed competition between 
solubilizate and lipid additives for space in the micelle hydrocarbon interior to be 
responsible. Alternately the increased hydrophobic character of the micelle due to 
additional lipids may not encourage partitioning of drugs unless they display a certain 
degree of hydrophobicity.
6.8 Physiological relevance of this investigation.
These in vitro investigations have demonstrated the ability of the major physiological 
surfactants found in the intestine, bile salts and lecithin, to increase the solubility of 
each steroid tested above their apparent aqueous solubility values. Upon arrival in the 
intestine therefore these hydrophobic drugs should theoretically dissolve to a greater 
extent in the presence of bile released from the gallbladder.
In vitro the concentration of bile salt / lecithin micelles appears to have a direct 
influence upon the degree of solubility enhancement of a drug, as demonstrated in this 
work for progesterone and reported in the literature by other workers232,233. In vivo 
bile salt concentration is low (3-5 mM) in the fasted state and the solubility 
enhancement of drugs can be assumed to be minimal, although the CMC of bile salt / 
lecithin micelles is normally exceeded. Stimulation of bile release in the fed state 
serves to increase micelle numbers, rather than promote micelle formation4, thereby 
increasing the solubilizing capacity of the GI tract. As food is the stimuli for release of 
bile from the gallbladder it follows that a high level of solubility enhancement is more 
likely upon dosage in the fed state. In the case of other lipids present in the fed state 
such as fatty acids and monoglycerides, when incorporated with bile salt the 
consequential larger volume of the intestinal mixed micelle may further enhance 
solubilization of drug. Once drug molecules are solubilized within a bile salt / lecithin / 
mixed lipid micelle they should remain in a soluble state ready for absorption across 
the intestinal membrane, although it should be remembered that micelles are dynamic 
structures.
At the stage of transfer of drug from the micelle across the UWL for absorption into 
enterocytes experimental work has demonstrated a potential disadvantage of drug 
solubilization within micelles. Intestinal absorption of the poorly water-soluble drug, 
albendazole, was noted in animal studies to be decreased in the presence of bile salt / 
fatty acid micelles when compared to absorption when using bile salt alone in the 
same concentration83. The inclusion of fatty acid was proposed to have increased 
micellar solubilization of drug and reduced the rate of micellar dissociation compared 
to that exhibited by bile salt micelles, with a resultant decrease in absorption.
In vitro studies254 demonstrated that despite an increase in griseofulvin solubility in 
bile salt and lecithin mixed micelles compared to bile salt micelles the dissolution rate 
did not increase in line with solubility. As dissolution rate depends on solubility and 
the diffusion coefficient, a decreased diffusivity rate of the micelle due to an increase 
in the micellar size caused by lecithin was suggested to be responsible. The diffusivity 
of danazol82 was dramatically decreased when solubilized within bile salt / lecithin 
mixed micelles however dissolution rate was still enhanced. A possible explanation is 
the higher amount of drug per micelle may offset the decrease in diffusivity rate 
compared to that of free drug.
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During studies of cholesterol dissolution in bile salt / lecithin micellar solution a 
negatively charged interfacial barrier was suggested to exist between the dissolution 
fluid and the surface of cholesterol255. Despite an increase in solubility the resulting 
electrostatic repulsive forces acted to decrease dissolution, suggesting that for 
extremely lipophilic drugs surface chemical effects could reduce the dissolution rate of 
drug in micellar solutions4.
In general micellar solubilization of drug appears to be advantageous in terms of 
increasing the dissolution rate of a hydrophobic drug, which is usually the rate limiting 
step to bioavailability. However from the above examples it should be remembered 
that the overall result of solubilization and the effect upon dissolution rate requires 
consideration on an individual basis for each drug.
6.9 Conclusions
This series of investigations demonstrated the ability of bile salt / lecithin / mixed lipid 
micellar solutions to increase the apparent solubility of the steroids tested compared 
to their aqueous solubility. The degree of solubility enhancement was dependent on 
micellar constituents and concentration and also increased in extent with increasing 
steroid hydrophobicity. Other factors are also involved as the relationship between 
hydrophobicity of the steroid and degree of solubilization is not linear. These could 
include the ease with which a particular drug structure can undergo specific spatial 
orientation into the palisade layer of the micelle.
Variation in the bile salt to lecithin ratio in mixed micelles has demonstrated that 
lecithin can have an inhibitory effect on solubility enhancement when included in low 
proportions compared to bile salt alone, but is able to increase steroid solubility when 
present in a sufficient high concentration, presumably by swelling the micellar volume. 
Inclusion of mixed lipids in bile salt micelles also showed an increase in steroid 
solubility, however these results would have been a more useful representation of in 
vivo conditions if the micelles had also contained lecithin.
The loss of clarity upon inclusion of lecithin in the mixed lipid / bile salt system was 
probably a result of an increase in the mixed lipid to bile salt ratio. Visual turbidity has 
been quoted as corresponding to a particle diameter of > 1000 A256 which
encompasses the size range of unilamellar vesicles. This suggests these may have been 
formed in the turbid solution along with mixed lipid / bile salt micelles. Together these 
structures represent the main phases of lipolytic product dispersal formed in vivo, and 
the turbid medium could thus be considered to simulate the fed state for further drug 
solubility studies. With development of a suitable method to enable analysis of the 
turbid solution such as HPLC, the influence of steroid log P upon solubility could be 
further assessed in a physiological representative media.
Choice of bile salt is another consideration regarding physiological representative 
media as several studies232,236,244 have demonstrated the degree of drug solubilization 
to differ slightly with bile salt. The bile salt used throughout this investigation was a 
conjugated form of deoxycholic acid which constitutes only 15 % of the bile acids 
present in the human257. However the relevance of bile salt used remains questionable 
as Bates et al210 concluded results from solubilization of drug in a simulated intestinal 
bile salt mixture were comparable with those from individual bile salts.
The potential of bile salt / lecithin micelles, released during the digestion of lipid, to 
improve the bioavailability of drugs is based on the assumption that an increase in the 
solubility of a drug will increase dissolution rate via the Noyes-Whitney equation 
(Equation 7.1). The influence of bile salt and lecithin upon dissolution rate has also 
been discussed in terms of increased effective surface area via wetting240. An overview 
of the literature cited in this chapter suggests the dominant mechanism by which 
surfactants may enhance or even decrease the dissolution rate of a drug is dependant 
on physicochemical properties of the drug in question.
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6.10 Experimental determination of log Phplc values for steroids used in this 
investigation.
6.10.1 Introduction
A quantitative measure of hydrophobicity was required to enable examination of the 
solubility enhancement of each steroid in aqueous micellar solution in terms of steroid 
hydrophobicity. The most commonly used parameter of drug hydrophobicity is the log 
of the partition coefficient (log Poet),258 defined as the ratio of a neutral unionised 
substance present in octanol to that in water; a system thought to reflect partitioning 
of drug between lipid membranes and extracellular fluids259. Log Poet values from the 
literature were only available for five of the ten steroids selected for the solubilization 
study and those for which figures were quoted often had several different values 
depending on the source of reference. An alternative method was thus required to 
rank the steroids in order of hydrophobicity.
Traditionally log Poet has been measured using octanol and water phases via the 
shaking flask method. Difficulties such as prolonged equilibration times and low 
aqueous solubility in the aqueous phase are encountered with this method if the log 
Poet is greater than four260. There is also the requirement for a relatively large amount 
of pure, stable compound261. An alternative approach to direct measurement of 
partition coefficients involves systematic calculation to estimate hydrophobicity. The 
Hansch and Leo’s hydrophobic substituent constants262,^, and Rekker's hydrophobic 
fragmental constants250,/, are methods based on findings of Fujita et al258 that the log 
Poet value of a solute is composed of the sum of individual contributions of functional 
groups which make up the solute. However this is not always the case if a substituent 
group causes steric or electronic effects within the parent molecule which can lead to 
inaccuracies in a calculated log Poet value258 when compared to a value determined 
experimentally.
The use of RP-HPLC for the determination of partition coefficients was suggested in 
1974 by Haggerty and Murrill263 on the basis that chromatography involves a 
partitioning process. A direct relationship can therefore be expected between the 
retention time of a compound within the chromatographic system and partitioning
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behaviour described by log Poet- The general procedure to determine log Poet values via 
RP-HPLC (reviewed by Terada264 and Lambert265) involves experimental assessment 
of the retention time of reference compounds, with known log Poet values, in a 
chromatographic system. The retention time is then used to calculate the capacity 
factor, k  (defined by Equation 6.5) which describes affinity of the compound for the 
stationary phase.
k' = ——— Equation 6.5
to
where (r = retention time of sample compound.
to -  retention time of an unretained reference compound.
A regression line between k  and the known log P^t values according to Equation 6.6 
allows construction of a calibration curve.
log k' = a + b log Poct Equation 6.6
where a and b = constants characteristic of a particular chromatographic system.
The log k  of the test compound can then be measured under the same experimental 
conditions, with the corresponding partition coefficient value being read from the 
calibration curve. As there is not a theoretical relationship between log k  and log Poet 
the partition coefficient determined is an apparent parameter related to it and is 
generally referred to as log P h p lc .
For log P h p l c  to reflect partitioning behaviour seen with the shake flask octanol / 
water method as closely as possible it is important to select a stationary phase which 
mimics the behaviour of octanol. Silica gel has been successfully coated with n- 
octanol to give a stable chromatographic system266 with the resulting linear
relationship between log Poet and log possessing a gradient very close to unity, 
indicating a direct relationship between the two terms. However the mobile phase 
used to prevent solubilization of n-octanol from the stationary phase is n-octanol 
saturated water, which does not allow elution of hydrophobic compounds with a log 
Poet > 3 within reasonable retention times267. Glyceryl coated controlled pore-glass 
beads is another stationary phase which enables accurate determination of log Poet 
values up to b268. This system has the added advantage that the linear relationship 
between log k* and log Poet has a slope of 2.26, which reduces retention time in 
relation to log Poet-
The most commonly used hydrocarbon stationary phase in RP-HPLC is octadecyl 
silica (ODS) which is composed of octadecyl groups covalently bonded to the silanol 
groups of silica gel. This type of column can be used to determine log Poet values of 
up to at least 6269 with good correlation between log k 'and log Poet, especially for a 
homologous series of compounds264. An organic modifier such as methanol is added 
to the mobile phase to aid elution of the compound from the column and thus reduce 
retention times, as an increase in organic solvent concentration will decrease solute 
affinity for the stationary phase.
A linear relationship, expressed in Equation 6.7, has been demonstrated between log 
kf and methanol concentration in the mobile phase, over a limited range of methanol 
concentrations270.
log k ' = log k'Q + mC Equation 6.7
where k'Q = the capacity factor in absence of methanol from the mobile phase 
C = concentration of methanol (% v/v)
The k? values for a series of compounds can be correlated with log Poet if the same 
organic solvent concentration is used for each determination via Equation 6.6. 
Alternatively the linear relationship expressed in Equation 6.7 can be used to obtain
268
the log k'Q value by extrapolation to zero percent organic solvent in the mobile 
phase264.
For this study RP-HPLC using an ODS stationary phase and methanol / water for the 
mobile phase was the method felt best suited for determination of the log P h p l c  values 
of the ten steroids, due to their suspected wide range of hydrophobicity. Log kf values 
were determined for each steroid using a range of methanol / water concentrations in 
the mobile phase. Log k'Q values were then calculated for each steroid by 
extrapolation of the relationship between log K and methanol concentration in the 
mobile phase according to Equation 6.7. Log k ’0 values determined showed a 
significant correlation with literature log Poet values available, thus allowing estimation 
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Method
Steroids (listed in section 6.2) were dissolved in methanol at an approximate 
concentration of 0.2 mg / ml and injected onto the column. The mobile phase 
consisted of a mixture of distilled water and methanol with methanol concentration 
expressed in terms of % v/v. The pH of the mobile phase was adjusted to 2.0 with 
phosphoric acid to prevent acid dissociation of the steroids. Retention times were 
assessed for each steroid using a minimum of 5 different methanol concentrations in 
the mobile phase. The methanol concentration in the mobile phase varied from 40 to 
90 % in 5 % steps, the range for each steroid being chosen so that the compound 
exhibited a retention time of 30 minutes or less.
6.10.3 Results
Retention times (fe) recorded for each steroid were the mean of at least three RP- 
HPLC measurements performed using the same concentration of methanol in the 
mobile phase. Injection of pure methanol onto the column showed an identical 
retention time with all mobile phase concentrations and was used to represent 
retention time of an unretained reference compound, (to) for the system. The 
resulting data ( tR and to) enabled calculation of the capacity factor (log kf) values via 
Equation 6.5 for each steroid at each respective concentration of methanol used. 
Figures 6.8a-b illustrate the dependence of log K on the concentration of methanol in 
the mobile phase. For each steroid log kf decreased linearly with increase in methanol 
concentration in the mobile phase, indicating organic modifier had lessened affinity of 
the solute for the stationary phase and hence decreased retention time. Demonstration 
of a linear relationship between log kf and the concentration of organic modifier 
enabled the use of Equation 6.7 to obtain the capacity factor in the absence of 
methanol from the mobile phase, l o g ^ . The log k*Q value was calculated for each 
steroid by extrapolation of the respective plot to zero percent methanol via linear 
regression analysis and the results are shown in Table 6.2. The correlation coefficients 
were all higher than 0.996.
To construct a calibration curve as described by Equation 6.6 between log Poet and 
experimental lo g ^  values, known log Poet values were required. Literature
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sources242,259,262,27L were found to quote up to seven different log Poet values for 
some steroids (listed in Table 6.2). This was probably due to the use of various 
methods and the inherent difficulties associated with log Poet determination as already 
discussed. To overcome this linear regression analysis was carried out on the log Poet 
values from each reference source individually and when combined and the results are 
shown in Table 6.3. Combined log Poet values were selected for construction of the 
calibration curve as higher statistical confidence was possible in the resultant 
regression line due to the greater statistical population (assuming random error).
The intercept and gradient values from the combined literature log Poet regression line 
(Table 6.3) were substituted into Equation 6.6 resulting in Equation 6.8.
log k' = 2.3199+ 0.5031 log P_f Equation 6.8
(01774) (0.0599)
Substitution of the experimentally determined log k ’0 value for each steroid into 
Equation 6.8 thus enabled calculation of log P ^ ^  for each steroid and the resultant
values are shown in Table 6.2. Figure 6.9 displays the calibration curve constructed 
from the combined literature log Poet values, together with the determined log P ^ ^  
value for each steroid (all listed in Table 6.2).
6.10.4 Discussion
For this work the logA^ value has been used as a measure of chromatographic 
retention. This parameter is independent of organic modifier effects, represents well 
shake flask partitioning and has dependence upon solute structure and function272. As 
methanol is required in the mobile phase to aid solute elution, logA^ has to be 
obtained by extrapolation of the observed linear relationship between log k' and 
methanol concentration. Whereas this relationship remains linear between 30 and 70 
% methanol273 outside of this range curvature has been observed which is more 
accurately described by the quadratic expression274 shown in Equation 6.9.
log k r = AC2 + BC + log k r0 Equation 6.9
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The use of methanol as organic solvent has been shown to give less curvature than 
other organic modifiers275 and will thus minimise error in linear extrapolation to 
logk ’Q, although even slight curvature can result in deviation from true log£' values. 
An alternative method for determination of log Poet is the use of a log k  value at a 
fixed concentration of methanol via Equation 6.6. This approach, in addition to 
convenience has been found to give good correlation264,276, which was improved 
further upon the use of lower concentrations of organic solvent in the mobile phase (< 
30 % )270.
In this study the broad range of lipophilicity exhibited by the steroids meant that a log 
k  value for all the compounds when using the same concentration of methanol in the 
mobile phase was not available. In view of this fact, in combination with the reduced 
curvature reported for methanol, linear extrapolation to logk'0 was used. It could be 
argued that accuracy of the log k ’0 values may be improved by quadratic extrapolation 
to zero per cent methanol. A study269 comparing linear and quadratic extrapolation 
to log k*0 upon the same experimental data set found close correlation between the 
two values for polar compounds, however for less polar compounds the quadratic 
values were higher. This was proposed to be a result of the extensive extrapolation 
required due to the higher methanol concentrations required for elution of 
hydrophobic compounds. As the steroids used in this study were hydrophobic in 
nature and the data obtained appeared linear this gave further support to the use of 
linear extrapolation to determine logk ’0.
A further influence which may affect the linear relationship expressed in Equation 6.6 
when using ODS as the stationary phase appears to be the ability of test compounds 
to form hydrogen bonds with either the stationary or mobile phase. Studies by Miyake
270 277 •et al ’ examined the relationship between log k  and log Poet using the same 
chromatographic system with compounds differentiated according to hydrogen 
bonding ability. Good correlation was observed within the same hydrogen bonding 
class which was reduced when all of the compounds were examined together.
Addition of hydrogen bonding terms to Equation 6.6 gave improved correlation for a 
wide range of compounds277 however their effect reduced with the concentration of 
methanol used to determine log k. The workers concluded that hydrogen bonding
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terms may not be required for correlation with log k'0 as in the absence of methanol 
hydrogen bonding was small or negligible.
In view of the use of log k ’0 for correlation with log Poet for the steroids investigated 
in this study and the similar functional groups and hydrogen bonding capabilities of 
the steroids it was not felt necessary to involve hydrogen bonding terms when 
evaluating these results.
In further support of the log P h p l c  values determined for steroids in this study the 
parameters of the chromatographic system used were examined. According to 
Terada264 the gradient of the regression line between log k  and log Poet for Equation
6 . 6  will improve accuracy of log Poet if the value is approximately 0.5. For the system 
in this work the gradient had an excellent value of 0.503. In addition the range of log 
k  values which can be determined accurately by HPLC were stated to fall within -0.3 
to 2.5264. For this study the experimental values of log k  also complied to this 
requirement, ranging between -0.155 and 1.93.
6.10.5 Conclusions
Upon comparison of the experimental log P h p l c  values determined here with the 
quoted literature log Poet values all were found to be within reasonable range of the 
literature values (Table 6.2). For hydrocortisone caprylate and testosterone enanthate, 
which are clearly very hydrophobic compounds from their retention behaviour, the log 
P h p l c  values determined were extremely high. It is difficult to have confidence in these 
values due to the large degree of extrapolation involved in their determination 
however the linearity of the relationship between log k  and methanol concentration 
provides some support to the results.
The determination of log P h p l c  has provided, by means of chromatographic retention 
behaviour, a parameter for ranking the series of steroids in order of hydrophobicity. 
Log P h p l c  values enabled correlation between steroid solubility enhancement (via 
micellar solubilization which is an interfacial partitioning process) and steroid 
hydrophobicity (section 6.5). In some ways the direct use of log k'Q as a 
hydrophobicity parameter may be a closer representation of steroid partitioning into 
micelles whereas a true log Pod value reflects partitioning between bulk phases.






Log P h p l c
Hydrocortisone 3.0947
(0.113)
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Table 6.2 For the steroids listed:
Experimental log k'Q values from linear extrapolation of capacity factors via 
Equation 6.7. (Values in parentheses = 95%  confidence limits).
Literature log Poet values (a262, b271, c242 and d259).
Predicted log Phplc values via Equation 6.8.
Literature Log 
P„ct values
Gradient Intercept i* n




















2.3199 0.9689 2 2
combined (0.0599) (0.1774)
Table 6.3 Correlation statistics for literature values of log Poet- 
r2 = correlation coefficent squared.
n = no. of observations.
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Figure 6.1 Solubility enhancement (S/S0) of Hydrocortisone acetate, Hydrocortisone 
capiylate and Progesterone as a function of the concentration o f bile salt / lecithin 
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Figure 6.2 Solubility enhancement (S/S0) o f steroids in the presence o f bile salt (15 mM) 
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Figure 6.3 Log Solubilization ratio (log SR) in bile salt micellar solution (15 mM) 
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Figure 6.5 Influence of the bile salt to lecithin ratio of the micellar solution on 
the extent of solubility enhancement (S/S0) for Progesterone.
LE 15Mm B/L=5: B/L=3:1
B/L = bile salt to lecithin ratio
Figure 6.6 Influence of the bile salt to lecithin ratio of the micellar solution on 
the extent of solubility enhancement (S/SQ) for Testosterone acetate.
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Figure 6.7 Influence of mixed lipid (fatty acid + monoglyceride) / bile salt micellar solution 
on the solubility enhancement (S/S0) of steroids as a function of log Phplc-
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Figure 6.8a Dependence of log capacity factor (log k’) on concentration 
of methanol in the mobile phase for steroids listed.
2.5
V  Hydrocortisone 
•  Hydrocortisone acetate 
■ Ethynylestradiol 
A  Hydrocortisone butyrate
□ Hydrocortisone valerate
Symbols = experimental data
Solid line = linear regression fit to the data
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Figure 6.8b Dependence of log capacity factor (log k1) on concentration 
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y* HB (3.58) 
T (3.19)
0 2 4 6 8 10
Log / HPLC
■ Experimentally determined log P ^ ^  (actual values in parentheses).
V  Literature log P ^  values used for construction of regression line (illustrated). 
Steroids as denoted below:
H = Hydrocortisone 
HA = Hydrocortisone acetate
E = Ethynylestradiol
P = Progesterone
TT , , T = Testosterone
HB = Hydrocortisone butyrate ^
TA = Testosterone acetate
HC = Hydrocortisone caprylate TE = Testosterone enanthate 
HV = Hydrocortisone valerate
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Chapter 7 - A mathematical model for estimation of the fraction dose absorbed
from an emulsion formulation.
7.1 Introduction
It is difficult to predict which drugs may benefit from formulation in a lipid based 
system and the literature gives sparse information on this. Recently the US Food and 
Drug Administration adopted the Biopharmaceutical Drug Classification scheme278. 
This scheme relates the rate and extent of drug absorption to the parameters of drug 
dissolution and permeability across the GI membrane. The drugs are classified 






Table 7.1 The Biopharmaceutic Drug Classes.
The majority of hydrophobic drugs would be expected to fall within Class II, as they 
easily cross the intestinal mucosa whilst exhibiting characteristics of low aqueous 
solubility. Dissolution into gastrointestinal fluid then becomes the rate limiting step of 
the absorption process as the rate at which drug dissolution occurs is too slow to 
enable all of the drug to dissolve within the transit time of the dosage form through 
the gut.
As most dosage forms for oral administration contain drug in the solid state, 
dissolution rate limitation can be a significant factor in the bioavailability of 
hydrophobic drugs. A modified version of the Noyes-Whitney equation (Equation 
7.1) 240 can be used to reveal factors likely to influence drug dissolution.
dX AD (  X d\  rDR = —— = —— A C .---- — Equation 7.1
dt h K s V )  4
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where
DR = dissolution rate 
A = surface area available for dissolution 
D  = diffusion coefficient of the drug
h = thickness of the boundary layer adjacent to the dissolving drug surface 
Cs = saturation solubility of the drug 
X d = amount of dissolved drug 
V = volume of dissolution media
The saturation solubility, Cs has a major influence on dissolution rate as the higher 
the concentration of drug in the boundary layer, the stronger the driving force for 
dissolution. If the aqueous solubility of a drug is less than 100 pg / ml or the volume 
of fluid required to dissolve a single dose of drug is greater than 1 litre Cs is likely to 
limit the rate of dissolution240. The size of the drug particles is also relevant to the rate 
of dissolution as shown by the term A in Equation 7.1, which indicates that the 
greater the surface area of the particle, the higher the dissolution rate.
Both Cs in the GI tract and A may be increased by selection of a lipid-based 
formulation for delivery of a hydrophobic drug. On the basis that lipid in the 
formulation stimulates the lipid digestion cascade, formation of high numbers of bile 
salt and lecithin micelles in the intestine would result. Cs may therefore be increased 
by means of solubilization of drug within the micelles. The amphipathic nature of the 
bile salts may also result in a greater effective particle surface area, A for dissolution 
through wetting effects.
Dissolution rate may be altered by other mechanisms upon transference of the GI tract 
from the fasted to the fed state4. Diffusivity, D of a drug when solubilized within a 
micellar structure in the fed state tends to decrease compared to that of a free drug 
molecule due to the larger size of the micelle. The presence of food usually increases 
viscosity of the GI fluid which in turn may decrease diffusivity and thus reduce 
dissolution rate of the drug. Variation in pH along the GI tract can change the 
dissolution rate of ionizable drugs, which exhibit different Cs values according to the 
pH of their environment. Whether this is advantageous to bioavailability would 
depend on the pKa of the drug.
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The overall effect on the dissolution rate of poorly water-soluble drugs through 
stimulation of the lipid digestion cascade, (whether by means of a formulation or 
food), has been observed from many in vitro studies to be specific to the particular 
drug under investigation. This suggests a combination of physicochemical properties 
of a drug to be relevant to dissolution. In vivo dissolution behaviour of a particular 
drug may also be affected by physiological factors which can vary greatly. The large 
number of variables which may influence dissolution complicates efforts to predict 
whether a particular drug will exhibit dissolution limited absorption. In vitro 
dissolution tests remain useful to provide a rough guideline.
Mathematical modeling is another approach which may be used to assess the rate- 
limiting processes in drug absorption. A model to correlate in vitro drug dissolution 
and absorption parameters with in vivo bioavailability would be extremely useful. This 
would allow a reduction in the number of in vivo studies required in humans, aid 
selection of suitable candidates during drug discovery and in the context of the work 
here, forward development of oral drug delivery strategies279. A comprehensive model 
to predict the bioavailability of a drug would require a prohibitively large number of 
variables due to the complexity of the GI tract. However when designing a model it is 
best to simplify the stages involved, which enables the parameters of a model to be 
examined in turn. This approach should reveal the main factors affecting the 
bioavailability of a particular drug in the model, with the assumption that this reflects 
the in vivo situation.
There have been many attempts (reviewed by Yu280) to develop a theoretical model to 
predict oral drug absorption in humans. The rate and extent of drug absorption 
depends to varying degrees upon the physicochemical characteristics of the drug in 
question, physiological factors and the choice of dosage form280. In general the 
models have a small number of parameters which describe the aqueous solubility, dose 
and membrane permeability of a drug4. Selection of a model for use depends upon the 
nature of the information required, which can range from general drug absorption 
trends through to the rate of drug absorption.
The models discussed throughout the remainder of this chapter are classified as 
steady-state models based on a mass balance approach. These models estimate the 
fraction of dose absorbed but provide no information regarding changes in the rate of
absorption with time. A relatively recent theoretical macroscopic mass balance 
approach279 enabled estimation of the fraction of dose absorbed in humans, based on 
parameters of drug solubility and membrane permeability. As an extension of this 
theory a further mathematical model using a microscopic mass balance (MMB) 
approach has been developed112. This model is particularly relevant for poorly water- 
soluble drugs as it takes into account dissolution rate and membrane permeability 
using a limited number of parameters. The MMB approach has been used with some 
success to predict the fraction of dose absorbed from aqueous suspensions of poorly 
water-soluble drugs.
To examine the bioavailability of poorly water-soluble drugs from a lipid-based 
formulation the MMB approach has been adapted here to an emulsion system. The 
MMB model as developed by Oh et al112 for aqueous suspensions is described in some 
detail below followed by the adaptations made in this work to enable prediction of the 
fraction of dose absorbed from lipid-based formulations.
7.2 The microscopic mass balance approach for aqueous suspensions of drug.
The suspension MMB model112 considers the intestine to be a cylindrical tube through 
which a suspension of drug particles of uniform radii is passed. Absorption of drug 
occurs from the tube through the intestinal membrane to the blood upon drug 
dissolution. The tube is divided into slices with the fluid within each slice assumed to 
be of uniform composition (complete radial mixing). For each slice the model has 
values for the volume of suspension flowing in and out, (the rate of which remains 
constant), the rate at which the drug is dissolving and the rate of drug absorption 
through the intestinal membrane to the blood. As one progresses from slice to slice 
the concentration of drug passed from one to the next consecutive slice is reduced and 
the size of the drug particle decreased. The slices are presumed to be of infinitesimal 
width, hence there are an infinite number of them and the model reduces to the 
solution of two differential equations. Figure 7.1 illustrates in simplified terms the 
compartments involved in the model.
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Figure 7.1 Flow diagram of the MMB approach112 used to predict the fraction dose 
absorbed of suspensions o f poorly water-soluble compounds.
Each column of compartments relates to a particular slice of which there are an 
infinite number. The first row of compartments represents the amount of drug in 
suspended particles in each slice, with the second row representing the amount of 
drug in solution in the intestinal fluid within the same slice. Arrows represent rates of 
drug motion between compartments - horizontal arrows represent flow associated 
with the physical flow of suspension along the intestine, whereas vertical arrows 
represent dissolution and absorption.
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The model is expressed by the following two differential equations (Equations 7.2 /
7.3) as derived by Oh et al112:
dr Dn \ - C  . _ 0— -  = ------------ -— Equation 7.2
dz 3 r
dC**- = Dn Do • r* ^ 1 -  C*) -  2An ■ C* Equation 7.3
dz
where the variables are defined as:
r* = The particle radius as a fraction of the initial particle radius. 
z = The position down the tube as a fraction of the total length of the tube. 
C* = The concentration of drug dissolved as a fraction of the aqueous 
solubility of the drug.
Only three dimensionless parameters are used to entirely characterize the efficiency of 
drug delivery in the model. These are the absorption number (An), the dose number 
(D o) and the dissolution number (D n) defined below:
^  _ radial absorption rate 
axial convection rate
~ dose concentration Do = -
solubility
^  residence timeD n - --------------------
dissolution time
An
The absorption number is a measure of how efficiently drug is transported from the 
intestinal fluid into the blood, with the value of An increasing with the efficiency of 
the process. It includes terms which relate the ability of a drug to permeate the
intestinal membrane (radial absorption rate) with flow rate of the intestinal fluid (axial 
convection rate).
Do
The dose number describes the ability of a particular dose of drug to dissolve in the 
volume of intestinal fluid available. It includes terms for drug solubility, dose and 
volume of intestinal fluid, providing an element of pharmaceutical control. A small 
dose number will increase the fraction of the dose absorbed but manipulation of Do is 
restricted by consideration of the therapeutic efficacy of a drug. If a drug therefore 
requires a large dose and has low solubility characteristics Do will be high, reflecting 
a situation where the amount of drug administered in the dose is sufficient to produce 
non-sink conditions in the volume of intestinal fluid available.
Dn
The dissolution number is a measure of how efficiently drug is transported from the 
solid drug particles into the intestinal fluid, with the value of Dn increasing with the 
efficiency of the process. It includes terms for drug solubility, diffiisivity, density and 
rate of change of the particle radius. The flow rate in the intestine is also included so 
that overall Dn relates the time taken for drug to dissolve (dissolution time) to the 
time the dosage form remains in the intestine (residence time). Dn is the main 
parameter of the model under pharmaceutical control, for example a reduction in the 
particle size of the drug will increase D n . This reflects an improvement in the 
dissolution rate of a drug which may be relevant to the bioavailability of poorly water- 
soluble drugs.
From Equations 7.2 and 7.3 an expression can be derived for the total flow rate of 
drug through the intestinal membrane into the blood in terms of the parameters of the 
model. This total flow rate multiplied by the residence time (the same as that used to 
calculate Dn) equals the total amount of drug delivered. The efficiency of drug 
delivery can then be expressed as the fraction dose absorbed, F , given by the total 
amount of drug delivered divided by the dose. F  is expressed in terms of the model 
parameters and variables by Equation 7.4.
Equation 7.4
where
r* (1) = The dimensionless radius of particles at the end of the intestine.
C* (1) = The dimensionless concentration at the end of the intestine.
7.2.1 Conclusions of the suspension MMB model.
Hydrophobic drugs in Class II of the Biopharmaceutical Drug Classification scheme 
would be expected to have a low dissolution number in the suspension MMB model 
reflecting their poor aqueous solubility. In addition the nonpolar nature of the drugs 
will confer high membrane permeability characteristics resulting in a large absorption 
number281. In the case of these drugs the suspension MMB model shows that when 
dissolution number is small, F  is low, hence only a small fraction of the dose will be 
absorbed. The value of F  is not improved when the absorption number is increased 
for drugs with a low dissolution number. The extent of drug delivery is therefore 
dissolution rate limited with no influence from the rate of drug absorption across the 
intestinal membrane. This describes a situation where, as soon as the drug has 
dissolved in the intestinal fluid, absorption across the intestinal membrane into the 
blood occurs almost instantaneously. The model also shows that the dose number has 
very little influence unless it is greatly increased.
7.3 Adaptation of the microscopic mass balance approach for oil in water 
emulsions.
From the analysis provided by the suspension MMB model112 it is apparent that if the 
flow of hydrophobic drug from the formulation into the intestinal fluid is increased, a 
higher fraction of the dose will be delivered. This may be achieved through the use of 
an alternative drug delivery method to enhance dissolution, such as a lipid-based 
formulation. The use of a lipid-based formulation for a Class II drug has been 
suggested throughout this thesis to be advantageous in avoiding dissolution by
various mechanisms. The majority of these mechanisms involved stimulation of the 
lipid digestion cascade, however simply administering the drug in a dissolved state 
within a lipidic solvent may be beneficial. This approach has potential to avoid the 
dissolution stage and enhance eventual drug bioavailability, irrespective of 
physiological lipid processing.
In the following discussion the MMB approach has been adapted in an attempt to 
model the fraction of dose delivered from an emulsion system. The aim was to 
examine the circumstances under which an emulsion system may give improved 
bioavailability compared to that from the same drug administered as an aqueous 
suspension. The adapted MMB model for emulsions (emulsion MMB model) 
represents a formulation where drug is in a dissolved state within lipid. Upon 
presentation of the formulation into the intestinal fluid the lipid disperses to form 
droplets of uniform radii. The lipid is regarded as non-digestible as the processes 
involved in lipid digestion are too complex to include within a predictive model.
The major adaptation made to the suspension MMB model is based on the Noyes- 
Whitney equation240 where dissolution is replaced in the emulsion MMB model by a 
partitioning process. For the suspension MMB model dissolution rate depends on 
drug dissolving into the boundary layer around a solid drug particle, from which drug 
diffusion into the bulk intestinal fluid occurs. In the case of the lipid droplets the rate 
of drug release depends on drug partitioning into the aqueous boundary layer around 
the droplet, followed by diffusion into the bulk intestinal fluid. Since the drug is 
partitioning across an interface between lipid and water, drug concentration in the 
lipid droplet, CUpid and in the aqueous boundary layer around it, are related by
the partition coefficient, P  of the drug. The drug concentration in the boundary layer 
can therefore be calculated from? which enables the release of drug from the lipid 
droplet into the intestinal fluid to be described in exactly the same manner as for the 
suspension. An equation (Equation 7.5) analogous to the Noyes-Whitney equation 
was thus derived for the emulsion system; the reasoning behind the derivation is 
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where Clayer = drug concentration in the aqueous boundary layer.
For solid drug particle For lipid droplet
Pr  — c r'-'layer layer ^
C lipid
where P  = the partition coefficient
D R  for the suspension = D R  for the emulsion
the Noyes Whitney equation240 = Equation 7.5.
Figure 7.2 The adaptation of the Noyes-Whitney equation for the emulsion MMB 
model.
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Equation 7.5 was employed to derive the differential equations (Equations 7.6 / 7.7)
analogous to Equations 7.2 / 7.3 using exactly the same MMB approach as Oh et
solubility of the drug. 
z  = The position down the tube as a fraction of the total length of the tube.
In the same manner as for the suspension MMB model three parameters appear, the 
absorption number, An the volume number, Vn and the diffusion number, D f . The 
absorption number remains as described for the suspension MMB model with no 
change. The parameters of Fwand D f specific to the emulsion MMB model are 
defined below:
The volume number
al112. A full derivation of the emulsion MMB model is given in Appendix A
Equation 7.6
l.An.C * Equation 7.7
where the variables are defined as:
C* = The concentration of drug in solution in the intestinal fluid as a fraction of
the aqueous solubility of the drug (this takes the place of r* for the 
suspension MMB approach).
ClPid = The concentration of drug in the lipid droplets as a fraction of the aqueous
y  _ volume of lipid in dose
luminal volume
The volume number is analogous to the dose number in the suspension MMB model 





The diffusion number is analogous to the dissolution number in the suspension MMB 
model and represents the efficiency with which the drug diffuses from the boundary 
layer into the intestinal fluid.
In the same manner as for the suspension MMB model an equation can be derived for 
the fraction of dose adsorbed into the blood, F . This is given by Equation 7.8.
The solution of these equations is simpler than for the suspension MMB model, and 
can be solved analytically. This gives the expression for F  in Equation 7.9.
Equation 7.8
where
C*tipid( 1) = The dimensionless concentration in the lipid droplets at the end of the 
intestine.
C* (1) = The dimensionless concentration in the intestinal fluid at the end of the 
intestine.
/
F  = 1 -  exp - 2  • An Equation 7.9
where P = the partition coefficient of the drug.
293
7.3.1 Results from the emulsion MMB model.
Initially the model was employed to examine how the hydrophobicity of a drug may 
alter the fraction of dose absorbed, F  from an emulsion system. In addition the effect 
of lipid droplet size on F  was also examined to determine if the quality of the 
emulsion formed by a lipid formulation would influence the bioavailability of a drug. 
The hydrophobicity of the drug was represented by the log of the partition coefficient, 
log P  which was increased from 0  to 1 0 . The quality of the emulsion was defined by 
the radius of the lipid droplets, which varied across a range of 1 to 1000 |im. Other 
parameters required were taken from the suspension MMB model112, where 
appropriate, and the drug was assumed to be delivered in 1 ml of lipid. F  was then 
calculated using these values and an An of 10 and the results are illustrated in Figures
7.3 and 7.4.
Figure 7.3 shows the variation of F  with lipid droplet radius for log P  values of 1, 2,
3 .4  and 5. It is apparent from this figure that as the lipid droplet radius is decreased,
F  increases from 0 to a constant saturated value. When log P  is high (> 5) the 
model shows that no drug is delivered, for drugs with a low log P (< 3) a saturated 
value of 1 is shown (representing complete delivery) and between these values the 
extent of delivery depends on log P . The most important conclusion to be drawn 
from Figure 7.3 is that the efficiency of drug delivery, represented by F , is 
unchanged if the radius of the lipid droplet is decreased below 50 ^m.
The same results are illustrated in Figure 7.4 from a different view point. F  is shown 
as a function of log P for lipid droplet radii of 1, 1 0 , 1 0 0  and 1 0 0 0  jxm. This 
perspective improves the visualization of log P  dependence on lipid droplet size in 
terms of the efficiency of drug delivery.
Manipulation of the model can alter the above results. The lipid droplet radius below 
which no further increase in F  is observed can be increased above the present value 
of 50 |un by increasing the residence time in the gut or by using a higher diffusivity. 
The fraction of dose delivered by high log P drugs can also be increased to a certain 
extent by increasing An or decreasing the volume number. In physical terms this
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corresponds to increasing membrane permeability of the drug and increasing the 
concentration of drug in the lipid droplets respectively.
An absorption number of 10 was used for the above calculations, as this value had 
been suggested by Amidon et al278 to represent drugs with the property of high 
membrane permeability. Since An is an estimated quantity it was desirable to assess 
the sensitivity of the model and the conclusions drawn from it with respect to 
variations in A n . A confidence in An of 50 % has been described280 therefore F  was 
calculated using absorption numbers of 5,10 and 15 (Figure 7.5) for a lipid droplet 
radius of 10 pm. Figure 7.5 shows that conclusions drawn from Figures 7.3 and 7.4 
are not altered by A n , although the maximum log P for efficient drug delivery tends 
to decrease slightly with decreasing A n .
As emulsification of lipid in the stomach has been found to result in lipid droplets with 
radii in the range of 0.5 to 50 pm17, it is reasonable to presume droplets in the same 
region could be achieved in vivo from a lipid-based formulation. By assuming a lipid 
droplet radius of less than 50 pm F  is effectively independent of the droplet radius 
and diffusivity. In view of this Equation 7.10 can be obtained (by taking an infinitely 
small r ).
F  -  1 -  exp^-2 • -— Equat ion 7.10
Therefore in order to calculate the fraction dose absorbed within the emulsion MMB 
model using Equation 7.10 the only parameters required are the partition coefficient 
and An of the drug and the volume number, Vn for the dose.
7.4 Can an emulsion system improve bioavailability of hydrophobic drugs 
over that given by an aqueous suspension ?
The emulsion and suspension MMB models enable prediction of the bioavailability of 
poorly water-soluble drugs when dosed as an emulsion or as a suspension 
respectively. To determine if an emulsion may improve the bioavailability of
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hydrophobic drugs compared to the use of an aqueous suspension, ten steroidal 
compounds (listed in section 6 .2 ) with varying degrees of hydrophobicity were 
selected. Certain parameters required by the models, namely Cs (represented by 
solubility in aqueous buffer solution) and P  (represented by P hplc)  had already been 
determined experimentally in Chapter 6  for these drugs.
The emulsion MMB model (Equation 7.10) was employed to calculate F  for each 
steroid using parameters of P hplc, an An of 10 (as used by Amidon et al278), a 
luminal volume o f250 ml and 1 ml of lipid to deliver the drug. The resulting 
calculated values of F  are shown in Table 7.2 as percent dose absorbed.
For the same steroids Equation 7.4 was applied to evaluate F  from an aqueous 
suspension. An was again taken to be 10, whereas Dn and Do for the drugs were 
evaluated using the same parameters as for digoxin by Amidon et al278, with 
appropriate adjustments made for a dose of 50 mg and differences in Cs . These 
values enabled calculation of F , which is expressed in Table 7.2 as percent dose 
absorbed.
Drug Log % dose absorbed
P hplc Suspension MMB Emulsion MMB
Hydrocortisone 1.54 1 0 0 . 0 1 0 0 . 0
Hydrocortisone acetate 2.74 9.8 99.8
Testosterone 3.19 14.3 93.8
Ethynylestradiol 3.30 1 2 .8 89.2
Hydrocortisone butyrate 3.58 65.3 70.8
Progesterone 4.10 1 .1 32.3
Hydrocortisone valerate 4.21 19.7 26.2
Testosterone acetate 4.71 0 . 2 9.3
Hydrocortisone caprylate 7.57 2 . 2 0 . 0 1
Testosterone enanthate 9.05 1.5 0.0004
Table 7.2 Percent dose absorbed calculated using a MMB approach for a range of 
steroidal compounds when delivered as a suspension or an emulsion.
Table 7.2 illustrates the predicted percentage of a 50 mg dose of steroid likely to be 
absorbed when using different delivery systems. Results from the suspension MMB 
model could be taken to represent a disintegrated tablet and reflect the influence of 
the aqueous solubility of a drug on efficiency of delivery. The emulsion MMB model 
reveals the influence of the hydrophobicity of a drug, represented by log P , on the
percentage of dose absorbed from lipid droplets. These droplets could be presumed to 
result from dispersion of a lipid-based formulation in intestinal fluid.
The results show that the delivery of drug is more efficient from the emulsion model 
for drugs with a log P in the range of 1.5 to 5. Both models delivered 100 % of the 
least hydrophobic drug tested (hydrocortisone, log P 1.54) which is probably due to 
the higher aqueous solubility of this drug. For a log P > 5 the suspension model 
showed minimal delivery whereas the emulsion model failed to deliver any drug. Lack 
of delivery for highly hydrophobic drugs from the emulsion model is probably 
unrealistic since the model does not take into account the process of lipid digestion, 
which is likely to improve drug delivery. The emulsion model therefore indicates the 
importance of digestion for absorption of drugs with high hydrophobicity, which may 
otherwise remain partitioned in lipid until excretion.
Overall the models suggest these steroids would benefit from delivery in an emulsion 
system as the predicted bioavailability is superior to that from a suspension (by a 
factor of up to 46, but typically 10) provided log P  is less than 5. For drugs with a 
higher log P  digestion of lipid gives further potential to increase the efficiency of 
delivery from an emulsion, whereas delivery from a suspension would remain severely 
limited by the low aqueous solubility of the drugs.
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Figure 7.3 Variation of fraction dose absorbed, F with lipid droplet radius, r 
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Figure 7.4 Variation of fraction dose absorbed, F  as a function of log P for lipid 
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Figure 7.5 Variation of fraction dose absorbed, F  as a function of log P for 
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Chapter 8  - Conclusions
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The work performed in this thesis has provided additional information regarding the 
use of lipid-based formulations for drugs which exhibit dissolution limited absorption. 
As physiological lipid processing has been suggested to enhance bioavailability from a 
lipid-based formulation1, the possible rate of digestion of lipid-based formulations in 
the duodenum was assessed using an in vitro model of lipolysis. This model enabled 
examination of the rate at which a lipid substrate was digested by lipase, in the 
presence of non-ionic surfactants likely to be included within a lipid-based 
formulation.
The results indicated that hydrophilic surfactants with hydrophile / lipophile balance 
(HLB) values in the range of 13 to 15 were, in general, potent inhibitors of lipase 
activity towards medium chain triglyceride. Surfactants with dominant lipophilic 
character were also able to inhibit lipase activity although the inhibition was less 
severe, with limited lipolysis able to occur from the start of the assay. When both 
hydrophilic and lipophilic surfactants were present in the system a further 
phenomenon was observed, where the lipophilic surfactant appeared able to relieve 
inhibition due to the hydrophilic surfactant.
A theory to explain the effect of non-ionic surfactants on the activity of lipase is 
proposed. Hydrophilic surfactants, orientated at the lipid / water interface may form a 
hydrophilic barrier around the substrate by means of their ethoxy chains. Initially this 
barrier would prevent access of colipase to the triglyceride interface, and thus inhibit 
lipase activity. However, eventually some colipase would be expected to bind 
followed by lipase, with the consequent production of lipolytic products. 
Accumulation of these products at the interface may act to promote partitioning of 
colipase into the substrate surface, with a resultant increase in lipase activity and 
reduction in the extent of inhibition from the surfactant molecules. Lipophilic 
surfactants when present in the system are suggested to speed this process up, either 
by containing lipolytic products as part of their composition or by providing an 
additional source of substrate for lipase.
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In any event inhibition caused by surfactants examined in this work is eventually 
overcome and hence is concluded to be of a reversible nature. This is important when 
relating the results from the in vitro model to a situation which may occur upon 
administration of a lipid-based formulation in vivo. A formulation which is initially 
unavailable to lipase activity in vitro will probably not remain in this state for long in 
vivo. The mechanisms of emulsification in the gut will disperse the formulation, and 
probably alter the nature of the interface between the GI fluid and the surface of the 
formulation droplets to such an extent that the inhibitory layer of hydrophilic 
surfactant is disrupted. Lipase present in the duodenum will thus be able to digest lipid 
in the formulation, with any remaining inhibition from the surfactant rapidly 
overcome. This proposal is based on the assumption that the concentration of lipid 
present within the formulation is sufficient to stimulate the ‘lipid digestion cascade’ 
and thus lipase secretion. If not, digestion of the formulation is unlikely, with the drug 
possibly remaining partitioned in the lipid until excretion. Administration of the 
formulation in the fed state would increase the likelihood of stimulation of the lipid 
digestion cascade, however this may introduce complications with regards to patient 
compliance and variation in the nature of the food eaten.
Alternatively, to bypass any requirement for stimulation of the lipid digestion cascade, 
the drug could be administered in a dissolved state within a self-emulsifying drug 
delivery system (SEDDS). The excellent dispersion of these formulations upon release 
into the aqueous GI fluid may alone be sufficient to improve drug absorption. The 
drug would partition from the fine dispersion of droplets formed by the SEDDS and 
be held in a dissolved state in the solubilizing phase formed by components of the 
formulation ready for absorption. The efficiency of the partitioning process of 
hydrophobic drugs from lipid droplets into the aqueous fluid has been predicted by the 
emulsion microscopic mass balance (MMB) model (see Chapter 7). This model 
suggests that partitioning of drug from a lipid droplet may be a promising method to 
improve the bioavailability of drugs with a log P < 5, over that achieved from an 
aqueous suspension of drug. Problems may thus be encountered with SEDDS if the 
drug is too hydrophobic to partition from the droplets formed by dispersion of the
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formulation. An additional complication may be introduced if the drug has a tendency 
to precipitate upon release into an aqueous environment.
A possible technique which may enable stimulation of the lipid digestion cascade 
without the use of a high lipid volume could involve the formulation of a SEDDS 
which includes as part of its composition lipolytic digestion products. These may be 
incorporated in the SEDDS by using surfactants for the formulation which contain 
lipolytic products as part of their make-up.
The limited concentration of lipolytic products formed by gastric lipase activity on 
ingested lipid have been stated to promote immediate release of pancreatic lipase upon 
entry into the duodenum16. Based on this administration of a SEDDS which forms a 
well dispersed solubilizing phase containing lipolytic products in the fasted state could 
mimic the fed state. The lipolytic products may stimulate secretion of bile and lipolytic 
enzymes from the gallbladder and pancreas respectively, thus bypassing any 
requirement for initial digestion of lipid.
The advantages of the lipid digestion cascade upon the bioavailability of poorly water- 
soluble drugs should then come into play. The partitioning of highly hydrophobic 
drugs from droplets of the formulation is likely to be enhanced by digestion. The 
resulting higher concentration of bile salt and lecithin micelles in the GI fluid will also 
raise the solubilizing capacity of the dispersion formed by the SEDDS for the drug.
The solubilizing capacity of bile salt and lecithin micelles for hydrophobic drugs 
(demonstrated in Chapter 6 ) may reduce the chance of precipitation of drug in the 
aqueous fluid and aid transport of drug in the micelles to the brush border membrane 
for absorption.
In terms of the suitability of a drug for formulation within a lipid-based system the log 
P of a drug provides a useful guideline. In general drug is required to be soluble 
within the lipid-based formulation, this has been assumed in the emulsion MMB model 
although it is by no means always the case. Manipulation of the formulation in terms 
of co-solvents and surfactants is sometimes required. The improved drug 
bioavailability noted from lipid-based solid dispersions1, where drug is present in 
excess of its solubility in a lipid vehicle, show that it may not be necessary to
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originally have the drug in a dissolved form; the presence of material to improve 
solubilization of the drug may be sufficient.
In summary lipid-based formulations can be considered to have potential to improve 
the bioavailability of poorly water-soluble drugs compared to that achieved from a 
solid dosage form. The major advantage being the ability to present the drug to the 
gut in a dissolved form thus enabling avoidance of the dissolution stage which is the 
rate limiting step to the absorption of these drugs. Further work investigating lipid- 
based formulations and their effect upon bioavailability is required to clarify the 
requirements of a lipid-based formulation. Comparison of the bioavailability from 
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Appendix A
Derivation of equations for emulsion microscopic mass balance model of drug
absorption.
In this appendix a derivation is given of the differential equations resulting from the 
Microscopic Mass Balance (MMB) model for drug delivery through the intestinal 
membrane from an emulsion, as described in Chapter 7. The model is analogous to 
that developed by Oh et al112 for drug delivery from a suspension, but describes the 
partitioning of the drug from lipid droplets into solution as opposed to a suspension of 
solid particles dissolving into solution.
In view of this, detailed attention is given only to those aspects of the emulsion MMB 
model that differ from the suspension MMB model. The paper published by Oh et 
al112 gives details of the other approximations that the two models have in common, 
and the reader is referred to this for further details.
Differential equations
The model consists of an emulsion flowing down an ‘intestinal’ tube, of length L and 
radius R , at a volume flow rate of Q . In exactly the same way as for the suspension 
MMB model the intestinal tube is divided into infinitesimal ‘slices’ of width dz and 
radius R . Applying the ‘mass balance approach’ implies that for each of these slices
(rate of drug flowing in) - (rate of drug flowing out) -
(rate of mass partitioning from lipid droplet to solution) = 0 (A. 1)





j p  ~
SP =
£.(£*-r 





and z is the distance along the intestinal tube.
The same approximations are used for the diffusion properties of the drug as for the 
suspension MMB model (pseudo steady state transfer at low Reynolds number). The 
symbols appearing in these equations are defined below:
M ml Mass of drug dissolved in lipid droplets flowing through the slice per unit
time.
j p Rate at which the drug partitions from the lipid droplet to the intestinal
fluid, per unit area of partition surface (see Chapter 7 - this equation 
replaces the Noyes-Whitney equation used for suspension MMB model).
Sp Total surface area of lipid droplets in the emulsion per unit volume.
CCT/ Concentration of drug dissolved in lipid droplets (this is a function of z ).
C Concentration of drug dissolved in intestinal fluid (this is a function of z  ).
r Radius of lipid droplets.
Q Volume flow rate of intestinal fluid.
N 0 /K0 Number of lipid droplets per unit volume.
D Diffiisivity of the drug.
P  Partition coefficient.
From these quantities and Equations A.2-A.5 a differential equation for the 
concentration of the drug in lipid droplets can be obtained,
dz Qr* \ P  ] K ’
Reducing this to the dimensionless variables, z* = z /L ,  C*7 = Coll / C1^  and 




This is Equation 7.6 in Chapter 7.
Next we turn our attention to the transport of drug across the intestinal membrane. 
The MMB approach gives us the relation:
(rate of dissolved drug flowing in) - (rate of dissolved drug flowing out)
+ (rate of drug partitioning from lipid droplet to solution)
- (rate of drug absorption across intestinal membrane) = 0 (A. 9)
time.
j w Rate at which the drug is adsorbed across intestinal membrane per unit surface
or
j f c . )  + j P.Sp.xR2 - j w (2nR) = 0 (A. 10)
where the new symbols are:
M sol Mass of drug dissolved in intestinal fluid flowing through the slice per unit
area.
Assuming sink conditions112 for the adsorption across the intestinal membrane these 
quantities are given by:
(A l l )
j w = P*rC  (A. 12)
where Peff is the effective permeability of the compound112. Reducing Equation A. 10 
to dimensionless variables,
z ' = z jL ,
s~r+   / r initial
oil ~  oil /  ^ o i l
and
c’ = c
and introducing the volume number, Vn, defined as
= (A. 13)
3 V0




An = —^ -------, (A. 14)
d C
dz'
f  s i *C= D fV n .\^ L - C ' | - 2 .A n .C \ (A.15)
This is Equation 7.7 given in Chapter 7.
Solution of the differential equations
The next step is the solution of Equations A. 8 and A. 15 in order to calculate the rate 
at which the drug is delivered. Substituting A. 8 into Equation A. 15 gives a second 
order linear differential equation, with solutions of the form
CM (z*) = Ae~m' + B e bz' (A. 16)
where A and B  depend on the concentration of drug within the lipid droplets at 
z = 0 , and a and b depend on D f , Vn, An and P . Equation A. 16 implies that the 
concentration of drug in the lipid decays along the intestine as a sum of two 
exponential functions. For any realistic values of the drug and intestinal parameters, 
only one of these decays is significant (here taken as the Ae a z contribution). The 
other term is negligible (due to small B  and large b ) and is ignored here.
Applying the boundary conditions that all of the drug is in the lipid droplets upon 
entry into the intestine, we arrive at the solution
Cal(z’) = exp 2. An
1 + Vn. P  + l.An.P
D f
.z (A. 17)
We can obtain the concentration in the intestinal fluid, C(z*), by substituting this 
expression into Equation A. 8.
Fraction of dose delivered
We are particularly interested in the fraction of the total drug delivered across the 
intestinal membrane, F . This is given by
330
F  = 1 - (mass drug out, in lipid + solution) /
(mass drug in, in lipid + solution) (A. 18)
or
r  i 4/3 3. A'q . C*oil (1) + C* (1). V0 
4/3 nr3.NQ
A further simplification can be made by noting that for the poorly water-soluble drugs 
of interest the amount of drug in the intestinal fluid is small (close to zero), and makes 
a negligible contribution to Equation A. 19. In view of this, and using Equation A. 17, 
Equation A. 19 can be written as
F -  1 -  exp 2. An
\ + Vn.P + 2. An. P  
D f
(A. 20)
This is Equation 7.9 in Chapter 7.
A further simplification can be made for the case of small lipid droplets. As r becomes 
smaller, the diffusion number becomes larger, so the fraction lAnP /D f  in Equation 
A. 20 becomes negligible. Hence we can say that in the limit r -» 0 the fractional dose 
absorbed is given by
F  = 1 -  exp 2. An 
l + Vn.P
(A.21)
This gives the fractional dose delivered when lipid droplet size is not a limiting factor 
in drug delivery, as discussed in Chapter 7.
